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EXECUTIVE SUMMARY 
 
This report describes the outcomes of a project that culminated in a workshop on thyroid 
disruption, held on 29th – 31st March 2017 in Maison-Alfort near Paris, France, on the 
premises of ANSES.  
The workshop objectives were: 
 To address and discuss interpretations of experimental laboratory studies, wildlife 
field data as well as human epidemiological data in relation to the identification of 
thyroid disrupting substances; and 
 To identify ways forward in addressing potential gaps in the test methods in 
relation to identification of thyroid disrupting substances 
As part of this project, case studies were conducted with the intention of elucidating 
several aspects and issues highlighted as important for understanding thyroid disruption. 
The case studies covered fipronil, mancozeb, perchlorate, PBDEs/perfluorinated 
compounds/PCBs and thyroid cancers, and dealt with the following topics (together with 
the substances chosen to elucidate the topics, listed in italics):  
• The rat as predictor of human effects – a re-evaluation on the basis of new 
insights: perchlorate, thyroid cancers, fipronil case studies 
• The relevance of compensatory effects in protecting against thyroid disruption: 
perchlorate case study 
• The role of hepatic metabolism in thyroid insufficiency: thyroid cancers, fipronil, 
PBDE/perfluorinated compounds/PCBs case studies 
• Better measures of down-stream effects of thyroid-disrupting chemicals: 
mancozeb, PBDE/perfluorinated compounds/PCBs, thyroid cancer case studies 
• The relevance of thyroid tumours that arise via thyroid hormones (TH) 
insufficiency: thyroid cancer case study 
To keep participants abreast of recent developments in thyroid disruptor research, a set 
of background papers was prepared. These papers focused on the following issues: 
 Possible adverse effects in the human following disruption of the hypothalamic-
pituitary-thyroid axis 
 The thyroid system in fish, amphibians and invertebrates – a comparison with 
mammalian species 
 Interpretation of data from epidemiology, experimental studies and wildlife data 
for the identification of thyroid disruptors 
 Current OECD test methods for the identification of thyroid disruptors, their gaps 
and possibilities of improvements 
During the workshop, three pairs of discussion groups were formed and run in parallel. 
These groups dealt with the following topics: 
• Discussion Group 1 a,b: Assays and endpoints for thyroid disruption – status 
quo and perspectives for enhancements 
  
 
• Discussion Group 2 a,b: The human relevance of models of thyroid disruption 
pathways 
• Discussion Group 3 a,b: Thyroid systems across taxa: the relevance of 
mammalian data in environmental assessments and of non-mammalian data in 
human health assessment 
During the course of the workshop it became clear that the interpretation of test results 
with thyroid disrupting agents is based on an “idealised view” of the thyroid system. 
According to this view, increases in thyroid stimulating hormone concentrations are 
expected to occur as a consequence of suppressions of circulating thyroid hormones. The 
emphasis often placed on measuring circulating thyroid hormones and thyroid stimulating 
hormone levels is informed by this idea. However, it is difficult to reconcile this view with 
observations that certain chemicals are capable of inducing thyroid hormone insufficiency 
without subsequent increases in thyroid stimulating hormone. Sometimes, thyroid 
stimulating hormone levels even decrease in the wake of thyroid hormone insufficiency. 
The idealised view also appears incomplete in the light of new evidence of autonomous 
regulation of thyroid hormone action at the tissue level, without involvement of the 
hypothalamic pituitary thyroid (HPT) axis and without the corresponding changes in 
serum thyroid hormones. 
The majority of workshop participants concluded that altered circulating levels of thyroid 
hormones and thyroid stimulating hormone should not be seen as the only markers of 
thyroid hormone action, or of thyroid disruption. Data sets of serum thyroid hormone 
measurements contained in many chemical dossiers should be supplemented by data on 
down-stream effects of an adverse nature, such as effects on the developing brain, or on 
other TH target organs. 
Workshop participants noted the deficiencies of current test guidelines in the OECD 
Conceptual Framework, and identified the absence of sensitive parameters for the 
detection of down-stream adverse effects diagnostic of thyroid disruption as a major gap 
in these guidelines. There was concern that the lack of such parameters hampers the 
reliable detection of substances as thyroid disruptors. 
Detailed suggestions for improvements of the test guidelines were elaborated. 
Participants highlighted a need to include endpoints for the identification of adverse 
effects on brain function and brain morphology. The inclusion of endpoints representative 
of thyroid hormone action at the cellular level, e.g. altered expression of thyroid 
hormone-dependent genes, was also deemed important, as was the implementation of in 
vitro assays that can capture mechanistic aspects of thyroid disruption. 
A strategy for improving test guidelines could unfold at three levels, by improving thyroid 
histology, by extending exposure periods to windows of sensitivity during development, 
and by incorporating downstream effects diagnostic of brain morphology and function, 
lipid metabolism and the cardiovascular system. 
Until these gaps are filled, it is necessary to evaluate substances on the basis of 
incomplete data on thyroid disruption. Following considerable discussion, all groups came 
to a consensus regarding the interpretation of changes in serum thyroxine (T4) levels in 
rodents. If such changes occur, for any reason, including altered hepatic clearance, they 
should be considered a thyroid effect, unless the mechanism of altered clearance (i.e. the 
specific enzymes or pathways impacted) can be determined not to be relevant to humans 
or wildlife of concern. Such findings should be regarded as relevant for regulatory 
decisions unless, on the basis of further compound specific information, it is possible to 
exclude the human relevance of such effects. 
Observations of thyroid disruption in rodent laboratory studies can be useful for the 
identification of thyroid disrupting properties in other wildlife mammalian species. 
Considering the preservation of the thyroid system across taxa, such data would also 
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raise concerns for e.g. birds, fish or amphibians, although species-species extrapolations 
will not be straight-forward due to differences in exposure routes (e.g. dermal in 
amphibians versus oral in rodents) and other factors (e.g. the presence of the placenta in 
mammals). 
Conversely, data from non-mammalian test species can be used to inform on the mode 
of action of putative thyroid disrupting chemicals in mammals. This is strongly supported 
by the observation that most amphibian thyroid disruptors have elicited positive 
responses also in rodent tests. 
 
 “The information and views set out in this report are those of the author(s) and do not necessarily 
reflect the official opinion of the Commission. The Commission does not guarantee the accuracy of the 
data included in this study. Neither the Commission nor any person acting on the Commission’s behalf 
may be held responsible for the use which may be made of the information contained therein.” 
  
  
 
List of abbreviations 
ADHD Attention-deficit hyperactivity disorder 
ADI Acceptable Daily Intake 
AhR Aryl hydrocarbon Receptor 
ANSES Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du 
travail 
AOP Adverse Outcome Pathways 
BDNF Brain-derived neurotrophic factor 
BTEB Basic transcription element binding protein 
CAR Constitutive androstane receptor 
CHO Chinese Hamster Ovary 
CI Confidence Interval 
CYP P450 Cytochrome P 450 
D1, D2 D3 Iodothyronine deiodinase types 1, 2, 3 
DAR Draft Assessment Report 
DEHP Diethyl-hexyl phthalate 
DNT Developmental Neurotoxicity 
ECHA European Chemicals Agency 
ED Endocrine Disruption 
EDC Endocrine Disrupting Chemical 
EDTA AG Endocrine Disrupters Testing and Assessment Advisory Group 
EDSP Endocrine Disrupter Screening Programme (USA) 
EFSA European Food Safety Authority 
EOGRTS Extended One Generation Reproductive Toxicity Study 
EPA Environmental Protection Agency 
ETU Ethylenethiourea 
EU European Union 
FDA Food and Drug Administration 
FTC Follicular Thyroid Cancer 
GABA Gamma Amino Butyric Acid 
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HPT Hypothalamic Pituitary Thyroid axis 
IARC International Agency for Research on Cancer 
IGF1 Insulin-like growth factor 1 
LOAEL Lowest Observed Adverse Effect Level 
MCT Mono Carboxylate Transporters 
MIE Molecular Initiating Event 
NHANES National Health and Nutrition Examination Survey 
NIS Sodium Iodine Symporter 
NTCP Na Taurocholate co-transporting polypeptide 
NOAEL No Observed Adverse Effect Level 
NOEC No Observed Effect Concentration 
NTP National Toxicology Programme (USA) 
OECD Organisation for Economic Cooperation and Development 
PAH Polycyclic aromatic hydrocarbons 
PBDE Polybrominated diphenyl ethers 
PCB Polychlorinated biphenyls 
PFAA Perfluoro alkyl acids 
PFOA Perfluoro octanoic acid 
PFOS Perfluoro octanoic sulfonic acid 
PND Postnatal Day 
PTC Papillary Thyroid Cancer 
PTU Propylthiouracil 
PXR Pregnane X receptor 
SD Sprague Dawley 
TBG Thyroxine Binding Globulin  
T3 Triiodothyronine 
T4 Thyroxine 
TH Thyroid hormones (includes T3 and T4) 
TPO Thyroid PerOxidase 
TR Thyroid hormone Receptor 
TSH Thyroid Stimulating Hormone 
  
 
TSHR Thyroid Stimulating Hormone Receptor 
TTR Transthyretin 
UDP Uridine diphosphate 
US EPA United States Environmental Protection Agency 
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1. INTRODUCTION 
 
This document is the Final Report for the project Supporting the organisation of a 
workshop on thyroid disruption. 
The objective of this project was to provide technical and administrative support for the 
preparation, execution and follow-up of a workshop on thyroid disruption. The workshop 
objectives were: 
 To address and discuss interpretations of experimental laboratory studies, wildlife 
field data as well as human epidemiological data in relation to the identification of 
thyroid disrupting substances; and 
 To identify ways forward in addressing potential gaps in the test methods in 
relation to identification of thyroid disrupting substances 
In line with the technical specifications for this service request, and on the basis of the 
above specific objectives, the study included the following tasks: 
Task 1. Set up a Scientific Expert Group which provides scientific and technical guidance 
on the drafting of the background and discussion papers for the workshop and on its 
design, planning and organisation. 
Task 2. Design and plan a workshop on thyroid disruption and develop and draft 
background and discussion papers to be used to provide a basis for the deliberations of 
workshop participants at the workshop. 
Task 3. Conduct the workshop on thyroid disruption. 
Contents of this report 
This report describes all the results obtained in relation to all tasks of the project, under 
the following headings: 
 The Scientific Expert Group and the Steering Group 
 The workshop concept 
 Workshop venue and programme 
 Case studies of thyroid disrupting chemicals 
 Additional background papers for the workshop 
 Background and topic outlines for the workshop discussion groups 
 Workshop report 
 Conclusions 
  
  
 
2. THE SCIENTIFIC EXPERT GROUP AND STEERING GROUP 
 
To secure scientific guidance from recognised scientists with expertise in the thyroid 
disruption area, a Scientific Expert Group was set up. The role of this group was in 
commenting on the workshop concept, on the content of the background and discussions 
documents that were to be drafted to prepare participants for the workshop, and on 
general aspects of workshop organisation. Furthermore, members of the scientific expert 
group were tasked with moderating the discussion groups that were formed from 
workshop participants. 
The following experts served on the scientific expert group for this project: 
• Dr Niklas Andersson, ECHA, Helsinki, Finland 
• Dr Marie-Noelle Blaude, Scientific Institute of Public Health WIV-ISP, Brussels, 
Belgium 
• Dr Patience Browne, OECD, Paris, France 
• Professor Nicolas Chevalier, Centre Hospitalier Universitaire de Nice, Nice, France 
• Professor Barbara Demeneix, Muséum National d'Histoire Naturelle, Paris 
• Dr Margareta Halin Lejonklou, KEMI, Stockholm, Sweden 
• Dr Timo Hamers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands 
• Dr Marie-Louise Holmer, Danish Environment Ministry, Copenhagen, Denmark  
• Professor Josef Koehrle, Charite Hospital, Berlin, Germany 
• Dr Martine Röhl, FPS Public Health, Brussels, Belgium  
• Dr Catherine Viguie, INRA, Toulouse, France 
• Dr Gro Dehli Villanger, Norwegian Institute of Public Health, Oslo, Norway 
• Professor Tom R Zoeller, University of Massachusetts, Amherst, USA 
 
The Steering Group for this project had responsibility for coordinating the implementation 
of this project. It was composed of: 
 Dr Peter Korytar, European Commission, DG ENV 
 Maiken Guldborg Rasmussen, European Commission, DG ENV 
 Dr Sharon Munn, European Commission, DG JRC 
 Dr Elise Grignard, European Commission, DG JRC 
 Dr Cecile Michel, ANSES 
 Dr Claire Beausoleil, ANSES 
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3. THE WORKSHOP CONCEPT 
 
The task was to organise a scientific workshop on thyroid disruption. In discussions with 
the Scientific Expert Group and the Steering Group the following specific workshop 
aims were agreed upon: 
• To discuss issues related to the interpretation of thyroid disruption test 
outcomes 
• To identify gaps in testing guidelines 
• To elaborate recommendations of how to fill these gaps  
• To reach a consensus on interpretation and testing issues (if possible) 
The workshop was to be held over three days on the premises of ANSES in Alfortville.  
The programme was to comprise formal presentations on key aspects of thyroid 
disruption, with the aim of providing up-to-date overviews of relevant aspects of the 
topic, as well as discussion groups composed of workshop participants. The discussion 
groups were to deal with specific aspects of thyroid disruption, identify the contours of 
diverging scientific opinions (if any) and, if possible, arrive at common recommendations 
and suggestions. 
Three discussion topics were identified: 
• Topic 1: Assays and endpoints for thyroid disruption – status quo and 
perspectives for enhancements 
• Topic 2: The human relevance of models of thyroid disruption pathways 
• Topic 3: Thyroid systems across taxa: the relevance of mammalian data in 
environmental assessments and of non-mammalian data in human health 
assessment 
To arrive at manageable group sizes, it was decided to set up two groups for each topic, 
here designated a and b, to be run in parallel. To ensure continuity of the groups’ 
discussion process, workshop participants remained with their chosen group for the 
duration of the workshop. 
Each group was moderated by two members of the Scientific Expert Group, and assisted 
by one member of the Study Team who acted as rapporteur and note taker. The 
discussion groups with their moderators and rapporteurs are shown in the workshop 
programme below. 
  
  
 
4. WORKSHOP VENUE AND PROGRAMME 
ANSES - Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et 
du travail – kindly agreed to host the workshop on their premises at: 
14 rue Pierre et Marie Curie 
94701 Maison-Alfort Cedex 
The workshop began on 29 March 2017 at 11:00 and closed on 31 March 2017 at 
15:00. 
The workshop programme is shown below. 
Wednesday 29th March  
10:30 Coffee and registration 
11:00   Welcome: Peter Korytar (DG ENV), Roger Genet (Director General of ANSES) 
11:15 Introduction to the workshop: aims, structure and logistics 
Andreas Kortenkamp (Brunel University London) 
11:30 Keynote lecture: thyroid disruptor research in the 21st century 
Tom Zoeller (UMass Amherst, USA), Barbara Demeneix (National Museum of 
Natural History, Paris), Josef Köhrle (Charite Berlin), Catherine Viguie (INRA 
Toulouse) 
12:30 Summary of pertinent aspects of case studies of thyroid disruption 
Andreas Kortenkamp, Ulla Hass, Olwenn Martin, Marta Axelstad (Brunel 
University London) 
13:00 Lunch 
14:00 Overview of test guidelines for thyroid disruption 
Patience Browne (OECD)  
14:30 New insights from eco-toxicological animal models (fish, amphibians) - 
implications for testing strategies 
Alice Baynes (Brunel University London) 
15:00 Substances interacting with the thyroid hormone synthesis might trigger 
adverse effects on the HPT and HPG axes – a case study on perchlorates 
from the ecotoxicological perspective 
Eva Fetter (Umweltbundesamt, Germany) 
15:30 Coffee 
16:00 Pathways of thyroid disruption and their relevance to human risk 
assessment – insights from a case study with fipronil 
Marta Axelstad (DTU) 
16:30 Discussion groups (DG) begin work in separate parallel sessions (two 
groups, a and b, deal with the same topic)  
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DG 1 a b: Assays and endpoints for thyroid disruption – status quo and 
perspectives for enhancements 
Moderators: 
DG 1a – Tom Zoeller (UMass Amherst), Patience Browne (OECD)  
DG 1b – Barbara Demeneix (National Museum of Natural History, Paris), Niklas 
Andersson (ECHA) 
DG 2 a b: The human relevance of models of thyroid disruption pathways 
Moderators: 
DG 2a – Timo Hamers (VU University of Amsterdam), Marie-Noelle Blaude 
(Scientific Institute of Public Health, Belgium) 
DG 2b – Josef Koehrle (Charite Berlin), Gro Dehli Vilanger (Norwegian Institute of 
Public Health) 
DG 3 a b: Thyroid systems across taxa: the relevance of mammalian data 
in environmental assessments and of non-mammalian data in human 
health assessment 
DG 3a – Margareta Lejonklou (KEMI Sweden), Catherine Viguie (INRA Toulouse) 
DG 3b – Marie-Louise Holmer (Danish Environmental Protection Agency), Martine 
Röhl (FPS Public Health) 
 
17:45 Working groups briefly report back to plenary 
18:30 Welcome drinks 
 
 
 
Thursday 30th March  
8:30 Coffee 
9:00 Hepatic metabolism and thyroid disruption - an example from REACH 
dossier evaluations 
Niklas Andersson (ECHA) 
9:30   Enigmatic effects patterns and down-stream TH effects - lessons from 
the PBDE and mancozeb case studies 
Olwenn Martin (Brunel University London), Marta Axelstad (DTU) 
10:00 The role of TSH elevation in thyroid cancers: Evidence from human 
studies and rodent tumour models 
Andreas Kortenkamp (Brunel University London) 
10:30 Coffee 
11:00 Thyroid disruption: Insights from human epidemiology 
Andreas Kortenkamp (Brunel University London) 
11:30 Discussion groups resume in separate sessions 
  
 
13:00 Lunch 
14:00 Discussion groups continue in separate sessions 
15:30 Coffee 
16:00 Discussion groups present the status of their deliberations for a first 
plenary discussion 
17:00 Close 
  
19:00 Workshop dinner 
 
Friday 31st March  
8:30 Coffee 
9:00 Discussion groups resume and prepare their conclusions for debate in 
the plenary session 
10:00   DG 1 a b: Assays and endpoints for thyroid disruption – status quo and 
perspectives for enhancements 
Presentation to plenary and discussion 
11:00 Coffee 
11:30 DG 2 a b: The human relevance of models of thyroid disruption pathways 
Presentation to plenary and discussion 
12:30 Lunch 
13:30 DG 3 a b: Thyroid systems across taxa: the relevance of mammalian data 
in environmental assessments and of non-mammalian data in human 
health assessment 
Presentation to plenary and discussion 
  
14:30 General discussion and wrap-up 
Andreas Kortenkamp (Brunel University London) 
15:00 Close 
Peter Korytar (DG ENV), Cécile Michel (ANSES) 
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5. CASE STUDIES OF THYROID DISRUPTING CHEMICALS 
 
The technical specifications of this project stipulated that a number of case studies of 
thyroid disrupting chemicals were to be conducted and supplied to workshop participants 
as material to enable effective preparation for the workshop. In discussions with the 
Scientific Expert Group and the Steering Group it was agreed that the case studies should 
focus on the following aspects and topics, all of which were deemed to be of relevance for 
the understanding of thyroid disruption: 
• The rat as predictor of human effects – a re-evaluation on the basis of new 
insights 
• The relevance of compensatory effects in protecting against thyroid disruption 
• The role of hepatic metabolism in thyroid insufficiency 
• Better measures of down-stream effects of thyroid-disrupting chemicals 
• The relevance of thyroid tumours that arise via thyroid hormones (TH) 
insufficiency 
Based on suggestions by the Study Team, the following substances were selected for 
these case studies: 
 Fipronil 
 Mancozeb 
 Perchlorate 
 PBDEs/perfluorinated compounds/PCBs 
It was also decided to make thyroid cancers and the role of thyroid stimulating hormone 
(TSH) in its genesis the topic of a separate case study. 
The substances selected for the case studies covered several of the aspects and issues 
highlighted as important for understanding thyroid disruption:  
• The rat as predictor of human effects – a re-evaluation on the basis of new 
insights: perchlorate, thyroid cancers, fipronil case studies 
• The relevance of compensatory effects in protecting against thyroid disruption: 
perchlorate case study 
• The role of hepatic metabolism in thyroid insufficiency: thyroid cancers, fipronil, 
PBDE/perfluorinated compounds/PCBs case studies 
• Better measures of down-stream effects of thyroid-disrupting chemicals: 
mancozeb, PBDE/perfluorinated compounds/PCBs, thyroid cancer case studies 
• The relevance of thyroid tumours that arise via TH insufficiency: thyroid cancer 
case study 
The case studies of fipronil, mancozeb, perchlorates and PBDEs/perfluorinated 
compounds/PCBs follow a common structure with the following headings: 
 Summary 
 Scope and aims of the case study 
 The substance and its uses 
  
 
 Observations from human studies with relevance to thyroid disruption 
 Observations from experimental studies 
Due to the nature of the subject matter, the case study on thyroid cancers and the role 
of thyroid hormone insufficiency somewhat deviates from this scheme. 
 
5.1 FIPRONIL CASE STUDY 
5.1.1 Summary 
The fipronil case study can be used as a starting point for exploring and discussing 
thyroid disrupting compounds that increase thyroid hormone (TH) clearance, via 
induction of liver enzymes, and the human relevance of this molecular initiating event 
(MIE).  
The effects of the insecticide fipronil on the thyroid hormone system have been 
investigated in a substantial number of repeated-dose toxicity studies.  Results from 
these studies have been included in the present case study based on study summaries 
from the EFSA Draft Assessment Report (DAR) (2004) and on peer reviewed papers 
found in the open literature. From all these studies, the same picture emerges, namely 
that in rats fipronil causes marked decreases in circulating levels of thyroxine (T4), even 
at very low oral doses (0.02 & 0.06 mg/kg/day). Increased TSH levels, increased thyroid 
gland weights and thyroid follicle hypertrophy have been consistently found at somewhat 
higher exposure levels (1.5 and 13-16 mg/kg/day) (DAR 2004, Leghait et al 2009). A 
statistically significant increase in incidences of follicular cell tumours has been observed 
in an oncogenicity study in rats (13-16 mg/kg/day) (DAR 2004). The mechanism behind 
the adverse effects on the thyroid hormone system is likely via induction of liver enzymes 
that contribute to increased TH clearance, since increases in the activity and mRNA 
expression of two types of phase II hepatic enzymes, the uridine 5’-diphospho (UDP)-
glucuronosyltransferases (UGT) and the sulfotransferases (SULT) have been observed 
after fipronil exposure (DAR 2004, Leghait et al. 2009, Roques et al 2012). The main 
metabolic pathway in the liver, leading to formation of the active metabolite, fipronil 
sulfone, is mediated by cytochrome P450 (CYP) enzymes, and is at least partly controlled 
by the constitutive androstane receptor (CAR) and pregnane X receptor (PXR) (Roques et 
al. 2013). 
Repeated-dose toxicity studies on fipronil have also been performed in mice, dogs and 
sheep. A study by Ferreira et al (2012) indicated that mice exposed to fipronil showed 
histopathological alterations in their thyroid tissues. In contrast, no thyroid toxicity was 
observed in a life-time cancer study in mice, and no thyroid toxicity has been seen in 
subchronic repeated dose toxicity studies in dogs (DAR 2004). In toxicity studies 
performed in sheep, an animal model more closely resembling  human thyroid 
physiology,  moderate alterations in free thyroxine (T4) clearance have been observed, 
but this did not lead to any adverse effects on thyroid hormone levels (Leghait et al 
2010). The reason for the species difference between sheep and rats could be that in 
sheep the concentrations of the active metabolite (fipronil sulfone) in plasma were much 
lower compared to rats (Leghait et al 2010). 
One aim of the present case study is to discuss the relevance of the rat as a model for 
assessing the risk of chemically induced thyroid disruption in humans, focusing on 
compounds which induce liver-mediated increase in TH clearance. Throughout the case 
study, several questions related to this subject are therefore discussed. Should 
chemically induced adverse effects in the rat thyroid system be viewed as relevant to 
humans? Are such alterations a sign of endocrine disruption, if they are mediated via the 
liver? Is this mode of action occurring in humans? And are statistically significant 
reductions in circulating T4 level in rats toxicologically relevant, in the absence of effects 
on other thyroid endpoints? 
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At the end of the present case study data from fipronil studies have also been compared 
to data from rats exposed to the biocide triclosan. Like fipronil, triclosan exposure 
decreases circulating T4 levels by induction of liver enzymes, via CAR/PXR. Until recently 
this MIE appeared to be the only relevant one for triclosan, however new research has 
shown that triclosan also binds to the carrier protein transthyretin (TTR) (Weiss et al 
2015). This binding could be an additional explanation for the observed decrease of free 
circulating T4 caused by triclosan. In contrast to fipronil, triclosan did not affect TSH 
levels in any of the performed studies. The implications of this difference contribute with 
an additional point of discussion in the present case study. 
   
5.1.2 Scope and aims of this case study 
The aspect of thyroid disruption which will be discussed, based on the present case 
study, is the relevance of the rat as a model for humans in the context of thyroid 
disruption caused by liver enzyme induction. More specifically, the following questions 
will be addressed, both in relation to their scientific implications and their regulatory 
significance and impact: 
- Are chemically induced adverse effects to the liver, and hence the thyroid gland, 
in rats relevant to humans?  Such effects have in “classical toxicology” often been 
dismissed as irrelevant, since rats (due to species differences in T4 half- lives and 
in carrier proteins) have been viewed as particularly sensitive to disturbances in 
their thyroid hormone system. However, more recent research has shown that 
half lives of the active hormone (T3) are much more similar in both species, and 
that TTR is the main physiologically relevant distributor in humans, perhaps 
making the “classical“arguments outdated?  
- Are effects on the hypothalamic-pituitary-thyroid (HPT) axis in rats (e.g. increased 
TSH or altered thyroid gland morphology) signs of endocrine disruption if they are 
attributed to a liver-mediated mechanism? And is this mode of action relevant 
when discussing endocrine disruption in humans?  
- Are statistically significant reductions in circulating T4 level in rats toxicologically 
relevant, in the absence of effects on TSH and thyroid gland weight and 
histopathology, and can/should significant T4 decreases in themselves be used for 
setting NOAEL/LOAEL values? 
In order to address these discussion points, the present case study includes information 
from fipronil studies found in the open literature as well as data from the EFSA Draft 
Assessment Report for Fipronil (DAR 2004). However, the presented case is not meant to 
be an exhaustive substance review, so only data relevant to the above mentioned 
specific discussion points is presented here.  
In order to properly address the last bullet point, data from Fipronil is compared and 
contrasted to data from the biocide triclosan, which also causes decreases in circulating 
T4 levels, but where no other apparent adverse effects on the HPT-axis are seen. 
Data from a developmental neurotoxicity study (US EPA guideline 1991) on Fipronil are 
also presented in the EFSA DAR (2004). These data showed that fipronil-exposed 
hypothyroxinemic dams gave birth to offspring which did not show deficits in motor 
activity or learning behaviour, as would have been expected after developmental 
hypothyroidism. These results will be discussed in the case study on Mancozeb, where 
the consequences of maternal TH insufficiency for the offspring will be discussed. 
5.1.3 Fipronil and its uses 
Fipronil (fluocyanobenpyrazole) is a widely used, second-generation phenilpirazol 
insecticide that is used in agriculture and veterinary medicine for protection against fleas, 
ticks, ants, cockroaches and other pests. The insecticide blocks the chloride channels 
associated with gamma-amino butyric acid (GABA) and glutamate (Glu) receptors in 
insects (Magalhães et al 2015). 
  
 
5.1.4 Observations from human studies with relevance to thyroid 
disruption 
The only epidemiology study that has investigated the associations between fipronil 
exposure and thyroid function in humans is that by Herin et al. (2011). The primary 
objective of the study was to test the hypothesis that chronic occupational fipronil 
exposure could be associated with abnormal thyroid function. In this study, 159 workers 
of a factory manufacturing fipronil-containing veterinary drugs were assessed, and serum 
concentrations of TSH, total thyroxine, free thyroxine, fipronil, and fipronil sulfone were 
measured. Positive and significant correlations were observed between serum fipronil 
levels or levels of the main metabolite, fipronil sulfone, and duration of fipronil exposure. 
No significant increases in thyroid function test abnormalities were seen, with increased 
exposures, but serum fipronil sulfone concentrations were negatively correlated with TSH 
concentrations. This is a pattern opposite to what is seen in rat studies, where TSH levels 
increase after fipronil exposure, which raises the possibility that in humans, fipronil could 
have a central inhibitory effect on TSH secretion. Larger epidemiological studies would be 
desirable in order to confirm and elaborate on these findings.  
5.1.5 Observations from experimental studies 
5.1.5.1 Toxicity studies performed in rats 
In the EFSA DAR on fiprionil (2004), results not published in the open literature from a 
substantial number of repeated-dose toxicity studies in rats investigating thyroid 
disruption are presented. For some of the study results, tables are available in the DAR, 
whereas other results are concluded upon, but not shown.  In all of the performed 
studies (28-day, 90-day, 2 year and 2-generation studies) oral fipronil exposures caused 
decreases in circulating levels of thyroxine (T4) in rats. Even at very low doses (0.02 & 
0.06 mg/kg/day) statistically significant decreases in T4 levels were seen, whereas 
increased TSH levels, increased thyroid gland weights and thyroid follicle hypertrophy 
were consistently found at somewhat higher exposure levels (1.5 mg/kg/day and above, 
in repeated dose-, oncogenicity- and 2-generation study) (DAR 2004). Generally, the 
doses required to induce adverse effects on the thyroid hormone system decreased with 
prolonged exposures to fipronil. In the oncogenicity study in rats, exposure to 13-16 
mg/kg/day also significantly increased incidences of follicular cell tumors in both males 
and females (DAR 2004).  
These unpublished studies have been complemented recently by studies available in the 
open literature. In 2009, Leghait et al published the first such study investigating the 
effects of fipronil exposure in rats, with the aim of evaluating the effects of fipronil on 
thyroid hormone (TH) concentrations and elimination. In thyroid-intact female rats, 
fipronil treatment at oral doses of 3 mg/kg bw/day for 14 and 28 days decreased both 
total and free TH plasma concentrations. Accordingly, thyroid stimulating hormone (TSH) 
plasma levels increased. Plasma concentrations of fipronil’s main metabolite, fipronil 
sulfone, were at least 20-fold higher than those of fipronil. Thyroidectomized + T3 
supplemented (euthyroid-like) rats were hereafter used to evaluate both total and free 
T4 clearances. This study showed that fipronil treatment induced a twofold increase in 
total and free T4 clearances. The treatment was also associated with an increase in 
hepatic microsomal 4-nitrophenol UDP-glucuronosyltransferase activity involved in T4 
glucuronidation. Thus, fipronil-induced thyroid disruption was likely mediated by 
increased hepatic enzyme activity (Leghait et al 2009).  
The same research group continued research in this area and investigated whether 
fipronil biotransformation into fipronil sulfone by hepatic cytochromes P450 (CYP) could 
act as a potential thyroid disruptor. The aim of this study was to determine if fipronil 
sulfone treatment could reproduce the fipronil treatment effects on T4 clearance and CYP 
induction in rats. The study showed that both fipronil and fipronil sulfone treatments 
increased total and free T4 clearances to the same extent, using THX + T3, euthyroid-
like rats. Both treatments induced a 2.5-fold increase in Ugt1a1 and Sult1b1 messenger 
RNA (mRNA) expressions and a twofold increase in UGT1A activity suggesting that T4 
elimination was mediated, at least in part, by hepatic uridine 5'-diphospho-
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glucuronosyltransferases (UGT) and/or sulfotransferases (SULT) induction. Both 
treatments induced a 10-fold increase in Cyp3a1 and Cyp2b2 mRNA expressions, 
concomitant with a threefold increase in CYP3A immunoreactivity and a 1.7-fold increase 
in antipyrine clearance, a biomarker of CYP3A activity. All these results showed that 
fipronil sulfone treatment could reproduce the fipronil treatment effects on T4 clearance 
and hepatic enzyme induction in rats. The authors concluded that the potential of fipronil 
sulfone to act as a thyroid disruptor was all the more critical, because it persists much 
longer in the organism than fipronil itself (Roques et al 2012).  
Investigations of the pathways involved in fipronil-induced liver gene expression 
regulations have continued by hepatic gene expression studies of rats treated with 
fipronil or vehicle. Fipronil treatment led to the upregulation of several genes involved in 
the metabolism of xenobiotics, including the cytochrome P450 Cyp2b1, Cyp2b2 and 
Cyp3a1, the carboxylesterases Ces2 and Ces6, the phase II enzymes Ugt1a1, Sult1b1 
and Gsta2, and the membrane transporters Abcc2, Abcc3, Abcg5, Abcg8, Slco1a1 and 
Slco1a4. Based on the large overlap with the target genes of constitutive androstane 
receptor (CAR) and pregnane X receptor (PXR), the authors postulated that these two 
nuclear receptors are involved in mediating the effects of fipronil on liver gene expression 
in rodents (Roques et al 2013).  
Recently Magalhaes et al (2015) tested the effects of fipronil in pregnant rat dams. A 
commercial product containing fipronil (0.1, 1 and 10 mg/kg/day) was administered 
orally to pregnant Wistar rats (n=10) from the 6th to the 20th day of gestation. The 
authors found an increase in maternal aggressive behaviour on PND 6, and concluded 
this to be mediated through effects on GABA(A) receptors, but saw no adverse effects on 
maternal thyroid gland histopathology (Magalhaes et al 2015). Unfortunately, thyroid 
hormone levels were not assessed. Since several previous studies in rats have shown 
fipronil to adversely affect thyroid gland weight and histopathology in rats at similar dose 
levels, it is most likely the relatively short time of exposure (2 weeks) chosen for this 
study explains why no adverse effects on thyroid histopathology were seen. 
5.1.5.2 Toxicity studies performed in other species 
In 2010, Leghait et al. performed a study in sheep. This species is more similar to 
humans compared to the rat, as far as thyroid carrier proteins are concerned. Sheep 
express thyroid binding globulin (TBG) at levels similar to those in humans and, unlike in 
the rat, this expression is not developmentally regulated.  Moreover, ovine TBG has 
pharmacological properties, such as T4 maximal binding capacity and affinity, close to 
those of human TBG. Since however new data suggests that TTR is the more relevant 
carrier protein in humans (Alshehri et al 2015), the species similarities between human 
and sheep may from a toxicological point of view be less important than first assumed.  
In the study in thyroidectomised T3-treated euthyroid like rams, a dose of 5 mg/kg of 
fipronil every 4 days for 11 weeks did not modify secretory profiles of TSH, tT3 and tT4 
and only a moderate effect on free T4 clearance was observed. According to the authors, 
one reason for this marked species difference between rats and sheep could be the 
differences in internal exposures to the active metabolite fipronil sulfone (Leghait et al 
2010), which is responsible for the adverse effects on the rat thyroid hormone system 
(Roques et al 2012). In rats which were continuously dosed with fipronil, the fipronil 
sulfone/fipronil ratio at steady state was higher than 40 (Leghait et al 2010), whereas in 
sheep this ratio was below 1 for the first 24 hours following administration, and 
fluctuated between 3 and 6 at steady state . This means that in sheep the concentrations 
of the active molecule may not have been high enough to induce adverse effects on the 
thyroid hormone system (Leghait et al 2010). In the Fipronil DAR (DAR 2004) repeated 
dose toxicity studies in dogs and mice are also reported. In one of the studies performed 
in beagle dogs (n=2/sex) exposed to 1, 10 or 20 mg/kg /day  for 3 weeks, T3, T4 and 
TSH levels were reported not to be significantly affected (though these data were not 
actually shown in the DAR report). Furthermore, after 6 weeks of treatment no effect on 
thyroid histopathology was evident (these data were not shown either). The highest dose 
in this study caused signs of systemic toxicity (weight loss) and the two highest doses 
caused adverse effects in the neurological examinations, indicating that in dogs adverse 
  
 
neurological effects of fipronil seem to be the critical endpoint. A 90-day toxicity study 
and two 1-year toxicity studies in dogs were also summarized in the DAR. These studies 
focused on examining adverse neurological effects of fipronil, and there was no 
mentioning of TH levels, thyroid weights or –histopathology. It is therefore difficult to 
determine whether these endpoints were not affected or simply not assessed in the latter 
dog studies.    
Whether thyroid gland weights and histopathology was investigated in a carcinogenicity 
study performed in mice is also somewhat difficult to assess, based on the information 
presented in the DAR. In this study, adult mice (n=20/sex) were exposed to low doses of 
fipronil (0.01 – 3.5 mg/kg bw/day) for 78 weeks. No adverse effects on thyroid weights 
or histopathology were mentioned in the DAR. Whether thyroid endpoints were actually 
investigated in the performed mouse study, is somewhat unclear, since the methods 
section in the DAR only stated that “selected organs were weighed and a comprehensive 
range of tissues preserved”. But as the study was a carcinogenicity study performed 
according to a USEPA guideline (1984), it seems reasonable to assume that thyroid 
tissue was assessed and found not to be affected by the tested doses of fipronil. If this is 
indeed the case, this indicates a clear species difference in sensitivity of thyroid effects 
between mice and rats for this compound. Ferreira et al (2012) have published a study in 
which female mice (n=5) received IP injections with fipronil for 7 days, at doses of 15, 25 
and 50 mg/kg bw/day. In this study the authors only investigated thyroid histopathology, 
and the publication unfortunately did not state whether these relatively high doses of 
fipronil caused any signs of systemic toxicity. It furthermore seems that the authors did 
not perform any statistical analysis of the data, but simply compared the histological 
appearance of slides from different exposure group. The results from this study are 
therefore not very reliable, but if indeed correct, they indicate that high doses of fironil 
could cause alterations in the thyroid tissue in mice, with follicular disorganization and 
decreased size of most follicles. The authors further claimed to have shown that the 
action of fipronil not only caused disorganization in the thyroid tissue, but also altered 
the chemical composition of the colloid itself (Ferreira et al 2012). These results will have 
to be repeated in a larger and better designed study, in order to assess whether 
histopathology of mouse thyroid glands is indeed affected by fipronil exposure.  
Roques et al (2013) investigated whether the fipronil-induced changes in liver gene 
expression seen in rats could be reproduced in mice, and further studied the effects of 
fipronil in wild-type, CAR- and PXR-deficient mice. They found that fipronil treatment and 
the subsequent induction of CAR and PXR thyroid-related target genes in mouse liver was 
not associated with a marked increase of total T4 clearance, as observed in rat (Roques 
et al 2013). In the CAR and PXR deficient mice, for most of the genes studied, gene 
expression modulations were abolished in the liver of PXR-deficient mice, but were only 
reduced in CAR-deficient mice, indicating that PXR may be more involved in mediating 
the effect of fipronil on liver gene expression than CAR (Roques et al 2013).  Previous 
studies have shown that other liver enzyme inducers which activate CAR and PXR, also 
have smaller effects on UDP-glucuronosyltransferase activity in mice compared to rats 
(Viollon-Abadie et al 1999). Thus, different regulation of phase II glucuronidation 
enzymes in mice and rats may well contribute to the different sensitivities of these 
species, in regards to compounds causing increased thyroid hormone clearance such as 
fipronil (Roques et al 2013).  
Taken together, the results of thyroid disruption in other species than rats do indicate 
that fipronil-induced thyroid hormone clearance seems to be much more marked in rats, 
than in dogs, sheep or mice. However, for several of the (non-rat) studies presented in 
the DAR, it was difficult to determine whether the thyroid gland can be ruled out as the 
target organ, or whether this was just not properly assessed. Fipronil sulfone is the main 
fipronil metabolite in rats, sheep and humans (Leghait et al 2010). However, the rate of 
fipronil sulfone formation is about fourfold higher in rat liver microsomes than in human 
ones (Tang et al., 2004), and accidental human exposure to fipronil has indicated that 
the ratio of fipronil sulfone/fipronil plasma concentrations at 24 h post-ingestion is about 
0.25–0.5 (Mohamed et al., 2004). This quantitative difference in fipronil metabolism 
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could by some be interpreted as a reason not to use the results from toxicity studies of 
fipronil performed in rats for human risk assessment. However, given the long half-life of 
firponil sulfone, it is very likely that after long term exposure in humans, the internal 
exposures of fipronil sulfone will be higher than those of the parent compound itself. 
Therefore human internal exposures have to be thought of in terms of exposure to the 
metabolite, and the fact that this fipronil sulfone is more efficiently and rapidly produced 
in the rat compared to humans and sheep, does not change the overall possibility of 
adverse effects occurring.  
Another point which is evident from the present case study is the importance of 
toxicokinetic data of compounds under investigation for thyroid disruption. In chemical 
registration dossiers this information is sometimes present from rat models, but often not 
available from any other species. Such information can however be very useful or even 
necessary when deciding how relevant an animal model is in relation to human risk 
assessment. 
5.1.5.3 In vitro and mechanistic studies 
Fipronil and fipronil sulfone have also been investigated for endocrine disrupting 
mechanisms in vitro.  In a thyroid hormone receptor (TRβ) assay, only fipronil sulfone 
showed anti-thyroid hormone activity with a RIC20 of 8.2 × 10(-7)M
1. Furthermore, 
molecular docking was employed to support the results in TR assay with lower MolDock 
score for fipronil sulfone (Lu et al 2015).  
Mitchell et al (2016) investigated transcript levels in primary human hepatocytes exposed 
to fipronil. Fipronil exposure was very effective in eliciting changes, as RNA-Seq showed 
that fipronil at 10 μM increased the levels of 2246 transcripts and decreased the levels 
for 1428 transcripts (Fipronil was 21-times more effective than the insect repellent DEET 
(N,N-diethyl-m-toluamide) even though the treatment concentration was 10-fold lower). 
The data indicated that fipronil can regulate the gene expression of several classes of 
phase I, II and III enzymes/ transporters some of which are potentially involved in 
hepatic thyroid hormone metabolism. In some instances, the pattern of regulation was 
similar to that seen in rodents, for example up-regulation of Cyp3A4, SULT1B1, 
SULT1A1, SYLT1C2. In other instances, the pattern differed between rodent and human. 
For example, deiodinase I gene expression was shown to be upregulated in response to 
fipronil in human hepatocytes, while it was not significantly affected in the mouse liver 
(Roques et al., 2013). 
Although this study was limited to gene expression in vitro and did not address protein 
expression and/or functional endpoints, those data indicate that human hepatocytes cells 
might, as rodents, respond to fipronil exposure through hepatic enzyme induction 
including pathways that are related to TH metabolism. However, nothing in the study 
allows the reader to determine if the pattern of exposure of the primary hepatocytes is 
similar to hepatic exposure in vivo, in particular in terms of fipronil-sulfone. In addition, if 
it is clear that there are qualitative similarities between human and rodent in the way 
thyroid-related hepatic metabolic pathways respond to fipronil and/or its metabolite 
exposure, there is so far no available data allowing a quantitative assessment of the 
similarities/discrepancies between the two species. All in all, the changes found in 
transcript levels in response to treatments will require further research to understand 
their importance in overall cellular, organ, and organismic function (Mitchell et al 2016). 
 
5.1.5.4 Is thyroid disruption in rats, mediated through increased liver 
catabolism, of toxicological relevance for humans? 
When performing toxicity studies in the rat, the tacit assumption is that the results can 
be used for human risk assessment, unless the adverse effects are caused by 
mechanisms which have specifically been shown not to be relevant for humans.  This 
                                                 
1
 RIC20: the concentration of the test chemical showing 20% of the antagonistic activity of 1 x 10
-8
 T3 via TRβ 
  
 
may possibly be applicable to the case of thyroid tumors in rats, in relation to identifying 
human carcinogens. In rats, a long period of overstimulation of the thyroid gland by 
increased TSH due to TH insufficiency will lead to thyroid tumor formation. So far, thyroid 
tumor development due to overstimulation of the thyroid gland by TSH has been 
considered unlikely in humans, however given both the epidemiological evidence and the 
considerations discussed in the case study dealing with thyroid tumors, this opinion may 
need to be revised.  
But apart from the discussions of thyroid carcinogenesis, possible species differences in 
relation to thyroid tumors are often used to dismiss all thyroid related effects in rats as 
being irrelevant for humans. An example of this was found in the Fipronil DAR, where the 
following text is included in the discussion of the repeated dose/oncogenicity study in 
rats (DAR 2004 -Annex B6, p. 155): “The thyroid gland in rats is particularly sensitive to 
disturbances in thyroid hormones compared to the human thyroid. Therefore the effects 
in this study, particularly the increase incidence of follicular cell tumors at the highest 
concentration, may have no relevance to humans”. This and similar arguments are often 
put forward in chemical registration dossiers and pesticide DARs, in order to dismiss not 
only thyroid cancer findings in rat studies, but all other indications of thyroid disruption. 
The toxicological stance of dismissing the rat as a predictor for any thyroid effects in 
humans is at least partly based on the premise that rats are believed not to have 
thyroxin binding globulin (TBG). However, TBG is expressed in rats, but varies according 
to age. In adult rats, its levels are low between 2-7 months of age (Savu et al 1991, 
Vranckx et al 1990, & 1989, Savu et al 1987) and transthyrethin (TTR) is the dominant 
T4 plasma carrier in adult rats. TTR has a lower affinity for T4 and is therefore less 
efficient in binding T4 than TBG. The primary function of carrier proteins is extrathyroidal 
storage of thyroid hormones to ensure sustained hormone action across tissues, and this 
contributes to the control of TH homeostasis and protection from peripheral elimination 
(Hurley 1998). Thus, in species in which TBG is not the major T4 carrier, the free fraction 
of the T4 is larger than in humans and total T4 half-life is shorter (around 24h in rats, 
versus 5-6 days in humans)   (Lewandowski et al 2004). For these reasons, the 
toxicological effects on thyroid function that derive from increased thyroid hormone 
catabolism in the rat have often been considered irrelevant to humans. However, even 
though TBG is the major and specific transport protein of thyroid hormones (TH) in 
humans, it has recently been shown not to be the physiologically most relevant (Alshehri 
et al. 2015). The most physiologically relevant carrier protein in humans is also TTR. 
Furthermore, the differences in half- lives of the active hormone T3 between rats and 
humans are much smaller than for T4, as T3 half-lives for humans are 22-24 h (Jonklaas 
et al 2015) and around 6h in rats (Lewandowski et al 2004). Based on these more recent 
findings, the previous assumptions about large qualitative species differences in thyroid 
hormone economy between rats and humans may be incorrect, and should not be used 
to dismiss the rat as a predictor for all thyroid related effects in humans.  
Furthermore, for TH insufficiency observed in the rat (as a result of induction of hepatic 
metabolism) to be dismissed as irrelevant to human risk assessment, robust results 
showing that liver enzyme induction leading to increased thyroid hormone (TH) clearance 
cannot occur in humans, would be needed. Such observations however do not exist. On 
the contrary, there is some evidence that chemical agents (primarily drugs) capable of 
inducing hepatic metabolism can affect T4 levels in humans. In a review paper by 
Ennulat et al (2010) it is stated that: “Effects of hepatic drug metabolizing enzymes 
(DME)-inducing agents on circulating thyroid hormone levels have been reported in a few 
human studies. In particular, the UGT1A enzymes facilitate T4 excretion and are induced 
by a wide variety of agents that activate human PXR, CAR, and/or AhR (Xie et al. 2003; 
Kato et al. 2008). Accordingly, decreased serum T4 and free T4 (fT4) in volunteers given 
rifampicin alone or with Phenobarbital or antipyrine for fourteen days were attributed to 
increased UGT-mediated T4 turnover (Ohnhaus and Studer 1983)”. Ennulat et al. 
conclude that “(…) the collective human literature suggests that little to no effect on 
thyroid function occurs in otherwise healthy subjects given DME-inducing agents. 
However, in persons with underlying thyroid conditions, increased incidence of 
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hypothyroidism has been infrequently reported in association with phase II enzyme-
inducing therapies (Takasu et al. 2006)”. The literature also provides evidence that this 
MIE can occur in humans, from studies of antiepileptic drugs.  For example, the effect of 
the drug 5,5'-diphenylhydantoin was examined in healthy volunteers, and it was shown 
that during oral administration, plasma thyroxine concentration decreased to about 80% 
of its pretreatment level, due to increased hepatic metabolism (Larsen et al 1970). 
Together, these studies indicate that we should not dismiss this mode of action as 
irrelevant for humans.  
5.1.5.5 Should adverse effects on the HPT-axis be viewed as endocrine 
disruption, if caused by increased liver catabolism? 
In relation to the importance of the mode of action by which a chemical induces thyroid 
disruption, a recent Joint Research Centre publication (JRC 2016) stated that: 
 
“Histopathological findings in rat thyroid and increased thyroid weight in presence of liver 
histopathology (including liver enzyme induction) were attributed to a liver-mediated 
mechanism not considered to be ED-mediated. Since in the frame of this screening 
methodology enhancement of the metabolism and excretion of thyroid hormones by the 
liver was not considered as an endocrine MoA, such effects were not considered relevant 
to conclude on ED”  
 
This statement is probably included in the JRC report because increased TH clearance 
due to liver effects is often considered as secondary, and not a primary endocrine 
disrupting effect. Hence, it would be possible to protect against TH insufficiency by 
regulating in relation to a “liver threshold” below which hepatic enzymes are not induced 
and consequently TH insufficiency cannot occur. On the other hand, an endocrinological 
perspective would not class TH clearance as a “secondary” effect, and rather evaluate 
this in the context of a balance between hormone-synthesising and –removing processes. 
From this point of view, it would be unusual and problematic to discard hepatic effects 
leading to increased TH clearance as “secondary” or not relevant for designating a 
chemical as a thyroid disruptor.  Additionally, activation of liver enzymes by a chemical 
could be reversible and/or not viewed as adverse; however, effects on target tissues 
(e.g. foetal brain) of thyroid hormone insufficiency during development caused by 
activation of liver enzymes in a pregnant animal would not be reversible and would not 
be considered “non-adverse” (Bellanger et al 2015). 
5.1.5.6 How to interpret significant reductions in circulating T4 level in 
rats, in the absence of other effects on thyroid endpoints? 
Another relevant example from the Fipronil DAR could be used for the discussion of the 
relevance of T4 decreases without any other concurrent effects on the thyroid hormone 
system. In the discussion of the repeated dose/oncogenicity study in rats (DAR 2004 -
Annex B6, p. 155) it is concluded that “slight [though significant and dose-related] 
effects on circulating T4 were noted at 0.5 and 1.5 ppm [the lowest tested doses] but in 
the absence of any morphological alterations and any concurrent effects on T3 or TSH, 
are not considered to be of toxicological importance”. This argument is also often seen in 
other chemical registration dossiers or pesticide DARs, in relation to interpretation of 
possible thyroid hormone disturbances. 
One example of a compound which in rat studies has been shown to effectively reduce T4 
levels, but only seems to induce very few other effects on the HPT-axis is the biocide 
triclosan. Triclosan has some years ago been shown to up-regulate both mRNA 
expression and activity of some phase I and phase II hepatic (PROD and UGT) enzymes 
in in vivo studies (Paul et al., 2010a), but more recent studies have shown that triclosan 
also has a very high affinity for TRR, actually higher than T4 itself (Weiss et al 2015). The 
key events leading to reduced T4 levels after triclosan exposure could therefore be 
displacement of T4 from TTR, together with induction of liver enzymes that induce 
increased T4 clearance and lower circulating T4 levels. 
  
 
Several in vivo triclosan studies have been performed at the US EPA, using different 
strains of rats and exposure periods. These studies have revealed that even a few days 
of triclosan exposure reduces circulating T4 levels in rats. Doses of and above 100 mg/kg 
bw/day caused marked T4 decreases in the first studies (Crofton et al. 2007, Paul et al., 
2010a), whereas results from a uterotrophic assay showed that even doses of 18.75 
mg/kg bw/day and above for three days, significantly reduced the levels of both free and 
total T4 (Stoker et al 2010). In studies investigating prolonged (3-5 weeks) exposure to 
triclosan, doses of 30 mg/kg bw/day and above were shown to cause marked reductions 
in circulating T4 levels (Zorilla et al, 2009, Stoker et al. 2010).  
In a developmental toxicity study, Paul et al (2012) found significant decreases in T4 
levels in dams on PND22 which had received triclosan at doses of 100 mg/kg bw/day and 
above during gestation and lactation. In the offspring, serum total T4 levels were 
significantly decreased in GD2O fetuses from the 100 and 300 mg/kg bw/day treatment 
groups, and in PND4 pups from the 300 mg/kg/day treatment group, but there were no 
effects on serum T4 levels in PND14 or PND21 offspring. 
This unique pattern of hypothyroxinemia, where serum T4 levels were decreased in 
fetuses and neonatal pups but not in older offspring had previously been seen in another 
developmental toxicity study of triclosan (Paul et al 2010b). This indicates that toxico-
kinetic/dynamic factors could have either reduced exposure or reduced the toxicological 
response in the offspring during the lactation period (Paul et al 2010b). Since serum and 
liver concentrations of triclosan demonstrated greater fetal than postnatal internal 
exposure, consistent with the lack of T4 changes in PND14 and PND21 offspring, this 
indicated that triclosan was probably only minimally transferred to the offspring through 
maternal milk (Paul et al 2012), but indeed argues for greater caution in terms of foetal 
exposure during pregnancy. A study by Axelstad et al (2013) confirmed this suspected 
minimal lactational transfer, showing that while triclosan exposed dams (50 and 150 
mg/kg/day) had low T4 levels during gestation and lactation, significant T4 decreases 
were not seen in the offspring on PND 16 in this study, but could be obtained if triclosan 
exposure was performed directly to the pups in the postnatal period (direct dosing from 
PND 3-16).  
In several of the above-mentioned studies, measurements of T3 levels were also 
performed, but in most of the studies were not found to be significantly affected by 
triclosan exposure, and the same holds true for TSH levels. T3 levels were however 
decreased at 300 and 1000 mg/kg bw/day in a study by Paul et al (2010). TSH levels 
were in this study not affected at doses up to 1000 mg/kg bw/day. The only other 
thyroid effect observed in the in vivo studies, was altered thyroid histopathology in one 
study, at a 10 times higher dose than the dose causing significant reductions in T4 (i.e. 
300 mg/kg bw/day for 5 weeks) in the study by Zorilla et al (2009). Triclosan therefore 
primarily seems to affect T4 levels and not the entire HPT-axis. 
Thus, the question in relation to chemical regulation is how to deal with such compounds. 
Based on a FIFRA Scientific Advisory Panel meeting in 2011 a report has been published 
by the US EPA (US EPA 2011. From the (at that time) available experimental data on 
triclosan, with decreases in T4 as the critical effect in rat studies,  an adverse outcome 
pathway for the effects of triclosan has been proposed, as shown in the figure below (US 
EPA 2011). 
 
 
 
5.1.5.7 Proposed adverse outcome pathway (AOP) for triclosan effects on 
the thyroid hormone system 
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According to this view, and based on human evidence linking developmental 
hypothyroxinemia with altered brain development in children, increased catabolism of 
thyroid hormones in rats (manifested as decrease in total levels of T4) is in this AOP 
linked to adverse neurological development (US EPA, 2011).  Because the fetus is 
dependent on maternal supply of thyroid hormones, decreased maternal T4 in early 
pregnancy means less T4 available for transfer to foetus. This could lead to decreased T4 
transfer to foetal brain, which could consequently have adverse neurodevelopmental 
effects. 
In the US EPA report (2011) the following argumentation for this causal link is used: 
There are multiple data sets associating the degree of disruption of thyroid function to 
adverse neurodevelopmental outcomes where the perturbations are mild to moderate. 
Haddow et al (1999) reported a 25% decrease in maternal free T4 during the second 
trimester in women and associated this with neurodevelopmental and cognitive eficits in 
children. Henrichs et al. (2010) associated maternal hypothyroxinemia with higher risk of 
verbal and nonverbal cognitive delay in early childhood. It should be noted that a 10% 
change is within normal experiment-to-experiment variation in control values, whereas 
the benchmark dose response (BMR) of 20% provides a more reliable BMR. The range of 
10-20% is interpreted as a balance between the biological and statistical significance of 
the reported changes in T4 and associated adverse outcomes.   
This reasoning is in contrast to the argument from the Fipronil DAR (but often 
encountered in other contexts as well) that Decreases in circulating T4 in the absence of 
any morphological alterations and any concurrent effects on T3 or TSH, are not 
considered to be of toxicological importance.  
Whether the experimental evidence for the link between decreased T4 and adverse 
effects on neurodevelopment is strong enough, for the authorities to regulate chemicals 
solely on the basis of decreased circulating T4 levels in rats, is therefore also a very 
important aspect to discuss in the present case study. 
5.1.6 References 
Alshehri B, D'Souza DG, Lee JY, Petratos S, Richardson SJ. 2015. The diversity of mechanisms 
influenced by transthyretin in neurobiology: development, disease and endocrine disruption. J 
Neuroendocrinol. 2015 May;27(5):303-23.  
Axelstad M, Boberg J, Vinggaard AM, Christiansen S, Hass U. 2013. Triclosan exposure 
reduces thyroxine levels in pregnant and lactating rat dams and in directly exposed 
offspring. Food Chem Toxicol.59, 534-540. 
Bellanger, Demeneix B, Grandjean P, Zoeller T, Trasande L 2015. Neurobehavioral 
deficits, diseases, and associated costs of exposure to endocrine-disrupting chemicals in 
the European Union. J Clin Endocrinol Metab. 2015 Apr;100(4):1256-66 
Crofton, K. M., Paul, K. B., Hedge, J. M., and DeVito, M. J. (2007). Short-term in vivo 
exposure to the water contaminant Triclosan: evidence for disruption of thyroxine. 
Environ. Toxicol. Pharmacol. 24, 194—197 
Draft Assessment Report (DAR) –public version. 2004. Initial risk assessment provided 
by the rapporteur Member State France for the existing active substance FIFRONIL of the 
second stage of the review programme referred to in Article 8(2) of the Council Directive 
91/414/EEC. January 2005. Downloaded from: http://dar.efsa.europa.eu/dar-
web/provision 
Ennulat D, Walker D, Clemo F, Magid-Slav M, Ledieu D, Graham M, Botts S, Boone 
L.2010. Effects of hepatic drug-metabolizing enzyme induction on clinical pathology 
parameters in animals and man. Toxicol Pathol. 2010 Aug;38(5):810-28 
 
  
 
Ferreira M, De Oliveira PR, Denardi SE, Bechara GH, Mathias MI.2011. Fipronil (active 
ingredient of acaricide Frontline®) acting on the mice thyroid. Microsc Res Tech. 2012 
Mar;75(3):265-70 
 
Haddow, J. E., et al. (1999): Maternal thyroid deficiency during pregnancy and 
subsequent neuropsychological development of the child. N. Eng. J. Med. 341(8): 549-
555.  
 
Henrichs, J. et al. (2010): Maternal Thyroid Function during Early Pregnancy and 
cognitive functioning in Early Childhood: The Generation R Study. J. Clin. Endocrinol. 
Metab. 95(9): 1-8. 
 
Herin F, Boutet-Robinet E, Levant A, Dulaurent S, Manika M, Galatry-Bouju F, Caron P, 
Soulat JM. 2011. Thyroid function tests in persons with occupational exposure to fipronil. 
Thyroid. 2011 Jul;21(7):701-6  
 
Hurley, P.M., 1998. Mode of carcinogenic action of pesticides inducing thyroid follicular 
cell tumors in rodents. Environ. Health Perspect. 106, 437–445. 
Jonklaas J, Burman KD, Wang H, Latham KR.2015. Single-dose T3 administration: 
kinetics and effects on biochemical and physiological parameters. Ther Drug Monit. 2015 
Feb;37(1):110-8. 
JRC 2016, Screening methodology to identify potential endocrine disruptors according to 
different options in the context of an impact assessment.  
https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-
reports/screening-methodology-identify-potential-endocrine-disruptors-according-
different-options 
 
Kato, Y., Suzuki, H., Ikushiro, S., Yamada, S., and Degawa, M. 2005. Decrease in serum 
thyroxine level by phenobarbital in rats is not necessarily dependent on increase in 
hepatic UDP-glucuronosyltransferase. Drug Metab Dispos 33, 1608–12. 
 
Lewandowski et al., 2004. Regulatory Toxicology and Pharmacology. 39, 348-362  
Lacroix MZ, Puel S, Toutain PL, Viguié C.2010. Quantification of fipronil and its metabolite 
fipronil sulfone in rat plasma over a wide range of concentrations by LC/UV/MS. J 
Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jul 15;878(22):1934-8.  
 
Larsen  PR, Atkinson AJ Jr, Wellman HN, Goldsmith RE.1970. The effect of 
diphenylhydantoin on thyroxine metabolism in man. J Clin Invest. 1970 Jun;49(6):1266-
79. 
Leghait J, Gayrard V, Toutain PL, Picard-Hagen N, Viguié C 2010. Is the mechanisms of 
fipronil-induced thyroid disruption specific of the rat: Re-evaluation of fipronil thyroid 
toxicity in sheep?  Toxicol Lett. 2010 May 4;194(3):51-7.  
 
Leghait J, Gayrard V, Picard-Hagen N, Camp M, Perdu E, Toutain PL, Viguié C. 2009. 
Fipronil-induced disruption of thyroid function in rats is mediated by increased total and 
free thyroxine clearances concomitantly to increased activity of hepatic enzymes. 
Toxicology. 2009 Jan 8;255(1-2):38-44.  
 
Lu M, Du J, Zhou P, Chen H, Lu C, Zhang Q. 2015. Endocrine disrupting potential of 
fipronil and its metabolite in reporter gene assays Chemosphere. 2015 Feb;120:246-51 
 
Magalhães JZ, Udo MS, Sánchez-Sarmiento AM, Carvalho MP, Bernardi MM, Spinosa HS. 
2015. Prenatal exposure to fipronil disturbs maternal aggressive behavior in rats. 
Neurotoxicol Teratol. 2015 Nov-Dec;52(Pt A):11-6 
 
 32 
 
Mitchell RD 3rd, Dhammi A, Wallace A, Hodgson E, Roe RM. 2016. Impact of 
Environmental Chemicals on the Transcriptome of Primary Human Hepatocytes: Potential 
for Health Effects. J Biochem Mol Toxicol. 2016 Aug;30(8):375-95.  
 
Mohamed, F., Senarathna, L., Percy, A., Abeyewardene, M., Eaglesham, G., Cheng, R., 
Azher, S., Hittarage, A., Dissanayake, W., Sheriff, M.H., Davies, W., Buckley, N.A., 
Eddleston, M., 2004. Acute human self-poisoning with the N-phenylpyrazole insecticide 
fipronil—a GABAA-gated chloride channel blocker. J. Toxicol. Clin. Toxicol. 42, 955–963. 
 
Ohnhaus, E. E., and Studer, H. 1983. A link between liver microsomal enzyme activity 
and thyroid hormone metabolism in man. Br J Clin Pharmacol 15, 71–76. 
 
Paul KB, Hedge JM, DeVito MJ, Crofton KM. 2010a. Short-term exposure to Triclosan 
decreases thyroxine in vivo via upregulation of hepatic catabolism in Young Long-Evans 
rats. Toxicol Sci 113, 367-79. 
 
Paul KB, Hedge JM, Devito MJ, Crofton KM. 2010b. Developmental Triclosan exposure 
decreases maternal and neonatal thyroxine in rats. Environ Toxicol Chem 29, 2840-4. 
 
Paul KB, Hedge JM, Bansal RR, Zoeller T, Peter R, DeVito MJ, Crofton KM. 2012. 
Developmental Triclosan exposure decreases maternal, fetal, and early neonatal 
thyroxine: A dynamic and kinetic evaluation of a putative mode-of-action. Toxicology 
300, 31— 45. 
 
Roques BB, Leghait J, Lacroix MZ, Lasserre F, Pineau T, Viguié C, Martin PG. 2013. The 
nuclear receptors pregnane X receptor and constitutive androstane receptor contribute to 
the impact of fipronil on hepatic gene expression linked to thyroid hormone metabolism. 
Biochem Pharmacol. 2013 Oct 1;86(7):997-1039.  
 
Roques BB, Lacroix MZ, Puel S, Gayrard V, Picard-Hagen N, Jouanin I, Perdu E, Martin 
PG, Viguié C.2012. CYP450-dependent biotransformation of the insecticide fipronil into 
fipronil sulfone can mediate fipronil-induced thyroid disruption in rats. Toxicol Sci. 2012 
May;127(1):29-41.  
 
Savu L, Vranckx R, Rouaze-Romet M, Maya M, Nunez EA, Treton J, Flink IL. A senescence up-
regulated protein: the rat thyroxine-binding globulin (TBG). Biochim Biophys Acta. 
1991;1097(1):19-22. 
 
Savu L, Vranckx R, Maya M, Nunez EA. A thyroxine binding globulin (TBG)-like protein in the 
sera of developing and adult rats. Biochem Biophys Res Commun. 1987;148(3):1165-1173 
 
Stoker, T.E., Gibson, E.K., and Zorrilla, L.M., (2010). Triclosan Exposure Modulates  
Estrogen-Dependent Responses in the Female Wistar Rat. Toxicological Sciences 117, 45-
53 
Takasu, N., Kinjou, Y., Kouki, T., Takara, M., Ohshiro, Y., and Komiya, I. 2006. Rifampin-
induced hypothyroidism. J Endocrinol Invest 29, 645–49. 
 
Tang, J., Amin Usmani, K., Hodgson, E., Rose, R.L., 2004. In vitrometabolism of fipronil 
by human and rat cytochrome P450 and its interactions with testosterone and diazepam. 
Chem. Biol. Interact. 147, 319–329. 
 
US EPA.Environmental Protection Agency (2011). Integrated approaches to testing and 
assessment strategy: use of new computational and molecular tools. FIFRA Scientific 
Advisory Panel Consultation, May 24—26, 2011. Arlington (VA): FIFRA Scientific Advisory 
Panel Meeting. Downloaded February 20107 from: 
https://yosemite.epa.gov/sab/sabproduct.nsf/373C1DB0E0591296852579F2005BECB3/$
File/OPP+SAP+document-May2011.pdf 
 
Viollon-Abadie C, Lassere D, Debruyne E, Nicod L, Carmichael N, Richert L. 1999. 
Phenobarbital, beta-naphthoflavone, clofibrate, and pregnenolone-16alphacarbonitrile do 
  
 
not affect hepatic thyroid hormone UDP-glucuronosyl transferase activity, and thyroid 
gland function in mice. Toxicol Appl Pharmacol 1999;155:1–12. 
 
Vranckx R, Rouaze M, Savu L, Nunez EA, Beaumont C, Flink IL. The hepatic biosynthesis of rat 
thyroxine binding globulin (TBG): demonstration, ontogenesis, and up-regulation in 
experimental hypothyroidism. Biochem Biophys Res Commun. 1990;167(1):317-322. 
 
Vranckx R, Savu L, Nunez EA. The microheterogeneity of rat TBG. FEBS Lett. 1989;244(2):343-
346. 
 
Weiss JM, Andersson PL, Zhang J, Simon E, Leonards PEG, Hamers T, Lamoree MH. 
2015. Tracing thyroid hormone-disrupting compounds: database compilation and 
structure-activity evaluation for an effect-directed analysis of sediment. Anal Bioanal 
Chem (2015) 407:5625–5634 
 
Xie, W., Yeuh, M. F., Radominska-Pandya, A., Saini, S. P., Negishi, Y.,Bottroff, B. S., 
Cabrera, G. Y., Tukey, R. H., and Evans, R. M. 2003. Control of steroid, heme, and 
carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane 
receptor. Proc Natl Acad Sci U S A 100, 4150–55. 
 
Zorrilla LM, Gibson EK, Jeffay SC, Crofton KM, Setzer WR, Cooper RL, Stoker 
TE.2009.The effects of triclosan on puberty and thyroid hormones in male Wistar rats. 
Toxicol Sci. 2009 Jan;107(1):56-64 
 
 
5.2 MANCOZEB CASE STUDY 
5.2.1 Summary 
The mancozeb case study can be used as a starting point for exploring and discussing the 
consequences of exposure to thyroid disrupting chemicals on the developing nervous 
system, i.e. explore the consequences of maternal (and early postnatal) thyroid hormone 
insufficiency in rats.  
 
Mancozeb is a fungicide from the dithiocarbamate family. These pesticides are widely 
used for the protection of fruits, vegetables, and field crops from fungal diseases. The 
main degradation product of many of the dithiocarbamates is ethylene thiourea (ETU) 
(WHO 1988), a compound that exerts various toxic effects in rats. The mode of action is 
believed to be through inhibition of the enzyme thyroid peroxidase (TPO) (Marinovich et 
al. 1997). The diminished production of T3 and T4 consequently increases TSH (thyroid 
stimulating hormone) release. The action of TSH causes thyroid follicular cell 
hypertrophy, changes in cell shape and loss of colloid from the thyroid follicle and 
increased thyroid weight, and conditions of prolonged exposure in rats leads to tumours 
of the thyroid gland. 
   
Mancozeb is a commonly sold fungicide in many countries, including  Norway (Nordby et 
al., 2005), and the United States (Acquavella et al., 2003). In an American agricultural 
health study, mancozeb exposure was strongly associated with increased incidence of 
thyroid disease in female spouses of pesticide applicators (Goldner et al., 2010), but 
most human studies have not shown any association between mancozeb exposure and 
adverse health outcomes. 
  
A vast number of repeated-dose toxicity and carcinogenicity studies have been 
performed with mancozeb, most of them in rats, but also in mice and dogs. Most of these 
studies have not been published in the open literature, and therefore assessment of this 
data was performed based on the summaries available in an EU draft renewal 
assessment report (DRAR, see Annex 1 & 3). The repeated dose toxicity studies have 
collectively shown that the thyroid is the major target organ of mancozeb, and that 
mancozeb, through its degradation to ETU, exerts numerous adverse effects related to 
the function of the thyroid gland.  
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The main aim of the present case study is to discuss the consequences of developmental 
exposure to a clearly thyrotoxic compound like mancozeb on neural development in the 
offspring, i.e. explore the consequences of maternal TH insufficiency in rats. This 
scientific problem has been investigated thoroughly in toxicity studies where 
developmental hypothyroidism has been caused by maternal PTU exposure or by 
thyroidectomy, and here the consequences for the offspring are quite clear (delayed 
development, decreased postnatal body weighs, hearing impairment, altered motor 
activity levels and deficits in learning and memory)(Akaike et al 1991, Brosvic et al 2002, 
Noda et al 2005, Goldey et al 1995, Kobayashi et al 2005). 
  
However, in contrast to what would be expected based on the clear disruptions by 
mancozeb of the thyroid hormone axis, no adverse effects on nervous system 
development have been observed in two developmental mancozeb studies (Beck 2008 in 
DRAR, see Annex 1, Axelstad et al 2011). Additionally, an extended one generation 
reproductive toxicity study (EOGRTS) with a DNT cohort has also been conducted with 
ETU, and here no adverse effects on brain development were seen either (Marty et al 
2013b, in DRAR).  
Therefore, the questions discussed in the present case study include the following:  
Why do marked maternal T4 reductions produced by certain chemicals lead to severe 
developmental neurotoxicity in the offspring, but not when such changes are produced by 
other chemicals, even though maternal T4 decreases during gestation are comparable?  
When are the critical windows of brain development in rats, i.e. does hypothyroxinemia 
have to occur both pre- and postnatally, if behavioral effects are to be evident in the rat 
offspring?  And are the present OECD test guidelines adequate for assessing the possible 
adverse effect on brain development caused by thyroid disruption, and if not, how could 
they be updated to include more sensitive downstream bioassay endpoints? 
   
5.2.2 Scope and aims of this case study 
In two developmental toxicity studies in rats, maternal TH insufficiency induced by 
macozeb exposure during gestation and lactation did not lead to any adverse 
neuropathological effects, or observable behavioral abnormalities in the offspring.  Thus, 
the mancozeb case study offers the opportunity of discussing the consequences of 
maternal TH insufficiency for the offspring, as well as the test methods presently used to 
assess this issue. The aspect of thyroid disruption which will be discussed in this case 
study are the downstream effects of maternal hytothyroxinemia/hyperthyroidism caused 
by a TPO inhibitor. More specifically, the following questions will be addressed, both in 
relation to their scientific implications and their regulatory significance/impact: 
 Why do marked maternal T4 reductions (e.g. ~50%) lead to severe developmental 
neurotoxicity effects when these are caused by PTU exposure, but not when caused 
by mancozeb (or ETU)? Since mancozeb exerts its thyroid disrupting effects through 
the same mode of action as PTU (inhibition of TPO), some aspects other than just the 
mode of action by which thyroid disruption is obtained, must be contributing to this 
difference in outcome. 
 When are the critical windows of brain development in rats, and is insufficient milk 
transfer of certain compounds the cause of these differences – i.e. does marked 
hypothyroxinemia/ hypothyroidism have to occur in both the pre- and postnatal 
period of rat brain development, if behavioural effects are to be evident in the rat 
offspring? 
 Or is brain development in the rat offspring in reality affected by all compounds 
causing prenatal hypothyroxinemia, but can the more subtle effects not be seen when 
using the test methods that are presently recommended/mandatory in OECD 
neurotoxicity guidelines?  
 What could be gained by updating the DNT guideline (along with the DNT cohort in 
the EOGRTs) with assessment of more sensitive downstream bioassay endpoints, and 
what should those be?    
  
 
In order to address these discussion points, the present case study includes information 
from mancozeb studies found in the open literature, and much data from the DRAR for 
Mancozeb with studies not available in the open literature. It is important to bear in mind 
that the presented case is not meant to be an exhaustive substance review, so only data 
relevant to the above mentioned specific discussion points has been presented.  
5.2.3 Mancozeb and its uses 
Mancozeb is a fungicide from the dithiocarbamate family. These pesticides are used for 
protection of fruits, vegetables, and field crops from fungal diseases worldwide (WHO, 
1988).  Mancozeb is a very commonly sold fungicide in Denmark (Danish EPA, 2010), 
Norway (Nordby et al., 2005), and the United States (Acquavella et al., 2003), and a 
recent publication shows that there are subpopulations around the worldwho experience 
very high mancozeb exposures (Van Wendel de Joode et al 2014). In this study 445 
pregnant women from Costa Rica, living in areas where mancozeb is aerially sprayed 
over banana plantations, were shown to have more than five times higher ETU 
concentrations in their urine, than those reported for other general populations. They 
also found that seventy-two percent of these women had estimated daily intakes above 
the RfD.  
5.2.4 Observations from human studies with relevance to thyroid 
disruption 
In 1997 Steenland et al published a paper investigating the effects of dithiocarbamate 
exposure on human thyroid hormone levels. Their relatively small study included 49 
heavily exposed Mexican workers who were spraying with mancozeb without protective 
equipment, 14 lightly exposed landowners and 31 non-exposed controls. Urinary ETU 
levels were used to compare exposure between groups. They found an increase in TSH (p 
= 0.05) among applicators compared to controls, which could indicate that effects on the 
thyroid gland of heavily exposed workers may occur, however no decreases in thyroid 
hormone (T4) were seen. In the American Agricultural Health Study, the authors 
examined the cross-sectional association between the use of several different pesticides 
and the risk of thyroid disease among female spouses (n = 16,529), and found that use 
of the fungicide maneb/mancozeb, was significantly associated with hypothyroidism 
(OR(adj) = 2.2 (95% CI: 1.5, 3.3) (Goldner et al 2010). A large Norwegian study based 
on the National registers in Norway (105,403 female and 131,243 male farmers, born in 
1925-1971, and their 300,805 children, born in 1952-1991) has shown a moderate 
association between mancozeb exposure and neural tube defects in newborns from 
farmer families, but no association between mancozeb exposure and thyroid cancer 
(Nordby et al., 2005). A few other epidemiology studies have also investigated 
associations between dithiocarbamate exposure and thyroid cancer, but have found none 
(De Fonso; 1976; Charkes et al, 1985; Vogel, 1990 in DRAR) 
In a recently published Italian epidemiology study (Medda et al 2017) the aims were to i) 
to evaluate thyroid effects of exposure to mancozeb in a sample of Italian grapevine 
workers, and ii) to verify whether the iodine intake may modulate the risk of thyroid 
disruption due to the mancozeb metabolite ethylenthiourea (ETU). 177 occupationally 
exposed male workers (29 from Chianti, a mild iodine deficient area, and 148 from 
Bolzano an iodine sufficient province) and 74 non-occupationally exposed male controls 
(34 from Chianti and 40 from Bolzano) were enrolled in the study. Serum biomarkers of 
thyroid function, as well as urinary iodine and ETU concentrations were assessed. 
Moreover all the recruited subjects underwent clinical examination and thyroid 
ultrasound. Multivariate comparisons showed lower mean serum levels of FT4 in Chianti-
workers as compared to Bolzano-workers. Moreover, an increased urinary iodine 
excretion (>250µg/L) was more frequently found among more exposed workers 
(ETU>20µg/L) than among less exposed ones and this effect was more pronounced in 
Chianti- than in Bolzano-workers. Chianti-workers also showed a significantly higher 
frequency of very low thyroid volume (≤6.0ml) as compared to controls. These findings 
indicated a possible mild thyroid disrupting effect due to occupational exposure to 
mancozeb, which was more pronounced in workers residing in an area characterized by a 
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mild to moderate iodine deficiency as compared to workers residing in an area covered 
by a long-lasting iodine prophylaxis program. 
5.2.5 Observations from experimental studies 
5.2.5.1 In vitro and mechanistic studies investigating thyroid 
disrupting mode of action 
The in vitro accivity of ethylenethiourea (ETU), the main metabolite of mancozeb, was 
tested in chinese hamster ovary (CHO) cells transfected with human TPO gene, at 
concentrations of 0.1 to 50 µM. In vitro cytotoxicity was assessed together with the 
effect on the thyroid peroxydase (TPO) activity. Shortly after ETU exposure to 
concentrations of 5 and 50 µM, TPO iodinating activity was markedly reduced, while 
cytotoxicity was unaffected, indicating that ETU blocks TPO iodinating activity even at low 
concentrations (Marinovich et al, 1997).  
Generally, in all of the performed in vivo studies with mancozeb and ETU, effects on 
circulating T4 levels tend to be seen at lower doses than those showing effects on thyroid 
weight and histopathology. This is consistent with TPO inhibition (and consequent 
reduction of T4) being the molecular initiating event (MIE). 
5.2.5.2 ADME studies on mancozeb and investigations of thyroid 
disrupting effects of ETU 
From the different ADME studies described in the DRAR, it appears that in mammals, 
mancozeb can be absorbed orally, dermally and by inhalation. It is rapidly metabolised 
into its breakdown products, the main one of these being ethylene thiurea (ETU) as 
demonstrated in rat, cow and human. ETU is notably found in several organs, but with 
the thyroid gland showing the highest level of 14C-containing residue. ADME studies have 
shown that the breakdown of mancozeb in rats and cows is quite similar. In cows, the 
level of 14C- containing residue in milk was about 1.5% of the ingested concentrations. 
Whether a similar percentage is transferred to the maternal milk of in rats and humans 
has not been investigated.  
Several studies in the DRAR describe how ETU is toxic to the thyroid hormone system in 
rats and other test species. Below is a short summary of these test results.  In the rat, 
ETU has been shown to affect the thyroid hormone system in the majority of the 
available repeated-dose toxicity studies. After ETU administration for 28 or 90 days (6 
studies in total), significant T4 and T3 decreases were seen at doses from 6-15 mg/kg 
bw/day and higher, whereas dosing for up to 120 days resulted in an effect level of 5 
mg/kg bw/day. All studies showed significant T4 decreases as the ‘first’ effect and altered 
thyroid weight, histopathology and TSH levels at the same or somewhat higher doses. In 
studies where ETU was administered for 2 years, changes in T4 and TSH were seen at 
doses from 1.25 mg/kg bw/day. Further evidence of disturbance of the HTP axis occurred 
at higher doses, with histopathological changes and thyroid follicular adenomas and 
carcinomas appearing at doses from 38 mg/kg bw/day in one study and from 9 mg/kg 
bw/day in another. 
In the mouse thyroid, ETU caused a similar spectrum of changes to those seen in the rat. 
In 28- and 90-day studies, changes in thyroid hormone levels, thyroid weight and 
histopathological findings were seen at doses from 17-20 mg/kg bw/day, and in a 2-year 
carcinogenicity study, ETU caused increased incidences of thyroid follicular adenomas and 
carcinomas at doses from 50 mg/kg bw/day. Administration of ETU to dogs and monkeys 
also caused disturbance of the HTP axis. After 52 weeks of ETU dosing in dogs, thyroid 
effects were seen at doses of 2 mg/kg bw/day and above, whereas ETU administration to 
monkeys caused adverse effects on T4, T3, TSH, thyroid weight and histopathology at 
dose of 2.5- 7.5 mg/kg bw/day.  
Based on this review of ETU data, there is no doubt that ETU, the main metabolite of 
mancozeb, disrupts the thyroid hormone system. The fact that adverse effects on the 
thyroid are seen in all the tested species (rat, mouse, dog and monkey) indicates that 
the mechanism of TPO inhibition is probably also a relevant MIE in humans.  
  
 
5.2.5.3 Repeated dose toxicity studies investigating thyroid effects 
of mancozeb in rats 
The effects of Mancozeb seem very similar to those seen after ETU exposure, however, 
the doses needed to obtain these effects seem to be somewhat higher than for ETU. 
Flippin et al. (2009)  dosed weanling female rats (8-16 per group) with 3.9, 7.8, 15.6, 
31.3, 62.5, 125, 250, 500 or 1000 mg mancozeb/kg bw for 4 days, and 24 hours after 
the last dose, serum T4  and liver microsomal enzyme activity was assayed. Mancozeb 
produced a dose-dependent decrease in circulating levels of T4 with statistically 
significant decreases from 31.3 mg/kg and an ED50 of 259 mg/kg bw/day. No induction of 
liver enzyme activity of EROD (ethoxyresorufin O-deethylase), PROD (pentoxyresorufin 
O-deethylase) or T4-UDPGT (uridine diphosphate glucuronyl transferase) was seen. 
The majority of toxicity studies on Mancozeb are not publicly available, and therefore the 
following summary is based on information from the DRAR. No 28-day studies 
investigating the effects of mancozeb on the thyroid hormone system in rats exist. In 90-
day studies effect doses leading to T4 reductions, increases in TSH and in thyroid weight 
have been shown to be at 15, 28 and 57 mg/kg bw/day in three different studies. 
Repeated inhalation exposure of rats to mancozeb aerosol for 13 weeks, has also been 
shown to reduce serum T4 levels and cause thyroid hyperplasia. Furthermore, three 
carcinogenicity studies with mancozeb have been performed in rats. In one 
carcinogenicity study, treatment-related effects on the thyroid (including thyroid 
adenomas and carcinomas) were seen at the top dose (~30-40 mg/kg bw/day), whereas 
no effects were seen at the lower dose (~5-7 mg/kg bw/day). In another guideline 
carcinogenicity study, decreased T4 levels and altered thyroid histopathology (but no 
tumourigenic response) was seen at the top dose of ~17-21 mg/kg bw/day, with no 
effects at ~4-5 mg/kg bw/day.  The lack of thyroid tumours in this study could be 
explained by the fact that the top dose was lower than in the first study.  
A cancer study was also conducted by Belpoggi et al. 2002. Groups of 75 male and 
female Sprague-Dawley rats, were administered mancozeb at the concentration of 10, 
100, 500 or 1000 ppm in feed for 104 weeks. Malignant thyroid gland tumours were 
increased in males at 500 and 1000 ppm, and in females at 10, 100 and 1000 ppm 
mancozeb. The study had some shortcomings but confirmed that mancozeb can cause 
thyroid follicular carcinomas in rats.  
Also two multi-generational studies performed in rats were described in the DRAR. In the 
first one, SD rats received mancozeb doses of 30, 120 or 1200 ppm for two generations. 
In parental animals the highest dose (corresponding to 70 mg/kg bw/day) caused 
decreased body weight and food consumption,  increased thyroid weights and altered 
thyroid and pituitary histopathology. In the other study, SD rats received mancozeb 
doses of 25, 150 or 1100 ppm for two generations. At 1100 ppm (65 mg/kg bw/day) 
mean thyroid weight was markedly increased in the males of both generations and 
moderately increased in females of both generations. Histopathology, however, revealed 
thyroid hyperplasia and hypertrophy in nearly all parental animals of the F0 and F1 
generation at the the high dose. Thyroid follicular cell adenomas were also found in five 
males of the F0 generation and in 11 males of the F1 generation at the high dose. No 
thyroid effects were seen at the 150 ppm dose (~7 mg/kg bw/d).  
Together, these studies clearly show that in rats, mancozeb has very similar effects to 
those of ETU, but that effects seem to occur at marginally higher doses (i.e effects doses 
seem to be ~15-75 mg/kg bw/day). As with ETU, the longer the exposure time used, the 
lower the doses needed to induce effects. 
5.2.5.4 Repeated dose toxicity studies investigating thyroid effects 
of mancozeb in other species 
Repeated-dose toxicity studies in mice and dogs have shown that in these species the 
thyroid is also the major target organ of toxicity. The DRAR describes some 28- and 90-
day studies in mice, where increased thyroid weights and thyroid hyperplasia was seen at 
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doses from 150, 180 and 200 mg/kg bw/day, respectively. In an 18-month 
carcinogenicity study, T4 was reduced at doses of 131 mg/kg bw/day, whereas effects on 
T3 were equivocal, TSH was unaffected and thyroid tumours were not seen.  
 In the dog, the thyroid hormone system is also adversely affected by mancozeb 
treatment. After 3-months administration, T4 and T3 levels were reduced, thyroid weight 
was increased and thyroid follicular cell hypertrophy was seen at doses of 30 mg/kg 
bw/day and above. Two longer term studies (52 weeks) were conducted in dogs and 
gave similar results to the 3 month study. Effects on T4, thyroid weight and 
histopathology were seen at doses of 23 mg/kg bw/day and above in one study and at 50 
mg/kg bw/day in the other. Thyroid tumours were not seen in any of the dog studies.  
Based on these data, the mouse thyroid appears to be less sensitive to mancozeb 
exposure than that of the rat, whereas the thyroid hormone system of dogs seems as 
sensitive as in rats. No thyroid tumours were seen the mouse and dog studies, but since 
ETU exposure has been shown to cause thyroid tumours in mice, it is possible that the 
tested mancozeb doses were simply not high enough to induce tumour formation in the 
mice.  
5.2.5.5 Developmental toxicity studies investigating thyroid 
disruption and neurotoxicity of mancozeb and ETU 
In toxicity studies where developmental hypothyroidism has been caused by maternal 
PTU exposure or by thyroidectomy, the consequences for the offspring are quite clear 
and include delayed development, decreased postnatal body weighs, hearing impairment, 
altered motor activity levels and deficits in learning and memory  
(Brosvic et al 2002, Noda et al 2005, Goldey et al 1995b, Kobayashi et al 2005 
).  In order to assess whether the mancozeb-induced hypothyroidism would affect brain 
development, two developmental neurtoxicity studies have been performed with 
Mancozeb, and one with ETU. Unexpectedly, none of them have shown any adverse 
effects on neurobehavioural development, even though the tested doses resulted in 
thyroid hormone disruption in the dams.  
A guideline developmental neurotoxicity study on mancozeb (performed according to 
OECD TG 426) was conducted to address the concern about the potential relationship 
between thyroid effects and adverse brain development (DRAR). The study consisted of a 
range-finding study with focus on measurements of thyroid endpoints (Beck, 2008a), and 
a final study assessing neurodevelopmental and neuropathological endpoints (Beck 
2008b). A detailed study description is included in Annex 1, for those readers interested 
in assessing the study results in more detail. Unfortunately, detailed results were only 
provided in the DRAR for some of the endpoints (thyroid hormone levels, thyroid 
histopathology and body weight gain) whereas no figures or tables showing results from 
the behavioral or neuropathological assessment were included. As the study report was 
not available to us, we have to trust the conclusion from the DRAR that indeed no effects 
indicating developmental neurotoxicity were observed. 
In the range-finding study, mancozeb was administered in the diet at target doses of 0, 
5, 30 and 60 mg/kg/d to female SD rats (n=15) from GD 6 to GD 20 or PND 21. Dams 
given 60 mg/kg bw/day of mancozeb showed signs of general- and thyroid toxicity and 
the offspring in this group had lower body weights and reduced T4 levels on GD20 and 
PND4. The dose of 30 mg/kg  caused moderately decreased maternal weight gain during 
gestation, higher mean serum concentrations of TSH, lower mean serum concentrations 
of total T4 and a marginally higher incidence of thyroid gland follicular cell hypertrophy. 
In the offspring, no significant effects on body weight or thyroid endpoints were seen. 
There were no treatment-related effects at 5 mg/kg/day.  
Based on the results of the range-finding study, dietary mancozeb doses of 5, 15 and 30 
mg/kg bw/day were chosen for the DNT study. Here, dams were exposed from gestation 
day 6 through to weaning, and the offspring were assessed in a number of 
neurobehavioural test and neuropathological analyses. In the highest dose group, 
maternal body weight gain was reduced following the onset of treatment. For gestation 
  
 
days 6-20, the decrease in body weight gain was 4.6%. However when litter size was 
used as a covariate in the statistical analysis of body weight gain, the reduction at 30 
mg/kg bw/day was 9.4%. In the range finding study the decrease in adjusted weight 
gain was 11%, at the same dose level. This indicates some degree of maternal toxicity at 
this dose level. Furthermore, in these high dose dams  absolute and relative mean 
thyroid weights were increased by 7.5% and 9.1%, respectively, and corresponded with 
an increased incidence of thyroid follicular cell hypertrophy; (6/24 dams with minimal 
follicular cell hypertrophy in controls vs. 11/25 in the high dose group).  Whether the 
changes in thyroid weight and histopathology were statistically significant is not stated in 
the DRAR.   
 
In the previously reviewed repeated dose toxicity studies with Mancozeb doses above 30 
mg/kg were needed to induce T4 reduction after 4 days of exposure, whereas doses of 
15-75 mg/kg bw/day for 90 days have been shown to cause adverse effects on the 
thyroid (DRAR). This indicates that the dams in the present study were exposed to 
mancozeb doses that were in the low range  of those previously shown to affect the 
thyroid hormone system after such a relatively short term exposure (GD6-PND 20= 35 
days).  There were no test substance-related effects on any of the F1 litter parameters 
including survival, clinical signs, FOB, growth, development, motor activity, startle 
response, learning and memory, brain morphometry and histopathology of the central 
and peripheral nervous systems (though no results were shown in the DRAR). Based on 
these findings, it was concluded that mancozeb had been adequately tested for DNT and 
that mancozeb was not a developmental neurotoxicant. Whether this conclusion can 
indeed be drawn based on the available data is discussed in the next chapter, together 
with discussion of the results from the other developmental neurotoxicity study on 
mancozeb (Axelstad et al 2011), and the EOGRTS study on ETU (Marty et al 2013b in 
DRAR). 
 
A study by Axelstad et al (2011) was also conducted to investigate if perinatal mancozeb 
exposure would cause neurobehavioural effects in rats. A detailed description of this 
study is provided in Annex 2. Wistar rats (n=9-21) were exposed to mancozeb at doses 
of 50, 100 or 150 mg/kg bw/day from gestation day 7 until lactation day 16. Because of 
systemic toxicity in the dams (body weight loss and hind limb paralysis) the high dose 
was reduced from 150 to 100 mg/kg on GD 16. Blood samples were collected for T4 
analysis from dams on GD15 and PND24 and from pups on PND16 and PND24. Thyroid 
glands were weighed and processed for histopathological evaluation from offspring on 
PND 16 and from dams on PND 24. Offspring were examined for motor activity on 
PND14, 17, and 23 (one male and one female pup per litter was assessed). On PND 24, 
1-2 animals per sex from each litter were weaned, and used for further behavioural 
analysis. The behavioural tests were performed in 2-7 month old offspring, and included 
assessment of spatial learning in a radial arm maze, motor activity measurements in 
activity boxes and acoustic startle response.  
Despite clear maternal hypothyroxinemia (T4 decreases on GD 15 of 22, 27 and 37% in 
the three dose groups respectively), no significant effects were seen in offspring  
behaviour or acoustic startle response,  in young or adults animals, and no dose-
dependent trends were seen. There was no effect in dams on PND 24 thyroid weights or 
histopathology, but this could be because these endpoints were assessed 8 days after 
exposure had stopped. In offspring no treatment-related effects on T4, thyroid gland 
weight or histopathology were seen on PND 16. The authors hypothesized that low 
transfer of mancozeb to the maternal milk could explain why no thyroid effects were seen 
in the offspring and why no behavioural effects were observed. 
A third study not showing any adverse neurobehavioural effects was performed with ETU. 
In an extended one generation toxicity study (performed according to OECD TG 443) ETU 
was administered to Sprague Dawley rats (27/sex) at  dose levels of 0, ~0.2, 2.0 and 10 
mg/ kg bw/day (0, 2.8, 28, 140 ppm) for approximately four weeks prior to breeding, 
and continuing through gestation and lactation. At weaning, F1 offspring were divided 
into cohorts for behavioural and neuropathological assessment.  A detailed study 
description of this study (as shown in the DRAR) is provided in Annex 3. 
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ETU caused no effects on reproductive toxicity or developmental neurotoxicity up to the 
top dose of 10 mg/kg bw/day. Thyroid toxicity (hypertrophy in adults) was seen at the 
mid and high dose. No data showing any results from the many neuropathological or 
behavioural assessments were shown in the DRAR, but it was concluded that none of 
these endpoints were affected. In high dose offspring a lower brain weight was seen in 
Cohort 2A. This was accompanied by decreases in overall brain macroscopic and 
microscopic measurements. According to the DRAR conclusions growth at 140 ppm was 
reduced during late lactation, juvenile and early adult periods. The differences in brain 
weight (6-7%) were relatively small compared to the effects on body weight (up to 
10%), and the morphometric analysis indicated that the brain was slightly small overall, 
rather than decreased in any specific region/layer. Consequently, in the absence of any 
effects on neurobehavioural endpoints or neuropathology, the differences in brain weight 
at 140 ppm ETU were considered to reflect the reduced growth during late lactation, 
juvenile and early adult periods and not to be evidence of specific developmental 
neurotoxicity. 
 
5.2.6 Why are the expected neurobehavioural effects of 
hypothyroxinemia not seen in these rat studies? 
Apart from the developmental studies on Mancozeb and ETU presented above, several 
other DNT studies investigating rodent offspring from hypothyroid/hypothyroxinemic 
dams have also shown that adverse behavioural outcomes are not always present. This is 
for instance the case with fipronil and perchlorate (both discussed in other case studies). 
The discussion points below will be dealing with the data from the present case study on 
Mancozeb/ETU, but the conclusions should be more broadly applicable.  
The key issue in this context is, why do marked maternal T4 reductions (and in some 
cases also other adverse effects on the maternal thyroid hormone system) not lead to 
any behavioural effects (or other assessed neurotoxicological endpoints) in the offspring?  
Listed below are some possible explanations for this question:   
1) The thyroid disrupting effects of mancozeb/ETU on the dams where not severe 
enough to lead to altered brain development in the offspring, because the tested 
doses were too low.  
2) The offspring were not hypothyroid themselves in the postnatal period (due to 
limited milk transfer) and since much brain development occurs postnatally in 
rats, the prenatal hypothyroxinemia was not severe enough to disrupt brain 
development. 
3) Offspring brain development was actually affected, but the used neurobehavioural 
assessment methods are not suited for the detection of subtle effects in the brain, 
caused by maternal hypothyroxinemia (to be discussed in the next section). 
4) The decreases in circulating T4 levels (due to TPO inhibition) lead to upregulation 
of peripheral deiodinase activity in the offspring brains, leading to a larger 
conversion of T4 to the active T3, which compensated for the low circulating T4 
levels and provided enough T3 for normal brain development. 
An equally relevant question is why there were no adverse effects on neurodevelopment 
seen in these three studies, when similar maternal T4 decreases caused by PTU exposure 
would most likely have resulted in a wide range of adverse effects. Since mancozeb/ETU 
exerts its thyroid disrupting effects through the same mode of action as PTU (inhibition of 
TPO), some aspects other than just the mode of action, must be contributing to this 
difference in outcome. 
 
Some possible explanations for this problem are listed: 
1) The majority of reported developmental PTU studies use very high doses of PTU 
and therefore cause very severe hypothyroidism. If PTU and ETU/mancozeb doses 
were chosen to result in an “identical” degree of hypothyroidism, an “identical” 
outcome regarding neurobehavioural development would also be seen. 
  
 
2) PTU has other modes of action than just TPO inhibition (also inhibition of 
deiodinase activity). This difference is responsible for the observed differences in 
outcome. 
5.2.7 How can OECD guidelines investigating DNT be improved to 
include more sensitive endpoints for adverse outcomes of 
thyroid disruption? 
In the case study on perchlorate, data from studies investigating neurological effects of 
perchlorate exposure during development are shown. A more detailed description of one 
of these studies (Gilbert and Sui, 2008) is provided below, in order to help discussions of 
which downstream endpoints could be useful to include in the OECD guidelines dealing 
with developmental neurotoxicity. 
Pregnant LE rats (106 dams used, n=26?) were exposed to 0, 30, 300, or 1,000 ppm (~ 
5, 44 and 140 mg/kg bw/day) of ammonium perchlorate in drinking water from 
gestational day 6 until weaning. Adult male offspring were evaluated in a series of 
behavioral tasks and neurophysiologic measures of synaptic function in the hippocampus. 
At the highest perchlorate dose T3 and T4 levels were reduced in pups on postnatal day 
21. T4 in dams was reduced relative to controls by 16%, 28%, and 60% in the 30-, 300-, 
and 1,000-ppm dose groups, respectively. TSH was significantly increased in the high-
dose group, whereas no changes were seen in serum T3. No group differences were seen 
in any of the behavioral studies (i.e. no effect on horizontal or vertical motor activity 
(n=8-11), no effect on latency to find the hidden platform in the Morris water maze 
(n=11-17), and no differences in trace fear conditioning or conditioning to context 
(original test box). Brain and hippocampal weights in the offspring were measured on 
PNDs 4, 14, and 21 in male and female offspring, and here also no significant effects 
were seen. However, in the adult offspring, synaptic transmission in the hippocampus 
was affected by perinatal perchlorate exposure, as significant reductions in excitatory and 
inhibitory synaptic transmission were observed in the dentate gyrus. The dose-dependent 
deficits in hippocampal synaptic function were indicative of an irreversible impairment in 
synaptic transmission in response to developmental exposure to perchlorate (Gilbert and 
Sui 2008). 
Additional methods for assessing neurotoxicity to those presently included in the OECD 
neurotoxicity guidelines, have also been used by Harry et al (2014), in an investigation of 
the neurotoxicological effects of perinatal exposure to the dioxin-like compound TCAB 
(3,3’4,4’-tetrachloroazobenzene). This chemical induced clear hypothyroxinemia, and the 
authors investigated guideline-like behavioural endpoints and conventional 
neuropathology in the offspring, but also investigate specific regions of the hippocampus, 
and glial cells – which have previously been shown to be very sensitive to thyroid 
disruption.  The study and its conclusions can be summarized in the follwing way:  
 SD rats were orally treated with 0.1, 1.0, or 10 mg TCAB/kg bw/day, for two weeks prior 
to cohabitation until post-partum day 3, and male offspring from post-natal day (PND)4-
21. In the dams, TCAB, induced dose-related reductions in serum T4 levels with no 
change in T3 or TSH. At PND21, the high dose animals showed a deficit in body weight 
gain. Conventional neuropathology detected no neuronal death, myelin disruption, or 
gliosis, and no effects were observed on post-weaning behavioral assessments in control, 
0.1 and 1.0mg/kg/day dose groups [the 10 mg/kg group was not assessed]. However, 
astrocytes displayed thinner and less complex processes at 1.0 and 10 mg/kg/day. At 10 
mg/kg/day, microglia showed less complex processes, unbiased stereology detected 
fewer hippocampal CA1 pyramidal neurons and dentate granule neurons (GC) and Golgi 
staining of the cerebellum showed diminished Purkinje cell dendritic arbor. At PND150, 
normal maturation of GC number and Purkinje cell branching area was not observed in 
the 1.0 mg/kg/day dose group with a diminished number and branching suggestive of 
effects initiated during developmental exposure. Based on this the authors concluded 
that the demonstrated sensitivity of hippocampal neurons and glial cells raises support 
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for considering additional anatomical features of brain development in future DNT 
evaluations (Harry et al 2014). 
Taken together, the results presented in the present case study indicate that more 
sensitive neurotoxicity endpoints would be useful to include in the presently conducted 
OECD guideline studies.  
If/when this is implemented, it may be possible in the future to assess how 
neurodevelopmental outcomes differ for different compounds, depending on their mode 
of action in causing thyroid disruption. 
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5.2.9 Annex 1. Description of OECT TG 426 DNT study on mancozeb 
from the DRAR 
 
Range-finding study (Beck 2008a) 
Methods: Mancozeb was given on a continuous basis in the diet to groups of 15 bred 
female SD rats from gestation day 6 until euthanasia (post partum day 21). The target 
test substance doses of 5, 30 and 60 mg/kg bw/d and the mean calculated doses during 
gestation/lactation were 5/6, 29/35, 55/73 mg/kg/d. One group of animals received the 
basal diet alone and served as the control group. Maternal clinical observations, body 
weight and food consumption were monitored. Five females/group were euthanized on 
GD 20 for maternal and foetal blood collection for determination of mancozeb and ETU 
concentrations in plasma. Maternal TSH and T4 were measured and the thyroid glands 
were weighed and examined microscopically. The remaining females were allowed to 
litter and to rear their offspring to day 21 post partum. Maternal blood samples were 
collected on LD4 from 5 females/group for determination of plasma mancozeb and ETU. 
Milk samples from 5 females per group were collected on LD4 and LD10 for 
determination of mancozeb and ETU. At termination on LD 21, maternal blood was 
collected for thyroid hormone assessment and the thyroid glands were weighed and 
examined microscopically. The offspring were weighed and observed at intervals. On PND 
4, litters were culled to 8 pups/litter; blood samples were collected for toxicokinetic 
evaluation from the culled offspring in litters whose dams were used for evaluation of 
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plasma mancozeb and ETU concentrations. All surviving pups were euthanized and 
necropsied on LD 21. 
Results: No test substance-related clinical findings were observed in parent females. At 
60 mg/kg/d, body weight, body weight gain and food consumption were significantly 
decreased during the gestation treatment period (by 10.5%, 37% and 16%, 
respectively; p<0.01). Significant reductions in gestation body weight gain and food 
consumption were also evident at 30 mg/kg/d (by 14% and 12%, respectively; p<0.01). 
Subsequently, mean body weights in the 60 mg/kg/d group females remained lower 
during lactation, but there were no test substance-related effects on mean body weight 
gain or food consumption. No test substance-related effects on mean body weights, body 
weight gains or food consumption were noted during gestation in the 5 mg/kg/d group or 
during lactation in the 5 and 30 mg/kg/d groups.  An increased incidence of thyroid gland 
follicular cell hypertrophy was noted in the 30 and 60 mg/kg/d groups on LD 21 and was 
associated with a statistically significant reduction in serum T4; increased TSH at 
60 mg/kg/d did not achieve statistical significance. Relative thyroid weights were 
increased in some of the 60 mg/kg/d group dams and associated with follicular cell 
hypertrophy. 
Summary of thyroid effects 
 Dose level of Mancozeb (mg/kg bw/day) 
0 5 30 60 
Total T4 (µG/dL) GD 20  1.32 0.82 0.59* 1.02 
TSH (ng/mL) GD 20 9.58 12.46 11.20 11.98 
Total T4 (µG/dL) LD 21  3.94 4.36 2.98* 2.22** 
TSH (ng/mL) LD 21 10.82 10.19 10.75 14.91 
Absolute thyroid weight (g) GD 20 0.0233 0.0213 0.0254 0.0260 
Absolute thyroid weight (g) LD 21 0.0240 0.0223 0.0216 0.0232 
Thyroid cyst, ultimobranchial, present GD 
20 
2/5 1/5 0/5 1/5 
Thyroid hypertrophy, follicular cell - minimal 
GD 20 
0/5 0/5 1/5 1/5 
Thyroid cyst, ultimobranchial, present LD 21 5/10 2/10 5/9 2/10 
Thyroid hypertrophy, follicular cell - minimal 
LD 21 
2/10 0/10 4/9 5/10 
Statistically significant difference from control *P<0.05, Statistically significant difference 
from control **P<0.01 
Mean gestation length and parturition were unaffected by mancozeb. The mean 
number of pups born, the percentage of males at birth, live litter size on PND 0, 
postnatal survival and general physical condition were unaffected by maternal exposure 
to mancozeb. Lower mean body weight gains were observed in the male and female pups 
in the 30 and 60 mg/kg/d groups during PND 4-7, 7-11 and 17-21, resulting in mean 
body weights that were 10.9% to 21.6% lower than the control group values during PND 
7-21. These body weight decreases were most marked on PND 7 and 11, but were not 
dose-related.  
  
 
Summary of pup body weights (g) selected days 
Post natal day  Dose level of Mancozeb (mg/kg bw/day) 
Males  Females 
0 5 30 60 0 5 30 60 
1 7.2 7.0 7.0 6.8 6.8 6.6 6.7 6.6 
4 (pre-cull) 9.5 9.3 8.8 9.0 8.9 8.7 8.3 8.6 
7 14.8 13.4 11.6* 12.3* 13.7 12.5 11.1 11.5 
14 28.5 26.6 24.2 24.7 26.8 25.1 23.4 23.5 
21 46.1 43.1 40.0 40.5 44.1 41.0 38.7 38.6 
Statistically significant difference from control *P<0.05 
There were no macroscopic findings in the pups that were found dead, euthanized in 
extremis or at the scheduled necropsy that could be attributed to maternal exposure to 
mancozeb. Plasma and milk analyses in the high dose animals (60 mg/kg/d) showed that 
the pups were exposed to residues of both mancozeb and ETU. The mean concentrations 
in plasma for GD 20 dams and foetuses were 0.356 ppm and 0.278 ppm, respectively. 
For LD 4 dam and PND 4 pup plasma, the mean concentrations were 1.18 ppm and 
0.037 ppm, respectively. The mean concentration in milk was 0.426 ppm in the LD 4 
samples and 0.440 ppm in the LD 10. ETU residues were found in plasma and milk from 
all dose groups. The ETU residue levels increased with increasing dietary concentration of 
mancozeb. 
Conclusions: In this DNT range-finding study, mancozeb was administered in the diet at 
target doses of 0, 5, 30 and 60 mg/kg/d to female SD rats from GD 6 to GD 20 or LD 21. 
Dams given 30 or 60 mg/kg/d mancozeb had lower mean body weights, body weight 
gains and food consumption, higher mean serum concentrations of TSH, lower mean 
serum concentrations of total T4 and a higher incidence of thyroid gland follicular cell 
hypertrophy which generally corresponded with increased relative thyroid weight at the 
highest dose. The offspring in the 30 and 60 mg/kg/d groups had decreased body 
weights and body weight gains. There were no treatment-related effects at 5 mg/kg/d. 
Therefore, dietary doses of 5, 15 and 30 mg/kg/d were selected for a definitive DNT 
study of mancozeb. 
Full DNT study (Beck 2008b) 
Method :Mancozeb was given on a continuous basis in the diet to groups of 25 bred 
female SD rats from gestation day 6 until euthanasia (post partum days 21-28). The 
target test substance doses of 5, 15 and 30 mg/kg bw/d were achieved. One group of 
animals received the basal diet alone and served as the control group. Clinical 
observations including FOB, body weight and food consumption were monitored for the 
females during the study. Dams were allowed to litter and rear their offspring to day 21 
post partum. At necropsy, thyroid weights were collected and the thyroids processed for 
histopathological examination. Pre-weaning developmental landmarks (pinna 
detachment, eye opening and surface righting response) were evaluated in offspring. On 
postnatal day (PND) 4, litters were culled to 8 pups/litter (4 pups/sex, when possible). If 
a litter failed to meet the sex ratio criteria (at least 3 pups/sex), the litter was not used 
for neurobehavioral or neuropathological evaluation. Following culling, a subset (Subset 
A) of 20 pups/sex/group was assigned to FOB (PND 4, 11, 21, 35, 45 and 60), acoustic 
startle response (PND 20 and 60), locomotor activity (PND 13, 17, 21 and 61) and 
learning and memory (PND 62). From this subset, 15 pups/sex/group were selected for 
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brain weight evaluations on PND 72; of these, 10 pups/sex/group were selected for 
neuropathological and morphometric evaluations on PND 72. A second subset (Subset B) 
of 20 pups/sex/group was selected for learning and memory tests (PND 22). A third 
subset (Subset C) of 15 pups/sex/group was selected for brain weight evaluations on 
PND 21; of these, 10 pups/sex/group were selected for neuropathological and 
morphometric evaluations on PND 21. Indicators of physical development 
(balanopreputial separation and vaginal patency) were evaluated for all F1 animals in 
Subset A. All F1 animals not selected for behavioural evaluations were euthanized and 
necropsied on PND 21. F1 animals selected for learning and memory assessment on PND 
22 were necropsied following completion of these assessments. 
Results: Dietary exposure to mancozeb from gestation day 6 through to weaning 
produced no test substance-related effects on clinical findings, FOB parameters, food 
consumption, gestation length, parturition or macroscopic findings at necropsy. Test 
substance-related effects were evident for maternal body weight gain, thyroid weight and 
thyroid histopathology at 30 mg/kg bw/d. Maternal body weight gain was reduced 
following the onset of treatment. The effect was statistically significant for gestation days 
6–9 and 6-12. For gestation days 6-20, the decrease in body weight gain was 4.6%. 
However, the effect on body weight gain was influenced by an incidentally higher litter 
size in the 30 mg/kg bw/d group compared to the concurrent control group (16.0 vs. 
14.7 pups/litter). When litter size was used as a covariate in the statistical analysis of 
body weight gain, the reduction at 30 mg/kg bw/d was highly significant. In addition, 
when the body weight gain data were normalized for litter size and gestation day 20 
conceptus weights, the decrease in gain during gestation days 6-20 was 9.4%. 
Therefore, 30 mg/kg bw/day was shown to be an ideal high-exposure level based on the 
OECD test guideline criteria. 
Summary of body weight change (g) during gestation 
Gestation Days  Dose level of Mancozeb (mg/kg bw/day) 
0 5 15 30 
6-9 12 11 11 7* 
6-12 27 25 24 20** 
6-15 42 42 40 36 
6-20 109 110 107 104 
Statistically significant difference from control *P<0.05, **P<0.01 
Summary of body weight change (g) during gestation at 30 mg/kg bw/day 
Gestation Days  Dose level of Mancozeb (mg/kg bw/day) 
Range Finding Study (N=15) Developmental Neurotoxicity 
Study (N=25) 
0 30 % 
Change 
0 30 % Change 
6-9 14 6** -57.1 12 7* -41.7 
6-12 31 22** -29.0 27 20** -25.9 
6-15 45 39 -13.3 42 36 -14.3 
  
 
6-20 122 105** -13.9 109 104 -4.6 
Adjusted value for 6-
20a 
122 108.6 -11 109 98.8 -9.4 
Statistically significant difference from control *P<0.05, **P<0.01 
a Adjusted body weight gain normalized for differences in litter size and historical 
gestation day 20 conceptus weight across groups  
A 30 mg/kg bw/d, absolute and relative mean thyroid weights were increased by 7.5% 
and 9.1%, respectively, and corresponded with an increased incidence of thyroid 
follicular cell hypertrophy; these changes were considered to be test substance-related. 
The maternal NOAEL was 15 mg/kg bw/d. 
Summary of thyroid effects 
 Dose level of Mancozeb (mg/kg bw/day) 
0 5 15 30 
Absolute thyroid weight (g) 0.0187 0.0192 0.0185 0.0201 
Thyroid weight (g/100g final body weight)b 0.00638 0.007 0.006 0.00696 
Thyroid hypertrophy, follicular cell - minimal 6/24 - - 11/25 
b Values for the 5 and 15 mg/kg bw/day groups expressed only to 3 decimal places. 
There were no test substance-related effects on any of the F1 litter parameters including 
survival, clinical signs, FOB, growth, development, motor activity, startle response, 
learning and memory, brain morphometry and histopathology of the central and 
peripheral nervous systems. Therefore, the DNT NOAEL was 30 mg/kg bw/d, the highest 
dose tested.   
Conclusions: Based on decreased body weight gain during gestation and an increased 
incidence of thyroid follicular cell hypertrophy at 30 mg/kg bw/d, the NOAEL for maternal 
systemic toxicity of mancozeb when administered orally in the diet was 15 mg/kg bw/d. 
There were no test substance-related effects on any of the F1 litter parameters 
investigated in this study; therefore, the DNT NOAEL was 30 mg/kg bw/d, the highest 
dose tested. Based on these findings and on the presence of ETU in pup plasma and in 
milk (investigated in the preliminary study), it can be concluded that mancozeb has been 
adequately tested for DNT and the results show that mancozeb has no developmental 
neurotoxicity. 
5.2.10 Annex 2. Description of the Axelstad et al (2011) 
developmental neurotoxicity study 
  
Methods: Two separate studies were conducted, a preliminary dose range-finder (6 
dams/group) and a large dose response study (22 dams/group). Time-mated Wistar rats 
were gavaged once daily from GD7 to PND16 (not on day of delivery). No information 
was available on the purity of mancozeb (supplied by VWR-Bie & Bernsten, Herley, 
Denmark; lot no. 371-131c). Mancozeb was formulated in corn oil; no verification of dose 
concentration was performed. Dose levels for the preliminary study were 0, 200, 350 or 
500 mg/kg bw/d. In the main study, dose levels were 0, 50, 100 or 150 mg/kg bw/d. 
The day after delivery pups were counted, sexed, weighed, checked for abnormalities 
and anogenital distance (AGD) measured. Body weights were measured on PND6, 13, 24, 
31 and 45. Offspring were examined for the presence of nipples/areoleas on PND13 and 
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for motor activity on PND14, 17, and 23. On PND16 three males and two females per 
litter (when possible) were killed, weighed, and testes, epididymis, ventral prostate, 
ovaries, liver, adrenals and thyroid glands removed, weighed and processed for 
histopathological evaluation. On PND 24, 2-4 pups per litter were weaned and the dam 
and one male per litter were killed. Thyroids were removed weighed and processed for 
histopathology. In the dams the number of implantation sites were scored and for the 
male offspring the testes were weighed and processed for histopathology. Blood samples 
were collected for T4 analysis: from dams on GD15 and PND24 and from pups on PND16 
and PND24. Testosterone was measured from male pups killed on PND16. Behavioural 
tests in 2-7 month old offspring were: spatial learning in a radial arm maze, motor 
activity measurement and acoustic startle response. Adult offspring were killed at 8 
months of age and ovaries and thyroids removed, weighed and prepared for 
histopathological examination. 
Results: Doses of 150 mg/kg bw/d and above caused toxic effects in the dams. In the 
preliminary study, severe weight loss and hind limb paralysis occurred in all groups after 
a few days and doses were halved on GD12. All animals in the two highest dose groups 
and two in the low dose group were killed on GD14 due to continued toxic signs. In the 
main study, two high-dose dams were killed on GD16 and the high dose was lowered to 
100 mg/kg bw/d. Maternal body weight and body weight gain was significantly lower 
than control in all dose groups throughout gestation. Body weight gain was generally 
higher than control in all groups throughout lactation but terminal body weight was 
significantly lower than control in the high-dose group. 
There were no effects on gestation length, litter size, post implantation loss, neonatal 
death, gender distribution, AGD or nipple retention. Offspring body weight was lower 
compared to controls in the high dose group at birth and on PND6, and remained slightly 
(but not significantly) lower than control until PND45. In dams, T4 was dose-dependently 
reduced in all treated groups on GD15. There was no effect on PND 24 and thyroid 
weights were also unaffected. In offspring no treatment-related effects on T4, thyroid 
gland weight or histopathology were seen. 
Effects of Mancozeb on T4 and testosterone in dams and offspring 
 Dose Mancozeb (mg/kg bw/day) 
Hormone measurement (nM) Control 50 100 150/100 
No. of samples 14-15 15-20 17-22 8-10 
T4 – dams GD15 41.4 32.7* 30.15* 26.26* 
T4 – dams PND24 24.8 21.2 19.6 23.14 
T4 – pups PND16 32.5 35.8 34.6 33.1 
T4 – pups PND24 18.5 19.8 22.1 24.3 
Testosterone PND16 1.05 1.58 1.54 1.65 
* Significantly different from control p< 0.0001 
There were no effects on offspring organ weights on PND16 (testes, epididymis, prostate, 
ovaries, liver), PND24 (testes) or in young adults (ovaries) and no histopathological 
effects in ovaries and testes (other organ not examined). None of the behavioural tests 
showed any effect of mancozeb exposure. 
Mancozeb at 150 mg/kg bw/d and above induced toxic effects in dams characterised by 
severe bodyweight loss and hind limb paralysis. The severity of the maternal toxicity was 
such that the dose had to be reduced to 100 mg/kg bw/d and some animals had to be 
terminated prematurely. Increased maternal T4 levels at 50 mg/kg bw/d and above did 
not affect offspring T4 levels, thyroid weights or histopathology on PND 16 and no effects 
on reproductive organ weights or behaviour in adult offspring. Overall, no developmental 
toxicity was seen in this study up to a dose of 100/150 mg/kg bw/d. Thyroid toxicity 
(increased T4 levels) was observed in the maternal animals from the lowest dose of 50 
mg/kg bw/d. These results indicate that in rats, maternal hypothyroxinemia during 
gestation does not necessarily lead to hyperactivity or reduced learning abilities in the 
  
 
offspring. Overall, a maternal LOAEL of 50 mg/kg bw/d can be identified from this study 
and a NOAEL > 100/150 mg/kg bw/d can be identified for developmental toxicity.  
It is noted that the maternal toxicity reported in this study was not consistent with that 
observed in other developmental toxicity studies. In regulatory guideline studies, 
pregnant rats have been shown to tolerate 160 mg/kg bw/d (Edwards, 2015c) with only 
a transient effect on body weight. Only the high dose level of 360 mg/kg bw/d (Tesh, 
1988) induced significant maternal toxicity, including transient, hindlimb paralysis. 
 
5.2.11 Annex 3. Description of OECT TG 443 EOGRTS ETU study (with 
DNT cohort) from the EU RAR (Marty et al 2013b in EU RAR) 
 
Methods :In an extended one generation toxicity study, ETU was administered in the 
diet to groups of 27 male and 27 female Sprague Dawley rats at nominal dose levels of 
0, ~0.2, 2.0 and 10 mg kg bw/d (0, 2.8, 28, 140 ppm) for approximately four weeks 
prior to breeding, and continuing through breeding (two weeks). After breeding, P1 
males continued on the test diets for an additional 5-7 weeks (11 weeks total exposure) 
and P1 females continued on the test diets through gestation and lactation (10-12 weeks 
total exposure). Dose levels were selected on the basis of a range-dosing study in which 
groups of 12 male and 12 female SD rats were fed diets supplying 0 (control), 0.2, 2.0, 
and 10 mg/kg/d ETU. Males were exposed for at least two weeks prior to breeding and 
continuing throughout breeding and post-breeding for approximately 8 weeks of 
exposure. The females were exposed for two weeks prior to breeding, continuing through 
breeding (up to two weeks), gestation (three weeks), and lactation (three weeks). In this 
preliminary study, palsma kinetics of ETU were also assessed in parental animals and F1 
offspring. In the main study, F1 offspring were divided into Cohorts 1A, 1B, 2A, and 2B 
at weaning (postnatal day (PND) 21).  
Cohort 1A (26/sex/dose) was used to evaluate reproductive toxicity, which included 
estrous cycle evaluation and post-mortem examination of reproductive organs, sperm 
assessment, and ovarian follicle counts on PND 90. This group was also used to assess 
general and thyroid toxicity, which included clinical chemistry/haematology parameters, 
thyroid hormone assessment, and urinalysis. Post-mortem evaluations in Cohort 1A (PND 
90) also included gross pathology, organ weights, and histopathology on a wide range of 
tissues, including thyroids. 
Cohort 1B animals (26/sex/dose) were known as the endocrine group and designated to 
clarify any equivocal responses seen in the Cohort 1A animals. This group was also used 
to assess general and thyroid toxicity, which included thyroid hormone assessments. 
Post-mortem evaluations in Cohort 1B (PND 120) included gross pathology and organ 
weights with a primary focus on tissues affected in Cohort 1A, including thyroids. 
The Cohort 2A and 2B animals (22/sex/dose) were used to assess potential 
developmental neurotoxicity (DNT).  Cohort 2A (12/sex/dose) was used for DNT 
assessments, which included functional observational battery (FOB), motor activity, and 
acoustic startle response (ASR). On PND 78, Cohort 2A F1 animals were perfused for 
central nervous system (CNS) and peripheral nerve neuropathology evaluation and brain 
morphometry.  
Cohort 2B (10/sex/dose) underwent necropsy on PND 22, which included brain weight 
collection and immersion fixation of tissues for examination of neuropathology.  
 
Weanlings not assigned to Cohorts 1-2 were considered “unselected” weanlings. On PND 
22, these unselected weanlings (15/sex/dose) were euthanized for assessment of 
systemic toxicity, which included thyroid hormone assessment, selected organ weights, 
and post-mortem examinations (gross pathology and histopathology). In addition, 
selected pups culled on PND 4 were used to assess thyroid hormone levels. 
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Results: Nominal dose levels (mg/kg bw/d) were achieved across both P1 and F1 
generations; however, during some study intervals (e.g., PND 35-56), F1 offspring had 
greater ETU intake per kg body weight than P1 males and prebreeding females. In the 
range-finding study, plasma concentrations of ETU in all groups were dose-proportional 
(linear) across all dose levels. Plasma AUC24h values on GD 20 were also dose 
proportional (linear) across all ETU-treated dose groups. There were no observed sex- or 
lactation-related differences in ETU kinetics. In LD 4 culled pups, mean plasma ETU 
concentrations were approximately 22% of dam plasma levels. Plasma concentrations of 
ETU in LD 21 pups were approximately 65% of dam levels. The higher pup-to-dam ETU 
plasma concentration ratio at LD 21 was likely due to pup consumption of ETU-containing 
diets, in addition to suckling. In the parental generation, high-dose ETU females had 
decreased body weight (7-8%) on lactation days (LD) 4 and 7, which coincided with 
decreased feed consumption (5-10%) and decreased F1 pup body weights on PND 14 
and 21 (decreased by 11-12% and 8-9%, respectively). The F1 body weights in the high-
dose males were significantly different from the controls from PND 21 through cohort 
termination or until PND 112 (7.4% decrease in body weight in Cohort 1B). The F1 high-
dose female body weights recovered to control values by ~ PND 56.   
ETU had no effect on male or female reproductive performance. Sperm numbers and 
mobility and estrous cycle length were unaffected. There were no effects on mean 
number of pups delivered per dam, pup survival rates of liveborn and stillborn pups or 
sex ratio. 
     Summary of female reproduction and delivery data 
Parental generation P1 
Dose [ppm] 0 2.8 28 140 
Animals per dose 27 27 27 27 
Female fertility     
- placed with males 27 27 27 27 
- mated [n] 27 27 27 27 
- mating index [%] 100 100 100 100 
- pregnant [n] 26 26 26 26 
- Fertility index [%] 96.3 96.3 96.3 96.3 
Pre coital interval [days] 2.3±1.1 3.4±2.4 2.3±1.1 2.8±1.2 
Duration of gestation
 [days] 
21.5±0.5 21.5±0.5 21.7±0.5 21.8±0.5 
Post implantation loss      
- dto per litter[mean %] 8.86±10.13 6.13±6.19 6.60±10.11 9.67±10.20 
Females with liveborn 26 26 26 26 
- Gestation index [%] 100 100 100 100 
Pups delivered [n] 348 363 365 357 
- per dam [mean n] 13.4 14.0 14.0 13.7 
  
 
- liveborn [n] 343 360 357 351 
- Live birth index [%] 98.6 99.2 97.8 98.3 
Treatment-related thyroid effects included significant changes in thyroid hormone profile, 
thyroid weights, and thyroid histopathology (follicular cell hyperplasia) at doses ≥ 2 
mg/kg bw/d ETU in both males and females at multiple life stages. There was a 
significant, treatment-related increase (65%) in serum TSH in high-dose PND 4 culled 
pups. T4 was decreased by 28% at this dose level. There were significant decreases in 
serum T4 in both male and female weanlings (PND 21) at the top dose. Serum T4 also 
was significantly decreased at 28 ppm in female weanlings. There were corresponding 
significant increases in TSH levels in both male and female weanlings at the top dose. 
Females also had significant increases in TSH in the 28 ppm group. Both male and female 
PND 22 weanlings from the 140 ppm group had treatment-related higher absolute and 
relative thyroid gland weights, which were associated with diffuse hyperplasia and 
hypertrophy of thyroid follicular cells. Very slight diffuse follicular cell hypertrophy of the 
thyroid gland was also present in 3/15 males and 3/15 females PND 22 weanlings from 
the 28 ppm group. 
     Serum T4 and TSH levels in male and female PND 4 Pups 
Dose (ppm) Males and Females 
T4 (µg/dL) % Change TSH (ng/mL) % Change 
0 0.82 NA 0.89 NA 
2.8 0.48* -41 0.92 -3 
28 0.72 -12 1.05 +18 
140 0.59 -28 1.47* +65 
     NA = not applicable,     * statistically different from control mean by Wilcoxon’s test,      
Bold type indicates the effects were interpreted to be treatment related 
     Serum T4 and TSH Levels in male and female PND 22 weanlings 
Dose 
(ppm
) 
Males Females 
T4 
(µg/dL
) 
% 
chang
e 
TSH 
(ng/mL
) 
% 
chang
e 
T4 
(µg/dL
) 
% 
chang
e 
TSH 
(ng/mL
) 
% 
chang
e 
0 3.73 NA 0.95 NA 3.11 NA 0.87 NA 
2.8 3.71 -0.5 0.89 -6 3.13 +0.6 1.03 +18 
28 3.23 -13 1.14 +20 2.35* -24 1.32$ +52 
140 1.76* -53 2.68$ +182 1.57* -50 2.40$ +176 
     NA = not applicable,     * statistically different from control mean by Dunnett’s test,      
$ statistically different from control mean by Wilcoxon’s test.      Bold type indicates the 
effects were interpreted to be treatment related 
No treatment-related effects on sexual maturation were observed in male or female F1 
pups. Body weight at the time of vaginal opening was significantly lower (7%) in the 
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high-dose females but this was indicative of the ETU-induced reduced growth rate as age 
at vaginal opening was not altered. Puberty onset was delayed by 1.9 days in the high 
dose group males, but this effect was considered to be related to body weight 
decrements and slightly delayed growth as confirmed by the observation that juvenile F1 
male pups in the high-dose group weighed 7% less than controls at PND 28, and 8% less 
than controls on PND 35 and 42. There were no significant, treatment-related differences 
in age at preputial separation in male offspring, absolute or relative anogenital distance 
and nipple/areolae retention in either male or female offspring. 
    Sexual maturation of F1 pups 
Sex Male Female 
 Age days Body weight 
[g] 
Age days Body weight 
[g] 
Dose     
0 43.5 ± 1.7 245.4 ± 19.4 31.7 ± 1.2 112.4 ± 9.8 
2.8 44.4 ± 2.1 243.2 ± 20.1 31.9 ± 0.9 109.9 ± 9.0 
28 44.5 ± 2.7 242.4 ± 17.5 31.8 ± 1.0 111.1 ± 9.5 
140 45.4* ± 1.9 239.5 ± 20.4 31.9 ± 0.9 104.1* ± 7.1 
     * statistically different from control mean by Wilcoxon’s test 
There were no treatment-related effects on clinical-chemistry and haematological 
parameters at any dose level in P1 adults. High-dose P1 males had significant decreases 
in serum concentrations of T4 (67%) and a coincident significant increase in serum TSH 
levels (326%). At the mid dose, P1 males had a significant decrease in serum T4 levels 
(23%), but TSH levels were not significantly altered. For high-dose P1 females on LD 22, 
there was a significant decrease (76%) in serum T4 levels and a corresponding 
significant increase (323%) in serum TSH concentrations. At the mid dose, P1 females 
had a significant decrease in serum T4 levels (36%), but TSH levels were not significantly 
altered. High dose P1 animals showed increased absolute and relative thyroid weights.  
High- and mid-dose P1 animals had statistically significant lower absolute and relative 
thymus weights. The decreased thymus weights were associated with atrophy of 
lymphoid tissue at the high dose only. Effects on the thymus were not seen in the F1 
offspring. 
Histopathology of the thyroid in parental animals revealed the presence of follicular cell 
hyperplasia at the mid- and high-dose. Slight follicular cell hypertrophy was also seen 
mainly at the top dose. Very slight follicular cell hypertrophy was noted at the low dose in 
P1 males and F1 cohort 1A males. Given the very mild severity of this finding in the low 
dose males and the absence of effects on thyroid hormone levels at this dose, the very 
slight follicular cell atrophy of the thyroid at 0.2 mg/kg bw/d was considered not to be 
adverse. Histopathology of the pituitary in parental animals revealed a significantly 
increased incidence of slight hypertrophy of individual cells of the pars distalis at the high 
dose. Slight hypertrophy was also seen at a very low incidence at the low and mid dose 
in males only of the P1 generation and F1 Cohort 1A generation. Given the low incidence 
of this finding at the low and mid dose, it was considered not to be adverse. 
Histopathology of the liver in parental animals showed slight hepatocyte vacuolation in 
high dose males only of the P1 generation. 
      Incidence of selected histopathological lesions in parental rats 
  
 
Dose [mg/kg] 0 3.8 38 190 0 2.8 28 140 
Sex male female 
Animals in group 27 27 27 27 27 27 27 27 
Thyroid gland # examined 27 27 27 27 27 27 27 27 
 - hyperplasia, follicular cell, diffuse         
 -very slight 0 0 14 4 0 0 7 1 
  -slight 0 0 1 23 0 0 0 26 
 - hyperplasia, nodular, follicular cell, 
focal 
        
 -slight 0 0 0 1 0 0 0 1 
- hypertrophy, follicular cell, diffuse         
 -very slight 4 20 21 4 2 2 12 1 
 -slight 0 0 1 23 0 0 0 26 
- adenoma, follicular cell, benign, 
primary 
0 0 0 2 0 0 0 0 
Pituitary # examined 27 27 27 27 27 27 27 27 
- hypertrophy, pars distalis, 
individual cells 
        
 -very slight 0 0 0 0 1 2 4 3 
 -slight 0 4 5 24 0 0 3 22 
Liver # examined 27 27 27 27 27 27 27 27 
- vacuolization, consistent with fatty 
change, hepatocyte, individual cells, 
multifocal 
        
 -very slight 23 24 26 18 3 0 0 2 
 -slight 0 2 0 8 0 0 0 0 
        Bolded values interpreted to be treatment related 
        Incidence of selected histopathological lesions in Cohort 1A rats – PND90 
Dose [mg/kg] 0 2.8 28 140 0 2.8 28 140 
Sex male female 
Animals in group 26 26 26 26 26 26 26 26 
 54 
 
 
Thyroid gland # examined 26 26 26 26 26 26 26 26 
 - hyperplasia, follicular cell, diffuse         
 -very slight 0 0 11 4 0 0 0 12 
  -slight 0 0 3 22 0 0 0 9 
 - hyperplasia, nodular, follicular cell, 
focal 
        
 -slight 0 0 0 1 0 0 0 0 
- hypertrophy, follicular cell, diffuse         
 -very slight 4 15 12 4 0 0 3 12 
 -slight 0 0 3 22 0 0 0 9 
- adenoma, follicular cell, benign, 
primary 
0 0 0 1 0 0 0 0 
Pituitary # examined 26 26 26 26 26 26 26 26 
- hypertrophy, pars distalis, 
individual cells 
        
 -very slight 3 9 9 6 0 0 0 0 
 -slight 0 0 6 13 0 0 0 0 
        Bolded values interpreted to be treatment related 
There was no evidence of treatment-related reproductive toxicity or effects on the 
estrogen- or androgen-related endocrine pathways at any dose of ETU. The a priori 
triggers for producing a second generation were not met; therefore, the F1 animals were 
not mated in this study. 
For developmental neurotoxicity, there were no effects on brain weights in the Cohort 2B 
animals (PND 22); however, there was a decrease in overall brain size (6-7% decrease in 
absolute brain weight) at the highest dose of ETU in the Cohort 2A females (PND 78) and 
Cohort 1A males (PND 90). The relative brain weight in Cohort 1A males on PND 90 was 
not statistically significantly different from controls (slightly increased) and for females in 
Cohort 2A the individual values were generally within the range of concurrent controls (2 
values 2.155 and 2.171 marginally below lowest control value of 2.174). 
Group mean body weights and brain weights 
Males 
 0 (Control) 140 ppm 
 Final body 
weight 
Brain weight 
(g) 
Final body 
weight 
Brain weight 
(g) 
Cohort 2B (PND 
22) 
56.8 1.543 52.0 1.527 
Unselected (PND 
22) 
55.2 1.496 54.3 1.487 
Cohort 2A (PND 
78) 
430.2 2.491 380.0 2.352 
  
 
Cohort 1A (PND90) 498.4 2.131 447* 2.017* 
Females 
 Final body 
weight 
Brain weight 
(g) 
Final body 
weight 
Brain weight 
(g) 
Cohort 2B (PND 
22) 
54.8 1.498 50.2 1.458 
Unselected (PND 
22) 
55.0 1.483 52.7 1.465 
Cohort 2A (PND 
78) 
251.5 2.385 243.0 2.227* 
Cohort 1A (PND90) 262.1 1.938 252.7 1.877 
 
The lower brain weight in the Cohort 2A animals was accompanied by decreases in 
overall brain macroscopic and microscopic measurements (1-4% decrease across all 
gross brain measurements: ≤ 5% change in microscopic measurements), but there were 
no differences in these parameters at ≤ 28 ppm.  The differences in brain weight and 
measurements at 140 ppm indicate a slightly smaller brain size with no specific brain 
region/layer showing a statistically significant effect.  
At 140 ppm there were effects on pup body weight from PND 14 which persisted in males 
until PND 112 (7.4% lower in Cohort 1B). In females body weights were not statistically 
significantly different from PND 56 but remained slightly lower than control. Overall, the 
data support the conclusion that growth at 140 ppm was reduced during late lactation, 
juvenile and early adult periods. Brain weight and body weight show a positive 
correlation and absolute organ weight is never an optimal endpoint for the evaluation of 
organ weight changes in the presence of body weight differences between the groups. 
The differences in brain weight (6-7%) were relatively small compared to the effects on 
body weight (up to 10%), many individual values were within the range of concurrent 
controls, and the morphometric analysis indicated that the brain was slightly small 
overall, rather than decreased in any specific region/layer. Consequently, in the absence 
of any effects on neurobehavioural endpoints or neuropathology, the differences in brain 
weight at 140 ppm ETU are considered to reflect the reduced growth during late 
lactation, juvenile and early adult periods and not to be evidence of specific 
developmental neurotoxicity. 
Conclusions 
In this guideline extended one-generation study, ETU caused no effects on reproductive 
toxicity or developmental neurotoxicity up to the top dose of 10 mg/kg bw/d. There was 
however parental toxicity and offspring toxicity from a dose of 2 mg/kg bw/d, manifested 
as effects on body weight (in adults and pups), thymus (decreased weight and atrophy of 
lymphoid tissue in adults), pituitary (hypertrophy in adults) and liver (vacuolation in 
adults) at the top dose and thyroid toxicity (hypertrophy in adults) at the mid and high 
dose. Overall therefore a NOAEL of 10 mg/kg bw/d is identified for reproductive toxicity 
and developmental neurotoxicity and a NOAEL of 0.2 mg/kg bw/d is identified for 
parental toxicity and offspring toxicity (Marty et al., 2013b). 
 
5.3 PERCHLORATE CASE STUDY 
5.3.1 Summary 
The effects of perchlorate have been investigated in humans on many occasions, 
including in studies from clinical and occupational exposures, studies with healthy 
volunteers and epidemiological studies. Results from a number of these publications are 
presented in this case study with the aim of elucidating the effects of the chemical on 
iodide uptake, thyroid function and its impact on the hypothalamus-pituitary-thyroid 
(HPT) axis in humans. From all these studies, a relatively consistent picture emerges: in 
healthy humans, an impact on thyroid function will only likely arise from prolonged 
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exposures to levels higher than 0.4 mg perchlorate/kg b.w. per day. However, this 
statement needs to be interpreted against the background of widespread iodine 
deficiency and  co-exposure to other iodide-uptake inhibitors, such as thiocyanate (from 
cigarette smoking) occurs which may exacerbate the effects of perchlorate. However, 
due to the limitations highlighted with epidemiological studies and the assessment of real 
exposures in populations, it is unclear whether lower dose could cause adverse effects in 
pregnant women, infants, children and people with low iodine intake or pre-existing 
thyroid dysfunction.  
In relation to evidence from animal studies, most of the data presented in this case study 
are from the rat model, even though studies have also been carried out in rabbits and 
mice. Sub-chronic and neurodevelopmental studies in the rat have shown that the rat is 
indeed a highly sensitive species, with changes in thyroid hormone levels at doses of 0.1 
mg/kg b.w. per day.  
As the aim of this study was to compare the sensitivity to perchlorate of the rat and 
humans, a large section is dedicated to comparing the outcome of short-term and long 
term exposures between the two species. One relevant point from this analysis is that 
the most vulnerable life stage in the rat is during gestation and postnatally. Even though 
the sensitivity of this life stage was compared to adult humans, a comparison to 
corresponding pregnant women or women post-partum is difficult to conduct due to a 
lack of relevant data.  
At the end of this case-study a section on approaches to the study of thyroid disruption 
from the ecotoxicology arena has been included. Here we propose a number of models 
using invertebrates, fish and fish embryos for consideration as potential alternatives to 
the rat as systems to investigate human thyroid disruption. 
5.3.2 Scope and aims of this case study 
The proper delivery of thyroid hormone to target cells and tissues both during 
development and in adulthood is dependent upon a variety of steps that are unique to 
this endocrine system. The aspect of the thyroid disruption to be discussed in this case 
study is the sensitivity of the rat model to iodide-uptake inhibitors in relation to humans, 
and whether the rat is an appropriate model for the identification of hazards and risks 
from sodium-iodide symporters to the human population. More specifically, the following 
questions are discussed, both in relation to their scientific implications and their 
regulatory significance and impact: 
 How do humans and rats compare in relation to their response to short and long 
term exposures to perchlorate?  
 If taking into account vulnerable subpopulations, such as pregnant women, 
newborns, infants, people with insufficient dietary iodine (defined by WHO) and 
people exposed to other chemicals that interfere with iodide uptake (eg: chlorate, 
nitrate, and thiocyanates), could the rat model be more representative of the 
effects in humans?  
 Could models widely employed to assess the impacts of thyroid disruptors in 
ecotoxicology be used for hazard identification? 
In order to address these points, the present case study includes information from 
perchlorate studies found in the open literature, as well as data from the NRC (NRC, 
2005) and EFSA scientific opinion paper on the risks of perchlorate to public health 
(EFSA, 2014). However, this paperis not meant to be an exhaustive substance 
evaluation, so only data relevant to the questions mentioned above is presented here.   
5.3.3 Perchlorate and its uses 
Perchlorate is an oxy-anion of chlorine which, when combined with cations like sodium, 
potassium, ammonium, forms perchlorate salts, such as sodium perchlorate, potassium 
perchlorate and ammonium perchlorate. Perchlorate occurs in the environment from 
natural and anthropogenic sources. The most common use of perchlorate salts is as 
  
 
oxidising agents in the manufacture of solid rocket propellants, explosives, pyrotechnics, 
grenades, signal flares and matches (Sijimil and Mohan, 2014).  
In terms of human exposure, different sources of contamination have been identified. 
These include the use of fertilisers of natural origin from countries with large natural 
deposits (such as the Atacama desert in Chile), industrial emissions of perchlorate into 
the environment, the natural formation of perchlorate in the atmosphere and surface 
water, and the formation of perchlorate during the degradation of chlorine-based 
products, such as sodium or calcium hypochlorite. In Europe, the use of natural fertilisers 
such as Chilean nitrate may lead to substantial concentrations in fruit and vegetables. 
Similarly, plant irrigation with perchlorate-contaminated groundwater can contribute to 
the accumulation of perchlorate in fruit and vegetables. Water disinfection with chlorine-
based biocidal products, potentially degrading to perchlorate, could be another notable 
source of contamination for drinking water and food. Perchlorate has been reported to 
occur in a wide range of foods, including vegetables, fruit, milk and dairy products, juice, 
beer, wine and bottled water (EFSA, 2014). An important issue to bear in mind is the fact 
that, in 2005, the FDA granted approval to using perchlorate as an anti-static agent in 
dry good plastic packaging. The chemical compound was already approved as an additive 
in sealing gaskets for food containers. Alarmingly, a report by Murray et al (2008) 
indicated that, unlike previously assumed, perchlorate is able to migrate from plastics 
into food and that almost 75% of all food types are contaminated with perchlorate.  
5.3.4 Mechanism of action of perchlorate 
The main toxic effect of perchlorate (both in humans and experimental animals) involves 
alterations in thyroid hormone levels, as a result of its competitive inhibition of thyroidal 
uptake of iodide into the thyroid follicular cells. 
  
The main function of the thyroid is to produce the thyroid hormones triiodothyronine (T3) 
and thyroxine (T4). One of the crucial steps of hormone synthesis in the thyroid involves 
the uptake of iodide into the thyroid follicular cells by the sodium iodide symporter (NIS) 
present in the basolateral membrane of the thyroid follicular cells. The perchlorate anion 
interacts with NIS competing with iodide for cell uptake. The perchlorate anion is then 
transported further into the thyroid lumen before it diffuses passively out of the thyroid 
gland into the blood supply and is eliminated in urine.  The NIS has been identified at the 
molecular level of some extrathyroidal tissues, such as the lactating mammary gland, the 
placenta, the salivary gland and gastric and intestinal mucosae, areas where the 
physiological functions of iodide transport have yet to be elucidated (reviewed in Leung 
et al., 2010). In breast tissue, the NIS is thought to play a role in the transport of iodine 
into breast milk. In addition to the direct effect in NIS, perchlorate is also able to reduce 
the levels of iodine in the thyroid by increasing free iodine loss from the organ. 
  
The effects of perchlorate on iodine availability should be seen in the context of other NIS 
inhibitors. These include thiocyanate, a metabolite of cyanide that is produced as a by-
product of cigarette smoke and found in a large variety of foods, and nitrate, which is 
produced naturally. Comparatively, perchlorate is a very potent inhibitor of the NIS; its 
effects are 15-fold greater than thiocyanate, 30-fold compared to iodide, and 240-fold 
compared to nitrate. Nonetheless, because exposure to thiocyanate and nitrate is 
ubiquitous, the additive effects on iodide uptake may be important when assessing iodine 
availability. Some have urged that the detection, concentrations and potencies of these 
other NIS inhibitors also be considered in studies reporting environmental perchlorate 
exposure, which were not assessed in the large U.S. population study reporting the 
adverse effects of perchlorate exposure on thyroid function in women (see section on 
“Observations from human studies with relevance to thyroid disruption”). 
 
Severe and sustained inhibition of iodine uptake in the thyroid following exposure to 
perchlorate can limit the availability of iodine required for the production of thyroid 
hormones T3 and T4, which could cause depletion of thyroid stores of these hormones 
and lower hormone serum levels. Decreases in circulating levels of thyroid hormones will 
trigger the hypothalamic-pituitary-thyroid (HPT) feedback pathway, resulting in an 
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increase in secretion of Thyroid Stimulating Hormone (TSH). TSH stimulates thyroid 
iodine uptake and the production and secretion of the thyroid hormones T3 and T4, and 
promotes growth of thyroid follicle cells. Persistent stimulation of the thyroid gland by 
elevated levels of TSH results in increases in thyroid gland size and weight (goitre), 
decreased colloid, hypertrophy and hyperplasia of thyroid follicle cells and thyroid 
tumours in rats (Fisher et al., 2012). Furthermore, thyroid hormones are essential for 
normal fetal growth and differentiation of many organs, especially in pre- and post- natal 
central nervous system and brain development. The fetus is dependent on maternal 
thyroid hormones until it can produce its own at approximately 16-20 weeks of gestation. 
Hence, during pregnancy, women with low T4 levels could be at risk of producing children 
with neuronal disabilities. 
 
5.3.5 Observations from human studies with relevance to thyroid 
disruption 
Here, we present a summary of the most relevant findings in terms of the human effects 
of perchlorate. This is not intended as an extensive review of the literature, but only to 
elucidate points of current debate.  
Potassium perchlorate was introduced as a form of therapy for thyrotoxicosis (overactive 
thyroid with increased production of thyroxin) in the 1950s. Several studies were 
published in the 1970s and 1980s analysing the side effects of perchlorate used to treat 
hyperthyroidism. A report by Wenzel and Lente (1984) presented the case of 18 patients 
suffering from Graves disease who were treated with 9mg ion/kg b.w. per day until the 
serum thyroid hormone levels were reduced. This was followed by a maintenance period 
of 12 months, when patients were treated with 0.4 – 1.2 mg perchlorate /kg b.w. per 
day for 12 months. During the maintenance therapy periods, the patients showed normal 
T3 and T4 levels and normal TSH-receptor stimulating antibodies and no side effects 
were reported in the study.  
In healthy adults, several reports have shown that exposure to levels of perchlorate 
ranging from 0.007 to 9mg ion/kg b.w. per day for periods between 14 days and 6 
months did not result in significant changes in hormone levels or thyroid function 
(Brabant et al., 1992; Lawrence et al., 2000; Lawrence et al., 2001; Braveman et al., 
2006). Endpoints analysed included serum total and free T4, total T3, thyroglobulin and 
TSH levels, and thyroid iodine uptake. In two of the studies (Lawrence et al., 2000 and 
Lawrence et al., 2001) there was a significant increase in relation to the baseline of 
thyroid hormones levels after treatment discontinuation, indicating an adaptive change of 
the iodine uptake in the presence of the inhibitory effects of perchlorate. However, a key 
issue here is that the levels of iodine in these different study populations was different, 
which affects the severity of the impacts seen in response to perchlorate.  
Of note is also the publication by Greer (2002) which reported the effect of perchlorate 
on the thyroid uptake of radiolabelled iodine in human volunteers in a study aimed at 
establishing the dose response in humans for perchlorate inhibition of thyroidal iodide 
uptake. For that, Greer and colleagues administered oral doses of perchlorate between 
0.007 and 0.5 mg/kg b.w. per day for 14 consecutive days. Iodine uptake statistically 
significantly decreased at ≥ 0.02 mg perchlorate/kg b.w. per day during the treatment 
period, reaching a mean inhibition of 67% at 0.5 mg/kg b.w. per day, whereas no 
statistically significant differences from the baseline were observed on the uptake on day 
15 (post-treatment). No statistically significant changes were observed in total T4, free 
T4, total T3 or TSH during the study period in any treatment group in comparison with 
the baseline levels, but these findings may not be surprising considering that the goal of 
this study was to determine the dose at which perchlorate reduced iodide uptake, and 
that T4 levels were predicted to remain unaffected.  
Retrospective epidemiological studies at the general population level, including sensitive 
subjects such as pregnant women and infants, showed varying results, some of them 
indicating changes in thyroid hormone levels in populations living in areas with known 
perchlorate contamination in drinking water (> 5 µg/L), others failing to demonstrate 
associations. 
  
 
 
Studies of infants and newborns exposed via mothers drinking tap water during the 
gestation period (Lamm and Doemland, 1999; Chang et al., 2003, Brechner et al., 2000, 
Buffer et al., 2006 and Pearce et al., 2010) did not find significant correlations between 
perchlorate levels and thyroid function. Outcomes evaluated included neonatal congenital 
hypothyroidism, neonatal thyroid parameters (T4 and TSH) and potential indicators of 
neurodevelopmental effects (attention deficit hyperactivity disorder and school 
performance). 
 
Associations between increasing concentrations in urine and a decrease in total T4 and 
increasing TSH in pregnant women have been seen (Steinmaus et al., 2016). Of note, 
Steinmaus et al. (2016) measured individual levels of perchlorate. An earlier study by 
Tellez et al. (2005) in which individual perchlorate levels were not measured did not see 
such an association (Tellez et al., 2005).Taken together, the changes reported in these 
epidemiological studies were of limited magnitude. Importantly, positive associations 
were mostly observed when potential exposure to perchlorate occurred in the presence of 
other risk factors, such as low dietary iodine intake, or exposure to other iodide uptake 
inhibitors, such as thiocyanate, via tobacco smoke (Steinmaus et al., 2013).  
 
However, it is important to bear in mind that many of these studies are of limited use for 
the evaluation of risks, because of the limited, or non-existent, information on individual 
exposure levels. For example, the study by Lamm and Doemland (1999) analysed 
neonate incidences of hypothyroidism in 6 counties in the states of California and 
Nevada, all known to have high levels of perchlorate in water. Concentrations varied 
between counties, but  the authors did not measure individual levels of perchlorate, but 
instead correlated the cases of congenital hypothyroidism with the concentrations of 
perchlorate in drinking water in the different counties. The use of city or state of 
residence as a surrogate for exposure invalidates the study. In order to identify a 
relationship between perchlorate and hypothyroidism, it would have been essential to 
determine the individual levels of the chemical in the affected individuals. Another issue 
with these studies is the general natural high variability of the thyroid hormone levels, 
and the presence of possible confounding factors that are not taken into account in the 
analysis (e.g. the potential effect of altitude on changes in thyroid hormone levels). 
 
On the basis of the body of evidence available from clinical studies, adult volunteers and 
epidemiological studies, NRC (NRC, 2005) and CONTAM (EFSA, 2014) concluded that 
hypothyroidism will likely only arise from a prolonged exposure to more than 0.4 mg 
perchlorate/kg b.w. per day in normal adults. At the same time, both NRC and EFSA 
stated that a lower, not further specified, dose could be sufficient to cause adverse 
effects in pregnant women, infants, children and people with low iodine intake or pre-
existing thyroid dysfunction. 
This is significant, considering that iodine deficiency is a substantial, global issue, with an 
estimated 2.2 million people (38% of the world's population) living in iodine-deficient 
areas. A report by US EPA estimates that at least 20% of pregnant women are already 
iodine deficient, resulting in T4 levels that put the fetuses’ developing brains at risk. For 
this population of pregnant women, it can be anticipated that any perchlorate exposure is 
likely to result in an even greater risk of impaired brain development in their children and 
potentially a lifetime of behavioral and learning difficulties. However, to date, no direct 
evidence is available to substantiate this possibility. 
5.3.6 Observations from experimental studies 
5.3.6.1 Experimental evidence – mammalian assays (rats) 
In a study by Siglin et al. (2000), Sprague-Dawley rats were exposed to ammonium 
perchlorate via the drinking water at doses ranging from 0.01 to 10 mg/kg b.w. per day 
for 90 days, followed by 30 days recovery period. After exposure, significant decreases in 
serum T3 and T4 were noted for both sexes at doses higher than 0.01 mg/kg b.w. per 
day. Significant increases were also seen in serum TSH in males at doses higher than 0.2 
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mg/kg b.w. per day and in females at 10 mg/kg b.w. per day. Increases in thyroid 
weight, thyroid follicular cell hypertrophy and colloid depletion were also noted in both 
sexes at the highest dose tested. Following the 30-day recovery period, significant 
decreases in serum T4 were found for males at all doses. In females, serum TSH was 
significantly increased at all doses and serum T3 was significantly decreased at the 
highest dose. Seeing as even the lowest dose induced thyroid hormone changes, the 
overall LOAEL for this study was considered to be 0.01 mg/kg b.w. per day. Similar 
results were reported by Stoker et al. (2006) who also saw dose-dependent decrease in 
serum T4 (125, 250 and 500 mg/kg doses), increase in TSH (doses: 125, 250 and 500 
mg/kg) and alterations in thyroid histology (at doses 62.5, 125, 250, and 500 mg/kg), 
namely follicular cell hypertrophy and decreased colloid area. 
Neurodevelopment effects 
In a study by York et al. (2004) investigating developmental neurotoxicity, female 
Sprague-Dawley rats were administered ammonium perchlorate continuously from GD0 
to PND 10 at concentrations ranging from 0.1 to 10.0 mg/kg b.w. per day. An increase in 
thickness of the corpus callosum was noted in pups at the highest dose. An increase in 
incidence of thyroid follicular epithelium hypertrophy and hyperplasia and a reduction in 
follicle size was seen for female pups at doses higher than 3 mg/kg b.w. per day and 
males pups at 10.0 mg/kg b.w. per day, making  histopathological effects the most 
sensitive endpoint. Decreases in thyroid hormone levels and increases in TSH levels were 
also noted at the highest dose tested. In another publication York and colleagues (2005) 
reported significant increases in the linear dimensions of a number of brain regions in 
male pups at all doses and a reduction in the size of certain brain regions in female pups. 
However, no effects on male rat brain weights or neuropathology were noted.  
In a later study by Gilbert and Sui (2008), female Long-Evans rats were exposed to 
ammonium perchlorate at 4.5, 44.2 and 140.3 mg/kg b.w. per day from GD6 to PND 30. 
Serum TSH levels in pups were significantly increased at 4.5 and 44.4 mg/kg b.w. per 
day. Significant decreases in serum T3 and T4 were noted at the highest dose were noted 
in pups. In adult male offspring (five to nine months old), significant dose-dependent 
reductions in baseline synaptic transmission were observed in hippocampal field 
potentials in all three doses. All serum hormone concentrations returned to normal in 
adulthood and no behavioural alterations were observed in hippocampal-based learning 
tasks. However, there was a significant reduction in baseline synaptic transmission in 
hippocampal field potential that persisted in the adult offspring suggesting that 
developmental exposures to perchlorate may result in permanent alterations in brain 
function.  
In summary, the studies described above demonstrate that perchlorate perturbs the HPT 
axis in the adult rat, pregnant and lactating dams and PND 22 pups of both sexes. This 
means that when serum TSH levels were elevated, the corresponding serum thyroid 
hormones were either decreased or maintained similar to control levels of thyroid 
hormones.  
Nevertheless, NRC (2005) and EFSA (2014) highlighted concerns regarding the 
interpretations of results of developmental neurotoxicity studies with perchlorate due to 
design and methodological problems and to the lack of sensitivity of the neurobehavioral 
tests for the detection of subtle changes in motor or cognitive function resulting from 
moderate reductions in thyroid hormone levels. Based on the available data and the 
limitations listed, the recent CONTAM panel (EFSA, 2014) concluded that ‘it is not 
possible to determine an association between exposure to perchlorate and development 
neurotoxicity from the studies in rats’.  
5.3.6.2 Interspecies differences in sensitivity to perturbation of thyroid 
homeostasis – comparison between rat and humans 
While the data strongly supports the notion that both humans and rats are affected by 
perchlorate in terms of thyroid dysfunction in both short and long term exposures, the 
evidence also shows that the two species exhibit differences in terms of thyroid hormone 
  
 
and HPT axis responses to the inhibition of iodide uptake caused by the chemical. Two 
reports, Lewandowsky at al., 2004 and Fisher et al., 2012 have addressed this issue by 
comparing the outcomes of a number of rat and human studies. The results from 
Lewandowsky et al., 2004 are summarised here: 
In the rat, thyroidal iodide uptake is markedly depressed after an acute intravenous dose 
of perchlorate, within the span of a couple of hours (Yu et al., 2002). A similar response 
is seen in adult humans within two days of exposure (Greer et al., 2002), however in this 
case the exposure was from drinking water. No other data is available for acute effects of 
perchlorate in humans.  
The situation is markedly different with longer perchlorate exposures. In this case, the 
differences between the rat and humans in terms of iodide uptake are more substantial. 
After administration of perchlorate in drinking water for 14 – 23 days, rats at various life 
stages (male, pregnant female and postnatal female dam) have less uptake inhibition 
and, in some cases, have iodide uptakes which are higher than pre-dosing baseline levels 
(Yu et al., 2002). In contrast, the human response after 14 days of perchlorate exposure 
is similar to the acute responses after two days (Lawrence et al., 2000; Greer et al., 
2002) with a significant decrease in iodide uptake.  
A similar pattern is reported for thyroid hormone levels. Lewandowski and colleagues’ 
(2004) analysis showed that male and female rats exhibit a clear upward trend in serum 
TSH with increasing perchlorate dose. The most sensitive life stages were shown to be 
the pregnant and postnatal female (LOEL of 0.1 mg/kg b.w. per day). The authors 
compared this to the human study of Greer (2002), where individuals given perchlorate 
at 0.4 mg/kg b.w. per day for 14 days did not have serum TSH levels that were 
significantly different from controls, and concluded that therefore the rat must be more 
sensitive than humans after 14 days exposures. However, no comparison was made with 
pregnant or postnatal humans exposed to perchlorate for the same period.  
Similarly, for T3 levels, data from a range of studies was compiled and results showed 
pronounced dose-response effects on rats with a LOAEL in pregnant rats, postnatal dams 
and neonates of 1 mg/kg b.w. per day for 14 days. The LOAEL for fetal rats and non-
pregnant adult rats was 0.01 mg/kg b.w. per day. This was compared with data in 
humans (Greer et al, 2002) and Lawrence et al. (2000, 2001) who did not see effects 
with doses as high as 0.48 mg/kg b.w. per day for a 14 day period. However, these 
studies on humans do not include data on pregnant women or newborns, so comparisons 
were not made for these subpopulations.  
Finally, for longer term exposures, comparisons were made for a number of species. The 
results are summarised in the following table published by Lewandowski et al. (2004): 
 
Figure 1 –Obtained from Lewandowski et al., 2004 
While the data clearly shows a higher sensitivity for acute effects for the adult rat in 
relation to all the other species, including adult humans, again, no comparison was 
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performed in relation to more vulnerable subpopulations, such as pregnant human, 
postnatal human or infant.  
As the evidence above shows, lower doses of perchlorate are sufficient to affect iodide 
uptake, thyroid hormone and TSH levels in rats, compared to humans. A number of 
physiological differences between both species have been highlighted as likely 
contributors to the toxicological differences. These are: 
 The half-life of thyroid hormones in adult rats is significantly shorter than in 
humans. As a consequence, the rat is significantly less able to compensate for 
perturbations in its thyroid axis than humans following exposure to thyroid disrupting 
chemicals (Lewandowski et al., 2004; Fisher et al., 2012).  
 
 The duration of exposure to perchlorate that is required to cause 
disturbances in circulating levels of serum thyroid hormones is shorter in the 
rat compared to humans. This is considered to be due to the rat thyroid gland 
having a smaller store of iodinated thyroglobulin (colloid), compared to humans, that 
is quickly depleted when iodine is limited (ASTDR, 2008). Close to birth, human fetal 
stores of iodine are also much greater compared to rat fetal levels, and the weight of 
the thyroid gland (relative to body weight) is also lower in the rat fetus, indicating the 
immature nature of the thyroid gland in the rat fetus near birth (Fisher et al., 2012). 
Nevertheless, it is important to point out that the newborn human has no stored 
thyroid hormone, and given that the ½ life of its T4 is much shorter than in adults, its 
requirements of iodine are high, in comparison with adults.  
 
 The occurrence of thyroid tumours (papillary/follicular adenomas and 
carcinomas), following exposure to perchlorate, have been noted in rats and 
mice. There has been no direct evidence of perchlorate causing thyroid cancer in 
humans (ATSDR, 2008). The development of thyroid tumours following exposure to 
perchlorate is seen as unlikely in humans (NRC, 2005). 
 
The implications of these physiological differences between humans and the rat led to the 
argument that ‘the rat is a problematic model to use in estimating human health risks for 
chemicals that perturb thyroid function’ (Lewandowski et al., 2004). The examination of 
T3 and T4 and, particularly, TSH responses to perchlorate in rats in comparison with 
humans has led to the suggestion that humans have a greater potential for adaptation 
after exposure to chemicals, without suffering changes in levels of serum thyroid 
hormones. Consequently, this evidence seems to suggest that the rat has much higher 
sensitivity to the effects of chemicals that affect the pituitary-hypothalamic-thyroid axis. 
This has led to the idea that whilst the rat can be considered a good model for screening 
thyroid disrupting chemicals and hazard identification, the current extrapolation tools 
routinely used in risk assessment are inadequate for extrapolating thyroid mediated 
disturbances and toxicity in rats to humans (Pickford, 2010; Lewandowski et al., 2004; 
Fisher et al., 2012). 
 
In the fipronil case study we compile more recent evidence of the prevalence of 
transport proteins in the rat and in particular about TTR that should be taken into 
account when considering the usefulness of the rat for purposes of hazard identification 
and hazard assessment. 
 
In any case, it is important to note that, due to a lack of robust epidemiological data, 
comparisons between the rat model and more sensitive humans subpopulations, such as 
pregnant women, infants, children, people with low iodine intake or pre-existing thyroid 
dysfunction and people exposed to other iodide-uptake inhibitors (such as thiocyanate in 
cigarette smoke) have not been conducted in detail. It is possible that, in these special 
cases, the high sensitivity of the rat model might be useful and relevant to estimate 
disturbances of thyroid function in humans. We believe this topic deserves further 
investigation in the future.  
 
5.3.7 Ecotoxicology evidence 
  
 
Based on the rat-human interspecies differences described above, it would be important 
to assess the applicability of alternative models for the testing of thyroid disrupting 
chemicals.  
 
Due to the prevalence of perchlorate in the environment, several ecotoxicological test 
systems have been developed and optimised in order to evaluate the impact of chemicals 
able to disturb the thyroid on wildlife species. 
  
5.3.7.1 Amphibians 
Studies in various amphibian species have demonstrated the ability of perchlorate to 
inhibit thyroid-dependant metamorphosis (Reviewed in Pickford, 2010). Perchlorate was 
selected for the OECD Phase II optimisation and validation exercise for the Amphibian 
Metamorphosis assay.  
Comparing perchlorate studies in rats and amphibians clearly indicates that both models 
are responsive to the impairment of thyroid hormone synthesis that results from the 
competitive inhibition of NIS by the perchlorate ion. Similar to the rat model, the most 
sensitive endpoint in the amphibian metamorphosis assay is the thyroid histopathology 
and the changes usually seen in thyroid structure are similar to those in the rat (e.g. 
increased gland size, colloid depletion and follicular hyperplasia). In terms of relative 
sensitivity of the rat and amphibian models, significant effects on thyroid structure have 
been reported at a dose level of 62.5 mg/kg day in the rat pubertal assay (Stoker et al., 
2006) and a test concentration of 62.5 μg/L in the OECD Phase II validation of the 
amphibian metamorphosis assay (OECD, 2007), though in neither study was a NOEL 
achieved for this endpoint.   
5.3.7.2 Fish 
The pathways involved in human thyroid development, as well as tissue architecture, 
function and feedback regulation by the hypothalamus-pituitary-thyroid (HPT) axis are 
conserved in a variety of fish species making them promising models for the study of 
thyroid-active compounds. The responses of species such as fathead minnows, zebrafish 
and Eastern mosquitofish all have displayed thyroid follicular hypertrophy, hyperplasia 
and altered TSH in response to perchlorate (Jomaa et al., 2013; Raldúa and Babin, 2009, 
Crane et al., 2005; Schmidt et al., 2012; Mukhi and Patiño, 2007; Bradford et al., 2005). 
Similarly, a growing number of studies are using the stickleback as a model to study the 
impact of perchlorate on thyroid homeostasis and development (Bernhardt et al., 2011). 
An assay to note here is the Zebrafish Eleutheroembryo Thyroid Assay (Thienpont et al., 
2011). The endpoint measured in this assay is T4 concentration in thyroid follicles of 5 
days postfertilization (dpf) zebrafish following 3 days of exposure to a water-borne 
chemical. On day 5 pf, larvae are fixed, and subjected to whole-mount 
immunofluorescence analysis using a polyclonal rabbit anti-T4 antibody. Total T4 
immunofluorescence in follicular cells is then quantified and compared with untreated or 
vehicle-treated controls. The assay has been shown to respond significantly to 
perchlorate. To compare the sensitivity of rats and zebrafish eleutheroembryos to 
perchlorate, significant effects on thyroid gland histology were reported at a dose level of 
62.5 mg/kg/day in a rat pubertal assay and 125 μg/L in the zebrafish Eleutheroembryo 
thyroid assay. However, it is difficult to compare dietary dose levels and aquatic test 
concentrations in the absence of robust data on uptake, distribution, and clearance of the 
test chemicals in the respective model organisms. According to a recent OECD scoping 
document, this assay has strong potential for identifying water soluble chemicals that 
directly affect thyroid function, and has the potential to be relevant to vertebrates in 
general if species differences in metabolism are taken into account. 
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5.4 PBDE/PERFLUORINATED COMPOUNDS/PCB CASE STUDY 
 
5.4.1 Summary 
PBDEs induce clear neurodevelopmental effects in the human (cognitive effects, low IQ), 
but the picture that emerges in relation to thyroid disruption is far from clear. In some 
epidemiological studies, decreases in serum TH levels were seen, in others the opposite 
was observed. There are issues with data interpretation, due to concurrent exposures 
with other persistent pollutants also suspected of affecting thyroid hormone (TH) levels, 
the biological activity of unmeasured metabolites, the temporal variability in exposure 
and hormone levels measurements and gender-dimorphic responses that may be masked 
when separate analyses are not carried out for both genders.  
In rodent studies, polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls 
(PCBs) and poly- and perfluorinated alkyl substances (PFASs) reduce total and free 
serum T4, but without corresponding increases in TSH, a pattern described as 
“enigmatic”.  In order to shed light on the significance of altered circulatory TH levels, 
the effects of PBDES, PCBs and PFASs and their metabolites on the Hypothalamus-
Pituitary-Thyroid axis, binding to proteins involved in peripheral TH transport, the 
regulation of intracellular levels of THs, binding affinity for thyroid receptors (TR), and 
downstream TH-mediated effects in some of the best studied organs (liver, brain, testes) 
were compared. The evidence available reveals both that these three classes of 
compounds can act, sometimes in opposite direction, centrally on the HPT axis, on tissue 
levels of TH by binding to peripheral transport proteins, cellular transporters or disrupting 
deiodinase action, and ultimately on TR-mediated genes. There is also clear evidence 
that one substance can elicit different responses in different tissues. It is therefore clear 
that interpretation of changes in peripheral TH levels is not ‘one size fits all’. Similar 
patterns of effects peripherally may mask the complexity of concurrent disruption of TH 
action on several regulatory processes centrally, peripherally and in different tissues. 
5.4.2 Scope and aims of this case study 
The aspect of thyroid disruption discussed in this case study is the “enigmatic” pattern of 
effects of PBDEs on circulating thyroid hormone (TH) levels, namely decreases in TH that 
are not accompanied by the corresponding increases in TSH as expected from negative 
feedback. The emphasis was placed on comparing recent evidence related to downstream 
effects of PBDE exposure mediated via thyroid receptors (TRs) in different organs and 
tissues. This was compared with similar effects observed following exposure to 
polychlorinated biphenyls (PCBs) and per- and polyfluorinated alkyl substances (PFAS) 
that display the same enigmatic pattern. This case study should inform discussions 
related to the scientific significance of effects on circulatory TH levels and their 
implication for bioassay development, particularly: 
- How should effects on circulating thyroid hormones T3 and T4 be interpreted in the 
absence of concurrent effects on TSH levels? 
- What are the implications of tissue-specific responses for bioassay development? 
  
5.4.3 PBDEs, PFAS and PCBs and their uses 
Polybrominated diphenyl ethers (PBDEs) are persistent organic chemicals widely used as 
flame retardants in consumer products since the 1970s. The commercial mixture penta-
BDE has been most often added to polyurethane foam used in furniture, while octa- and 
deca-BDE commercial mixtures have been used in electronics and other plastic products. 
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PFAS are a class of man-made organofluorine compounds widely used as surfactants and 
commonly differentiated by the length of their carbon chain. Perfluorooctanoic acid 
(PFOA) and perfluorooctanesulphonic acid (PFOS) have been the most extensively 
produced and studied. The strong C-F bonds exclude normal degradation pathways. 
Parent compounds are thought to be transformed to their acid, and both short- and long-
chain perfluoroalkyl acids (PFAAs) are considered being metabolically inert (Danish EPA, 
2015).  
PCBs are organochlorine compounds formed of two benzene rings substituted by up to 10 
chlorine atoms, resulting in up to 209 congeners. They were widely used as coolants and 
insulating fluids. In a manner akin to PBDE congeners, the lower circulating levels of T4 
observed following exposure to PCBs has been assumed to be due to increased hepatic 
T4 clearance. 
5.4.4 Observations from human studies with relevance to thyroid 
disruption 
The epidemiological evidence of the neurobehavioural effects of PBDEs is now little 
disputed and will not be elaborated on here. Instead, this section will focus on the 
substantial number of epidemiological studies that have investigated the association 
between PBDE exposures and thyroid hormone levels.  
In studies of mixed-gender adult populations, including specific ethnic groups such as 
Inuits (Dallaire et al. 2009) or occupationally exposed workers (Eguchi et al. 2015; 
Makey et al. 2016; Wang et al. 2010) as well as Chinese volunteers (Huang et al. 2014), 
no consistent pattern of effect emerges. Interestingly, Eguchi and colleagues (2015) 
reported a significant increase in TSH with total PBDE exposure when the analysis was 
carried for women only (67 women and 44 men were included in this study). Several 
studies have focused on men, including some highly exposed via their occupation 
(Julander et al. 2005; Pettersson et al. 2002) or recreational activities such as fishing 
(Bloom et al. 2008) and  the consumption of fish (Hagmar et al. 2001; Turyk et al. 
2008), whilst others were recruited via fertility clinics (Abdelouahab et al. 2011; Meeker 
et al. 2009; Johnson et al. 2013). Again, no consistent pattern of effect on TSH can be 
detected, however statistically significant increases in free T4 tended to be reported more 
often. The two Swedish studies examining small samples of workers in electronic waste 
dismantling plants carried out repeated measurements over time and noted considerable 
fluctuations in PBDE levels (Julander et al. 2005; Pettersson et al. 2002). One 
epidemiological study has considered non-pregnant adult women alone. Interestingly, 
as this study examined the association between PBDE exposure and clinical 
hypothyroidism rather than circulating TH levels, it included women currently taking 
thyroid medication, a population typically excluded from epidemiological studies in 
pregnant women (Oulhote et al. 2016). This cross-sectional study found a higher 
prevalence of hypothyroidism in highly exposed women, a significant relationship that 
became stronger when only younger women were considered.  
No consistent pattern of effect is evident from studies in children (Gascon et al. 2011; 
Jacobson et al. 2016; Xu et al. 2014; Roze et al. 2009) or adolescents (Kicinski et al. 
2012; Leijs et al. 2012). Both Jacobson et a. (2016) and Xu et al. (2014) reported that 
PBDE concentrations were higher in girls than boys, however no study has reported 
gender specific analysis of associations between TH and PBDE levels. 
Due to the potential neurodevelopmental effects on the developing fetus, maternal 
thyroid hormone levels and PBDE exposure during early and late pregnancy have been 
the focus of considerable research efforts (Kim et al. 2013; Chevrier et al. 2010; Zheng 
et al. 2017; Abdelouahab et al. 2013; Vuong et al. 2015; Stapleton et al. 2011; Mazdai 
et al. 2003; Miranda et al. 2015; Lignell et al. 2016; Shy et al. 2012; Lin et al. 2011; Kim 
et al. 2011; Zota et al. 2011). Despite such efforts, no consistent associations between 
total PBDE exposure and maternal thyroid hormone levels have emerged, possibly 
because of the different stages of pregnancy studied. It should be recalled that TH and 
TSH levels during early pregnancy are exceedingly variable because of the enhanced 
requirements for TH particularly during early pregnancy and because human chorionic 
  
 
gonadotrophin stimulates the thyroid in this period leading to a physiological decrease in 
TSH levels.  Hence each lab has to establish norms for their thyroid measurements and 
cohort/ exposure studies require large numbers to obtain sufficient statistical analytical 
power.  
It is nonetheless interesting to note that recently, whilst investigating Chinese pregnant 
women residing in the vicinity of an electronic waste recycling plant, Zheng et al (2017) 
found that a significant decrease in total T4 could be detected when restricting their 
analysis to women who had lived in the area for over 20 years. This suggests that the 
duration of exposure may be as important a variable as measured PBDE levels. Similarly, 
Zota et al (2011) did not find significant associations when considering the sum of 
PBDEs. However when they restricted their analysis to either hydroxylated PBDE 
metabolites or when they weighted PBDEs or their metabolite by their affinity for binding 
to transport proteins, significant TSH increases became apparent.  
Correspondingly, the exposure of newborns and infants has also been the focus of 
considerable research (Lignell et al. 2016; Kim et al. 2009; Kim et al. 2011; Kim et al. 
2012; Kim et al. 2015; Leonetti et al. 2016; Herbstman et al. 2008; Chevrier et al. 2011; 
Eggesbø et al. 2011). The majority of studies infer neonates’ exposure from maternal 
blood, cord blood or breast milk and do not detect clear associations with newborns’ TH 
levels. Two recent studies measured PBDEs in neonates’ blood (Lignell et al. 2016) or 
placenta (Leonetti et al. 2016). Lignell et al (2016) report a positive association between 
total PBDE levels and total T3 at three weeks that was no longer significant at three 
months of age. Leonetti et al (2016) report a marginally significant association between 
total PBDEs and T3 in girl infants only, whilst in boys a marginally significant positive 
association with T3 sulfate was found. Placental PBDE congener levels tended to be 
higher for boys compared to girl infants. 
Many of the studies cited here also investigated concurrent exposures with other 
persistent pollutants such as PCBs or PFASs. These co-exposures could confound any 
associations. Other confounding factors such as iodine status are not routinely corrected 
for, and methods to correct for blood lipids are subject to debate (Chevrier et al 2013).  
Furthermore, the majority of studies do not measure exposure to metabolites, 
particularly hydroxylated metabolites that are considered potentially more biologically 
active than the parent compound as will be illustrated in the following section. 
Additionally, it appears that PBDE levels are variable and that duration of exposure may 
be as important a variable as a concentration measured in one sample. Indeed, as TH 
regulate lipid metabolism and can also influence the metabolism of xenobiotics, some of 
the discrepancies in the literature observed with studies of associations with spot 
analyses of PBDEs adjusted for limits may be explained by reverse causality (Chevrier et 
al 2013). The temporal variability in both hormone levels and PBDEs may in any case 
hamper the detection of statistically significant associations. Further, gender dimorphic 
responses may be masked when studies have considered men and women, or boys and 
girls together. Finally, this summary has focused on reported associations with the sum 
of measured PBDEs and a detailed analysis of the consistency of significant associations 
with specific congeners was considered beyond the scope of this summary. 
5.4.5 Observations from experimental studies – comparisons with PCBs 
and PFASs 
Concerns arose regarding the PBDE congeners and their potential to disrupt thyroid 
processes due their structural similarity with T3. Reductions in serum levels of T4 are 
consistently observed in rodents following PBDE exposure. It has long been presumed 
that it is because PBDEs induce hepatic microsomal enzymes that increase T4 clearance, 
thereby reducing serum T4 in an analogous manner to the effects of phenobarbital 
(Bansal et al. 2014). However, the concurrent up-regulation in circulatory TSH expected 
from negative feedback mechanisms, as observed following anti-thyroid drug 
propylthiouracil (PTU) or phenobarbital-induced reductions in serum T4, is typically not 
detected. Similar patterns of effects have been observed with PCBs and PFAS (e.g. 
Zoeller et al., 2000; Lau et al., 2007). 
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The hepatic microsomal enzymes induced by PBDEs and PCBs are also involved in the 
detoxification of xenobiotic compounds and catalyse the addition of hydrophilic groups to 
the lipophilic phenolic structures resulting in metabolites that more readily excreted. 
These metabolites themselves may interfere more significantly with T3 effects on thyroid 
receptor (TR) activation than the parent compounds (Blanco et al. 2014). Moreover 
PBDEs can also displace T4 and bind antagonistically to TH transport proteins (Blanco et 
al. 2014; Bansal et al. 2014; Meerts et al. 2002). 
In the following section, we briefly review the evidence on the binding affinities of PBDEs 
and their metabolites on TR isoforms, transport protein and their TH-mediated 
downstream effects in different organs. 
5.4.5.1 The HPT axis 
The production of Thyroid Releasing Hormone (TRH) in the hypothalamus stimulates the 
release of TSH by the pituitary which in turn initiates TH production in the thyroid gland. 
In a negative feedback loop, T3 levels regulate the production of TRH by the 
hypothalamus and TSH by the pituitary. A decrease in circulating THs would therefore be 
expected to increase the production of TRH and TSH. In rats, as in humans, the integrity 
of the HPT-axis is examined by administering synthetic TRH. Khan and Hansen (2003) 
evaluated the functionality of the HPT-axis in juvenile female rats by administering TRH 
following acute exposure to PCBs 95 or 101 (32 mg/kg for 2 consecutive days). Serum 
TSH levels were elevated in response to TRH but were only 40% of the response in 
controls. To our knowledge, no such TRH stimulation tests having been carried out 
following exposure to PBDEs or PFASs. Chang et al. (2008) investigated the secretion of 
TSH following TRH stimulation in the excised pituitary of rats previously dosed orally with 
3mg/kg potassium PFOS per day for 7 consecutive days and saw no effect of PFOS 
exposure on TRH-mediated TSH release.  
5.4.5.2 Pituitary 
TSH is composed of two subunits synthesized separately. The GPHα subunit is identical to 
that of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), so it is the TSHβ 
subunit that determines the hormone’s functional specificity (Lema et al. 2008).  
In the fathead minnow, TSHβ mRNA was elevated in both sexes by the lower dose of 
BDE-47, consistent with negative feedback from decline in circulating T4. At the higher 
dose, transcripts for GPHα were depressed in both sexes without a change in TSHβ 
(Lema et al 2008), suggesting that alternative regulatory mechanisms or toxic effects 
may occur depending on the dose. Conversely, Bansal et al (2014) did not observe any 
increase in TSH mRNA in male rats exposed to DE-71. 
The zebrafish has proven a popular experimental model to investigate the relationship 
between PBDE exposure and TSHβ gene expression (e.g. Chen et al. 2012; Zhao et al. 
2016; Yu et al. 2010). Gene expression is however typically determined in whole body 
homogenates and this model does not allow the investigation of tissue specific responses. 
On the other hand, PFOS and PFOA exposure produced similar tissue specific responses 
in Atlantic salmon (Spachmo & Arukwe 2012). Both upregulated TSHβ gene expression in 
body region, and downregulated it in the head region.  
Of ecological relevance, Couderc et al. (2016) measured PBDEs, PCBs and PFASs in the 
muscle tissue of the critically endangered yellow and silver European eels sampled in the 
Loire (France). Significant negative correlations between several PCB and PBDEs and 
lower plasma free T4 were detected in yellow individuals. It was not the case for PFASs. 
TSHβ gene expression in brain tissue was only significantly correlated with some PCBs.  
5.4.5.3 Thyroid 
Iodine is the major constituent of THs. Iodide is actively transported into thyroid follicular 
cells via the sodium-iodide symporter (NIS), where it is conjugated to thyroglobulin 
molecule (TG), a process catalysed by thyroid peroxidase (TPO).  
  
 
 
FRTL-5 is a rat thyroid follicular cell line that has been used to study the influence of 
chemicals on iodide uptake and TH synthesis. Wu et al. (2016) found that BDE-47 was a 
non-competitive inhibitor of NIS (Ki = 77.8 μM). The authors also examined the 
transcriptional expression of three genes involved in TH synthesis, Slc5a5, Tpo, and Tgo, 
and three thyroid transcription factor genes, Pax8, Foxe1, and Nkx2-1, using rt- PCR in 
the same cell line. BDE-47 decreased the level of Tpo but no significant changes in the 
expression of any other genes were observed (Wu et al. 2016).  
Intraperitoneal injection doses from 10 to 1000 μg/kg/day PCB118 for 13 weeks caused 
significant decreases in NIS and TG mRNA expression levels in rats (Tang et al. 2013). In 
pig thyrocyte cell culture, 306 nM PCB126 did not affect the gene expression of TG, TPO, 
or the TSH receptor (TSHR), while it downregulated the gene expression of NIS (Pocar et 
al. 2006). In FRTL-5 cells exposed to mono-ortho PCB 156 and its hydroxylated 
metabolites 4'-OH-PCB 159, 4'-OH-PCB 121, and 4'-OH-PCB 72, significant increases of 
TG concentrations were observed in the medium of cells exposed to 4'-OH-PCB 121 and 
4'-OH-PCB 72 at concentrations as low as 1 nM, but not to the other compounds (Yang et 
al. 2008). 
The activities of TPO, NIS, and TSHR mRNA in the thyroid of male rats were unaffected 
by  15.0 mg/L of PFOS in drinking water for 91 consecutive days (Yu et al. 2009).  
In zebrafish, Pax8, Nkx2-1, Slc5a5 and Tgo were also upregulated following exposure to 
BDE-209, BDE-47 or DE-71 (Yu et al. 2010; Chen et al. 2012; Zhao et al. 2016). Pax8, 
and another gene involved in early thyroid development in the zebrafish, hhex, were also 
investigated following of exposure to PFOS. Du et al. (2013) found that both genes were 
upregulated when embryos were exposed to up to 500 μg/L PFOS for 7 consecutive days, 
while Shi et al. (2008) found that the effect was no longer significant at doses above to 
1mg/L. No similar study was found for PCBs. 
Effects related to iodide uptake were also investigated in clams (Song et al. 2016), 
minnows (Li et al. 2014) and gulls (Techer et al. 2016) following exposure to PBDEs, and 
chicken (Katarzynska et al. 2015) and gulls (Techer et al. 2016) following exposure to 
PCBs.  
5.4.5.4 Cellular levels of thyroid hormones 
Proteins in the serum reversibly bind THs establishing two pools of circulating T4 and T3 
(i.e., protein-bound and free). The major circulating TH binding proteins differ in rodents 
and humans, with transthyretin (TTR) being the major protein in the rat and Thyroxine 
Binding Globulin (TBG) in humans. The free plasma TH is in equilibrium with tissues and 
affects TH signalling. 
Peripheral transport - binding affinity for transport proteins 
One hypothesis to explain the decrease in T4 often seen after PBDE exposure is that it is 
caused by the displacement of T4 from transport proteins.  
The hydroxylated PBDE metabolites (OH-PBDE) have the potential to displace thyroid 
hormones from transport proteins, as they demonstrated much greater binding affinity to 
transport proteins than the hormones to both transthyretin (TTR) (Hamers et al. 2006; 
Meerts et al. 2000) and thyroxine-binding globulin (TBG) (Marchesini et al. 2008). 
Binding affinities of OH-PBDEs appear to be related to bromination, increasing 
significantly from 1 to 4 bromine atoms with no further increase with 5- and 6-
brominated diphenyl ethers (Cao et al. 2010). In rodents, PBDE exposure has also been 
found to decrease Ttr mRNA expression (Szabo et al. 2008; Richardson, Staskal, Ross, 
Diliberto, DeVito & Birnbaum 2008). Binding to TTR and its mRNA expression following 
exposure to PBDEs have also been investigated in birds (Crump et al. 2008; Ucan-Marin 
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et al. 2009; Techer et al. 2016) and the zebrafish (Chen et al. 2010; Zheng et al. 2012; 
Chan & Chan 2012; Zhao et al. 2016). 
Similarly, hydroxylated PCB metabolites (OH-PCBs) have a binding affinity for TTR similar 
to that of T4 and orders of magnitude greater than the parent compounds (Cheek et al. 
1999; Hamers et al. 2011). The same cannot be said of their affinity for TBG for which 
they display an affinity in vitro about 100-fold lower than T4 (LANS et al. 1994). 
Recently, some lower-chlorinated OH-PCBs were identified as excellent substrates for 
cytosolic sulfotransferases (SULTs). These PCB sulfates were found to be able to bind 
TTR with an affinity similar to that observed for T4 (Grimm et al. 2013). The ability of 
OH-PCBs to displace T4 from TTR has also been observed in rodents, in vivo and ex vivo 
(Darnerud et al. 1996; Hallgren & Darnerud 2002). Binding to TTR and its mRNA 
expression following exposure to PCBs have also been investigated in birds (Ucan-Marin 
et al. 2009; Techer et al. 2016) and the frog (Shirey et al. 2006). 
There still is relatively little information on the interaction of PFASs with TH transport 
proteins. PFAS tend to bind only weakly to TTR with binding potency 12.5-50-fold lower 
than the natural ligand T4. No binding activity could be detected for fluorotelomer 
alcohols (Ren et al. 2016; Weiss et al. 2009). PFAS do not appear to bind or display very 
low affinity for TBG (Ren et al. 2016; Weiss et al. 2009). The structure-binding analysis 
revealed that the binding affinities of PFASs to TTR are associated with the carbon chain 
length and the charge of the end group, with a medium chain length and a sulfonate acid 
group being optimal. In zebrafish, PFOS was found to down-regulate TTR gene 
expression in a concentration-dependent manner (Shi et al. 2009). 
Transport into cells 
THs transit in and out of cells via several different membrane transporters regulating 
intracellular thyroid hormone availability. Serum concentrations of circulating TH may 
therefore not be representative of intracellular T3 concentration, particularly if this 
transport system is disrupted. Solute carriers known to transport THs include 
monocarboxylate transporters (MCTs), Na+ /taurocholate co-transporting polypeptide 
(NTCP), organic anion transporters (OATs), amino acid transporters, and organic anion 
transporting polypeptides (OATPs). These carry both T4 and T3, and some, such as 
members of the MCT family facilitate not only cellular uptake, but also the efflux of THs. 
Transport is facilitated by specific substrate–transporter interactions and predominantly 
driven down concentration gradients. However, the physiological role of the transporters 
does not depend solely on their relative affinities for THs but also upon tissue- and cell-
specific expression patterns. Finally, several thyroid hormone transporters do not 
transport thyroid hormones exclusively. For example, the OATPs transport a wide variety 
of both endobiotics and xenobiotics and possess multiple substrate binding sites (Bianco 
et al 2014). Evidence for PBDEs, PCBs or PFASs interactions with transporters appears 
sparse or particularly focused on the interactions of one class of substances with one 
class of receptors. 
MCTs have been investigated with PBDEs in mice (Richardson et al., 2008) and more 
recently clams (Song et al. 2016), a rare study on molluscs. In juvenile mice, hepatic 
expression of Mct8 mRNA decreased significantly only at the highest dose of BDE-47 
(100 mg/kg/day for 4 days), while in clams the same effect was observed in the μg/L 
range. No studies of PCBs or PFASs interactions on MCTs were found. 
The interaction of three PFAS and NTCPs were investigated in human and rat 
hepatocytes and in a Chinese Hamster Ovary cell line (CHO) (Zhao et al. 2015). The 
results demonstrated that perfluorohexane sulfonate (PFHxS), perfluorobutane sulfonate 
(PFBS) and PFOS can be transported by both human and rat NTCP.  This illustrates the 
point that the main concern of studies of PFAS and transporters is their long half-lives 
and the hepatic accumulation of PFOS in humans, rather than the impact of these 
interactions on intracellular TH levels. 
Similarly, the cellular uptake of PBDEs and PFAs mediated by OATPs and OATs has been 
studied in vitro and in vivo and do demonstrate that these classes of compounds can 
  
 
indeed interact with these transporters. However, some have considered the inhibition of 
cellular uptake of steroid hormone conjugates rather than THs (e.g. Pacyniak et al. 2011; 
Pacyniak et al. 2010; Yang et al. 2010; Yang et al. 2009). Of note, OAT4 is expressed in 
the human placenta. In an ex vivo study with human placenta, passage of PFOS and 
PFOA was modified by OAT4, indicating that OAT4 may decrease the fetal exposure to 
some PFASs (Kummu et al. 2015). In gulls, PBDE levels were positively correlated with 
transcription levels of OATP1C1 in the brain, while no such association was reported for 
PCBs (Techer et al. 2016).  
Deiodinases 
The modern paradigm of TH action recognizes that TH levels in individual tissues, and 
therefore TH signaling, can change even as serum hormone concentrations remain 
normal. The underlying mechanism is the local activation or inactivation of THs. The 
iodothyronine deiodinases types I, II, and III (D1, D2, and D3, respectively) regulate the 
activity of TH via removal of specific iodine moieties from the precursor molecule T4 
(Bianco and Kim 2006). 
Szabo et al (2009) observed decreased hepatic D1 enzyme activity and mRNA expression 
in male pups administered DE-71 perinatally. Inhibition of deiodinase activity in the 
human liver following exposure to some OH-PBDEs was confirmed in vitro (Butt et al. 
2011). Kato et al (2004) also observed a significant decrease in the activity of hepatic D1 
following treatment with PCBs in both Wistar and Gunn rats, a mutant strain of Wistar 
rats deficient in UGT1A isoforms, one of the UDP-glucuronyl transferase induced by PCBs 
(and PBDEs) and commonly assumed to be responsible for the decrease in serum T4. 
Treatment with PFOS similarly lowered hepatic DIO1 mRNA at 15.0 mg/L, however it was 
found to increase thyroidal DIO1 mRNA dose dependently (Yu et al. 2009). Dong et al. 
(2016) investigated the involvement of microRNAs (miRNAs) in PFOS-induced 
hepatotoxicity. They observed changes in transcripts that may mediate PFOS-induced 
effects on TH homeostasis including: activation of the CAR/PXR pathway, phase II/III 
enzymes, and deiodinase. These changes are consistent with low serum TH due to 
enhanced metabolic clearance of TH. However, most TH hepatic target genes were not 
altered in a manner consistent with reduced TH signalling. 
The effects of exposure to PBDEs, PCBs and PFAS on deiodinase(s) have also been 
investigated in fish (Yu et al. 2010; Zhao et al. 2016; Dong et al. 2014; Buckman et al. 
2007; Schnitzler et al. 2011; Thornton et al. 2016), birds (Techer et al. 2016), clams 
(Song et al. 2016), and frogs (Shirey et al. 2006). 
5.4.5.5 TH mediated responses in cells and tissues 
Binding affinities for TR 
TRs act as ligand-activated transcription factors by inducing or repressing the 
transcription of genes containing thyroid response elements (TREs). There are three 
isoforms able to bind thyroid hormone, TRα1, TRβ1 predominately expressed in brain, 
liver and kidney and TRβ2 whose expression primarily limited to the hypothalamus, 
pituitary and sensory systems (ear and eye). In all vertebrates studied to date, distinct 
expression patterns of the TRα and TRβ isoforms suggest, and transcription studies 
confirm (Lezoualc’h et al., 1992), that TRs have tissue-specific and developmental-state 
specific functions (Lema et al. 2008). 
PBDEs have been shown to interfere with the capacity of T3 to activate transcription 
through TR dependent mechanisms (Wang et al., 2011). However, using in silico 
modelling studies, some of their hydroxylated metabolites (OH-PBDEs) appear to exhibit 
higher binding affinity to TRs (Wang et al. 2011) suggesting PBDEs or their metabolites 
may be able to affect TH-regulated pathways in target tissues. The binding affinity and 
subsequent activity of different OH-PBDEs appear to be dependent on their degree of 
bromination. Low-brominated compounds appear to enhance T3 action whilst higher 
brominated compounds may function by interfering with T3 action (Ren et al. 2013). 
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Furthermore, the magnitude and/or nature of the effect on interference with T3 action at 
the cellular level  may also depend on the TR isoform expressed in the target cell 
(Schriks et al. 2007). 
PCBs and OH-PCBs have weak binding affinity for TRs but at least some OH-PCBs have 
been shown to be able to suppress TR-mediated transcription on several artificial TREs 
due to partial dissociation of TR from TRE (Cheek et al. 1999; Amano et al. 2010; 
Arulmozhiraja et al. 2005). Using combined in vitro, in vivo, and computational data, Ren 
et al (2015) found evidence to suggest that some PFCs also disrupt the normal activity of 
TR pathways by directly binding to TR. 
T3-responsive genes contain TREs.  In certain tissues and at certain developmental 
stages, transcripts for TRα and TRβ are auto-induced by T3. This auto-induction means 
that TR transcripts can be used as markers for assessing TH-induced activation of gene 
transcripts in target tissues (Lema et al. 2008). 
Liver 
The liver has long been considered as the major target organ for PBDEs, PCBs and PFAs. 
Enzymatic activity, due to their presumed role in T4 clearance, has been the focus of 
most of the research. In a study with male rat pups perinatally exposed to DE-71, Szabo 
et al. (2009) found that, in addition to glucuronidation, deiodination, active transport and 
sulfation may be involved in disrupting the levels of hormones available to bind nuclear 
receptors. While PCBs and PFASs have been also shown to affect deiodination, there are 
differences in their affinities to bind transport proteins, as previously discussed. 
The liver has the second highest density of TRs in the body and several TH–responsive 
proteins have been identified. For example, as with fat tissue, TH stimulates lipogenesis 
in the liver by activating the expression of key enzymes involved in the synthesis of fatty 
acids, such as malic enzyme (ME) (Bianco et al 2014), that has been investigated 
following exposure to PBDEs, PCBs and PFAS.  
Bansal et al (2014) investigated three TH-related genes in male rats and found an 
increase in ME expression instead of expected decrease. However, the two other TH-
regulated genes S14 and Mdr1a were not similarly affected, neither did they decrease. A 
possible explanation for this inconsistency may be that TH-related genes are also 
regulated by non-thyroidal pathways. 
Hitomi et al. (1993) fed rats fed a PCB-containing diet for 1 day and observed elevated 
hepatic mRNA levels of ME prior to the induction of enzyme activity. The mRNA levels of 
ME in the kidney, lung, spleen, heart, and testis, were not affected by PCBs. 
Female rats were given a single oral dose of 15 mg potassium PFOS/kg body weight. At 
intervals of 2, 6, and 24 h thereafter, measurements were made for serum fT4, TT4, TT3, 
reverse triiodothyronine (rT3), TSH, and PFOS concentrations, as well as liver PFOS 
concentrations, UDP-glucuronosyltransferase 1A (UGT1A) family mRNA transcripts, and 
ME mRNA transcripts and activity. ME mRNA transcripts were increased at 2 h and 
activity was increased at 24 h (Chang et al. 2008). 
Hepatic cell cycle 
In some cells T3 is a powerful inducer of cell proliferation. Among other mechanisms, T3 
increases the levels of cyclin D1 leading to cell cycle transition from G1 to S phase. T3 
also stimulates the activation of phosphorylated protein kinase Akt via PI3K signalling 
that in turns restrains the activity of GSK3β avoiding the exclusion of cyclin D1 from the 
nucleus and its proteasomal degradation (Blanco et al 2014).  
In rodents, long-term exposure to PBDE leads to hepatocyte hypertrophy, necrosis and 
increased vacuolisation in rodents, which is suggestive of deregulation of the cell cycle 
(Blanco et al 2014). High perinatal PBDE exposure has been found to reduce protein 
levels of cyclin D1 and phosphorylated protein kinases Akt and GSK3β (Blanco et al 
  
 
2014). The expression of TR isoforms was also decreased. It is mediated by the 
concentration of TH and a decrease in TH would be expected to result in an increase in 
predominant isoforms as an adaptive mechanism to maximise TH response, and vice-
versa. Blanco et al (2014) suggested that this counter-intuitive result may be due to the 
direct activation of this autoregulatory mechanism by PBDEs and OH-PBDEs creating a 
state that mimic intracellular hyperthyroidism. 
The decrease in cyclin D1 could be due to increased metabolism of TH or due to direct 
repression by increased availability of T3 (Lopez-Juarez et al., 2012). OH-PBDEs may 
also inhibit nongenomic actions of TH related to the activation of the PI3K/Akt pathway. 
An alternative explanation could be related to reactive oxygen species (ROS) synthesised 
as secondary products by several CYP enzymes and a decrease in the active form of Akt 
related to the increase in intracellular ROS levels (Blanco et al 2014).  
Conversely, PCB-153 has been shown to induce hepatocytes proliferation and the 
mechanism invoked for this promoting activity was thought to be related to oxidative 
stress (Lu et al. 2003). In MCF10A epithelial breast cells, PCB-153 elicited similar effects 
to PBDEs, namely a decrease in cyclin D1 protein levels and inhibition of AKT and GSK3β 
phosphorylation (Venkatesha et al. 2010). 
A low dose of PFOS (< 200 μM) stimulated the human liver cell line HL-7702 cell viability 
and increased cyclin D1 levels (Cui et al. 2015). PFOA treatment stimulated peripubertal 
mammary gland development in mice, but the increased cyclin D1 levels were attributed 
to a mechanism involving steroid hormones produced by the ovary (Zhao et al. 2010). 
On the other hand, PFOS was shown to attenuate the proliferation of neural stem cells 
C17.2 in a dose and time-dependent manner (X. Dong et al. 2016). 
The section above demonstrates both that one compound can have different or even 
opposite effects in different cells and that substances with similar effects on circulatory 
levels of TH do not necessarily display the same properties in cells or tissues.  
5.4.5.6 Brain and central nervous system 
Because of the neurobehavioural effects observed in both experimental animals and in 
humans, the brain is fast emerging as potentially the most sensitive organ to toxic action 
by PBDEs. THs exert numerous important actions in the processes of neuronal 
maturation and differentiation and are involved in stem cell proliferation and neuronal 
differentiation in fish and mammals (Lema et al 2008, Lopez –Juarez et al. 2012). There 
could be direct PBDE effects on TR, but in vitro binding affinities are in the micromolar 
range, which seems high for this to offer a convincing explanation. On the other hand, 
studies examining expression patterns of TR-dependent genes showed activity in the nM 
range (Xiong et al. 2012; Ibhazehiebo et al. 2011). 
Brain TRs 
The TRα and TRβ play distinct roles in neural development. TRα regulates stem cell 
proliferation (Lopez-Juarez et al 2012) whereas TRβ mediates the differentiation of these 
newly proliferated cells into neurons and other neural cell types (Lema et al 2008, Bernal 
2012).  
In the fathead minnow, there are sex differences in the level of transcripts of TRα, while 
there are no differences between males and females in TRβ. Responses to BDE-47 
exposure also demonstrated sex dimorphism for TRα (gene transcripts were elevated in 
females but not in males), whilst TRβ expression was depressed in both male and 
females (Lema et al 2008). These changes may result from the BDE-induced T4 decline 
or via interactions between BDE-47 and TRs or their corepressors. For example, PBDEs 
are known to interact with the nuclear steroid and xenobiotic receptor (SXR), that itself 
interacts with the corepressor SMRT (silencing mediator for retinoid and thyroid 
receptors). PBDE-induced impacts on SXR might therefore play a role in changes in TR 
gene transcription (Lema et al 2008). No changes in TR isoforms expression was 
 74 
 
detected in the cortex and hippocampus of male rats following perinatal exposure to 
BDE-99 (Blanco et al. 2013), in contrast to what had been observed in vitro (Blanco et al. 
2011). 
RC3/Neurogranin 
RC3/neurogranin is the rat homolog of the TH-responsive neuron-specific Neurogranin 
gene. Its mRNA expression has been studied in the fetal brain following PCB exposures. 
Maternal exposure to Arochlor 1254 increases RC3/Neurogranin mRNA expression in the 
fetal hippocampus, cerebellum and cortex of pups (Zoeller et al. 2000; Gauger et al. 
2004; Lein et al. 2007). Interestingly, RC3/Neurogranin mRNA expression was depressed 
at the same life stage in an experimental hypothyroid rat model (perchlorate and 
methimazole treatment of pregnant dams), clearly demonstrating that PCB exposure 
does not simply mimic the effects of low TH (Bansal & Zoeller 2008).  
Targeted literature searches did not identify any study of RC3/Neurogranin expression 
following PBDE exposure. For PFAS, it appears to have only been studied in birds. Some, 
but not all, PFAS increased RC3/Neurogranin mRNA expression in ovo (chicken embryo) 
or in vitro in chicken or herring gull embryonal neurons (Cassone et al. 2012; 
Vongphachan et al. 2011). 
Brain-derived neurotrophic factor - BDNF 
One of the key proteins regulated by TH is the brain-derived neurotrophic factor (BDNF), 
a neurotropin involved in the process of long-term potentiation (LTP), one of the best-
known mechanisms underlying learning and memory. Reduction of LTP has been 
observed in rodent offspring following acute exposure to BDE-47 or chronic maternal 
exposure of BDE-209 (Blanco et al. 2013). The mRNA expression of BDNF is significantly 
downregulated in offspring hippocampi after perinatal exposure to BDE-99 and BDE-209 
or co-exposed to BDE-47 and PFOS (Viberg et al. 2008; Blanco et al. 2013; F. Wang et 
al. 2011). However, BDE-47–induced changes in BDNF protein levels observed in 
neonates were rarely consistent with that of BDE-209 (Viberg et al., 2008, Wang et al., 
2011). 
Basic Transcription Element-Binding protein (BTEB) 
The TH-regulated gene BTEB has been shown to mediate T3-induced neural 
differentiation and neurite branching via TH activation of TRβ. It encodes a zinc-finger 
transcription factor that binds GC-box domains to facilitate or inhibit TH-mediated gene 
transcription. The T3 induced BTEB protein also binds the promoter of the TRβ gene to 
regulate its autoexpression by THs (Bianco et al 2013). 
Bianco et al (2013) found that female rats have lower levels of BTEB transcripts than 
males, but its expression was only reduced in males following perinatal exposure to BDE-
99.  PFOS exposure also resulted in up-regulation BTEB mRNA expression, however it 
presented an inverted U-shaped dose response pattern (Cheng et al. 2011). 
Purkinje cells 
Purkinje cells are large neurons located in the cerebellar cortex of the brain in 
vertebrates and play a role in motor movement. Perinatal hypothyroidism is associated 
with decreased dendrite arborisation and synaptogenesis of Purkinje cells and an in vitro 
experimental model using primary cell cultures of newborn rat cerebellum has been 
developed to study TH-induced dendrite arborisation. BDE-209 inhibited dendrite 
arborisation in this system whereas BDE-47 that does not suppress TR action did not 
supress Purkinje cell dendrite development (Ibhazehiebo et al. 2011). Some OH-PCBs 
exhibited the same suppressive properties on dendrite development in this system 
(Kimura-Kuroda et al. 2005).  
  
 
Neuronal differentiation - Oligodendrocytes 
Oligodendrocytes are myelin forming cells whose main functions are to provide support 
and insulation to axons in the central nervous system of some vertebrates. TH plays a 
role in oligodendrocyte differentiation and myelination during development or after 
injury. The effects of PCB exposure on white matter composition were examined by 
exposing pregnant rats to Arochlor 1254, with or without treatment with goitrogens as 
experimental hypothyroidism model. Both hypothyroidism and PCB exposure decreased 
the total cell density of the fetal corpus callosum and anterior commissure, but only 
hypothyroidism disproportionately affected oligodendrocyte density (Sharlin et al. 2006). 
An in vitro system using primary normal human neural progenitor (NHNP) cells. NHNP 
cells differentiate into neurons, astrocytes, and oligodendrocytes in culture and they 
express a variety of metabolism enzymes and nuclear receptors. Both T3 and PCB-118 
treatments lead to a dose-dependent increase of oligodendrocytes was blocked by 
retinoic acid and the thyroid hormone receptor antagonist NH-3 (Fritsche et al. 2005).  
5.4.5.7 Testis 
The testis is also considered a thyroid-responsive organ and thyroid hormone plays a role 
in the development and function of Leydig cells (Sarkar et al. 2016). T3 is involved in 
induction of Leydig cell differentiation and steroidogenesis in rat testis. T3 stimulates 
mouse Leydig tumor cell (mLTC-1) steroidogenesis by upregulating the expression of 
StAR mRNA through SF-1. THs also control androgen biosynthesis and signaling through 
direct and indirect regulation of steroidogenic enzyme expression and activity. In rodent 
Leydig cells, T3 has been found to stimulate steroid production. Nonetheless, the 
mechanisms by which T3 regulates testicular steroidogenesis remain poorly understood 
(Sarkar et al 2016).  
Mice treated with a high dose (950 mg/kg/day) of BDE-209 showed a marked down-
regulation in testicular mRNA levels of SF-1, StAR, CYP11A1, 3β-HSD and 17β-HSD 
compared to controls (Sarkar et al., 2016). Moreover, immuno-labelling with PCNA, a 
nuclear proliferation marker, revealed that spermatogenesis was also decreased in the 
testis of treated mice suggesting arrest and suppression of spermatogenesis (Sarkar et 
al., 2016). 
In adult Leydig cell cultures, BDE-47 and PBDE-710 increased the production of StAR 
protein levels or mRNA expression, respectively (Zhao et al. 2011; K.-L. Wang et al. 
2011), while perfluorododecanoic acid inhibited StAR mRNA expression (Shi et al. 2010). 
5.4.8 Discussion 
In rodent studies, polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls 
(PCBs) and poly- and perfluorinated alkyl substances (PFASs) reduce total and free 
serum T4, but without corresponding increases in TSH, a pattern described as 
“enigmatic”.  
To shed light on the significance of altered circulatory TH levels, the effects of PBDES, 
PCBs and PFASs and their metabolites on the HPT axis, binding to proteins involved in 
peripheral TH transport, the regulation of intracellular levels of THs, binding affinity for 
TRs, and downstream TH-mediated effects in some of the best studied organs (liver, 
brain, testes) were compared.  
The evidence available reveals both that these three classes of compounds can act, 
sometimes in opposite direction, centrally on the HPT axis, on tissue levels of TH by 
binding to peripheral transport proteins, cellular transporters or disrupting deiodinase 
action, and ultimately on TR-mediated genes. There is also clear evidence that one 
substance can elicit different responses in different tissues. For example, the impacts of 
PBDE on gene transcripts do not conform to the expectations predicted by general 
hypothyroidism. TR-mediated downstream effects of PBDE exposure may be driven not 
only by circulating TH levels but also by the fact that PBDEs and their metabolites can 
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compete with T3 directly to either bind to transport proteins or modulate T3 interaction 
and activation of TR isoforms thereby deregulating the expression of TH-mediated gene 
expression. This overall picture is further complicated by the different binding affinities 
exhibited by specific PBDE congeners or corresponding metabolites (Ren et al. 2013), as 
well as their selectivity for different TR isoforms (Schriks et al. 2007). Furthermore, there 
is evidence that PBDEs can interfere selectively with T4 uptake into tissues (Bansal et al., 
2014). 
It is therefore clear that interpretation of changes in peripheral TH levels is not ‘one size 
fits all’. Similar patterns of effects peripherally may mask the complexity of concurrent 
disruption of TH action on several regulatory processes centrally, peripherally and in 
different tissues. In short, serum T4 levels do not necessarily reflect downstream effects 
as PBDE, PCBs and PFAS can have multiple effects on hormone clearance, tissue uptake, 
receptor activation and regulation producing a complex pattern of effects on development 
and adult physiology.  
The concept that circulating T3/T4 levels do not reflect tissue levels and tissue responses 
is now well accepted. Hence there is a need for both a complex suite of in vitro tests 
complemented with better endpoints for physiological effects of PBDEs and related 
chemicals,- particularly in the brain and specific brain areas. 
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5.5 THYROID CANCER CASE STUDY 
5.5.1 Summary 
This case study considers the role of thyroid stimulating hormone (TSH) in the genesis of 
thyroid cancers, and compares and contrasts evidence from human studies, transgenic 
rodent models and traditional toxicological studies of thyroid carcinogenesis. 
Two recent large meta-analyses of studies of the predictive value of TSH levels for 
thyroid cancers in humans have shown that elevated serum TSH levels are associated 
with increased risks of papillary and follicular thyroid cancer. However, these studies 
cannot resolve whether TSH plays a role in initiating thyroid cancer or whether it merely 
promotes the growth of pre-existing lesions. 
Analyses of the role of TSH in normal follicular cells of the thyroid have revealed the 
hormone’s unique character in stimulating cell proliferation and differentiation at the 
same time in the same cell. TSH is the decisive factor in follicular cell mitogenesis, but 
has to act in concert with other growth factors such as insulin and IGF1 which have a 
permissive role. 
Improved understanding of signalling pathways in normal thyrocytes has proven 
invaluable in predicting key effectors that are dysregulated in human thyroid cancers. 
Genetic alterations found in human thyroid cancers involve the TSH pathway and 
constitutively activated elements of de-differentiating signalling pathways such as the 
RAS/RAF/ERK and PI3K/AKT systems. Accordingly, experiments with transgenic rodent 
models have demonstrated that TSH signalling is a necessary, but not sufficient, 
condition for thyroid carcinogenesis. In addition, the activation of de-differentiating 
pathways involving growth factor signalling is required for thyroid cancers to occur. 
Chemicals that can induce elevated TSH levels in rodents are often also capable of 
producing thyroid tumours in rodents, mostly of the follicular thyroid cancer type. Modes 
of action that can lead to this disruption of the thyroid system include inhibition of iodine 
transport and thyroid hormone synthesis, increased thyroid hormone clearance through 
induction of hepatic conjugating enzymes and iodine deficient diets. The relevance of 
these effects for human cancer risk assessment is often debated in view of quantitative 
differences in the dynamics of the thyroid system of rats and humans. The higher 
turnover and clearance of thyroid hormones are thought to render the rat more sensitive 
to chemicals that produce thyroid hormone insufficiency and correspondingly elevated 
TSH with the risk of thyroid tumours. However, this does not explain why mice with their 
equally high thyroid hormone clearance are much less susceptible to thyroid cancer. 
Recent evidence from transcriptomics studies with conazoles that do not produce 
elevated serum TSH levels in rats suggest that signalling pathways leading to increased 
mitogenesis and de-differentiation might play a role in the formation of rat thyroid 
cancers, but further studies are necessary to substantiate these ideas.  Until such 
evidence emerges there appears to be little reason to deviate from the USEPA and IARC 
guidance regarding the identification of thyroid carcinogens. This guidance rests on the 
presumption that rodent thyroid carcinogens may pose a cancer hazard to humans, and 
that in the absence of chemical-specific data humans and rats should be assumed to be 
equally sensitive. 
5.5.2 Scope and aims of this case study 
The role of thyroid disruption in the causation of human thyroid cancers is poorly defined. 
The toxicological literature describes many examples from rat models where chemically 
induced thyroid hormone (TH) insufficiency, with corresponding increases in thyroid 
stimulating hormone (TSH), has led to thyroid tumours. However, it is often argued that 
the rat is a poor model of thyroid carcinogenesis in the human. Purportedly less able than 
the human to compensate for perturbations of the thyroid hormone system, the rat is 
held to be particularly sensitive to thyroid disruption. For this reason, thyroid cancers in 
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the rat that arise via stimulation of the thyroid by TSH are often considered not relevant 
for human cancer risk assessment. 
This case study examines the relationship between stimulation of the thyroid by TSH and 
the risk of developing thyroid tumours, first by considering evidence from human studies. 
In a second step, our understanding of the role of TSH in normal thyrocytes will be 
analysed in the context of knowledge about genetic alterations in human thyroid cancers 
and their impact on dysregulated signalling pathways. Against this background, thyroid 
specific transgenic rodent models will be assessed with the aim of elucidating what can 
be learnt about TSH signalling and thyroid cancer. 
5.5.3 Human thyroid cancer 
Thyroid cancers are the most rapidly rising type of all human malignancies in both 
women and men, with average annual increases of 6% year on year (Howlader et al. 
2012, Kitahara and Sosa 2016). The reasons for this rise are not clear. Recognised risk 
factors include age, radiation exposure, obesity and a family history of thyroid cancer. 
Some argue that improved diagnosis might play a role, but the emerging consensus is 
that other factors are also involved. 
There are several types of human thyroid cancers. The overwhelming majority of thyroid 
malignancies derive from follicular thyroid cells, with papillary thyroid carcinoma (PTC) 
representing around 80% and the more aggressive follicular thyroid carcinoma (FTC) 10-
15% of all thyroid cancers. The remainder of follicular-derived thyroid neoplasms are 
poorly differentiated thyroid cancer and anaplastic thyroid cancer (Kirschner et al. 2016). 
A very small proportion of thyroid cancer derives from parafollicular C-cells (Xing 2013). 
PTC is the driver of the rapid rise in thyroid cancer in the USA (Kitahara and Sosa 2016). 
Papillary thyroid cancer affects women more than men, with an incidence approximately 
3 times higher in women than men. This is indicative of a significant estrogen-driven 
component in thyroid cancer in women. Accordingly, papillary thyroid cancer incidence 
peaks within a woman’s reproductive period, while there is a linear increase with age 
among men (Wang et al. 2015). 
5.5.3.1 Elevated levels of TSH as a predictor of thyroid cancer in humans 
TSH stimulates the synthesis of TH, thyroid gland growth, induces changes in thyrocyte 
morphology, and regulates the activation of the sodium iodide symporter (NIS) and 
thyroid peroxidase (TPO), among other events. 
Surprisingly, evidence for TSH as a predictor of thyroid malignancies in humans has 
emerged relatively late. Boelaert et al. (2006) were the first to describe that serum TSH 
is elevated in patients with malignant thyroid nodules when compared to subjects with 
benign thyroid tumours. Since then, several studies analysed in two large meta-analyses 
(McLeod et al. 2012, Zheng et al. 2016) have confirmed that higher serum TSH is 
associated with an increased risk of follicular and papillary thyroid cancer. The data 
presented by McLeod et al. (2012) predict a doubling of the odds of developing thyroid 
cancer for TSH serum levels between 0.65 and 4 mU/liter (Figure 1). 
 
  
 
 
Figure 1, from McLeod et al. (2012): Dose-response relationship for serum TSH and 
thyroid cancer odds ratios (OR). The black line represents the best estimate of OR, with 
confidence belts in dark grey. The grey dots and lines are from the underlying individual 
studies. The larger the dots, the smaller the variance in these studies. 
The studies that formed the basis of these meta-analyses were of a cross-sectional 
design. This limits the possibility of discerning whether raised TSH levels play a causative 
role in thyroid cancer. Without prospective studies it is difficult to decide whether TSH 
facilitates or even initiates thyroid cancer development, or whether it merely promotes 
the growth (and hence diagnosis) of pre-existing thyroid malignancies. 
5.5.3.2 Evidence from studies of associations between iodine status and 
thyroid cancer 
Recently, Zimmermann and Galetti (2015) have reviewed the role of iodine in thyroid 
cancer. The available evidence suggests that iodine deficiency is a risk factor for thyroid 
cancer, particularly the more aggressive FTC. However, the picture is confounded by 
other, as yet unrecognised factors that might also influence thyroid cancer. For example, 
thyroid cancer in the USA is steadily increasing since the mid 1980s, and iodine intake 
has declined over the same period. In contrast, Switzerland and China, both countries 
with iodine supplementation programmes and relatively stable iodine intake, have also 
experienced increases in thyroid cancer in recent years (Zimmermann and Galetti 2015).  
To elucidate the role of TSH in thyroid cancer it is first necessary to establish the role of 
TSH signalling in normal thyrocytes. The ground is then prepared for a description of 
advances in our understanding of the molecular pathogenesis of human thyroid cancers 
and of genetic alterations in key signalling effectors. 
5.5.4 TSH signalling in normal thyroid follicular cells 
The role of TSH in thyroid cell proliferation and differentiation has been studied in in vitro 
models with established cell lines and in primary cell cultures. Permanent rat thyroid cell 
lines are the most popular model. Four species have been used mainly for primary cell 
cultures: the dog, pig, sheep and humans (Kimura et al. 2001). 
Surprisingly, the signalling pathways and mechanisms that have been uncovered in these 
models differ in important aspects and depend strongly on the species, the culture 
conditions, the age (passage number) of the cells and even the “pre-history” of the cell 
cultures (Kimura et al. 2001, Roger et al. 2010). As a result, the interpretation of many 
of these studies is complicated. Generalisations from observations with in vitro models 
have to be made with careful consideration and usually require validation in in vivo 
systems such as transgenic rodent models or clinical observations in humans. 
With these provisos, the features described below are based on observations with 
primary thyroid cell cultures from dogs which are viewed as most closely resembling TSH 
signalling in normal human thyroid cells (Kimura et al. 2001, Roger et al. 2010): 
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TSH is a glycoprotein hormone that interacts with the TSH receptor (TSHR), a G-protein 
coupled receptor. Upon binding of TSH, the receptor induces the coupling of various 
proteins which stimulate adenylate cyclase to form cyclic AMP (cAMP). This in turn 
activates the protein kinase PKA. In keeping with the main function of thyrocytes, this 
pathway also leads to the upregulation of components of the iodine machinery (including 
TPO and NIS), essential for the synthesis of thyroid hormones (TH). 
Unlike many other mitogenic factors, TSH is capable of promoting cell division and 
differentiation programmes in the same cell at the same time. This is achieved in concert 
with other growth factors which signal via receptor tyrosine kinases, most importantly 
insulin and insulin-like growth factor (IGF1). TSH is the decisive mitotic trigger, while 
IGF1 is a permissive factor. The molecular basis for this relationship is in the activation of 
the cell cycle protein p27 by protein kinase A (PKA) via TSH and cAMP (Figure 2 a, from 
Roger et al. 2010). 
 
Figure 2 A, from Roger et al. (2010): Summary of cooperative signalling of TSH with 
IGF1 derived from dog thyrocyte studies. Dashed green arrows are activations, dashed 
red lines are inhibitions. 
Protein p27 is needed to facilitate the assembly of the cyclin D3/CDK4 complex. This 
complex, a key element of the cell cycle machinery, phosphorylates specific residues on 
pRB, the “master brake” of the cell cycle. These phosphorylation events “release the 
brake” and promote cell cycle entry and differentiation signals at the same time. 
Ultimately, the function of IGF1 signalling is to provide sufficient levels of cyclin D3 for 
the aggregation of the cyclin D3/CDK4 complex. This is achieved by IGF1 signalling via 
PI3K and PKB. There are also negative feedback loops within thyrocytes, also activated 
  
 
by TSH. These make sure that only one cell division ensues after stimulation of the 
cAMP/PKA/p27 pathway by TSH. 
Accordingly, IGF1 on its own only weakly stimulates cell cycle entry: the limiting factor is 
p27 which has to be provided by TSH signalling via cAMP and PKA (Roger et al. 2010). 
Other growth factors, such as epidermal growth factor (EGF) block the provision of p27, 
and instead signal via RAS/RAF/MEK/ERK to promote p21 and cyclin D1. These are 
needed for the assembly of another cell cycle complex, cyclin D1/CDK4. Cyclin D1/CDK4 
phosphorylates pRB sites different from those phosphorylated by cyclin D3/CDK4. As a 
result, pRB now blocks differentiation, promotes de-differentiation signals similar to the 
epithelial-mesenchymal transition and strongly stimulates cell cycle entry (Kimura et al. 
2001, Roger et al. 2010). These pathways appear to be required e.g. during the 
development of the thyroid (Figure 2 B, from Roger et al. 2010). 
 
Figure 2 B, from Roger et al. (2010): Summary of growth factor signalling in 
thyrocytes. Dashed green arrows are activations, dashed red lines are inhibitions. 
Effectors labelled in green are mutated in human thyroid cancers, see section below.  
Of note is a recent paper by Morgan and colleagues (Morgan et al.2016). When cell 
numbers were counted, instead of the usual measurement of DNA synthesis by 
incorporation of tritiated thymidine, no cell proliferation was observed in cultures of 
primary human thyrocytes exposed to TSH with or without IGF1. Although this paper 
casts doubt on some observations in vitro, the cell proliferative effects of TSH in cell 
cultures agree well with the hypoplasia seen in experimental animal after administration 
of agents that increase TSH levels (see below).  
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5.5.5 Molecular pathogenesis of human thyroid cancers and its 
recapitulation in rodent models 
Human thyroid cancers and adenomas harbour genetic alterations that dysregulate 
elements of the normal thyroid cell signalling pathways, including components of the 
cAMP pathway and key effectors of MAP kinase pathways such as RAS/RAF/MEK/ERK. 
However, the origins and causes of these genetic alterations remain obscure. 
5.5.5.1 Common genetic alterations in human thyroid cancers 
Activating mutations of the TSH receptor that confer constitutive activity are found in 
thyroid adenomas. These mutations lead to continuous stimulation of the cAMP-mediated 
mitogenic pathways that involve PKA and p27.  
The activating point mutation BRAFT1799A is the most frequently found genetic alteration 
in papillary thyroid cancer (PTC), the most prevalent form of human thyroid cancers. It 
encodes the constitutively active serin kinase BRAFV600E which continuously stimulates the 
MEK/ ERK signalling pathway and ensures that the cell cycle machinery receives constant 
activating signals. In addition, components of the iodine machinery (TPO, NIS) are down-
regulated. The ensuing deficiency in thyroid hormones triggers a substantial rise in TSH 
(Xing 2013). 
Activating mutations of all three RAS genes (HRAS, KRAS, NRAS) are prevalent in 
follicular thyroid cancers (FTC) and in PTC. These mutations de-regulate the MAP kinase 
and the PI3K - AKT pathways, with constant promotion of cell division.   
Many thyroid cancers harbour gene amplifications and copy number gains in genes 
encoding elements of the PI3K-AKT pathway. 
There are also gene translocations, the most frequent of which involves the receptor 
tyrosine kinase RET. Its intracellular kinase domain is fused with a variety of other gene 
fragments which possess dimerization domains. This brings the truncated RET kinase 
domains together to initiate autophosphorylation, leading to stimulation of RAS/RAF/ERK 
and PI3K/AKT with promotion of cell division (Xing 2013, Roger et al. 2010). 
5.5.5.2 Transgenic rodent models of thyroid cancers 
The relative importance of several of the genetic alterations found in human thyroid 
cancers has been studied in transgenic rodent models, typically involving mice. In these 
models, the genetic alterations under investigation were targeted to the thyroid. This was 
achieved by utilizing recombinase-mediated gene modifications in the Cre/Lox system 
(for reviews see Kim and Zhu 2009, Kirschner et al. 2016). 
Here we focus on studies aimed at elucidating the role of TSH signalling in the 
development of thyroid tumours and at clarifying whether TSH may have a role in the 
initiation of thyroid cancer. These have all shown that growth stimulation by TSH is a 
necessary, but not a sufficient condition for cancer development. Concurrent activation of 
different MAP kinase pathways is also required for the occurrence of thyroid cancers. 
Lu et al. (2009) employed mice with a knock-in of a dominantly negative, inactivating 
mutation of the thyroid hormone receptor beta gene (THRB), termed PV. The PV gene 
was derived from a patient with thyroid hormone resistance syndrome, the features of 
which are elevated TH and non-suppressible TSH. The PV mice recapitulated the human 
syndrome, with increased TH and TSH serum levels. As these mice aged, they developed 
follicular thyroid tumours (FTC). To investigate the importance of TSH signalling in this 
process, the effect of TSH signalling had to be eliminated in these mice. To achieve this, 
PV mice were crossed with TSH receptor knock-out mice. The offspring of these crosses 
showed impaired thyroid growth, but did not develop FTC. The experiment shows that 
growth stimulation by TSH is necessary for the development of FTC. However, TSH 
signalling alone is not sufficient for FTC to arise. Detailed analyses of PV mice uncovered 
constitutively activated MAP kinase pathways which were also required for FTC. 
  
 
In a subsequent study (Zhao et al. 2012) the same group of researchers took this work 
further by utilizing a heterozygous PV mouse model with only 1 mutated PV allele. These 
mice do not develop FTC upon ageing. However, when TSH levels were raised by 
treatment with propylthiouracil, FTC appeared. The wild type siblings of the heterozygous 
PV mice did not develop FTC, despite being exposed to propylthiouracil. Further analyses 
of the FTC from the heterozygous PV mice showed that the cyclin D1 / CDK4 pathway 
was activated. To interpret this observation, it is important to realise that functional 
THRB suppresses cyclin D1. If that suppression of cyclin D1 / CDK4 signalling is lost, due 
to a dysfunctional THRB allele in the heterozygous PV mice, then FTC can develop under 
TSH stimulation via propylthiouracil. Again, this shows that activation of the TSH 
pathway is essential, but also demonstrates the importance of strong signalling to the 
cell cycle machinery for driving the development of FTC.     
Franco et al. (2010) analysed the role of the most frequently found genetic alteration in 
papillary thyroid tumours, mutations of the BRAF gene. They used transgenic mice with 
BRAFT1799A targeted to the thyroid. Cells expressing BRAFV600E became transformed and 
progressed to PTC. Due to the accompanying downregulation of genes of the iodine 
machinery, these mice became severely hypothyroid with strongly elevated TSH levels. 
To examine the importance of TSH signalling in the process of PTC development, the 
BRAFV600E mice were crossed with TSH receptor knock-out mice. Although BRAFV600E was 
active in these crosses, the suppression of TSH signalling meant that PTC did not 
develop. Similar observations were made with BRAFV600E mice that were crossed with 
mice with disrupted GSH signalling due to deleted G-protein genes. These findings show 
that the cooperation between TSH signalling and BRAF signalling in inducing PTC is 
mediated via cAMP and again demonstrates the importance of TSH in the formation of 
PTC. 
Zou et al. (2015) studied the interactions between KRAS signalling and TSH in the 
development of FTC in mice. They utilized thyroid-specific knock-in mice with a 
constitutively active, mutated KRAS gene. In these mice, the RAS/RAF/MEK/ERK and 
PI3K/AKT pathways are activated, with stimulation of cell cycle entry and de-
differentiating signals. As expected, there was mild thyroid enlargement in these mice, 
but no FTC development. However, when TSH levels were increased by treatment with 
propylthiouracil, massive thyroid enlargement occurred. After 14 months, these mice 
developed FTC. 
Taken together, these observations underline the importance of TSH signalling in the 
development of thyroid malignancies. Without TSH signalling, malignancies do not 
develop. However, the data also show that growth factor signalling pathways that 
stimulate cell cycle entry and promote de-differentiating signals also need to be activated 
for thyroid cancer to occur. These results echo the epidemiological observations of 
associations between elevated serum TSH and thyroid cancer risk in humans (McLeod et 
al. 2012, Zheng et al. 2016). 
5.5.5.3 The role of iodine in rodent models of thyroid cancer 
The role of iodine in rodent models of thyroid cancer is of interest because of the rise in 
TSH that normally accompanies iodine deficiency. Accordingly, provision of iodine 
deficient diets to female rats for 6 to 20 months led to the appearance of follicular 
adenoma and FCT (Axelrad and Leblond 1955, Isler et al. 1958, Isler 1959, Schaller and 
Stevenson 1966, reviewed in Zimmermann and Galetti 2015). With iodine excess, there 
were increases in thyroid weight and histological changes, but no thyroid tumours were 
observed. 
5.5.6 Toxicological studies of thyroid cancers in rats exposed to chemicals 
that produce TH insufficiency 
As analysed by Hurley et al. (1998), 10% (24 of 240) of the pesticides screened by the 
USEPA until 1998 for carcinogenicity induced follicular thyroid cancers (FTC) in rodents. 
These malignancies appeared to be rat specific; the only pesticides that produced FCT in 
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the rat and the mouse were amitrole and ethylene thiourea. Furthermore, male rats 
appeared to be more sensitive to tumour induction than female rats. 
With the possible exception of acetochlor, mutagenicity does not seem to play a 
significant role in the thyroid carcinogenicity of these pesticides. Instead, there were 
strong indications of thyroid disruption with 19 of the 24 pesticides considered by Hurley 
et al. (1998). Modes of action affecting the thyroid included: inhibition of iodine uptake 
(NIS), inhibition of TPO, inhibition of TH release, and enhanced TH clearance through 
induction of liver conjugating enzyme systems (UDPGT). All these modalities led to 
increases in serum TSH levels. 
As is well established, persistently elevated TSH stimulates the thyroid to deplete its TH 
stores. Unable to keep up with the demand for TH, the thyroid follicular cells divide, 
leading to thyroid hyperplasia and eventually to cancer. 
Thus, elevated TSH is regarded as the molecular initiating event that may lead to thyroid 
tumours in rodents (Dellarco et al. 2006). Of considerable current interest are agents 
that produce thyroid cancers in rodents via elevated TSH through the induction of 
conjugating liver enzymes (UDPGT) that remove TH. Examples of such chemicals are 
listed in Table 1 below. 
Table 1: Chemicals that produce thyroid cancers through the induction of 
hepatic conjugating enzymes and elevated TSH  
 
Dellarco et al. (2006) considered the example of thiazopyr and discussed the applicability 
of this mode of action to human risk assessment within the 2006 IPCS Human Relevance 
Framework. They pointed out that although there are differences in the dynamics of the 
thyroid systems between the rat and the human, the fundamental mechanisms of 
regulation are similar. Thus, in principle, chemicals that induce TH decreases in the rat 
could also do so in the human, with consequent increases in TSH. 
However, Dellarco et al. (2006) also emphasised quantitative differences between rat 
and human which in their opinion diminish the applicability of findings in the rat to 
human risk assessment: The increased clearance of TH in the rat (half-life of 12 h versus 
5-9 days in the human) is compensated by higher TH production, with correspondingly 
higher basal TSH levels. As a result, so the argument, humans are less sensitive than 
rats to chemicals that produce TH decreases and corresponding TSH rises, with 
correspondingly lower thyroid cancer risks. 
5.5.6.1 Unexplained species differences 
However, as pointed out by Hurley et al. (1998), the discussion of dynamic differences in 
TH regulation between the rat and humans leaves one fact unexplained: Mouse and rat 
have similar TH hormone half-lifes, so both these species should be equally sensitive to 
TSH increases after exposure to agents that accelerate TH clearance. However, the 
mouse appears significantly less sensitive developing FCT when treated with agents that 
produce cancers in rats. 
5.5.6.2 An alternative pathway leading to thyroid tumours in rodents, not 
involving elevated TSH serum levels 
In general there is little information about gene alterations in chemically or otherwise 
induced rodent thyroid cancers that would allow comparison with the gene alterations 
Compound Effect Species Dose (mg/kg d) Duration Hepatic enzymes Thyroid hormones Comment References
Fluopyram FCA Mouse 105 12 months CAR+, PXR+ T4-, TSH+ Rouquie 2014
Nelfinavir mesylate FCT, FCA SD rat 300, 1000 24 months UDPGT+, CYP 3A1+ TSH+ Burns-Nass 2005
Perchlorate FCT Wistar rat 1% in drinking water 18 months na na silent BRAF mutations Carmona-Lopez 2012
Thiazopyr FCT, FCA SD rat 44, 136 24 months UDPGT+ TSH+ Naylor, McDonald 1992
Pronamide FCT, FCA CD BR rat 42 24 months UDPGT+ T4-, TSH+ Bailey 1990; Papinemi 2015
Triadimefon FCT Rat 300, 1800 ppm food 24 months UDPGT+ T3, T4- TSH unchanged Wolf 2006, Hurley 1998
Trifluralin FCT Fischer 344 rats 6500 ppm food 24 months UDPGT+ T3, T4-, TSH+ Saghir 2008, Emmerson 1980
FCA: Follicular cell adenoma; FCT: Follicular cell tumour Increases: + Increases: +
Decreases: -
  
 
found in human tumours (see above). This gap has only recently begun to be filled with 
studies of conazole pesticides.  
Wolf et al. (2006) have drawn attention to triadimefon (highlighted in red in Table 1) as a 
case that may help elucidating the events leading to thyroid tumours in rodents. Unlike 
many other chemicals which act via the hepatic route by induction of UDPGT and lead to 
TH decreases and corresponding TSH elevations, triadimefon is capable of inducing 
UDPGT and reducing TH levels, but does not lead to increases in TSH. Yet it produces 
follicular thyroid cancer in rats. 
This unique effect pattern opens up the way for exploring alternative pathways in the 
induction of thyroid tumours in the rat, not solely dependent on elevated TSH. 
Hester and Nesnow (2008) analysed this hypothesis further by conducting comparative 
transcriptomic studies in the thyroid of rats treated with triadimefon and myclobutanil. 
Both chemicals induce hepatic UDPGT to a similar extent with consequent decreases in 
TH. However, an increase in TSH was missing in both cases, yet only triadimefon, but not 
myclobutanil, produced thyroid tumours in a 24 month cancer bioassay. 
After 30 days of treatment with triadimefon, there was expression of genes related to cell 
cycle G-S transition, the estrogen receptor alpha nuclear pathway, and platelet-derived 
growth factor signalling via MAPK.  By matching core genes from the triadimefon gene 
set with those from human thyroid tumours, Hester and Nesnow (2008) found 10 
common genes. This enabled them to produce a gene interaction network which they 
interpreted as one indicative of a cellular environment promoting cell proliferation. On 
the basis of these data, they hypothesised that triadimefon activates PPAR gamma with 
consequent transcription of genes controlling cell growth and proliferation. 
In this, there are echoes with the studies involving transgenic rodent models which show 
the importance of growth factor-mediated signalling in the formation of thyroid cancers. 
It remains to be seen whether the hypothesis formulated by Hester and Nesnow (2008) 
is applicable to other chemicals that produce thyroid tumours via increased clearance of 
TH or by thyroid hormone imbalance induced by other mechanisms. To resolve this issue, 
classical toxicological studies of thyroid carcinogenesis will need to be complemented by 
transcriptomics analyses of the thyroid. If these de-differentiating and proliferative 
pathways can be shown to be operating in the rat thyroid also with other thyroid 
carcinogens, the relevance of observations in the rat for human risk assessments could 
be evaluated better. 
5.5.7 USEPA and IARC guidance on rodent thyroid cancer 
To support the interpretation of observations of thyroid tumours in rat studies, USEPA in 
1998 developed science policy guidance (Hill et al. 1998). This guidance recognised that 
TSH plays a role in thyroid cancer and should be taken as an indicator of potential human 
cancer hazards, even if it turns out that the role of TSH is only permissive. On the other 
hand, this guidance recognises that the human may be less sensitive than the rat to 
developing thyroid cancer as a result of perturbations of the thyroid system. Against this 
background, USEPA adopted three science policy positions: 
1. There is the presumption that chemicals that produce rodent thyroid cancers may 
pose a cancer hazard to humans. 
2. In the absence of chemical-specific data, it is presumed that humans and rats are 
equally sensitive. 
3. Thyroid gland enlargements following short-term changes in thyroid hormone 
levels are presumed to present a non-cancer hazard. 
The International Agency for Research on Cancer (IARC) has used the following criteria 
for the application of mechanistic evidence in evaluations of rodent thyroid carcinogens 
which were developed by Capen et al. (1999) (IARC 2001):  
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Chemicals leading to the development of thyroid neoplasia through an adaptive 
physiological mechanism are viewed as belonging to a category different from those that 
produce thyroid neoplasia through genotoxic mechanisms or through mechanisms 
involving pathological responses with necrosis and repair. Agents that cause thyroid 
tumours in rodents through hormonal imbalance (without genotoxicity) can be 
distinguished from other thyroid carcinogens by a lack of genotoxic activity in vivo and in 
vitro. Hormone imbalance has to be demonstrated under the conditions of the 
carcinogenicity bioassay, and the mechanism through which the agent leads to hormone 
imbalance should be established. In cases where tumours are observed both in the 
thyroid and at other sites, they should be evaluated separately on the basis of the modes 
of action of the agent. 
  
It should be assumed that chemicals capable of inducing thyroid follicular-cell tumours in 
rodents by interfering with thyroid hormone homeostasis can also interfere with thyroid 
hormone homeostasis in humans if exposure is at sufficiently high levels and for 
sufficient durations. At exposures not leading to alterations in thyroid hormone 
homeostasis, these chemicals are assumed not to be carcinogenic in humans. 
 
Evidence for hormonal imbalance could include measurements of serum thyroid hormone 
and TSH and of morphological changes characteristic of increased TSH stimulation, 
including increased thyroid gland weight and diffuse follicular-cell hyperplasia and/or 
hypertrophy. 
 
5.5.8 Conclusion  
It would appear that traditional toxicological studies of thyroid carcinogenesis with their 
focus on analysing TH levels are likely missing key events leading to thyroid cancer in the 
rat. These events seem to revolve around the activation of de-differentiating and 
proliferative pathways in the thyroid, accessible only through functional and 
transcriptomics analyses not normally conducted in classical toxicological studies. Further 
studies of this kind are needed to substantiate the relevance of de-differentiating 
signalling pathways for the induction of follicular thyroid tumours in the rat. Until such 
evidence emerges there appears to be little reason to deviate from the USEPA and IARC 
guidance regarding the identification of thyroid carcinogens. 
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6. ADDITIONAL BACKGROUND PAPERS FOR THE WORKSHOP 
With the aim of keeping participants abreast of the latest developments in the area of 
thyroid disruption, a further set of background papers was prepared and circulated in 
advance of the workshop. These papers focussed on the following topics: 
 Possible adverse effects in the human following disruption of the hypothalamic-
pituitary-thyroid axis 
 The thyroid system in fish, amphibians and invertebrates – a comparison with 
mammalian species 
 Interpretation of data from epidemiology, experimental studies and wildlife data 
for the identification of thyroid disruptors 
 Current OECD test methods for the identification of thyroid disruptors, their gaps 
and possibilities of improvements 
 
6.1 BACKGROUND PAPER 1: POSSIBLE ADVERSE EFFECTS IN THE 
HUMAN FOLLOWING DISRUPTION OF THE HYPOTHALMIC-
PITUITARY-THYROID AXIS 
6.1.1 Summary 
Thyroid dysfunction is characterised by under- or over-activity of the gland (hypo- or 
hyper-thyroidism, respectively). Hypothyroidism is more common than hyperthyroidism. 
Thyroid dysfunction has an impact on four major adverse health outcomes: 
neurodevelopment and brain function, cancer, cardiovascular disease and lipid 
metabolism, with impacts on body weight and body temperature.  
Maternal subclinical hypothyroidism, characterised by normal thyroid stimulating 
hormone (TSH) with thyroid hormone (TH) levels towards the lower end of the population 
distribution, is associated with compromised cognitive development in their children (IQ 
loss). Recent studies also suggest associations with autism spectrum disorder, attention 
deficit hyperactivity disorder and schizophrenia. 
Rises in the serum levels of TSH within the normal range are associated with increased 
risks of thyroid cancer, the fastest rising cancer among women and men. 
Hyperthyroidism is associated with irregular heart beat and increased blood pressure. 
Hypothyroidism leads to a reduction in cardiac output, a decrease in heart rate and 
increases in peripheral vascular resistance. Hypothyroidism also leads to elevations in 
cholesterol levels. 
Several studies have uncovered associations between exposure to pollutants and TH 
patterns typical of hypothyroidism. This is the case with combined exposures to 
perchlorate and thiocyanate, when accompanied by iodine deficiency. Similar associations 
have been shown with mercury, certain arsenic species, certain organochlorine 
pesticides, poly-aromatic hydrocarbons and perfluorinated compounds.  
6.1.2 Introduction: the thyroid system 
The focus of this paper is to give an overview of the adverse health effects in humans 
following disruption of the thyroid system. This will be addressed first by summarising 
the evidence from the clinical and epidemiological literature that describes associations of 
thyroid dysfunction with major diseases. The scene is then set to describe associations 
between thyroid disruption and exposure to chemical pollutants. 
Thyroid hormones (TH) have essential roles in growth, development, especially of the 
nervous system, cell differentiation and homeostasis. TH are the ligands of several TH 
receptors, highly conserved ligand-dependent transcription factors present in all tissues, 
  
 
but exhibiting different patterns of expression in different tissues, and which control gene 
expression by interaction with specific regulatory  DNA sequences. There is also evidence 
of receptor-independent “non-genomic” response pathways which do not engage the 
binding to specific DNA sequences. 
TH synthesis is controlled by the hypothalamo-pituitary axis. The production of Thyroid 
Releasing Hormone (TRH) in the hypothalamus stimulates the release of Thyroid 
Stimulating Hormone (TSH) by the pituitary which in turn initiates TH production (T3, T4) 
in the thyroid gland. Although T3 is the active TH – its affinity to thyroid hormone 
receptors is approximately 10 times higher than that of T4 – T4 is the prohormone that is 
most important in blood. Deiodination of the reservoir of T4 establishes an additional 
layer of regulation that ensures remarkable stability of circulating T3 levels. In a negative 
feedback loop, elevated T4 levels down-regulate the production of TRH by the 
hypothalamus and TSH by the pituitary. TH concentrations can also be modulated at 
numerous other physiological levels, including deiodination of T4 in peripheral tissues, 
removal of T3 by metabolism in the liver or interference with iodine uptake in the 
thyroid, which is required for hormone synthesis (Figure 1). For example, about 80% of 
T3 in the brain and pituitary are generated locally by deiodination (for more detail about 
the correlations between serum levels of various components of the thyroid system see 
Annex 1). 
 
Figure 1: The thyroid system and its regulation (from: WHO/UNEP 2013) 
Although there are some differences in detail, the basic principles of TH production, 
action and regulation are conserved across many taxa (see Background Paper 2 The 
thyroid system in fish, amphibians and invertebrates – a comparison with mammalian 
species, section 6.2). 
6.1.2.1 Factors determining differential sensitivity to thyroid 
disruption across life stages 
During the first trimester of pregnancy, maternal T4 is the only source of supply of TH to 
the fetus. The mother remains an important source of TH supply through to late 
gestation, contributing approximately 30% of the fetus’ demand (reviewed by Ginsberg 
et al. 2007). 
There are very low levels of TH in mother’s milk. For this reason, newborns cannot 
anymore rely on mother’s TH and have to synthesise their own supply. However, 
newborns have quite low functional reserves of TH, and the reserves available in the 
adult are not yet established. This makes newborns more vulnerable to perturbations of 
the thyroid system. Several factors play a role (Ginsberg et al. 2007): 
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 The serum half-life of T4 is lower in neonates than in adults (3 days vs 7-10 
days). 
 The rate of TH replacement in neonates must therefore be higher than in adults. 
 The storage capacity of the neonatal thyroid is less than 1 day’s worth of TH 
demand, compared to the adult gland which can store the demand of several 
months. 
6.1.2.2 Diagnostic criteria: overt and subclinical hyper- and 
hypothyroidism 
Overt hyperthyroidism is defined in terms of suppressed TSH serum levels and free TH 
levels above the reference range (see Jabbar et al. 2017 and reference cited therein). 
Subclinical hyperthyroidism is diagnosed when serum TSH is below 0.3-0.4 mU/L with 
free T3 and T4 levels within the population reference range. 
Overt hypothyroidism occurs with TSH serum levels higher than 10 mU/L and T4 levels 
below the reference range. Subclinical hypothyroidism is diagnosed as “mild” with 
normal TSH serum levels between 4 and 10 mU/L and free T4 below the 10th percentile 
of the reference range. The criteria for “severe” subclinical hypothyroidism vary 
somewhat. It is sometimes defined as TSH levels exceeding 10 mU/L. Other authors 
classify “severe” hypothyroidism with TSH in the normal range and free T4 levels below 
the 5th percentile of the reference range (see the epidemiological studies on cognitive 
development in children discussed below). 
As there is no consensus on the upper normal range of TSH, there is a controversy about 
the definition and clinical relevance of subclinical hypothyroidism (Hamilton et al. 2008).   
6.1.2.3 Prevalence of hyper- and hypothyroidism 
In general, hyperthyroidism is less common than hypothyroidism. 
Overt hyperthyroidism occurs in 0.5% of the population (Cooper and Biondi 2012) and 
subclinical hyperthyroidism in 2% (Cappola et al. 2006). 
Overt hypothyroidism is estimated to occur in 0.2-2% of the population (Tunbridge et 
al. 1977). Subclinical hypothyroidism is more common. Between 4 and 20% of the 
population show the symptoms, with women and the over 60 years old more likely to be 
affected (Biondi and Cooper 2008). 
6.1.3 Adverse effects in the human resulting from thyroid disruption 
Thyroid over- or underactivity is associated with four major diseases: Neurodevelopment 
and brain function, cancer, cardiovascular disease and alterations of lipid metabolism. 
More recent studies reveal effects also on the programming of other physiological effects 
during pregnancy. 
6.1.3.1 Neurodevelopment and brain function 
Of concern in relation to neurodevelopment and cognitive ability is hypothyroidism in the 
mother, due to the key role played by TH in neurodevelopment. 
Maternal hypothyroidism and cognitive development in children 
Several recent epidemiological studies have established the critical role of TH during the 
early stages of brain and cognitive development. 
Of note is a study by Henrichs et al. (2010) in which the association between maternal 
thyroid function in early pregnancy and children’s cognitive development was 
investigated. Henrichs and colleagues defined mild and severe hypothyroidism in 
pregnant women as free T4 levels below the 10th and 5th percentile, respectively, with 
normal TSH levels. Children’s expressive vocabulary at 18 and 30 months of age was 
assessed. Both mild and severe maternal hypothyroidism was associated with delays in 
children’s language development. Maternal TSH levels were unrelated to children’s 
  
 
language development. The study shows that maternal hypothyroidism is a risk factor for 
cognitive delay in early childhood. 
Fan and Wu (2016) conducted a meta-analysis of six studies that investigated the 
relationship between hypothyroidism in women during pregnancy and its impact on 
neuropsychological development in their children. The outcomes assessed included 
intelligence scores and motor scores. This meta-analysis showed that children of women 
with subclinical hypothyroidism had mean intelligence scores several points lower than 
children from women with healthy thyroid status. The meta-analysis conducted by Wang 
et al. (2016) showed similar results. 
Ghassabian et al. (2014) not only investigated the impact of maternal hypothyroidism on 
children’s cognitive development, but also analysed brain morphology. The children of 
mothers with hypothyroidism in early pregnancy (defined as free T4 in the lowest 5% of 
the sample, with TSH in the normal range) scored 4.3 IQ points lower than the children 
of mothers with normal thyroid status. However, no associations with global brain 
volumes, cortical thickness, and brain surface area were found in these children. 
The hippocampus is the brain component involved with short-term, long-term and spatial 
memory. Motivated by observations of abnormal hippocampus development in rodents 
with gestational TH deficiencies, Willoughby et al. (2014) investigated whether children 
of women who exhibited hypothyroidism during pregnancy also show hippocampal 
abnormalities. 54 children aged 9 to 12 years were studied, 30 from women with normal 
thyroid function during pregnancy and 24 from women with hypothyroidism. Children 
from mothers with hypothyroidism showed significantly smaller right and left 
hippocampal volumes and scored significantly lower on several memory indices, and 
these were correlated with hippocampal volumes. 
Other neurological outcomes: autism spectrum disorder, attention deficit 
hyperactivity disorder, schizophrenia 
Considering that transient gestational hypothyroxinemia in rodents induces cortical 
neuronal migration (a brain lesion resembling those found in autistic patients), Roman et 
al. (2013) investigated the association between maternal hypothyroidism in pregnancy 
(gestational weeks 6-18) and autistic symptoms in children. In line with earlier studies 
from this Dutch group, severe maternal subclinical hypothyroidism was defined as free T4 
levels below the 5th percentile with normal TSH. Six year old children (4,039) were 
examined for behavioral and emotional symptoms suggestive of autism. Children of 
mothers with severe subclinical hypothyroidism had higher scores of autistic symptoms 
by age 6 years. 
There is also evidence of associations with attention deficit hyperactivity disorder 
(ADHD). In a prospective, population-based Finnish birth cohort (9362 pregnancies; 
9479 infants) Pakkila et al. (2014) analysed maternal TSH, free T4, and thyroid-
peroxidase antibodies (TPO-Abs) from early pregnancy samples (5791 women). Teachers 
evaluated the children's ADHD symptoms at 8 years (5131 mother-child pairs). The 
authors analysed whether children with symptoms of lack of attention had mothers with 
hypothyroidism. The likelihood of inattention in girls, but not boys, increased with 
increases in maternal TSH during pregnancy. There were no associations with low 
maternal free T4 or the levels of antibodies against thyroid peroxidase. The authors 
concluded that increases in maternal TSH in early pregnancy showed weak but significant 
association with girls' ADHD symptoms. 
Gyllenberg et al. (2016) tested the idea that maternal hypothyroidism from early to mid-
pregnancy is associated with schizophrenia in their children. Maternal subclinical 
hypothyroxinemia (free T4 lower than the 10th percentile with normal TSH) was 
associated with an increased likelihood of schizophrenia. 
 
6.1.3.2 Cancer 
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Thyroid cancers are the most rapidly rising type of all human malignancies in both 
women and men, with average annual increases of 6% year on year (Howlader et al. 
2012, Kitahara and Sosa 2016). The reasons for this rise are not clear. Recognised risk 
factors include age, radiation exposure, obesity and a family history of thyroid cancer.  
The overwhelming majority of thyroid malignancies derive from follicular thyroid cells, 
with papillary thyroid carcinoma (PTC) representing around 80% and the more 
aggressive follicular thyroid carcinoma (FTC) 10-15% of all thyroid cancers. PTC is the 
driver of the rapid rise in thyroid cancer in the USA (Kitahara and Sosa 2016). 
Papillary thyroid cancers affect women more than men, with an incidence approximately 
3 times higher in women than men. Accordingly, papillary thyroid cancer incidence peaks 
within a woman’s reproductive period, while there is a linear increase with age among 
men (Wang et al. 2015). 
Low levels of TH lead to rises in TSH, and TSH in turn stimulates thyroid gland growth. 
Boelaert et al. (2006) were the first to describe that serum TSH is elevated in patients 
with malignant thyroid nodules when compared to subjects with benign thyroid tumours. 
Since then, several studies analysed in two large meta-analyses (McLeod et al. 2012, 
Zheng et al. 2016) have confirmed that higher serum TSH is associated with an increased 
risk of follicular and papillary thyroid cancer. The data presented by McLeod et al. (2012) 
predict a doubling of the odds of developing thyroid cancer for TSH serum levels between 
0.65 and 4 mU/liter, well within the normal range. 
The studies that formed the basis of these meta-analyses were of a cross-sectional 
design. This limits the possibility of discerning whether raised TSH levels play a causative 
role in thyroid cancer. In any case, TSH has a clear role in thyroid cancer, whether in its 
initiation or in the promotion of pre-existing lesions. 
Further details can be found in the case study on thyroid cancers (see section 5.5). 
6.1.3.3 Cardiovascular disease 
TH play an important role in the proper functioning of the heart and the cardiovascular 
system. TH regulate contractility and systolic function in heart muscle cells 
(cardiomyocytes). TH also influence heart rate and regularity of heart beat through 
effects on components of the adrenergic receptor complex and on various ion channels in 
cardiomyocytes. They help controlling the dilation of the vasculature.  
The effects of TH on the cardiovascular system came to light at the end of the 19th 
century when a women with severe hypothyroidism was found to have an enlarged heart 
and thickened vessels (myxoedema) (see Jabbar et al. 2017). 
Cardiovascular disease and overt and subclinical hyperthyroidism 
The risk of atrial fibrillation and heart arrhythmia is increased in both overt and 
subclinical hyperthyroidism (Cooper and Biondi 2012). Patients with hyperthyroidism 
show an approximately 40% prevalence of pulmonary arterial hypertension (Jabbar et al. 
2017 and references therein). 
Studies of associations between subclinical hyperthyroidism and cardiovascular disease 
have produced more varied results, but a recent meta-analysis of relevant studies (Collet 
TH et al. 2012) has shown significant associations. In this study, individual data on 52 
674 participants from 10 cohorts were pooled and coronary heart disease events and 
atrial fibrillation analysed. Subclinical hyperthyroidism was associated with increased 
total mortality, coronary heart disease and atrial fibrillation. Risks for coronary heart 
disease mortality and atrial fibrillation were higher for TSH levels below 0.10 mU/L when 
compared to subjects with levels between 0.10 and 0.44 mIU/L. 
  
 
Cardiovascular disease and overt and subclinical hypothyroidism 
Overt hypothyroidism affects the cardiovascular system in several different ways. It can 
lead to a reduction in cardiac output, a decrease in heart rate and increases in peripheral 
vascular resistance (Jabbar et al. 2017). 
In subclinical hypothyroidism the most frequent abnormality is diastolic dysfunction 
where left ventricular filling is abnormal and accompanied by elevated filling pressures. 
Subclinical hypothyroidism can also impair the relaxation of vascular smooth muscles 
(Jabbar et al. 2017). 
However, owing to differences in subjects’ age, sex, TSH levels, or preexisting 
cardiovascular disease, observations of associations between subclinical hypothyroidism 
and cardiovascular disease in prospective cohort studies have varied somewhat. A recent 
meta-analysis of 55 287 participants from 11 cohorts (Rodondi et al. 2010) has 
addressed these issues by analysing the risk of coronary heart disease and total mortality 
for adults with subclinical hypothyroidism. The risk of coronary heart disease events and 
mortality increased with higher TSH serum levels, particularly in subjects with TSH levels 
above 10 mU/L. These risks did not significantly differ by age, sex, or preexisting 
cardiovascular disease. 
Subclinical hypothyroidism does not seem to be linked with increased blood pressure 
(although some studies suggest such a link) (Jabbar et al. 2017). 
Programming of metabolic set point and cardiovascular function during 
pregnancy 
Rytter et al. (2016) investigated whether maternal hypothyroidism in week 30 of 
pregnancy may affect blood pressure and adiposity in their children when they have 
reached the age of 20 years. It was found that the children of subclinical hypothyroid 
women had higher systolic blood pressure and a tendency toward higher diastolic blood 
pressure when compared to the offspring of women with normal thyroid function. This 
association was not found in relation to measures of adiposity such as body mass index 
and waist circumference. Thus, maternal thyroid under-function during the third 
trimester of pregnancy may affect long-term blood pressure in their children. 
Thrombosis and blood clotting 
Overt and subclinical hyperthyroidism have been associated with alterations in the 
coagulation pathway (see the review by Jabbar et al. 2017), although it is too early to 
decide whether the observed biochemical abnormalities have any clinical consequences. 
Alterations in coagulation parameters seen in subjects with subclinical hypothyroidism 
are thought to have a role in the development of atherosclerosis (Jabbar et al. 2017). 
6.1.3.4 Lipid metabolism 
TH regulate lipid metabolism through several mechanisms (reviewed in Jin and Teng 
2014). TH contribute to the regulation of 3-Hydroxy-3-Methyl-Glutaryl Coenzyme A 
Reductase (HMGCR), the rate-limiting enzyme in cholesterol synthesis (Mullur et al. 
2014). In hypothyroid subjects, HMGCR mRNA levels are reduced. 
TH also control the expression of genes involved in the hepatic cholesterol clearance, 
such as LDL-R and ABCA1/ABGG5/8 (Jin and Teng 2014).  
TH play a role in lipogenesis and lipolysis through the regulation of Lipoprotein Lipase 
(LPL) which is an essential enzyme responsible for removing triglycerides and 
lipoproteins (Kuusi et al. 1988, Nikkila and Kekki 1972, Abrams et al. 1981). 
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Hyperthyroidism and lipid metabolism 
In patients with overt hyperthyroidism, the serum levels of total cholesterol are 
decreased, while triglyceride levels are either slightly elevated, normal or reduced (Tan 
et al. 1998, Abrams and Grundy 1981, Heimberg et al. 1985) and oxi-low density lipid 
levels are increased (Sundaram et al. 1997, Azizi et al. 2003). The reasons for this mild 
hypertriglyceridemia in patients with overt hyperthyroidism are not clear. 
Hypothyroidism and lipid metabolism 
Overt hypothyroidism is accompanied by increased levels of serum total cholesterol, low 
density lipids and lipoproteins, while serum levels of triglycerides and high density 
lipoprotein are normal or only slightly increased (Pearce 2012). 
The results of studies of serum lipid levels in patients with subclinical hypothyroidism are 
rather varied (Pearce 2012). The lipid profile of patients with subclinical hypothyroidism 
with higher serum TSH level is similar to that in patients with overt hypothyroidism. 
Other pregnancy outcomes 
Su et al. (2011) investigated the effects of maternal thyroid dysfunction on pregnancy 
outcomes and infant development. In 1017 women with singleton pregnancies TH serum 
levels were analysed during the first 20 weeks of pregnancy. The outcomes investigated 
included fetal loss, malformations, birth weight, preterm delivery, fetal stress, neonatal 
death, and infant development. Maternal overt hypothyroidism was associated with 
increased fetal loss, low birth weight, and congenital circulation system malformations. 
Subclinical hypothyroidism was linked with increased fetal distress, preterm delivery, 
poor vision development, and neurodevelopmental delay. Low T4 levels were related to 
fetal distress, small for gestational age, and musculoskeletal malformations. Women with 
elevated T4 serum levels experienced more spontaneous abortions. 
 
6.1.4 Evidence of the possible role of chemical exposures in thyroid 
disruption from epidemiological studies 
Because of the number of key proteins in the thyroid endocrine system, chemicals may 
interfere with thyroid hormone action at many different molecular initiating events (MIEs) 
(see Figure 1). This includes inhibition of iodine uptake, inhibition of hormone production 
(thyroid peroxidase), displacement of TH from serum distributor proteins (thyroid binding 
globulin, albumin, transthyretin),  with increased clearance by liver conjugating enzymes, 
induction of liver conjugating enzymes, inhibition of TH converting enzymes, interference 
with cellular uptake of T3 and/or T4, and potential interactions at the TH receptor level. 
Many, but not all of these perturbations will lead to changes in the serum levels of TH, 
with follow-on effects on TSH levels. 
Because methods for measuring changes in serum levels of TH and TSH are readily 
available and in widespread clinical use, epidemiological studies that aimed at elucidating 
the possible role of chemical exposures in disrupting the thyroid system have mostly 
relied on these outcome measures. Very few studies have used other indicators of 
disruption of the thyroid hormone system such as the binding capacity of thyroid 
hormone binding globulin. 
Key epidemiological findings of thyroid disruption are discussed in the case studies on 
fipronil, maconzeb, PBDE (and PCBs and PFOCs) and perchlorate, and will not be dealt 
with here (see section 5). In this paper, we summarise evidence of human thyroid 
disruption by substances or combinations of substances not already covered in the case 
studies.  
6.1.4.1 Exposure to multiple inhibitors of iodine uptake, low iodine 
status 
Not only perchlorate, but also thiocyanate and iodine deficiency can negatively impact 
iodide intake into the thyroid gland and diminish TH synthesis. Steinmaus et al. (2013) 
  
 
investigated the combined effect of all three of these factors on TH levels in humans. By 
using data from the 2007-2008 National Health and Nutrition Examination Survey 
(NHANES), they categorised subjects into exposure groups based on their urinary 
perchlorate, iodine, and thiocyanate levels and compared mean serum T4 levels between 
groups. The individual effects of perchlorate, thiocyanate and low iodine were rather 
small. However, subjects with high perchlorate, high thiocyanate, and low iodine 
combined had T4 levels 12.9% lower than subjects exposed to perchlorate, low 
thiocyanate, and with adequate iodine supply. These data suggest that combined 
exposure to perchlorate, thiocyanate, and low iodine can reduce T4 levels.   
Similar results were obtained in a study from Thailand by Charatcharoenwitthaya et al. 
(2014). As would be expected from exposure to a iodine uptake inhibitor, rising levels of 
perchlorate were positively associated with increased TSH and with decreased T4 in first-
trimester pregnant women. Thiocyanate exposure was also positively associated with 
TSH in a subgroup of pregnant women with iodine deficiency. 
Suh et al. (2014) also analysed data available from the US NHANES database to assess 
the combined effects of exposure to perchlorate, thiocyanate and nitrate on circulating 
TH. Increasing urinary nitrate was associated with decreases in serum T4 levels in non-
pregnant women with low iodine supply in the NHANES 2001-2002 data base. The 
authors conclude that risk assessments for perchlorate should consider co-exposure to 
nitrate and thiocyanate. 
6.1.4.2 Heavy metals 
Chen et al. (2012) investigated the relationships between TH and the levels of Pb, Hg, 
and Cd in blood and Cd in urine by analysing a sample of adolescents and adults from the 
2007-2008 NHANES survey. While there were no associations with Pb, rising blood Hg 
levels were associated with decreasing levels of serum TH in adults. The opposite pattern 
was observed with Cd where increasing urinary levels were accompanied by rising serum 
levels of TH.  
The association of Hg with decreasing TH levels was also apparent in women of 
reproductive age, suggesting potential negative impacts on brain development.  These 
findings are in agreement with a proposed mechanism for Hg-induced TH insufficiency 
where Hg accumulates in the thyroid and reduces iodide uptake at the sodium/iodide 
symporter by binding to iodide (Nishida et al. 1986). Hg also inhibits TH deiodinases in 
peripheral tissues, enzymes important in supplying active TH (Soldin et al. 2008; Tan et 
al. 2009). 
A somewhat weaker association between Hg and decreased TH serum levels was 
observed in the study by Llop et al. (2015) who analysed 1407 pregnant women 
participating in the Spanish INMA birth cohort study. Hg levels were marginally 
significantly associated with total T3 but not with free T4 or TSH. The association 
between Hg and decreased T3 levels was stronger among mothers who consumed iodine 
supplements. 
Using the data from the 2007-2010 NHANES survey, Jain (2016 a) analysed associations 
between various arsenic variables in urine and free and total T3 and T4, TSH and 
thyroglobulin. The various chemical arsenic species had different effects on the TH 
profiles. For iodine deficient men, dimethylarsinic acid was associated with decreasing 
total T4 levels and correspondingly rising TSH. Arsenic adjusted for arsenobetaine was 
correlated with declining total T4 levels in both iodine deficient and iodine replete 
women. In iodine replete women, TSH levels increased with total arsenic and 
arsenobetaine.  
6.1.4.3 Organochlorines and poly-aromatic hydrocarbons (PAHs) 
Jain (2014) took the data from the 2001-2002 NHANES survey to analyse the 
relationships between TH and TSH and exposures to oxychlordane, p,p′-DDE, trans-
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nonachlor, and heptachlor epoxide. In 20–39 year old iodine deficient males as well as 
iodine replete males, TSH levels increased with increases in trans-nonachlor exposure. 
In iodine replete females rising trans-nonachlor levels were associated with declining 
total T4 levels. In 20–39 year old iodine deficient females, oxychlordane exposure was 
associated with rising TSH levels. In iodine replete females, Mexican Americans had 
higher TSH levels when the exposure to oxychlordane was medium than when the 
exposure was low. In iodine replete females rising oxychlordane led to declines in total 
T4. In non-Hispanic black people, heptachlor epoxide led to decreases in total T4. In 
iodine replete females above age 60 years, there was a positive association between TSH 
and heptachlor epoxide levels. 
In a similar vein, Jain (2016 b) examined the 2007-2008 NHANES survey data for 
associations between TH and the following poly-aromatic hydrocarbons (PAH): 1-
hydroxynaphthalene, 2-hydroxynaphthalene, 2-hydroxyfluorene, 3-hydroxyfluorene, 9-
hydroxyfluorene, 1-hydroxyphenanthrene, 2-hydroxyphenanthrene, 3-
hydroxyphenanthrene, and 1-hydroxypyrene. For females, increased levels of 2-
hydroxynapthalene, 2-hydroxyphenanthrene, and 1-hydroxypyrene were associated with 
elevated levels of total T3. For males, increased levels of 1-hydroxyphenanthrene, 2-
hydroxyphenanthrene, and 9-hydroxypyrene were associated with decreased levels of 
free T4. 
Julvez et al. (2011) measured PCBs, DDE and HCB in maternal pregnancy serum and 
milk from a population-based mother child cohort of 182 children. TH and TSH were 
measured in maternal and cord serum. Resin T3 uptake ratio (T3RU) was also assessed 
as an estimate of the amount of thyroxine-binding globulin sites unsaturated by T4. The 
T3RU is high in hyperthyroidism and low in hypothyroidism. There were consistent 
inverse and monotonic associations between PCB, DDE and HCB levels and T3RU after 
covariate adjustments. Associations with other thyroid parameters were not observed. 
T3RU was positively associated with improved performance on most of the 
neuropsychological tests. The authors concluded that these results suggest that PCB, 
DDE and HCB exposures may decrease the T3RU during early life, which is a proxy 
measure of the binding capacity of TBG. 
 
6.1.4.4 PFOA and other perfluorinated compounds 
Winquist and Steenland (2014) analysed 2109 cases of functional thyroid disease from 
an area surrounding the mid-Ohio River Valley where perfluorooctanoic acid (PFOA) was 
released from a chemical plant, exposing the surrounding community to PFOA for more 
than 50 years. Thyroid disease hazard ratios increased with rising exposure among 
women, suggesting associations for hyperthyroidism and hypothyroidism among women. 
Webster et al. (2014) Associations between maternal serum PFASs, including 
perfluorohexanesulfonate (PFHxS), perfluorononanoate (PFNA), perfluorooctanoate 
(PFOA) and perfluorooctanesulfonate (PFOS) and repeated measures of maternal thyroid 
hormones, including free thyroxine (fT4), total thyroxine (TT4) and thyroid stimulating 
home (TSH) were examined. PFASs were not associated with free or total T4 or TSH 
among women with normal antibody titre against TPO. However, among the 9% of 
women with high TPO antibody, rises in PFASs were associated with increases in 
maternal TSH and with decreases in maternal free T4. The authors concluded that PFASs 
were positively associated with TSH, and weakly negatively associated with free T4 in the 
subset of pregnant women with high TPO antibody titre. PFASs may therefore exacerbate 
the already high TSH and low free T4 levels in these women during early pregnancy. 
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6.2 BACKGROUND PAPER 2: THE THYROID SYSTEM IN FISH, 
AMPHIBIANS AND INVERTEBRATES – A COMPARISON WITH 
MAMMALIAN SPECIES 
 
6.2.1 A comparison of thyroid systems in mammalian and non-
mammalian species 
In the last century, the thyroid system (as with many other hormones) was considered 
the preserve of vertebrates. However, more recently it has been shown that thyroid 
hormone (TH ) functions also occur in invertebrate chordates, echinoderms (Heyland et 
al. 2004). Very recently, possible mollusc thyroid receptors have been identified (Kaur et 
al. 2015; Huang et al. 2015). Our understanding of the function of these more primitive 
thyroid systems is still in its infancy, therefore the focus of this document will be on non-
mammalian vertebrate models. However, as our understanding grows, it may be 
necessary to also develop non-vertebrate thyroid test models. 
Thyroid endocrinology is generally well conserved across vertebrate taxa, with similarities 
in thyroid synthesis, metabolism and mechanism of action. Therefore, chemicals which 
disrupt the thyroid system by targeting thyroid receptors as agonists or antagonist, 
thyroid hormone transport proteins, thyrotropin releasing hormone (TRH), or alter 
thyroid synthesis or metabolism could impact a wide range of vertebrate species. 
6.2.1.1 Thyroid hormone synthesis and release 
  
 
Iodine is the major constituent of THs. Iodide is actively transported into thyroid follicular 
cells via the sodium-iodide symporter (NIS), where it is conjugated to thyroglobulin 
molecule (Tg), a process catalysed by thyroid peroxidase (TPO). Tg had until recently 
only been investigated in mammals. However, Tg orthologs have now been identified in 
several non-mammalian vertebrates including  xenopus, zebrafish, and sea lamprey 
(Holzer et al. 2016). NIS and TPO homologs have been identified in amphibians, fish and 
birds (Tindall et al. 2007; Opitz & Kloas 2010; Opitz et al. 2011; Katarzynska et al. 2015; 
Li et al. 2011; Opitz et al. 2006). Disruption to Tg, NIS or TPO would inhibit TH synthesis 
and therefore could be considered important targets for chemical disruption. 
As in mammalian species, thyroid hormone (TH) release from thyroid follicles is regulated 
by pituitary thyroid stimulating hormone (TSH). Circulating TH negatively influences the 
activity of the hypothalamus and pituitary and, when TH levels are reduced or 
“disrupted,” the activity of the hypothalamus–pituitary increases to elevate TH production 
by the thyroid follicles to restore its circulatory set point concentrations, and vice versa. 
Thus, the activity of the HPT axis is regulated by negative feedback (Carr & Patino 2011). 
In mammals, thyrotropin-releasing hormone (TRH) controls the release of TSH. However, 
although present in non-mammalian vertebrates, it does not always act as a thyrotropin 
(TSH)-releasing factor, whereas corticotropin-releasing hormone (CRH) appears to be a 
potent stimulator of hypophyseal TSH secretion (De Groef et al. 2006). A recent review 
suggests additional close interactions between adrenal/interrenal and thyroidal axes, 
highlighting that corticoids also affect the expression of deiodinases (ID2) and thyroid 
hormone receptors (Watanabe et al. 2016). 
6.2.1.2 Activating and de-activating deiodinases 
In humans, 3 iodothyronine deiodinase (ID) enzymes are involved in converting, 
recycling and degrading T4 and T3. Homologs of ID genes have been found in non-
mammalian vertebrates such as xenopus, zebrafish, chicken and alligator (e.g. NCBI 
gene search). Two of the deiodinases, ID1 and ID2, work in activating the outer ring-
deiodinating pathway by converting T4 to T3 (considered the more active form of TH). In 
contrast, the inactivating or inner ring-deiodinating pathway is catalyzed primarily by 
ID3, which converts T4 and T3 to inactive metabolites (reverse triiodothyronine [rT3] and 
3,3’-diiodothyronine [T2], respectively). Because of their essential function in controlling 
thyroid homeostasis, IDs have been suggested as potential biomarkers for thyroid 
disruption (Orozco & Valverde-R 2005). However, because of their central role in the HPT 
axis, IDs may also be prone to compensatory mechanisms, thus some chemicals may 
exert no effects on IDs although the thyroid system may be disrupted at other sites. 
Similarly, alterations observed in IDs may be driven by indirect processes (Jarque & Pina 
2014). Jarque and Pina (Jarque & Pina 2014) warn that measurements of IDs  alone 
could lead to erroneous conclusions and that changes in IDs need to be taken only as 
indications of interactions of chemical and thyroid system, with further evidence required 
to show physiological effects.    
6.2.1.3 Thyroid hormone transporters and binding proteins 
In the blood stream, thyroid hormones (T3, T4) are in the majority bound to transport 
proteins with only a very small percentage (~0.5%) being ‘free’. In humans, around 75% 
of serum T4 is bound to thyroid binding globulin (TBG), 15% to transthyretin (TTR) and 
<5% to albumin. These three proteins are synthesized by the liver and secreted into the 
bloodstream, where they distribute thyroid hormones from the thyroid gland to cells 
throughout the body (Richardson et al. 2005). In humans, all three proteins have a 
higher affinity to T4 than T3. TBG has the highest afﬁnity for T4 and T3 (1.0 x 1010 and 
4.6 x 108/M, respectively), TTR has intermediate afﬁnity (7.0 x 105 and 1.4 x 107/M, 
respectively) and albumin has the lowest afﬁnity (7.0 x 105 and 1.0 x 105/M, 
respectively) (Alshehri et al. 2015). 
Due to its higher affinity TBG had been considered ‘more important’ than the other 
transport proteins. However, due to the different dissociation rates TTR is actually 
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responsible for the majority of TH delivery to tissues. Alshehri et al. neatly use the 
metaphor of ‘Goldilocks and the three bears’ to describe the relationship, in that, TBG 
binds THs too tightly to deliver signiﬁcant quantities under healthy conditions; albumin 
binds THs too loosely; and TTR has ‘just right’ dissociation rates (Alshehri et al. 2015). 
Similar dissociation rates for TTR have been found across species (Richardson 2007; 
Chang et al. 1999).  
TBG is not found in all species, with albumin being found most frequently as the binding 
protein in a survey of 150 species of adult vertebrates (summarised in (Richardson 2002; 
Richardson et al. 2005)). 
In many vertebrate species, the production of certain thyroid binding proteins is transient 
and related to specific developmental stages. For example, in rats TBG is only present 
during early development and senescence, while adult birds and many adult mammals 
have TTR as their main form of thyroid binding transport protein. In fish and amphibians, 
hepatic TTR synthesis is primarily found during early development, metamorphosis and 
smoltification (salmonids) (Richardson et al. 2005). Richardson et al. (Richardson et al. 
2005) proposes that, across species, total TH levels are elevated in serum during critical 
developmental windows in part by regulated expression of genes coding for thyroid 
binding proteins with higher affinity to those already present in serum (Richardson et al. 
2005). For example, TBG has a higher affinity for TH than TTR. More recently, sensitive 
molecular techniques have detected TTR expression in the liver of adult amphibians 
(Ishihara et al. 2012) and fish (Li et al. 2011), however, although these levels are still 
generally much lower than at metamorphic or developmental stages they likely still play 
an critical role in delivering TH to tissues .  
Only one of the transport proteins, TTR, is synthesised in the brain of mammals 
(specifically choroid plexus) and involved in transporting TH across the blood-brain 
barrier. TTR is also synthesised in the choroid plexus of non-mammalian terrestrial 
vertebrates (birds, reptiles) but not aquatic vertebrates (fish, amphibians) (Schreiber 
2002). TTR was first described in mammals as thyroxine (T4) binding protein. However, 
it seems mammals are the exception among vertebrates in respect to the function of 
TTR, as in teleost fish, amphibians, reptiles and birds TTR preferentially binds 
triiodothyronine (T3), which is the active form of thyroid hormone (TH) (Richardson 
2015). It is also important to note, when comparing results in different test species, that 
total T4 and total T3 levels in blood vary between classes of vertebrates (Hulbert 2000). 
Disruption to thyroid binding proteins (e.g. TTR), either by altered expression or by 
preferential binding, could be considered an important target for disruption in humans 
and other vertebrates. 
6.2.1.4 Physiology 
Although much of the machinery of the thyroid system is fairly-well conserved across 
taxa, there are some striking physiological differences. For example, teleost species can 
have heterotopic thyroid tissue, often with dispersed follicles (Figure 2), whereas, 
reptiles, birds and amphibians (Figure 2) generally have medial or paired glandular 
structures.  
  
 
 
Figure 2. Location of thyroid tissue in non-mammalian vertebrates. (A) Scattered thyroid follicles 
in a hagfish (Eptatretus burgeri). (B) Discrete thyroid gland of the shark (Triakis scyllium). (C) 
Diffuse thyroids of the Japanese eel (Anguilla japonica) (left) and the Pacific salmon (Oncorhynchus 
masou) (right). (D) Paired thyroids in the bullfrog (Rana catesbeiana). (E) Medial thyroid gland in 
neck of the lizard (Takydromas tachydromoides). (F) Paired thyroid glands in a bird, the Japanese 
quail (Coturnix coturnix japonicus). (G) Scattered thyroid follicles (yellow dots) in Platy fish 
(Xiphophorus maculatus). Adapted from http://slideplayer.com/slide/686415/  
 
6.2.2 Observations from experimental studies 
 
6.2.2.1 Amphibian metamorphosis in validated OECD test guidelines 
TH has a well established key role during early development in vertebrates. One of the 
most notable models for studying disruption to this function is amphibian metamorphosis 
(see Figure 3 D). However, many other vertebrates also require TH during key 
developmental events, such as hatching or post-hatch development in bird and reptiles 
(Figure 3 A-C) (De Groef et al. 2013), metamorphosis of flatfish (Schreiber et al. 2010), 
and parr-smolt transformation ‘smoltification’ in salmonids (Larsen et al. 2011).   
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Figure 3 Generalized patterns of plasma hormones associated with hatching in (A) a precocial 
bird (chicken), (B) an altricial bird (European starling) and (C) a non-avian sauropsid (saltwater 
crocodile), E, embryonic day; P, post-hatch day; CORT, corticosterone; GH, growth hormone, (D) 
Correlation of the levels of endogenous TH and mRNAs of TRα, TRβ and RXRα genes with 
development. The embryos hatch around stage 35 and tadpole feeding begins at around stage 45. 
The plasma concentrations of T3, mRNA levels for TRα (solid line), TRβ (broken line) and RXRα 
(bold line) are based on published data are all plotted on arbitrary scales for ease of visualisation. 
Adapted from (De Groef et al. 2013; Wen & Shi 2016). 
 
In 2010 Pickford conducted a critical comparison of mammalian and amphibian models 
for screening thyroid disrupting chemical. The most sensitive and robust endpoint in 
metamorphic xenopus assays (OECD screening test, TG 231) is generally considered to 
be disruption to thyroid histopathology (Pickford 2010). 
6.2.2.2 Recent amphibian studies with additional endpoints 
More recently several studies have integrated additional endpoints (e.g. molecular, TH 
measures) alongside traditional histopathological and developmental scores to help 
eluate the mechanism/target of disruption. 
These studies have shown that modulations of gene expressions of components of the 
iodine machinery are often more sensitive effect markers. The same is true for genes 
related to TH metabolism and for gene expression in the brain.   
Tietge et al. (Tietge et al. 2013) exposed Xenopus tadpoles to 2-mercaptobenzothiazole 
(MBT) a TPO inhibitor, for 7 or 21 days (Tietge et al. 2013). In both the 7 and 21-day 
studies thyroid histopathology was disrupted in all concentrations tested (≥ 18 µg/L), but 
effects were seen at a higher frequency with increased concentration and longer 
exposure. Metamorphic development was only significantly affected in the 21-day study. 
However, in the 7-day study, where additional endpoints (e.g. thyroidal T3, T4, NIS gene 
expression, serum TSH and T4) were measured, thyroidal T3 and T4 were found to be 
the most sensitive measures of disruption, whereas reduced serum T4 was a much less 
sensitive marker (Tietge et al. 2013).   
  
 
Triadimefon (TDF) a triazole-derivative fungicide caused a reduction in developmental 
rates and significantly decreased whole body thyroid hormone (T4 and T3) levels in X. 
laevis tadpoles (Li et al. 2016). Downregulation of thyroglobulin (Tg) and upregulation of 
genes related to thyroid hormone metabolism (ugt1ab) in TDF exposed tadpoles may 
have been responsible for the decreased thyroid hormone concentrations. Treatment with 
TDF also significantly increased mRNA expression of genes involved in TSH possibly as a 
compensatory response to the lowered TH (Li et al. 2016). 
In X. laevis tadpoles a high dose (5000 µg BDE-47/g food) of BDE-47 hindered growth 
and development; however, thyroid hormone-associated gene expression was 
downregulated in the brains of tadpoles at all doses tested (50, 500 or 5000 µg BDE-
47/g food). These results show that BDE-47 disrupts thyroid hormone signalling at the 
molecular and whole-organism levels and suggest that gene expression in the brain is a 
more sensitive endpoint than metamorphosis (or gene expression in the tail). 
Furthermore, the altered gene expression patterns among BDE-47-exposed tadpoles 
provide insights into the mechanisms of PBDE-induced thyroid disruption (e.g. via 
reduced dio2 and organic anion transporting polypeptide 1C1 (OATP1C1) expression) and 
highlight the potential for PBDEs to act as neurodevelopmental toxicants (Yost et al. 
2016). Histopathology of the thyroid gland was conducted as part of this study, but was 
inconclusive due to insufficient numbers for statistical analysis (n=4) (Yost et al. 2016).  
6.2.2.3 Thyroid disruption in fish and birds 
There are currently no specific OECD tests for thyroid disruption in fish or birds. Recent 
studies suggest several possible endpoints for thyroid disruption in fish and birds, as 
follows:  
Thyroid histopathology 
As with amphibians and rats, the histopathology of thyroid follicles of fish and birds can 
be assessed and has been shown to be sensitive to disruption. For example, exposure to 
perchlorate has resulted in disruption to thyroid follicles in stickleback fish (Furin et al. 
2015), zebrafish (Mukhi & Patino 2007), Japanese quail (Chen et al. 2008) and northern 
bobwhite quail (Gentles et al. 2005). 
TTR 
In other models (in vitro, mammalian) PBDEs exhibit the potential to influence the levels 
of circulating THs by competitive binding of TTR (reviewed in (Yu et al. 2015)). In fish 
laboratory studies PBDEs (DE-71, BDE-209, or BDE-47) exposure resulted in reduced 
TTR transcriptional and protein levels and reduced whole body T4 concentrations 
(reviewed in (Yu et al. 2015)). Similarly, life-cycle exposure to BDE-47 resulted in 
significantly reduced (at 10 µg/L) T3, T4 plasma (F0 adult) and body (F1 eggs, F1 larvae) 
concentrations along with significantly reduced TTR expression in the liver of F0 adult (at 
1, 5 and 10 µg/L) and F0 and F1 larvae (at 1 and 5 µg/L) (Zhao et al. 2016). 
TTR expression was also significantly reduced in adult fathead minnow exposed to BDE-
47 in the diet (41.22 µg/pair/day), however possible impacts on T3 or T4 were not 
measured in this study (Thornton et al. 2016). Yu et al. suggest that although the 
mechanisms of reduction in TTR levels are not well-understood, the down-regulation of 
TTR mRNA and protein levels caused by PBDEs exposure could impact the binding and 
transport of THs and thus pose a potential risk to thyroid functions (Yu et al. 2015). 
In comparison to PBDEs, permethrin has recently been shown to up-regulate TTR and 
increased T3 and T4 concentrations in zebrafish larvae (Tu et al. 2016), in silico docking 
models indicated permethrin could also bind to TTR. 
Deiodinase activity 
Jarque and Pina (Jarque & Pina 2014) reviewed natural and chemical factors that can 
modulate deiodinases in teleosts. PBDEs, HBCD, PFOA, PFOS, pharmaceuticals and 
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metals have all been shown to modulate specific deiodinases levels in different tissues of 
fish (reviewed in (Jarque & Pina 2014)). However, as yet the exact mechanisms of 
disruption are not well characterised. For example, PBDEs (and metabolites) have been 
suggested to act directly on deiodinases expression, as ‘T4 mimetic substrates’ for 
deiodinases or indirectly due to pregnane X receptor (PXR) activation, where ID1 and ID2 
are upregulated to try and maintain TH levels (reviewed in (Jarque & Pina 2014)).     
 
Less information could be found for birds. However, in a chicken embryo model, TTR was 
down-regulated in the liver by in ovo exposure to hexachlorocyclopentadienyl-
dibromocyclooctane  (HCDBCO, brominated flame retardant) (Egloff et al. 2011). 
Whereas, 1,2-bis(2,4,6-tribromophenoxy)ethane (BTBPE) down regulated ID3 in ovo and 
in vitro (chicken embryonic hepatocytes) and decabromodiphenylethane (DBDPE) 
increased ID1 in vitro only (Egloff et al. 2011). 
In a chicken thyroid explant experiment (ex vivo) PCB 126 and TCDD significantly 
increased expression of TPO and Tg, but not NIS, along with decreased T4 and T3 
(Katarzynska et al. 2015).  
Swim-bladder inflation 
The involvement of TH in swim-bladder development in fish has been highlighted by Liu 
and Chan (Liu & Chan 2002). They demonstrated that in larval zebrafish excessive TH 
treatment (10, 40 nM T4, 5 nM T3) resulted in failure of the swim bladder to remain 
inflated. Co-treatment with amiodarone (TR antagonist, 50 nM) and methimazole 
(goitrogen, 0.3 nM) resulted in retarded swim-bladder development (but not 
individually), which could be ‘rescued’ by addition of 10 nM T4 (Liu & Chan 2002). The 
swim bladder consists of two chambers separated by a narrow duct. The posterior 
chamber is developed and inflated first, in what are described as ‘swim-up’ fry -this 
posterior chamber is inflated initially by the fish gulping air at the water surface. It 
operates as a vital hydrostatic organ to regulate buoyancy. The anterior chamber 
develops later and functions primarily as an acoustic resonator to aid hearing. TH is also 
important in regulating otolith (‘ear’ bone) (Schreiber et al. 2010) and lateral line 
(sensory organs) development/ regeneration in fish (Bouzaffour et al. 2010; Levin 2010). 
PFOS has been shown to impair posterior swim-bladder inflation in developing zebrafish 
(Hagenaars et al. 2014). The swim-bladder impairment was seen alongside spinal 
curvature and resulted in decreased swimming ability (speed). However, no thyroid 
specific endpoints were assessed in this study. Similarly zebrafish developmentally 
exposed to 6-OH-BDE-47 show delayed swim bladder, fin, and pigmentation 
development (Macaulay et al. 2017). Impaired anterior swim-bladder inflation has been 
reported in zebrafish (350 µg/L MBT) (Stinckens et al. 2016) and fathead minnow (1000 
µg/L MBT) (Nelson et al. 2016) exposed to thyroid peroxidase inhibitor 2-
mercaptobenzothiazole (MBT). In these studies, thyroid endpoints were assessed. In 
fathead minnows MBT induced follicular cell hypertrophy (500 and 1000 µg/L), whole 
body T3 and T4 were reduced however, TPO mRNA suggested compensation (Nelson et 
al. 2016). In zebrafish T4 was reduced and anterior chamber surface was positively 
correlated with whole body T4 levels (Stinckens et al. 2016). The lack of effect on 
posterior swim-bladder inflation in these MBT studies was proposed to be related to the 
earlier development of the organ (compared to anterior swim-bladder) and maternal 
transfer of TH (Nelson et al. 2016; Stinckens et al. 2016).  
Due to its vital importance in fish health, aquaculture papers also describe disruption to 
normal swim-bladder inflation. It has been linked to maternal nutrition in gilthead 
seabream (Tandler et al. 1995), suboptimal water temperature (Sanabria et al. 2009) in 
freshwater angelfish, and bathing eggs/fry in some aquaculture disinfectants i.e. 
hydrogen peroxide, acriflavin or methylene blue (Sanabria et al. 2009). Interestingly, the 
impacts of methylene blue on swim-bladder development were timing specific; exposure 
for up to 1 day post-hatch did not affect swim bladder non-inflation, but exposure from 2 
days onwards significantly increased swim bladder non-inflation (Sanabria et al. 2009).  
  
 
Behaviour 
Exposure of zebrafish larvae to tetrabromobisphenol A (TBBPA) or propylthiouracil (PTU) 
resulted in quite similar visual and behavioural disruptions despite very different 
molecular responses of thyroid system-related genes (TRα, TRβ, TPO, TSH, DIO1, DIO2 
and DIO3) (Baumann et al. 2016). Both TBBPA and PTU reduced relative eye size, 
morphology and pigmentation and altered ocular motor reflex. Swimming activity was 
also altered by both TBBPA and PTU, whereas light:dark preference was only altered in 
PTU treated fish (Baumann et al. 2016). 
Altered behaviour has also been found in stickleback (fish) exposed to perchlorate 
(Bernhardt & von Hippel 2008). F1 fish showed a range of altered behaviours including 
those which might imped survival and successful reproduction i.e. nest building, 
spawning, nursery formation, or fry production (Bernhardt & von Hippel 2008).    
Perchlorate has also been shown to impact bird behaviour. Developmental exposure to 
high concentrations of perchlorate (1000 µg/g) in Zebra finch resulted in greater begging 
intensity, decreased motivation for spontaneous movement (e.g., attempts to fly), and 
reduced capacity to wean themselves from parental care (Rainwater et al. 2008). flight 
attempts were also significantly reduced in birds exposed to lower concentrations (10 and 
100 µg/g), and overall the proportion of perchlorate-dosed birds attempting flight was 
less than half that in the control group (Rainwater et al. 2008). 
Juvenile European starlings exposed to Aroclor 1254 during development were also 
slower and more error-prone than controls in experiments testing: habituation, learning, 
cue selection, and memory (Zahara et al. 2015). Aroclor 1254 exposure resulted in 
significant increases in mass, fat, and moulting and decreasing plasma thyroid hormones 
over time. High dosed birds (1.05 µg Aroclor 1254/g) showed a delayed migratory 
orientation (Flahr et al. 2015). 
6.2.3 Observations from wildlife 
Many of the more serious adverse effects found in experimental studies 
(delayed/disrupted hatching, delayed metamorphosis, disrupted swim-bladder inflation, 
locomotion etc.) would result in predation or starvation in the wild. However, many 
impacts of thyroid disruption in environmental exposures are likely to be subtler. Animals 
in the wild (as humans) will be exposed to a multitude of lower levels of compounds with 
diverse targets, rather than single high doses as found in experimental studies. Without 
robust and sensitive methods or biomarkers to determine explicit thyroid effects it is not 
surprising it is so difficult to specifically ascribe thyroid disruption in wild animals. 
Most wildlife studies that investigate possible thyroid disrupting effects focus on 
persistent organic pollutants. These generally measure contaminate load in the tissues 
and correlate them with circulating TH levels or more recently mRNA of thyroid related 
genes in tissues. However, these approaches are often confounded by intrinsic variability 
due to the animals varying age, sex, breeding stage, time of year, nutritional state, etc. 
In 2011 Carr and Patino reviewed the literature on disruption of the hypothalamus-
pituitary-thyroid (HPT) axis in wild amphibians and teleost by environmental 
contaminants, and found no evidence to clearly link contaminant-induced HPT alterations 
to impairments in wild population health (Carr & Patino 2011).  
A recent review by Yu et al. (Yu et al. 2015) has summarize the effects of PBDEs on the 
thyroid and reproductive systems and the cross-talk between the two systems in fish, 
including lab and field data. Song et al. (reviewed in (Yu et al. 2015)) found decreased 
T4 and increased TSH in juvenile Crucian Carp (Carassius auratus) caught from a river 
close to an electronic waste (e-waste) site in Zhejiang, China compared to a control site, 
the ‘e-waste’ site fish had PBDE 400 times those in the control site. However, no 
population level effects were determined.  
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In wild urban gulls from Montreal, Canada, Técher et al. (Techer et al. 2016) investigated 
correlations between contamination with organochlorines (OCs) and polybrominated 
diphenyl ether (PBDE) flame retardants and thyroid related gene expression (mRNA) or 
circulating TH. The authors found positive correlations between liver concentrations of 
several polychlorinated biphenyls (PCBs), PBDEs as well as chlordanes and total plasma 
T4 levels. Hepatic concentrations of several PBDEs were negatively correlated with mRNA 
levels of ID3, TPO, and TRβ in the thyroid gland. Liver PCB (deca-CB) correlated 
positively with mRNA levels of NIS and TRα. In the brain, concentrations of most PBDEs 
were positively correlated with mRNA levels of organic anion transporter protein 1C1 and 
TTR, while PCBs positively correlated with expression of TRα and TRβ as well as ID2. The 
authors concluded that OCs and PBDE could be acting though several mechanisms (direct 
or compensatory), thus potentially perturbing the HPT axis of highly organohalogen-
contaminated gull population (Techer et al. 2016).  
Ideally, better integration between wildlife and laboratory studies, and improved models 
(in silico, in vitro and in vivo) could help understand (and prevent) possible adverse 
effects in wild animals. 
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6.3 BACKGROUND PAPER 3: INTERPRETATION OF DATA FROM 
EPIDEMIOLOGY, EXPERIMENTAL STUDIES AND WILDLIFE DATA 
FOR THE IDENTIFICATION OF THYROID DISRUPTORS 
 
6.3.1 Introduction 
In this paper we describe issues that have an impact on the interpretation of data from 
epidemiological and experimental studies of thyroid disruption. 
6.3.2 Data from human epidemiological and clinical studies 
This section is intended to give some orientation as to the relevance of measures of 
thyroid function in epidemiological and clinical studies. It also summarises issues 
discussed in the literature that need to be taken into account for the interpretation of 
findings, especially relating to differences of the human thyroid system across life stages. 
6.3.2.1 Thyroid hormone measurements and diagnostic criteria 
Overt hyperthyroidism is defined in terms of suppressed TSH serum levels and free TH 
levels above the reference range. Subclinical hyperthyroidism is diagnosed when 
serum TSH is below 0.3-0.4 mU/L with free T3 and T4 levels within the population 
reference range. 
Overt hypothyroidism occurs with TSH serum levels higher than 10 mU/L and T4 levels 
below the reference range. Subclinical hypothyroidism is diagnosed as “mild” with 
normal TSH serum levels between 4 and 10 mU/L and free T4 below the 10th percentile 
of the reference range. The criteria for “severe” subclinical hypothyroidism vary 
somewhat. It is sometimes defined as TSH levels exceeding 10 mU/L. Other authors 
classify “severe” hypothyroidism with TSH in the normal range and free T4 levels below 
the 5th percentile of the reference range (see the epidemiological studies on cognitive 
development in children discussed below). 
There is no consensus on the upper normal range of TSH which leads to a controversy 
about the definition and clinical relevance of subclinical hypothyroidism. For references 
see Background Paper 1 <BG1 adverse effects human>.The prevailing method to 
diagnose thyroid illnesses uses limit values based on the distribution of THs or TSH in 
euthyroid disease-free individuals. The underlying assumption is that the limits derived 
from this curve are applicable to all people. However, TSH distribution and reference 
limits increase or decrease with age depending on iodine intake, and are unique for 
different ethnic groups (Surks and Boucai 2010). It has also been found that fT3 levels 
vary remarkably among different age groups and gender, decreasing with age, while fT4 
remains relatively stable. The magnitude of the fT3 decrease may also be gender-specific 
(Kumari et al. 2015). 
6.3.2.2 Variation of thyroid hormone levels across life stages 
During the first trimester of pregnancy, maternal T4 is the only source of supply of TH to 
the fetus, until it can produce its own at approximately 16-20 weeks of gestation. TH and 
TSH levels during early pregnancy are exceedingly variable because of the enhanced 
requirements for thyroid hormone particularly during early pregnancy and because 
human chorionic gonadotrophin stimulates the thyroid in this period leading to a 
physiological decrease in TSH levels. The mother remains an important source of TH 
supply through to late gestation, contributing approximately 30% of the fetus’ demand 
(reviewed by Ginsberg et al. 2007). 
There are very low levels of TH in mother’s milk. For this reason, newborns cannot 
anymore rely on mother’s TH and have to synthesise their own supply. However, 
  
 
newborns have quite low functional reserves of TH, and the reserves available in the 
adult are not yet established. This makes newborns more vulnerable to perturbations of 
the thyroid system. Several factors play a role (Ginsberg et al. 2007): 
 The serum half-life of T4 is lower in neonates than in adults (3 days vs 7-10 
days). 
 The rate of TH replacement in neonates must therefore be higher than in adults. 
The storage capacity of the neonatal thyroid is less than 1 day’s worth of TH demand, 
compared to the adult gland which can store the demand of several months. 
These factors need to be taken into account when considering acceptable levels of 
exposure to thyroid disrupting chemicals, but are sometimes ignored. 
6.3.2.3 Endpoints used in human epidemiological studies and their 
interpretation 
The endpoints most commonly measured in epidemiological studies include TSH, total T4 
(TT4), total T3 and sometimes the free THs (fT3 and fT4). 
Ethnicity, iodine intake, gender, age, and body mass index will all influence serum TSH, 
while pregnancy is associated with major changes in both TH and TSH concentrations 
(Koulouri et al. 2013). Hence each lab has to establish norms for their thyroid 
measurements and cohort/ exposure studies require large numbers to obtain sufficient 
statistical analytical power. 
Changes in circulating binding proteins (e.g. elevated TBG in pregnancy) can also 
seriously confound interpretation of TT4 and TT3 concentrations. Another challenge 
concerns the measurement of free TH levels and methodological differences and 
limitations of commercially available immunoassays. The same sample may yield 
markedly discordant fT4 concentrations when run on different assay platforms (Koulouri 
et al 2013). Immunoassays have been reported to be influenced by the concentration of 
T4-bound transport proteins. The concentration of protein-bound T4 has been found to 
positively bias the fT4 readings generated by most immunoassays and measurement of 
free T3 would be expected to be similarly biased (Chevrier 2013). 
6.3.2.4 Significance of altered TH levels in subclinical hyper- and 
hypothyroidism 
By definition, subclinical hyper- or hypothyroidism describe altered TH levels without 
overt signs of disease. As such, for the individual patient, the interpretation of such 
alterations in terms of disease risk or prognosis is complicated. 
However, at the population level, other interpretations are possible and necessary. In 
pregnant women, reductions in T4, accompanied by normal TSH levels (subclinical 
hypothyroidism) are associated with compromised cognitive development in their 
children (IQ loss) and other effects (see Background Paper 1 <BG1 adverse effects 
human>). These observations have to be taken into account when interpreting 
epidemiological studies showing associations between pollutant exposures and reduced 
T4 levels (as e.g. with mercury, certain arsenic compounds, certain organochlorine 
pesticides, perchlorate, thiocyanates, polyaromatic hydrocarbons and perfluorinated 
compounds. 
Similarly, increases in TSH levels within the normal range that may arise in the wake of 
reduced TH levels are associated with increased risk of thyroid cancer (see case study 
on thyroid cancer <CS TSH thyroid cancer>). 
6.3.2.5 Other factors with impact on thyroid hormone status: 
nutritional status, other illnesses and alcohol consumption 
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Some of the modifiable factors that may also have an impact on thyroid hormone status 
include nutritional status, non-thyroidal illnesses (NTIs) and alcohol consumption. 
The reduction in leptin levels that accompanies malnutrition are thought to directly impair 
hypothalamic TRH secretion and induce central hypothyroidism (decrease in TH without 
concomitant increase in TSH. A role for excess endogenous glucocorticoids has also been 
postulated (Koulouri et al 2013).  
Iodine is the major constituent of THs. It is remarkable that an element that is relatively 
scarce in the environment should play such an important role in embryogenesis, growth, 
metabolism, cognition, and adaptation to disease states. The sea is the main source of 
iodine; iodine-containing clouds are formed over the oceans, and deposited over the land 
by wet deposition. The iodine content of plants, crops, and animals in any specific 
geographical region depends on the retention of iodine in the soil. Iodine deficiency can 
pose a serious threat to the thyroidal capacity to synthesize thyroid hormones and about 
1.5 billion people live in geographic areas of iodine insufficiency (Bianco et al 2014). 
The thyroid is one of the organs with the highest selenium content because it expresses 
several specific selenoproteins including deiodinases that are implicated in thyroid 
hormone metabolism and others play an antioxidant defence role. The main source of 
selenium is proteinaceous foods (meat, fish, shellfish, offal, eggs, cereals, etc.), but 
bioavailability of the selenium they contain is variable and the selenium content of 
cereals is dependent on the selenium content of the soil where they are grown. The soils 
of most European countries have a low selenium content. Although only very severe 
selenium deficiencies appear to affect thyroid function, and namely T3 synthesis, 
selenium status appears to have an impact on the development of thyroid pathologies 
(Drutel et al 2013). 
Changes in TH (especially T3) and TSH may be seen as early as 24 h after the onset of 
NTIs characterized by a variety of abnormal thyroid function patterns, which may change 
with progression or resolution of the underlying primary disorder.  Reductions in TT4, and 
in particular TT3, are common even in mild NTI. Additionally, a number of drugs are 
recognised to increase serum TBG concentrations including oestrogen, raloxifene, 
tamoxifen, mitotane, fluorouracil, methadone and heroin. In contrast, androgens, chronic 
glucocorticoid therapy and nicotinic acid have all been shown to inhibit TBG synthesis 
(reviewed in Koulouri et al 2013). 
6.3.3 Data from experimental studies with mammalian species 
There are notable differences in the systemic regulation of thyroid hormones levels 
between commonly used rodent experimental models, particularly the rat, and humans. 
As illustrated in the case studies on perchlorate, fipronil and thyroid cancers (see 
section 5) quantitative species-specific differences in hormone synthesis and serum 
binding have been used to draw conclusions regarding the susceptibility of experimental 
models to TH perturbation and therefore the human relevance of experimental results. 
Additionally, peripheral TH levels do not reflect tissue levels and therefore do not predict 
tissue responses, as illustrated by the PBDE/perfluorinated compounds/PCB case 
study (section 5.4).  
6.3.3.1 Species differences in relation to the thyroid system and 
their relevance in interpreting the outcome of animal studies 
The HPT axis and basic processes of TH synthesis and release are qualitatively similar 
across species. The negative feedback loop between circulatory TH levels and synthesis 
of thyrotropin-releasing hormone (TRH) by the hypothalamus, and thyrotropin (TSH) by 
the anterior pituitary is a primary signalling pathway to maintain homeostasis. There are 
however notable quantitative species-specific differences in hormone synthesis and 
serum binding.  
When released to the bloodstream, the two thyroid hormones T3 and T4 are bound to 
transport proteins that protect them from metabolic degradation and reduces their 
  
 
elimination via the kidneys. In humans, approximately 68% of the total circulating T4 
(TT4) is bound to thyroxine-binding globulin (TBG), a specific, high affinity transport 
protein. The remainder is bound to less specific transport proteins such as albumin and 
transthyretin (TTR), with less than 1 percent existing as the free (biologically active) 
hormone (fT4) (Lewandowski et al. 2004; Fisher et al. 2012). TBG is found in primates, 
as well as in dogs and certain ungulates. In rats however, it is found in the serum of the 
young peaking at about one month of age, then drops to very low levels by two months, 
before returning to higher levels in old age, beginning at about seven months and 
reaching levels that are approximately 25% of the peak post-natal levels by about 20 
months of age. Between the ages of two to seven months typically used in subchronic 
toxicology studies, levels of TBG are therefore hardly detectable. Instead, T3 and T4 are 
bound to primarily TTR and to some extent albumin that both have lower affinity. In 
humans, TBG-bound TH acts as a stable reserve that may be used if additional amounts 
of thyroid hormones are required. In species in which TBG is not the major T4 carrier, 
the free fraction of the T4 is larger than in humans and total T4 half-life is shorter 
(around 24h in rats, versus 5-6 days in humans) (Lewandowski et al 2004). This 
increased clearance is compensated by higher production of THs with corresponding 
higher basal TSH levels.  
This is also reflected in species-specific differences in thyroid histology. Thyroid hormone 
production requires the transport of iodide into thyroid follicular cells by the sodium 
iodide symporter (NIS) where it is oxidised to iodine by the enzyme thyroglobulin 
peroxidase (TPO). Iodine is then coupled to tyrosine residues on the thyroglobin molecule 
(TG) and stored within the lumen, a cavity inside the thyroid follicle, in the form of a 
viscous substance called colloid. This reserve pool of TH precursor can be called upon in 
response to decrease serum TH levels. In the rat, thyroid follicles tend to be smaller and 
contain less colloid than primate follicles.   
These differences, as well as the examination of T3 and T4 and, particularly, TSH 
responses to perchlorate in rats in comparison with humans (see case study) has led to 
the suggestion that humans have a greater potential for adaptation after exposure to 
chemicals, without suffering changes in levels of serum thyroid hormones. For these 
reasons, the toxicological effects on thyroid function that derive from increased thyroid 
hormone catabolism in the rat have often been considered irrelevant to humans. 
However, newborns have lower storage capacity (see above). 
However, even though TBG is the major and specific transport protein of thyroid 
hormones (TH) in humans, it has recently been shown not to be the physiologically most 
relevant (Alshehri et al. 2015). The most physiologically relevant carrier protein in 
humans is also TTR (see fipronil case study, section 5.1). Furthermore, the differences 
in half- lives of the active hormone T3 between rats and humans are much smaller than 
for T4, as T3 half-lives for humans are 22-24 h (Jonklaas et al 2015) and around 6h in 
rats (Lewandowski et al 2004). It is also important to point out that the newborn human 
has lower stored thyroid hormone and the half-life of its T4 is much shorter than in 
adults.  
6.3.3.2 Commonly used endpoints for measuring thyroid disruption 
and their interpretation in terms of adversity and thyroid 
disruption 
Repeated-dose toxicity as well as reproductive and developmental toxicity studies include 
endpoints relevant to identifying thyroid hormone mediated effects. The studies involving 
exposure of developing animals are particularly important in this context: TG421/422 
reproductive/developmental toxicity screening study), TG 443 (extended one-generation 
study) and TG426 (developmental neurotoxicity) (see Background Paper 4 below on 
the gaps in current testing methods). 
Common difficulties that arise when interpreting  observed changes on these endpoints 
are summarised in the next section and illustrated in all case studies.  
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6.3.3.3 Adversity of TH reductions and enigmatic effect profiles and 
difficulties of their interpretation 
The case study on fipronil (see section 5) describes the debates that surround 
interpretations of reductions in T3 and T4 levels, and whether these should be judged as 
“adverse” per se. 
The case studies on Mancozeb and PBDEs/perfluorinated compounds/PCB (section 5) 
illustrate some effect profiles that remain unexplained and highlight the difficulties in 
interpreting experimental studies reporting effects on circulating TH levels. 
Mancozeb is thought to exert its thyroid disrupting effects through the same mode of 
action as PTU (inhibition of PTO). However, whereas the marked maternal reductions in 
T4 following PTU exposure lead to severe developmental neurotoxicity in offspring, 
hypothyroxinemia following maternal exposure to mancozeb does not lead to significant 
effects in offspring behaviour or acoustic startle response. Several other DNT studies 
investigating rodent offspring from hypothyroid dams have also shown that adverse 
behavioural outcomes are not always present. This is for instance the case with fipronil 
and perchlorate (see case studies).  
The majority of reported developmental PTU studies use very higher doses of PTU than 
those used in mancozeb studies. It remains to be seen whether higher doses of 
mancozeb would induce neurobehavioural effects. PTU has other modes of action than 
just TPO inhibition, including inhibition of deiodinase activity. Decreases in circulating T4 
levels (due to TPO inhibition by mancozeb) could have led to upregulation of peripheral 
deiodinase activity in the offspring’s brains and compensated for the low circulating T4 
levels by providing enough T3 for normal brain development. Since much brain 
development occurs postnatally in rats and the offspring in mancozeb studies were not 
hypothyroid in that postnatal period (due to limited milk transfer), the prenatal 
hypothyroxinemia may not be severe enough to disrupt brain development. Finally, it is 
also possible that neurobehavioural assessment methods are not suited for the detection 
of subtle effects in the brain.  
In rodent studies, polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls 
(PCBs) and poly- and perfluorinated alkyl substances (PFASs) reduce total and free 
serum T4, but without corresponding increases in TSH, a pattern described as 
“enigmatic”.  In order to shed light on the significance of altered circulatory TH levels, 
the accompanying case study compared the effects of PBDES, PCBs and PFASs and their 
metabolites on the Hypothalamus-Pituitary-Thyroid axis, binding to proteins involved in 
peripheral TH transport, the regulation of intracellular levels of THs, binding affinity for 
thyroid receptors (TR), and downstream TH-mediated effects in some of the best studied 
organs (liver, brain, testes). The evidence available reveals both that these three classes 
of compounds can act, sometimes in opposite direction, centrally on the HPT axis, on 
tissue levels of TH by binding to peripheral transport proteins, cellular transporters or 
disrupting deiodinase action, and ultimately on TR-mediated genes. There is also clear 
evidence that one substance can elicit different responses in different tissues. It is 
therefore clear that interpretation of changes in peripheral TH levels is not ‘one size fits 
all’. Similar patterns of effects peripherally may mask the complexity of concurrent 
disruption of TH action on several regulatory processes centrally, peripherally and in 
different tissues.  
6.3.4 Data from experimental studies with non-mammalian species 
The thyroid system was long considered the preserve of vertebrates. However, more 
recently it has been shown that TH functions also occur in invertebrate chordates, 
echinoderms, and possibly molluscs. Thyroid endocrinology is generally well conserved 
across vertebrate taxa, with similarities in thyroid synthesis, metabolism and mechanism 
of action. Therefore, chemicals which disrupt the thyroid system by targeting thyroid 
receptors as agonists or antagonist, thyroid hormone transport proteins, thyrotropin 
releasing hormone (TRH), or alter thyroid synthesis or metabolism could impact a wide 
range of vertebrate species. The following section summarises key points from 
  
 
Background Paper 2, “The thyroid system in fish, amphibians and invertebrates – a 
comparison with mammalian species” (see previous section) 
6.3.4.1 Commonalities and differences of thyroid systems 
Iodine is the major constituent of THs. Iodide is actively transported into thyroid follicular 
cells via the NIS, where it is conjugated to TG, a process catalysed by TPO. TG had until 
recently only been investigated in mammals. However, TG orthologs have now been 
identified in fish and amphibians, and NIS and TPO homologs in amphibians, fish and 
birds. As in mammalian species, TH release from thyroid follicles is regulated by pituitary 
TSH and the activity of the HPT axis is regulated by negative feedback by circulating THs. 
In mammals, TRH controls the release of TSH. However, although present in non-
mammalian vertebrates, it does not always act as a TSH-releasing factor, whereas 
corticotropin-releasing hormone (CRH) appears to be a potent stimulator of hypophyseal 
TSH secretion. A recent review suggests additional close interactions between 
adrenal/interrenal and thyroidal axes, highlighting that corticoids also affect the 
expression of deiodinases and thyroid hormone receptors. In humans, 3 iodothyronine 
deiodinase (ID) enzymes are involved in converting, recycling and degrading T4 and T3. 
Homologs of ID genes have been found in non-mammalian vertebrates such as xenopus, 
zebrafish, chicken and alligator. 
In humans, TBG had been considered ‘more important’ than the other transport proteins 
due to its higher affinity. However, due to the different dissociation rates TTR is actually 
responsible for the majority of TH delivery to tissues. Alshehri et al. neatly use the 
metaphor of ‘Goldilocks and the three bears’ to describe the relationship, in that, TBG 
binds THs too tightly to deliver signiﬁcant quantities under healthy conditions; albumin 
binds THs too loosely; and TTR has ‘just right’ dissociation rates (Alshehri et al. 2015). 
Similar dissociation rates for TTR have been found across species (Richardson 2007; 
Chang et al. 1999). TBG is not found in all species, with albumin being found most 
frequently as the binding protein in a survey of 150 species of adult vertebrates. In many 
vertebrate species, the production of certain thyroid binding proteins is transient and 
related to specific developmental stages. While adult birds and many adult mammals 
have TTR as their main form of thyroid binding transport protein, in fish and amphibians, 
hepatic TTR synthesis is primarily found during early development, metamorphosis and 
smoltification (salmonids). Only one of the transport proteins, TTR, is synthesised in the 
brain of mammals and involved in transporting TH across the blood-brain barrier. TTR is 
also synthesised in the choroid plexus of non-mammalian terrestrial vertebrates (birds, 
reptiles) but not aquatic vertebrates (fish, amphibians). TTR was first described in 
mammals as T4 binding protein. However, it seems mammals are the exception among 
vertebrates in respect to the function of TTR, as in teleost fish, amphibians, reptiles and 
birds TTR preferentially binds the active form T3. It is also important to note that total T4 
and total T3 levels in blood vary between classes of vertebrates.  
Although much of the machinery of the thyroid system is fairly-well conserved across 
taxa, there are some striking physiological differences. For example, teleost species can 
have heterotopic thyroid tissue, often with dispersed follicles, whereas, reptiles, birds and 
amphibians generally have medial or paired glandular structures. 
6.3.4.2 Use of amphibians and fish for the identification of thyroid 
disruptors 
TH has a well-established key role during early development in vertebrates. One of the 
most notable models for studying disruption to this function is amphibian 
metamorphosis. The most sensitive and robust endpoint in metamorphic xenopus assays 
(OECD screening test, TG 231) is generally considered to be disruption to thyroid 
histopathology (Pickford 2010). More recently several studies have integrated additional 
endpoints (e.g. molecular, TH measures) alongside traditional histopathological and 
developmental scores to help eluate the mechanism/target of disruption. These studies 
have shown that modulations of gene expressions of components of the iodine machinery 
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are often more sensitive effect markers. The same is true for genes related to TH 
metabolism and for gene expression in the brain. 
There are currently no specific OECD tests for thyroid disruption in fish or birds. Recent 
studies suggest several possible endpoints for thyroid disruption in fish and birds (see 
background paper 2 in this ection). 
6.3.4.3 From the laboratory to the field 
To anticipate the effects of thyroid disrupters in the field, the ecotoxicological effects that 
are considered relevant are those likely to affect populations. As such, the main focus is 
on effects affecting the growth, survival or reproduction of species. As illustrated in 
background paper 2, guideline studies have been validated for the screening of thyroid 
disrupting properties. The endpoints included were therefore selected on the basis of 
their sensitivity rather than their relevance to field conditions. While some of the more 
serious adverse effects found in experimental studies such as delayed/disrupted hatching 
or delayed metamorphosis may be included, other subtler effects are likely to be 
disregarded in the absence of documented effects on growth, reproduction or survival. It 
is unclear whether the effects on fish or bird behaviour described in background paper 2 
would be considered despite their relevance potential relevance to predation. In turn, the 
impact of increased predation on populations will depend on the life history traits of the 
species considered as well as its ecological environment. 
Moreover, there are questions related to the ecological relevance of experimental animal. 
It is clear that endpoints related to thyroid disruption have only been validated in a few 
taxonomic groups. Furthermore, within these taxonomic groups, test species are 
generally selected on the basis of experimental and economic considerations rather than 
their ecological relevance to a given environmental context. These considerations are not 
however specific to thyroid disrupters. 
6.3.4.4 Endpoints for populations and ecosystems 
Most wildlife studies that investigate possible thyroid disrupting effects focus on 
persistent organic pollutants. These generally measure contaminate load in the tissues 
and correlate them with circulating TH levels or more recently mRNA of thyroid related 
genes in tissues. However, these approaches are often confounded by intrinsic variability 
due to the animals varying age, sex, breeding stage, time of year, nutritional state, etc. 
(see background paper 2 in this section). 
Many of the more serious adverse effects found in experimental studies 
(delayed/disrupted hatching, delayed metamorphosis, disrupted swim-bladder inflation, 
locomotion etc.) would result in predation or starvation in the wild. However, many 
impacts of thyroid disruption in environmental exposures are likely to be subtler. Animals 
in the wild (as humans) will be exposed to a multitude of lower levels of compounds with 
diverse targets, rather than single high doses as found in experimental studies, as well as 
other environmental pressures on their habitat, physical climate change or disease. 
Without robust and sensitive methods or biomarkers to determine explicit thyroid effects 
it is not surprising it is so difficult to specifically ascribe thyroid disruption in wild animals. 
Nonetheless, increased predation itself, even without marked effect on population size, 
may have subtler effects relevant to the conservation of biodiversity. Chemical exposures 
may result in the selection of a resistant phenotype, thereby potentially reducing the 
genetic diversity of an exposed population in the wild. Inbreeding can be an important 
determinant of the vulnerability of populations to environmental stressors. Evidence for 
an interaction between inbreeding and chemical exposure in the wild is extremely limited. 
Studies on the Florida panther have found that this species is now significantly inbred 
and animals also contain high levels of a range of EDCs, including mercury and PCBs. 
However this has been linked to the known reproductive effects of these chemicals at the 
detected levels (Brown et al. 2009). 
6.3.5 Controversies 
  
 
The main controversies in interpretation of experimental data are related to predicting 
effects on human health, namely; the human relevance of the rat model, whether effects 
on TH alone without any effect on TSH are adverse, and finally whether TH decreases 
due to hepatic clearance can be considered indirect effects. 
The rat model has been labelled as problematic with regards to its human relevance (see 
perchlorate and fipronil case studies. The rat, due to species differences in T4 half- lives 
and in carrier proteins, has been viewed as particularly sensitive to thyroid disturbances. 
However, assumptions about the importance of such quantitative difference were based 
on interspecies differences in the half-lives of T4. The half-lives of the active hormone T3 
are much more similar in both species. Further, TBG was thought to be the main 
physiologically relevant transport protein in humans whereas it is hardly detected in adult 
rats. However, it was recently shown that TTR is the main physiologically relevant 
distributor in humans also. It is therefore timely to reconsider the significance of these 
species differences when interpreting experimental data. 
Further, the interpretation of effects on TH in the absence of corresponding effects on 
TSH has been questioned in terms of their adversity. Such effects have been seen with 
PBDEs, PCBs and PFASs (see case study). The fact that peripheral TH levels are poor 
predictors of TH levels and actions in tissues is now well recognized. Another interesting 
perspective on whether T4 decreases should be considered adverse comes from 
clinicians. Subclinical hypothyroidism is defined as T4 <10th percentile (severe is defined 
as <5th percentile) but without increased TSH. It is therefore difficult to generalise 
conclusions on the basis of these endpoints alone. This also illustrates that the relevance 
of animal models should be interpreted in relation to the relevance of specific pathways. 
Increased TH clearance due to liver effects is often considered secondary or an indirect 
effect, and therefore not a primary endocrine disrupting effect (see fipronil case study). 
The assumption here is that it would possible to protect against TH insufficiency by 
regulating in relation to a “liver threshold” below which hepatic enzymes are not induced 
and consequently TH insufficiency cannot occur. On the other hand, an endocrinological 
perspective would not class TH clearance as a “secondary” effect, and rather evaluate 
this in the context of a balance between hormone-synthesising and –removing processes. 
Additionally, activation of liver enzymes by a chemical could be reversible; however, 
effects on target tissues (e.g. fetal brain) of thyroid hormone insufficiency during 
development caused by activation of liver enzymes in a pregnant animal would not be 
reversible.  
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6.4 BACKGROUND PAPER 4: CURRENT OECD TEST METHODS FOR 
THE IDENTIFICATION OF THYROID DISRUPTORS, THEIR GAPS 
AND POSSIBILITIES OF IMPROVEMENTS 
 
6.4.1 Introduction 
In this paper we map relevant assays within the OECD Conceptual Framework for Testing 
and Assessment of Endocrine Disrupting Chemicals (here referred to as the OECD 
Framework 2012) and identify the gaps in these validated test methods in relation to the 
identification of thyroid disrupting effects. This overview is structured according to the 
different Levels detailed in the OECD Framework (Levels 1-5), dealing with mammalian 
assays and non-mammalian assays separately. 
We also summarize currently debated suggestions for improvements in order to better 
identify substances causing adverse effects via disruption of the hypothalamic-pituitary-
thyroid-axis. 
 
6.4.2 Existing data, non-test methods, in vitro assays with 
mechanistic data (OECD framework Levels 1 - 2) 
Level 1 information of the OECD Framework deals with “Existing Data and non-test 
information”. There are ongoing activities aimed at improving non-test information on 
thyroid disrupting effects. A Quantitative Structure Activity Relationship (QSAR) 
computer model for predicting TPO inhibition is presently being developed in 
collaboration between the US EPA and the Technical University of Denmark (Rosenberg 
et al 2016). QSAR models for predicting binding to CAR/PXR receptors (possibly leading 
to increased liver catabolism of thyroid hormones) are also being developed (Rosenberg 
et al 2017). Predictions from these types of QSAR screenings are already in use in a 
tiered approach to prioritize potential thyroid disrupting chemicals for further evaluation. 
Level 2 of the OECD Framework details in vitro assays for selected endocrine modalities. 
There are currently no OECD in vitro assay test guidelines assessing modalities relevant 
to thyroid disruption. 
6.4.3 In vivo tests (OECD framework levels 3-5) 
Test methods in mammalian species Level 3 include in vivo assays that provide data 
about specific endocrine mechanisms or pathways.  Level 3 mammalian toxicology assays 
for the screening of endocrine disrupting effects include the two screening assays for 
estrogenic and androgenic/anti-androgenic chemicals, namely the Uterotrophic and the 
Hershberger assays (OECD TG 440 & 441). No thyroid related endpoints are mandatory 
in these test guidelines, but T3 and T4 measurements are optional in the Hershberger 
assay. 
 
Levels 4 and 5 mammalian assays include repeated dose toxicity studies, as well as 
those investigating reproductive and developmental toxicity. Level 4 in vivo assays 
provide some data on adverse effects on endocrine relevant endpoints, whereas levels 5 
are in vivo assays provide more comprehensive data on adverse effects on endocrine 
relevant endpoints, and over more extensive parts of the life cycle of the organism. A 
complete list of studies in the OECD Framework can be seen in annex 1. Thyroid related 
endpoints in Level 4 and 5 TGs (mammalian) are presented in Table 1, below. The TGs 
have here been divided into two groups, one where exposure occurs only in adult animals 
and one where both adult individuals as well as animals exposed during foetal and 
postnatal development are examined. Because of the importance of thyroid hormones 
during brain development, especially the studies involving exposure of developing 
animals are important in this context.  
 
  
 
OECD Test 
Guideline 
Study name Thyroid endpoints measured in the guideline 
ADULT EXPOSURE ONLY 
407 Repeated Dose 28-
Day Oral Toxicity 
Study 
After 28 days of exposure, assessment of thyroid gland 
histopathology is mandatory, thyroid gland weight, T3, 
T4 and TSH levels are optional 
408* Repeated Dose 90-
Day Oral Toxicity  
Study in rodents 
After 90 days of exposure, assessment of thyroid gland 
histopathology is mandatoy 
451-3 Chronic toxicity and 
carcinogenicity 
studies 
After 2 years of exposure; assessment of thyroid gland 
weight, and histopathology (including thyroid tumours) 
is mandatory 
STUDIES WITH DEVELOPMENTAL EXPOSURE 
414 Prenatal 
developmental 
toxicity  study  
Dams and offspring are sacrificed on the day before 
birth. At present no thyroid related endpoints are 
included in guideline, but work is ongoing in the OECD 
to include mandatory TH measurements in this 
guideline.  
415 1-generation 
reproduction toxicity 
study  
No assessment of thyroid endpoints is included in this 
guideline, but this test guideline has essentially been 
replaced by TG 443 
416 2-Generation 
reproduction toxicity 
study  
Thyroid gland histopathology in parental animals (P and 
F1) is mandatory. 
421 Reproductive 
screening test  
This guideline has very recently been updated to 
include TH measurements. Mandatory; T4 
measurements in blood from PND 13 offspring and 
adult males (P) at study termination. If relevant T4 is 
also measured in pups on PND 4 and dams on PND 13. 
Assessment of other hormones (T3, TSH) is optional, as 
well as thyroid gland weight and histopathology. 
422 Combined 28-
day/reproductive 
screening assay  
As in TG 421 
426 Developmental 
neurotoxicity study 
No assessment of thyroid endpoints per se, but 
investigation of adverse effects on the developing 
brain.  
443 
Extended One-Gen 
Repro-Tox Study 
Some measurements of thyroid hormone levels are 
mandatory; T4 and TSH levels in F1 offspring from 
cohort 1A at termination (PND 22) Furthermore, T4 
measurement in surplus offspring on PND 4 are 
optional.  
At necropsy, thyroid gland weight and histopathology 
are assessed and in cases where the DNT cohort is 
included, some limited investigations of adverse effects 
on the developing brain are also conducted.  
* TG 409 (repeated dose 90 day oral tox in non-rodents) includes thyroid weight and 
histopathology, TG 411 & 413 (subchronic dermal & inhalation) includes thyroid 
histopathology  
Table 1 OECD test guidelines in mammals, included in the conceptual framework (OECD 2012) 
with focus on assessing thyroid disruption.  In the next revision of OECD Guidance Document 150 
(probably finalised ~2018), TG 409, 411, and 413 will most likely be included whereas TG 415 will 
not.  
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Furthermore, the US EPA has TG for the male and female pubertal rat assay that includes 
thyroid gland weight, thyroid histopathology as well as TSH and T4 measurements. 
 
6.4.4 Summary of key ‘gaps’ in mammalian test species 
In the presently available REACH registrations, often very little information is available on 
a chemical’s possible effects on the thyroid hormone system. Until recently, none of the 
guidelines included mandatory assessment of thyroid hormone levels, so in many cases 
the only available information regarding thyroid toxicity was thyroid gland histopathology 
from repeated dose toxicity studies. As seen in many of the presented case studies, and 
as also reviewed by Pickford (2010), several chemicals can significantly lower circulating 
T4 levels at exposures where no adverse histopathological effects on the thyroid gland 
are seen. Some compounds are even seen to have “enigmatic” patterns where T4 levels 
are decreased but no adverse effects on the thyroid gland (or TSH levels) are seen even 
at quite high doses. In the review by Pickford (2010) thyroid disrupting chemicals were 
grouped by their thyroid disrupting mode of action, and the author investigated which 
endpoints seemed to be the most sensitive in both amphibian and rodent models. It was 
shown that for chemicals interfering with thyroid hormone transport, metabolism and 
elimination, (exemplified by PCBs, the PBDEs and phenobarbital) significant reductions in 
thyroid hormone levels are often seen at exposure levels where no adverse 
histopathological effects or TSH increases are seen. This means that negative findings on 
thyroid histopathology do not necessarily eliminate a concern for thyroid disruption. 
This “gap” is presently being dealt with, by including assessment of thyroid hormone 
levels into more test guidelines (TG 407/408, TG 421/22, TG 443, and ongoing work 
regarding TG 414). All of these TGs are included in the REACH Information 
Requirements, and therefore much more information on which chemicals affect thyroid 
hormone levels in rats will be available during the next decade.  
One issue that is presently very poorly dealt with in the guideline studies is how to assess 
the adverse downstream effects of such alterations to the thyroid hormone levels. 
Thyroid hormones control many important functions in the adult organism, but the main 
concern in human health risk assessment regarding thyroid disrupting chemicals is that 
chemical exposure may interfere with the proper delivery of thyroid hormone to the 
developing brain, which could consequently cause neurotoxicity. 
 
At present, no guideline studies are designed to fully assess this issue. The TG 426 DNT 
study and the TG 443, EOGRTS (with DNT cohort) are at present the studies best 
designed to address this, but both have shortcomings. In the TG 426, no thyroid 
hormone measurements are performed, and in TG 443 often the DNT cohort is not 
included, and even when it is, fewer neurotoxicity endpoints are assessed than in the TG 
426. Furthermore, several behavioural studies performed according to these guidelines 
have not been able to show any adverse effects in behaviour or on brain histopathology, 
even in severely hypothyroxinemic animals. This has lead scientists in the field of 
neurotoxicology and thyroid disruption to suggest that new endpoints which are more 
sensitive to perinatal thyroid disruption should be added to these guidelines, in order to 
better assess adverse effects on neurodevelopment (OECD 2006, Harry et al 2014).  
 
From Background Paper 1 (see this section) it is obvious that thyroid disruption has 
negative impacts on the cardiovascular system, on lipid metabolism and peripheral 
neuropathies in the human. Endpoints relevant to these effects are currently missing 
altogether. 
 
6.4.5 Non-mammalian test species 
The only OECD test guidelines using non-mammalian animals which specifically detect 
thyroid endpoints are TG 241 and TG 231. These assays both employ Xenopus laevis 
frogs from tadpole to juvenile stage (Table 2). The OECD Conceptual Framework for 
Testing and Assessment of Endocrine Disrupters (as revised in 2012) includes a large 
number of non-mammalian models at different levels. However, many of these assays 
are either still under development or do not include thyroid related endpoints.  
  
 
Level 3 In vivo assays providing data about selected endocrine 
mechanism(s)/pathway(s). The Amphibian Metamorphosis Assay (TG 231) is currently 
the only TG with any thyroid specific endpoints at this level. The main thyroid related 
endpoints considered are comparative metamorphic stage (delayed/precocious compared 
to controls, hind limb length), growth (weight, snout-vent length) and thyroid 
histopathology. Unlike in the rodent model T4 and TSH are not measured in TG 231.   
Level 4 The Larval Amphibian Growth and Development Assay (LAGDA) (TG 241) is 
currently the only non-mammalian TG with thyroid specific endpoints at this level. TG 
241 covers an extended time period compared to TG 231, and includes sex ratio and 
sexual development (gonad histopathology) alongside the traditional growth, 
metamorphic and thyroid histopathology endpoints.  
Level 5 There are no non-mammalian TGs that include specific thyroid endpoints at this 
level. 
Test 
Guideline 
name and 
no. 
Species 
Model 
Conceptual 
Framework 
Level 
Life 
stage(s) 
Embryo (E) 
Juvenile 
(J) 
Adult (A) 
Generation: 
(F0, F1) 
 
Specific 
thyroid 
endpoints: T4, 
TSH, 
Histopathology 
Non-specific 
endpoints 
that could 
indicated 
thyroid 
disruption: 
altered 
behaviour 
(B), 
development 
(D), growth 
(G) 
241: The 
Larval 
Amphibian 
Growth and 
Development 
Assay 
(LAGDA) 
Xenopus 
laevis  
Level 4 J  
(F0) 
Thyroid 
histopathology 
(larval sub-
sample) 
Time to 
metamorphosis 
B D G 
240: Medaka 
Extended One 
Generation 
Reproduction 
Test 
(MEOGRT) 
Oryzias 
latipes (fish) 
Level 5 A E J 
(F0, F1) 
- B D G 
236: Fish 
Embryo Acute 
Toxicity (FET) 
Test 
Danio rerio - E 
(F0) 
- D 
234: Fish 
Sexual 
Development 
Test 
Gasterosteus 
aculeatus 
Oryzias 
latipes 
Danio rerio 
Level 4 E J  
(F0) 
- B D G 
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231: 
Amphibian 
Metamorphosis 
Assay (AMA) 
Xenopus 
laevis (frog) 
Level 3 J 
(F0) 
Thyroid 
histopathology 
(larval sub-
sample) 
Time to 
metamorphosis 
B D G 
230: 21-day 
Fish Assay 
Pimephales 
promelas 
Oryzias 
latipes 
Danio rerio  
Level 3 A  
(F0) 
- B 
229: Fish 
Short Term 
Reproduction 
Assay 
Pimephales 
promelas 
Level 3 A 
(F0) 
- B 
215: Fish, 
Juvenile 
Growth Test 
Oncorhynchus 
mykiss 
- J 
(F0) 
- B D G 
210: Fish, 
Early-life 
Stage Toxicity 
Test 
e.g. 
Oncorhynchus 
mykiss 
Oryzias 
latipes 
Pimephales 
promelas 
Danio rerio 
- E J 
(F0) 
- B D G 
206: Avian 
Reproduction 
Test 
Anas 
platyrhynchos 
Colinus 
virginianus 
Coturnix 
japonica 
Level 4 A E J 
(F0, F1) 
- B D G 
Table 2 OECD test guidelines, using of non-mammalian test species which could be subject to 
thyroid disruption, from OECD Guidelines for the Testing of Chemicals, Section 2 ‘Effects on Biotic 
Systems’ (http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-
section-2-effects-on-biotic-systems_20745761) 
 
6.4.6 Summary of key ‘gaps’ in non- mammalian OECD test species 
The preceding description allows us to summarise the gaps in non-mammalian 
tests as follows :  
 There are no direct measures of TH – T3/T4 or TSH (little link with current 
mammalian endpoints) 
 Less integration of multiple endocrine endpoints in non-mammalian tests 
 There are no set neurological or behavioural end points 
 Embryo culture techniques are not covered 
 Maternal transfer is not covered in non-mammalian tests   
  
 
 There is no avian model 
6.4.7 Possibilities of addressing gaps in mammals and non-
mammalian species 
6.4.7.1 In vitro test methods 
OECD has published a scoping document (OECD 2014) on in vitro and ex vivo assays for 
the identification of chemicals that can interact with the various elements of the thyroid 
system. The scoping document groups in vitro and other non-animal assays by utilising a 
scheme developed by Murk et al. (2013) which assigns test methods to organisational 
aspects and target sites of the thyroid system, as follows: 
 Central regulation of thyroid hormone synthesis 
 Thyroid hormone synthesis 
 Hormone secretion and transport 
 Hormone metabolism and excretion 
 Local cellular concentrations 
 Cellular responses 
 Short-term assays that integrate multiple modes of action 
 Integrative cellular assays 
For each of these groups of assays (“blocks”), the document assesses their readiness to 
be taken forward to the validation process. On the basis of this assessment, the OECD 
Scoping Document identified five assays as top candidates for pre-validation in the short 
term:  
 Thyroid peroxidase inhibition,  
 Transthyretin binding,  
 Thyroxine-binding globulin binding, 
 Thyroid transmembrane transporter, 
 Thyroid receptor transactivation. 
Several other assays were judged to be ready for validation in the medium to long term: 
Thyrotropin-releasing hormone receptor activation, thyroid stimulating hormone receptor 
activation, sodium-iodide symporter (NIS) inhibition, deiodinase up- or down-regulation, 
zebrafish embryo and thyroid gland explant cultures.  
Following on from the OECD scoping effort, the next logical step would be to determine 
whether these assays can be supported for optimisation and inter-laboratory validation, 
as part of a test method validation process. 
However, a key question with this issue of in vitro and ex vivo assays is that there is very 
little information about the relationship between interference with these single molecular 
initiating events, circulating levels of thyroid hormone, and downstream “adverse” 
effects.  Moreover, there is virtually nothing about the impact of having multiple MIEs 
targeted at once, and there are single chemicals that have this potential. For example, 
mancozeb can activate liver enzymes reducing serum T4, but also can inhibit TPO.  What 
is the consequence of this?  How would this be altered in the setting of low dietary iodine 
or perchlorate exposure (or smoking)?  Thus, even if these in vitro endpoints are 
established and validated, interpretation will continue to be difficult. 
 
6.4.7.2 Addressing the gaps in mammalian test systems 
As exemplified in the mancozeb case study (section 5) the presently used test methods 
for assessing developmental neurotoxicity (OECD TG 426 and the DNT cohort of TG 443) 
may be inadequate for assessing alterations in brain development caused by thyroid 
disruption. 
Presented below (Table 3) is an overview of additional endpoints which could be 
considered relevant to include in the two guidelines investigating developmental 
neurotoxicity, and possibly also in the developmental screening study (TG 421/22). 
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These endpoints all seem to be more sensitive to the effects of thyroid disrupting 
chemicals, than the endpoints which are presently included in these guidelines (brain 
weight and histopathology, and assessment of animal behaviour).  
Endpoint Comments Ref 
Neuronal 
Migration 
(subcortical 
heterotopias) 
Elements of cognitive deficits are linked to neuronal 
migration disorders.  Lissencephaly, cortical band and 
subcortical heterotopias, disorganization of cortical 
layers all are associated with cognitive deficits and 
linked to thyroid hormone during human (and rodent) 
development. These endpoints have been investigated 
in PND 14 offspring in developmental toxicity studies 
and could therefore be included in both TG 421/22, TG 
443 and TG 426.    
 
Gilbert et al 
2014, 
Korevaar et 
al 2016, Yu 
et al 2015, 
Tamijani et 
al 2015 
Neuronal 
Proliferation 
Thyroid hormone plays an important role in neuronal 
proliferation during early development and also in 
adults.  However, this effect is not observed uniformly 
through the brain.  Rather, thyroid hormone alters 
neuronal proliferation in specific cell populations at 
specific times during the life cycle.   
 
 
Preau et al 
2015, 
Kapoor et al 
2015, Ernst 
et al 2015, 
Remaud et 
al 2014, 
Ernst et al 
2014 
Oligodendrocyte 
differentiation 
Oligodendrocytes are myelin forming cells in the 
central nervous system.  Hypomyelination is causative 
for neurological and cognitive impairment in humans.  
Multiple Sclerosis is a myelin-degenerating disorder in 
humans with severe repercussions.  Thyroid hormone 
is important in oligodendrocyte differentiation and 
myelination during development and it is essential in 
remyelination after injury in adults.  Thyroid hormone 
is linearly related to oligodendrocyte number in 
rodents and assessment of this endpoint could 
possibly be developed into be a useful endpoint in 
guideline studies. 
 
Dugas et al 
2012, 
Tamiji et al 
2015, Noda 
et al 2015, 
Lopez-
Espindola et 
al 2014, 
Sawano et 
al 2013, 
Silvestroff 
et al 2012, 
Picou et al 
2012, 
Dell’Acqa et 
al 2012 
Cerebellar 
histogenesis 
Cerebellar development is well-known to be dependent 
upon thyroid hormone.  This is linked to human 
neurological disorders and specific deficits in cognitive 
domains.  This would be a relatively simple endpoint 
to capture in regulatory studies. 
Picou et al 
2012, 
Dezonne et 
al 2015, 
Ortiga-
Carvalho et 
al 2014, 
Faustino et 
al 2014, 
Fauquier et 
al 2014, 
Ibhazehiebo 
et al 2011 
Table 3. Additional neurotoxicity endpoints, which could be considered relevant to include in 
guidelines investigating  adverse effects on offspring perinatally exposed to thyroid disrupting 
compounds. 
Furthermore, including gene expression of thyroid regulated genes in key tissues 
(including different areas of the brain) in the studies dealing with developmental 
exposure (TG 421/222, TG 426 and TG 443) would help inform us on the mechanism 
  
 
occurring after chemical exposure. Moreover, analysis of perturbation of some of these 
DNT-related endpoints (i.e., neural progenitor cell proliferation, migration and 
differentiation toward oligodendrocytes), resulting from thyroid hormone decrease, has 
been promisingly carried out on human in vitro models (Moors et al., 2009; Fritsche et 
al., 2005; Schreiber et al., 2010). 
 
The gold standard of endpoints of thyroid “disruption” would be to identify and validate 
easily captured endpoints of thyroid disruption that would be sensitive and specific for a 
thyroid MOA and be reflective of adverse outcome. Having such a battery would allow 
one to discriminate between a benign reduction in serum T4 or an adverse effect even in 
the absence of a change in serum T4. These would have to be debated, identified and 
validated. A possible strategy to accomplish this is base on the CLARITY-BPA study that 
is a collaboration between the US NIH, FDA and NTP (Heindel et al. 2015; Schug et al. 
2013).  In brief, the core study would be a guideline, GLP-compliant study (the TG to be 
agreed upon by an international committee). The TG would be completed and tissues 
collected as prescribed.  Guideline endpoints would be captured by the core lab.  In 
addition, however, selected tissues would be coded and three samples of each tissue 
would be shipped to participating labs through the EU.  Each putative thyroid endpoint - 
agreed upon previously by committee – would then be captured by three independent 
labs and sent (coded) to the core facility that would break the code and analyse the data.  
This would significantly streamline the identification and acquisition of endpoints.  These 
endpoints would have to be tailored to the TG in relation to timing and duration of 
chemical exposure and the timing of sacrifice.   
It would also be timely to develop endpoints relevant for assessing the effects of thyroid 
disruption on the cardiovascular system and on lipid metabolism in mammalian test 
organisms.  
6.4.7.3 Addressing the gaps in non-mammalian test species 
One area for broadening non-mammalian TG endpoints to link with mammalian TGs, 
would be the addition of TH measures in thyroid tissue or plasma. However, the timing 
and location of sampling would need to be considered. For example, disruption to 
thyroidal T3 and T4 has been shown to be more sensitive than plasma T4 in 7-day 
exposed metamorphic Xenopus (Tietge et al. 2013). It would also be important to 
consider the balance of information gained or lost (or number of additional animals 
required).  For example, would it be possible to ‘split’ thyroid tissue between TH and 
histopathological analysis in Xenopus (TG 231, 241), or would the tissue be too small? 
Similarly, plasma samples are already taken in many of the current TG for measuring 
endocrine effects in fish (e.g. TG 229, 230, 234 and 240) and amphibians (i.e. TG 241) 
for vitellogenin (female specific yolk protein) analysis (as a biomarker oestrogenic 
action). In smaller species (medaka, zebrafish) or small/young animal(s) plasma volume 
might be too low to measure multiple biomarkers/endpoints. However, technical 
advances are enabling highly sensitive enzyme-linked immunosorbent assay (ELISA) to 
measure vitellogenin in fish mucus (from external swabs). Therefore, if TH measures are 
considered valuable there could be ways of including them into non-mammalian TGs. 
Traditionally, in the Xenopus model, the metamorphic state was considered the most 
sensitive window for chemical disruption. More recently, the important role of thyroid 
system in early embryos of frogs and fish has been highlighted (Schnitzler et al. 2016; 
Thienpont et al. 2011; Duarte-Guterman et al. 2010). 
Owing to their shorter exposure period, reduced ethical concerns and lower cost, embryo 
culture techniques are increasingly being considered for screening water soluble 
chemicals for endocrine activity. Currently, this possibly sensitive time point for thyroid 
disruption is not captured in the OECD TGs (detailed in Table 2). However, several 
promising embryo test methods for thyroid system are being developed, including a new 
Xenopus test guideline, ‘Xenopus Embryonic Thyroid Signalling Assay’ (GFP-Xenopus 
Embryo, Project 2.39), which is on OECD Work plan for Test Guidelines and the 
‘Zebrafish Eleutheroembryo Thyroid Assay’ (Thienpont et al. 2011; Raldua et al. 2012) 
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which was recently included in an OECD scoping document (OECD series on testing and 
assessment no. 207, 2014). The Zebrafish Eleutheroembryo Thyroid Assay focuses on T4 
concentration in the follicle cells of 5-day post fertilisation (dpf) embryos using whole 
mount immunofluorescence analysis. It was suggested in the OECD scoping document 
that additional endpoints such a quantifying mRNA levels of certain genes (PCR) or 
proteins (ELISA) would provide a fuller picture of disruption to the developing thyroid 
system (OECD series on testing and assessment no. 207, 2014). These molecular and 
protein approaches have been used by several authors to help elucidate specific targets 
of thyroid disrupting chemicals e.g. (Jia et al. 2016; Liang et al. 2015; Tu et al. 2016). 
Specific neurological or behavioural end points are lacking from any of the non-
mammalian TG. There is an increasing volume of fundamental research using zebrafish 
as a model for neurological development (Wyatt et al. 2015), therefore there are a 
growing number of possible assays that could be developed for regulatory testing using 
this species. Similar methods to the ‘Zebrafish Eleutheroembryo Thyroid Assay’, have 
recently been developed to examine thyroid hormone deiodinase expression in embryonic 
and larval zebrafish (Dong et al. 2013). Using 6-OH-BDE-47 to test the model Dong et al. 
found increases in mean intensity of Dio1 and Dio3 expression in the periventricular zone 
of brain and pronephric duct, respectively. This visual in vivo model highlights how 
compounds can have complex localised responses, which could affect neurodevelopment 
(Dong et al. 2013).   
Zebrafish larvae high throughput assays have also recently been developed for 
neurological research and pharmaceutical testing (Pelkowski et al. 2011; Richendrfer & 
Creton 2013; Clift et al. 2014; Clift et al. 2015). These methods have shown promise to 
measure behavioural effects in zebrafish larvae exposed to environmental chemicals 
(Lovato et al. 2016). 
Compared to the standard rodent model, the test methods for non-mammalian species 
have less integration of multiple endocrine endpoints to be assessed in one test 
organism. With the recent inclusion of TG 241 (LAGDA) some developmental 
masculinising or feminising endpoints are considered along with thyroid disruption. 
However, none of the Xenopus tests assess parental exposure on offspring, which 
considering the importance of maternal transfer of hormones and nutrients in early 
development in egg laying species e.g. (Brown et al. 2014) might be considered a ‘gap’ 
in testing. Interestingly, work with zebrafish has demonstrated maternal TH is essential 
for neural development (Campinho et al. 2014). The addition of thyroid specific endpoints 
into the Medaka extended one generation test (TG 240) could be a possibility to address 
this gap (in fish) if it was considered a high enough priority. There is also a ‘Zebrafish 
Extended One Generation Reproduction Test’ (ZEOGRT) under test guideline 
development (Project 2.59), although it is not known if thyroid disruption endpoints have 
been proposed in this test.   
There are a growing number of transgenic models designed to investigate the endocrine 
system of fish which might be of use in testing of endocrine active (including thyroid 
active) chemicals. Their application for ecotoxicology testing has recently been reviewed 
by Lee et al. (Lee et al. 2015). For example, for specific thyroid endpoints, zebrafish with 
fluorescent proteins under the control of TSHβ (Ji et al. 2012) and thyroglobulin (Fetter 
et al. 2015) have been developed. 
In addition, although the Avian reproduction test covers many of the important life 
stages where the thyroid system may be disrupted no specific thyroid measures (T4, 
TSH, thyroid histopathology, etc.) are assessed. An ‘Avian 2-Generation Reproductive 
Toxicity Assay’ had been tabled as a new guideline under development (Project 2.4). 
However, it has been removed from the most recent (July 2016) OECD Test Guidelines 
Programme (TGP) work plan. In non-standardised avian tests, chemicals such as 
perchlorate, have been shown to induce hypothyroidism (thyroid gland hypertrophy and 
lower thyroid hormone storage) alongside decreased embryo development and delayed 
hatching in maternally exposed Japanese quail chicks (Chen et al. 2008). Importantly, 
the US EPA published its ‘Avian Two-generation Toxicity Test in the Japanese Quail’ 
  
 
(OCSPP 890.2100) in 2015. This EPA guideline includes thyroid specific endpoints (TH 
and thyroid histopathology) in Adult (F0, F1), chicks (F2) and embryos (F1).  
6.4.7.4 Future testing strategies 
In addition to the ‘gaps’ in in vivo testing highlighted above, it is important to bring 
thyroid testing in line with other endocrine disruption assays. For instance, compared to 
androgenic or estrogenic assays there are no validated OECD in vitro TG for thyroid 
activity. A whole host of in vitro assays are needed to include thyroid hormone 
production, biotransformation, transport, clearance, and receptor mediated responses to 
fully capture possible disruption.   
A key issue within the thyroid disruption field is the difficulty in linking a thyroid 
mechanism of action to an adverse outcome. Therefore, a complementary approach is 
needed to link in vitro and in vivo endpoints, to gain a better understanding of which 
adverse effects are related to which target(s). Until such an approach is developed, it 
seems difficult to rely entirely on batteries of in vitro assays for the identification of 
thyroid disrupting chemicals.  
One step toward in mapping these pathways out is using the Adverse Outcome Pathway 
(AOP) approach. For both mammals and non-mammals (amphibian and fish) there are a 
number of AOPs under development (AOPwiki). Of the ten non-mammal AOPs, six have 
amphibian metamorphosis (or disruption to) as their adverse outcome (AOP 175, 176, 
188, 189, 190 and 191). These AOPs have inhibition of thyroperoxidease (TPO), Sodium 
Iodide Symporter (NIS), iodothyronine deiodinase 1, 2 and 3 (ID1, ID2, ID3) or 
Iodotyrosine deiodinase (IYD) as their Molecular Initiating Event (MIE). Another four 
relate to reduced young of year survival via (disruption to) anterior or posterior  swim-
bladder inflation in fish (AOP 155-158).These have MIE relating to ID1 or ID2 e.g. AOP 
155 ‘Deiodinase 2 inhibition leading to reduced young of year survival via posterior swim 
bladder inflation’.   
Eight mammalian AOPs are also under development. In two of these the adverse 
outcome is developmental neurotoxicity in humans, with inhibition of the Sodium Iodide 
Symporter (NIS) (AOP 54) and interference with transthyretin (TTR) binding (AOP 152), 
as the MIEs. Adverse neurodevelopmental outcome in mammals is also the adverse 
outcome in three AOPs being developed in the US EPA. Here increased thyroid hormone 
catabolism via activation of hepatic nuclear receptors (AOP 8), inhibition of thyroid 
peroxidase (TPO) (AOP 42) and inhibition of NIS (AOP 134) are the MIEs. The last two 
AOPs include the adverse outcome of follicular cell adenomas and carcinomas in rats and 
mice, and link this to the MIE of inhibition of NIS (AOP 110) and TPO inhibition (AOP 
119).  
Once these conceptual pathways have been built, the next challenge will be to network 
them, as we well know it is unlikely that MIE occur alone, and to consider at which point 
these net effects breach the tipping point to initiate adversity.       
Another issue is whether additional non-mammalian test models are needed. In a review 
paper by Pickford, the following conclusion can be found: “… Given our responsibility to 
reduce, refine, and replace the use of animals in toxicity testing and the variety of in vivo 
and in vitro approaches available, use of an amphibian metamorphosis assay alongside 
well-validated rodent assays in a screening battery might ultimately represent an 
unnecessary and unjustifiable redundancy. …” (Pickford 2010). On the other hand, the 
findings by Wegner et al. (2016) suggest that there is added value in non-mammalian 
assays.  
“… the movement of toxicology and hazard assessment toward a pathway-based 
paradigm opens numerous opportunities in applying non-traditional approaches for 
hazard screening and understanding the risks of chemical exposures. Alternative species 
can provide valuable and relevant information more rapidly, and at lower cost, than 
traditional species used for human chemical risk assessment. In a pathway centric world, 
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all species can provide information to protect other species, each with different 
advantages in use, sensitivity, and accessibility. Given this perspective, the distinctions 
between the disciplines of human health and ecotoxicology are blurring and heading 
towards a more unified and integrated application of toxicological data.” (Perkins et al. 
2013) 
Therefore, the question of developing more OECD tests for thyroid disruption perhaps 
comes down to the question(s) we are interested in answering, i.e. are we interested in 
tests that support the regulatory status-quo or do we want to develop robust test data 
sets to feed into future non in vivo methods and programs? 
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Annex 1 
OECD Conceptual Framework for Testing and Assessment of Endocrine 
Disrupting Chemicals (as revised in 2012) as included in the OECD Guidance 
Document No. 150 (Annex 1.4)  
 
Mammalian and non-mammalian Toxicology 
Level 1 
Existing Data 
   Physical & chemical properties, e.g., MW reactivity, volatility, 
biodegradability 
 All available (eco)toxicological data from standardized or non-
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and Non-Test 
Information  
standardized tests. 
  Read across, chemical categories, QSARs and other in silico 
predictions, and ADME model predictions 
 
Level 2 
In vitro 
assays 
providing data 
about 
selected 
endocrine 
mechanism(s) 
/ pathways(s) 
(Mammalian 
and non- 
mammalian 
methods) 
  Oestrogen or androgen receptor binding affinity  
 Oestrogen receptor transactivation  (OECD TG 455 – OECD TG 457) 
 Androgen or thyroid transactivation  (If/when TGs are available) 
 Steroidogenesis in vitro (OECD TG 456) 
 MCF-7 cell proliferation assays (ER ant/agonist) 
 Other assays as appropriate  
 
  Mammalian Toxicology  Non-Mammalian Toxicology 
 
Level 3 
In vivo assays 
providing data 
about 
selected 
endocrine 
mechanism(s) 
/ pathway(s)1  
  Uterotrophic assay (OECD 
TG 440) 
 Hershberger assay (OECD 
TG 441)  
  Xenopus embryo thyroid 
signalling assay (When/if TG is 
available) 
 Amphibian metamorphosis 
assay (OECD TG 231) 
 Fish Reproductive Screening 
Assay (OECD TG 229) 
 Fish Screening Assay (OECD TG 
230) 
 Androgenized female 
stickleback screen (GD 140) 
 
Level 4 
In vivo assays 
providing data 
on adverse 
effects on 
endocrine 
relevant 
endpoints 2 
  Repeated dose 28-day study 
(OECD TG 407) 
 Repeated dose 90-day study 
(OECD TG 408)  
 1-generation reproduction 
toxicity study (OECD TG 
415) 
 Male pubertal assay (see GD 
150, Chapter C4.3)3 
 Female pubertal assay (see 
GD 150, Chapter C4.4)3 
 Intact adult male endocrine 
screening assay (see GD 
150, Chapter Annex 2.5) 
 Prenatal developmental 
toxicity  study (OECD TG 
414) 
 Chronic toxicity and 
carcinogenicity studies 
(OECD TG 451-3) 
 Reproductive screening test 
(OECD TG 421 if enhanced) 
  Fish sexual development test  
(OECD TG 234) 
 Fish Reproduction Partial 
Lifecycle Test (when/If TG is 
Available) 
 Larval Amphibian Growth & 
Development Assay (when TG 
is available) 
 Avian Reproduction Assay 
(OECD TG 206) 
 Mollusc Partial Lifecycle Assays 
(when TG is available) 4 
 Chironomid Toxicity Test (TG 
218-219) 4  
 Daphnia Reproduction Test 
(with male induction) (OECD TG 
211) 4 
 Earthworm Reproduction Test 
(OECD TG 222) 4  
 Enchytraeid Reproduction Test 
(OECD TG 220) 4  
 Sediment Water Lumbriculus 
  
 
 Combined 28-
day/reproductive screening 
assay (OECD TG 422 if 
enhanced) 
 Developmental neurotoxicity 
(OECD TG 426) 
Toxicity Test Using Spiked 
Sediment (OECD TG 225) 4  
 Predatory mite reproduction 
test in soil (OECD TG 226) 4  
 Collembolan Reproduction Test 
in Soil (TG OECD 232) 4  
 
Level 5 
In vivo assays 
providing 
more 
comprehensiv
e data on 
adverse 
effects on 
endocrine 
relevant 
endpoints 
over more 
extensive 
parts of the 
life cycle of 
the organism 
2  
  Extended one-generation 
reproductive toxicity study 
(OECD TG 443)5 
 2-Generation reproduction 
toxicity study (OECD TG 416 
most recent update) 
 
  FLCTT (Fish LifeCycle Toxicity 
Test) (when TG is available) 
 Medaka Multigeneration Test 
(MMGT) (when TG is available) 
 Avian 2 generation reproductive 
toxicity assay (when TG is 
available) 
 Mysid Life Cycle Toxicity Test 
(when TG is available)4  
 Copepod Reproduction and 
Development Test (when TG is 
available)4 
 Sediment Water Chironomid 
Life Cycle Toxicity Test (OECD 
TG 233) 4 
 Mollusc Full Lifecycle Assays 
(when TG is available) 4 
 Daphnia Multigeneration Assay 
(if TG is available) 4 
 
 
Footnote and notes to the OECD Revised Conceptual Framework (Figure 1) 
1 Some assays may also provide some evidence of adverse effects. 
2 Effects can be sensitive to more than one mechanism and may be due to non-ED 
mechanisms. 
3 Depending on the guideline/protocol used, the fact that a substance may interact with a 
hormone system in these assays does not necessarily mean that when the substance is 
used it will cause adverse effects in humans or ecological systems. 
4 At present, the available invertebrate assays solely involve apical endpoints which are 
able to respond to some endocrine disrupters and some non-EDs. Those in Level 4 are 
partial lifecycle tests, while those in Level 5 are full- or multiple lifecycle tests. 
5 The Extended one-generation reproductive Toxicity Study (OECD TG 443) is preferable 
for detecting endocrine disruption because it provides an evaluation of a number of 
endocrine endpoints in the juvenile and adult F1, which are not included in the 2-
generation study (OECD TG 416) adopted in 2001.  
 
Note 1: Entering at all levels and exiting at all levels is possible and depends upon the 
nature of existing information and needs for testing and assessment. 
Note 2: The assessment of each chemical should be made on a case by case basis, 
taking into account all available information. 
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Note 3: The framework should not be considered as all inclusive at the present time. At 
levels 2, 3, 4 and 5 it includes assays that are either available or for which validation is 
under way. With respect to the latter, these are provisionally included.  
  
  
 
7. BACKGROUND AND TOPIC OUTLINES FOR THE WORKSHOP 
DISCUSSION GROUPS 
 
Briefing papers were prepared to structure the deliberations of the three Discussion 
Groups. These papers outlined the background to the three topics and made suggestions 
for discussion topics. 
7.1 BACKGROUND AND TOPIC OUTLINE FOR DISCUSSION GROUPS 
1 A, B: ASSAYS AND ENDPOINTS FOR THYROID DISRUPTION IN 
MAMMALIAN ORGANISMS – STATUS QUO AND PERSPECTIVES 
FOR ENHANCEMENTS 
 
Background 
Material supporting the discussions of this group can be found in the following 
background documents: 
Information on the basics of the thyroid system and on pathways that induce thyroid 
hormone alterations are in Background Paper 1 <BG1 adverse effects human> 
which describes evidence from epidemiological and clinical studies. 
A description of current OECD guidelines, together with perspectives on some 
enhancements that could be used to address thyroid disrupting modes of action can be 
found in Background Paper 4 <BG4 current test methods gaps>. Key points from 
this material are: 
 In vitro assays relevant to thyroid disruption are currently not part of testing 
guidelines. 
 In mammalian assays of level 3 of the OECD framework, thyroid-related endpoints 
are not mandatory. In levels 4 and 5, there are very few test guidelines that 
include both, measurements of thyroid hormone levels and thyroid 
histopathology. 
 No current guideline study addresses the issue that correct levels of thyroid 
hormone may not reach the developing brain, which could consequently cause 
developmental neurotoxicity. 
 Endpoints and assays informative of thyroid hormone downstream effects (e.g. 
taking account of non-uniform distribution of brain cells sensitive to TH, 
hippocampal gene expression, alteration in hippocampal anatomy and function, 
etc are not implemented 
 The importance of timing of exposure to thyroid disrupting chemicals is 
insufficiently covered. 
 The impact of thyroid disruption on cardiovascular disease and lipid metabolism is 
currently a blind spot in test systems relevant to thyroid disruption. 
 
Background Paper 4 <BG4 current test methods gaps> also maps out possibilities 
of including endpoints and assays that may fill the gaps listed above: 
 Inclusion of measures of down-stream effects on the brain, incorporating 
information about neuronal migration and proliferation, oligodendrocyte 
differentiation and cerebellar histogenesis 
 Inclusion of endpoints relevant to the effects of thyroid disruption on the 
cardiovascular system and on lipid metabolism 
Important aspects of the above issues are discussed in the case studies of fipronil, 
PBDE and mancozeb (see section 5). 
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Suggested reading of background documents in preparation of GD 1 ab 
Information useful for this Discussion Group may be found in the following background 
documents: 
 Background paper 1 adverse effects human 
 Background paper 4 current test methods gaps 
 Case study fipronil 
 Case study PBDE/perfluorinated compounds/PCB 
 Case study mancozeb 
Suggested discussion topics and questions 
1. Which in vitro and in vivo endpoints can be regarded as indicating a thyroid mode 
of action? 
2. Which non-guideline assays or studies and new endpoints, and which 
enhancements to current internationally accepted guideline assays/studies could 
be used to address most adequately thyroid disrupting modes of action and/or 
adverse outcomes? 
3. How could these new endpoints or assays be included in new test strategy 
developments? 
4. In the context of identification of thyroid disrupting substances, should the 
adverse effects of thyroid hormone under- or over-activity on the cardiovascular 
system and on lipid metabolism documented in the human be considered? If so, 
how? 
5. Can a combination of in vitro assays support judgements of adversity with 
relevance to the human, and can this replace studies in whole animals? 
 
7.2 BACKGROUND AND TOPIC OUTLINE FOR DISCUSSION GROUPS 
2 A, B: THE HUMAN RELEVANCE OF MODELS OF PATHWAYS OF 
THYROID DISRUPTION 
 
Background 
A description of pathways relevant to thyroid disruption and particularly thyroid hormone 
insufficiency can be found in Background paper 1 (section 6). This includes inhibition of 
iodine uptake (NIS), inhibition of thyroid hormone synthesis (TPO inhibition), 
upregulation of hepatic metabolism relevant to the clearance of thyroid hormones, 
displacement of thyroid hormones from serum distributor proteins and/or cellular 
transmembrane transporter proteins for TH. 
Human clinical and epidemiological studies show that maternal subclinical 
hypothyroidism, characterised by normal thyroid stimulating hormone (TSH) with thyroid 
hormone (TH) levels towards the lower end of the population distribution, is associated 
with compromised cognitive development in their children (IQ loss). Recent studies also 
suggest associations with autism spectrum disorder, attention deficit hyperactivity 
disorder and schizophrenia. 
Rises in the serum levels of TSH within the normal range are associated with increased 
risks of thyroid cancer, the fastest rising cancer among women and men (see case study 
on thyroid cancers in section 5). 
Several studies among humans have uncovered associations between exposure to 
pollutants and TH patterns typical of subclinical hypothyroidism. This is the case with 
combined exposures to perchlorate and thiocyanate, when accompanied by iodine 
deficiency. Similar associations have been shown with mercury, certain arsenic species, 
certain organochlorine pesticides, poly-aromatic hydrocarbons and perfluorinated 
compounds (see Background Paper 1 in section 6 and the case studies in section 5). 
  
 
Decreases in TH levels as a result of administration of chemical substances have been 
seen in numerous rodent studies (for further detail see case studies on fipronil and 
perchlorate, section 5). The relevance of these observations for human risk assessment 
is often questioned with reference to quantitative differences of the rat thyroid system 
relative to the adult human system (see case studies on thyroid cancer and perchlorate, 
section 5). 
However, new evidence suggests that the capacity of the thyroid system to compensate 
for the effects of chemicals leading to thyroid insufficiency depends on the life stage, 
both in humans and rats (summarized in Background Papers 1 and 3). Newborn 
babies do not have the reserves of the adult thyroid system and are therefore more 
sensitive to exposures to thyroid disruptors (Background Papers 1 and 3). 
Furthermore, decreases of TH in rodents are often not judged to be adverse, in the 
absence of other effects (e.g. thyroid histopathology etc.) (case study on fipronil). 
The debate about evaluations of observations in the rat is important when it comes to the 
identification of substances as thyroid carcinogens and their relevance to human risk 
assessment. Many rodent thyroid carcinogens lead to increased TSH levels, mainly in 
male rats, often through a mechanism involving increased TH clearance through 
upregulation of hepatic conjugation reactions. A rise in TSH is seen as the key event of 
thyroid carcinogenesis (see case study on thyroid cancers). USEPA and IARC guidance 
regarding the identification of thyroid carcinogens rests on the presumption that rodent 
thyroid carcinogens may pose a cancer hazard to humans, and that in the absence of 
chemical-specific data humans and rats should be assumed to be equally sensitive. 
Nevertheless, the relevance of this pathway for human risk assessment, and for 
identifying substances as thyroid disruptors is often called into question. In the recent 
European Commission Joint Research Centre (JRC) screening methodology for 
identification of endocrine disruptors in the context of an impact assessment (for more 
detail see case study on fipronil) this point is summarised as follows: 
Histopathological findings in rat thyroid and increased thyroid weight in presence of liver 
histopathology (including liver enzyme induction) were attributed to a liver-mediated 
mechanism not considered to be ED-mediated. Since in the frame of this screening 
methodology enhancement of the metabolism and excretion of thyroid hormones by the 
liver was not considered as an endocrine MoA, such effects were not considered relevant 
to conclude on ED. 
However, from an endocrinological viewpoint, both hormone synthesising and removing 
pathways will be viewed as important in evaluating impacts on thyroid hormone action, 
including increased clearance by hepatic metabolism (see case study on thyroid 
cancers). 
Suggested reading of background documents in preparation of DG 2 ab 
Information useful for this Discussion Group may be found in the following background 
documents: 
 Background paper 1 adverse effects human 
 Background paper 3 interpretation of data 
 Case study fipronil 
 Case study TSH thyroid cancer 
Suggested discussion topics and questions 
1. In the context of thyroid disruption and the identification of thyroid disrupting 
substances: Which in vivo endpoints in experimental studies should be regarded 
as adverse? 
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2. Should the induction of thyroid hormone insufficiency through increased hepatic 
conjugation reactions be judged as thyroid disruption? 
3. What is the human relevance of different mechanisms for thyroid disrupting 
effects? 
4. Should the induction of thyroid tumours in rodents be taken to designate a 
substance as a presumed human carcinogen? Are USEPA and IARC guidelines 
which presume that rodent thyroid carcinogens may pose a cancer hazard to 
humans still valid? In the absence of chemical-specific data, should humans and 
rats be assumed to be equally sensitive? 
5. Should the induction of thyroid tumours in rodents be taken to identify a 
substance as a thyroid disruptor and/or a carcinogen? 
6. Should the human relevance of thyroid disrupting effects in animals be judged in 
terms of species (e.g. “the rat is not relevant”) or should these judgements be 
made in relation to specific pathways and mechanisms of thyroid disruption? 
 
7.3 BACKGROUND AND TOPIC OUTLINE FOR DISCUSSION GROUPS 
3 A, B : THYROID SYSTEMS ACROSS TAXA: THE RELEVANCE OF 
MAMMALIAN DATA IN ENVIRONMENTAL ASSESSMENTS AND OF 
NON-MAMMALIAN DATA IN HUMAN HEALTH ASSESSMENT AND 
POSSIBILITIES OF ENHANCING TEST GUIDELINES 
ACCORDINGLY 
 
Background 
The basic features of the thyroid system are conserved across all taxa, although there 
are differences in detail (see Background Paper 2, section 6). 
A description of endpoints and test organisms relevant to non-mammalian species 
currently used in OECD test guidelines can be found in Background Paper 4, section 6. 
An issue for debate is the extent to which the outcome of non-mammalian assays can 
inform the hazard identification of thyroid disruptors in the human toxicology arena. 
Conversely, to what degree are mammalian thyroid disruptor assays informative in terms 
of anticipating the impact on ecosystems? 
Relevant to this debate are the gaps in current OECD test guidelines for thyroid 
disruption in non-mammalian tests. Background Paper 4 has summarised these gaps 
as follows: 
 In test guidelines for non-mammalian species, there are no measurements of 
thyroid hormone levels or TSH which complicates evaluations in relation to 
mammalian assays 
 There is little integration of multiple endocrine endpoints in non-mammalian tests 
 No set neurological or behavioural end points are established in non-mammalian 
assays 
 The OECD conceptual framework does not incorporate embryo culture techniques 
 The maternal transfer of chemicals to offspring is not covered in non-mammalian 
tests   
 There are currently no avian models relevant for thyroid disruption 
Background Paper 4 makes specific suggestions for dealing with these gaps, and 
proposes to consider new, sensitive non-mammalian assays for the identification of 
thyroid disruptors. These are also considered in the case study of perchlorate, section 5. 
  
 
Suggested reading of background documents in preparation of GD 3 ab 
Information useful for this Discussion Group may be found in the following background 
documents: 
 Background paper 4 current test methods gaps 
 Background paper 2 thyroid disruption across taxa 
 Case study perchlorate 
 
Suggested discussion topics and questions 
1. In which respect can data from rodent studies be used to inform about effects on 
rodents/mammals in the environment? 
2. In which respect can data from amphibian or fish studies be used to inform about 
possible effects in rodents/mammals? 
3. When and how during testing should we take into consideration that the thyroid 
hormone system is highly conserved between taxa? 
4. Should current testing guidelines be enhanced by adding additional endpoints and 
assays? 
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8. WORKSHOP REPORT 
This section describes the proceedings of the workshop on thyroid disruption held on 29-
31 March 2017 at ANSES in Maisons-Alfort, France. 
The workshop concept, its objectives and its agenda can be found in sections 3 and 4 of 
this report. 
The workshop was conducted on the basis of extensive material distributed to all 
participants in advance. This material consisted of: 
 Case studies (section 5) 
 Background papers (section 6), and 
 Background and topic outlines for the workshop discussion groups (section 7). 
8.1 Workshop participants 
Invited workshop participants were from EU Member State competent authorities, 
competent authorities from the USA, Canada and Japan, industry, academia and non-
governmental organisations. All members of the Scientific Expert Group and the Steering 
Group (section 2) also attended. 
A list of participants can be found in Annex 1 of this report. 
8.2 Workshop report: Summary of formal presentations 
In this section, a brief summary of formal workshop presentations is given. The 
presentations are available in Annex 2 to this report. 
Peter Korytar (DG ENV, European Commission) and Roger Genet (Director General of 
ANSES) welcomed the participants and Andreas Kortenkamp (Brunel University London, 
UK) introduced the concept of the workshop.  
Tom Zoeller (University of Massachussetts, Amherst, USA) delivered the keynote lecture 
of the workshop, co-authored by Barbara Demeneix, Josef Koehrle, and Catherine Viguie: 
"Thyroid disruptor research in the 21st century". He developed what can be referred to 
as the “idealized view” of the thyroid system, where decreases in circulating thyroid 
hormones are compensated by increases in TSH which in a feedback loop restore serum 
thyroid hormones to their original levels. However, this view is at odds with observations 
from experimental studies in which decreases in T4 following chemical exposures were 
not always accompanied by decreases in T3 or increasing serum levels of TSH. 
Specifically referring to a paper by Klaassen and Hood (Tox Pathol 29, 34) he 
emphasized examples where T4 reductions left TSH concentrations entirely unchanged, 
depending on the chemicals used to induce T4 decreases. There are even examples 
where continued suppression of T4 after exposure to certain chemicals resulted in 
decreases of serum TSH. Thus, the “idealized view” cannot explain observations of 
chemically induced alterations of the thyroid system. This may render the data sets of 
serum thyroid hormone measurements contained in many chemical dossiers difficult to 
interpret. He further presented evidence that altered thyroid hormone serum 
concentrations can be associated with adverse effects even though the hormone levels 
remain within the population reference range. The traditional reliance on the diagnostic 
value of serum thyroid hormone concentrations is further complicated by new evidence of 
autonomous regulation of thyroid hormone action at the tissue level, without involvement 
of the HPT axis and corresponding changes in serum thyroid hormones. The inevitable 
conclusion is that altered TSH levels are not the “be-all and end-all” marker of thyroid 
hormone action. Another example illustrating this point is the Allan-Herndon-Dudley 
Syndrome which is caused by mutations in the thyroid hormone transporter MCT8. This 
results in low serum T4, elevated serum T3 and normal to elevated TSH, a clear case 
where low T4, together with normal to slightly elevated TSH, leads to adverse outcomes 
in male humans. This disease cannot currently be treated. He also discussed examples 
  
 
that challenge the received opinion about the compensatory capacity of the thyroid 
system. For example, PTU exposure leads to reductions in circulating T4, which the brain 
counteracts by maintaining T3 tissue levels through increased activity of deiodinases 
which convert the remaining T4 stores to T3. However, despite the resulting relatively 
stable T3 brain tissue levels, the expression of a neuronal specific gene representative of 
intracellular T3 action (RC3) decreases. The importance of serum thyroid hormones also 
has to be interpreted carefully in the context of equilibria formed with distributor 
proteins, such as thyroxine-binding globulin (TBG), transthyretin (TTR) and albumin. 
Patience Browne (OECD, France) gave an overview of the existing test guidelines for 
thyroid disruption. Although some of the OECD Conceptual Framework Level 4-5 studies 
incorporate thyroid endpoints, there are currently no validated Level 2 in vitro 
mechanistic assays, and limited Level 3 in vivo studies to support the evaluation of 
thyroid disrupting effects. 
Alice Baynes (Brunel University London, UK) presented new insights from ecotoxicological 
animal models (fish, amphibians). Despite some differences in physiology and anatomy, 
there is significant conservation of the basic make-up of the thyroid hormone system 
across taxa. The current battery of tests for thyroid disruption in wildlife is strongly based 
on amphibians, with a neglect of other taxa. The presentation was based on Background 
paper 2 (section 6.2).  
Eva Fetter (Umweltbundesamt, Germany) gave an overview of substances interacting 
with thyroid hormone synthesis and their ability to trigger adverse effects on the HPT and 
HPG axes from an ecotoxicological perspective. She illustrated important principles with a 
case study of perchlorate. 
Marta Axelstad (Technical University of Denmark, Denmark) presented a summary of the 
fipronil case study which dealt with the relevance of the rat as a model for humans in the 
context of thyroid hormone insufficiency caused by induction of hepatic conjugating 
enzyme systems (see section 5. 1).  
Niklas Andersson (ECHA, Finland) discussed the approaches employed by the European 
Chemicals Agency (ECHA) in its evaluations of thyroid disrupting chemicals, especially in 
interpreting the relevance of thyroid hormone insufficiency produced via induction of 
hepatic conjugating enzyme systems. ECHA’s requests for information from data 
submitters have to be proportional and tailored to information needs. However, this is 
currently problematic due to a lack of validated in vitro tests indicative of thyroid 
disruption and the gaps in in vivo tests regarding thyroid-relevant endpoints. 
Olwenn Martin (Brunel University London, UK) and Marta Axelstad (Technical University 
of Denmark, Denmark) jointly presented the results of the PBDE/perfluorinated 
compounds/PCB and mancozeb case studies. These case studies discussed the 
consequences of down-stream effects of maternal and early post-natal thyroid hormone 
insufficiency and other mechanistic aspects of thyroid disruption (see sections 5.4 and 
5.2, respectively). 
This was followed by presentations from Andreas Kortenkamp (Brunel University London, 
UK) in which he summarized the case study on the role of TSH in thyroid cancer (section 
5.5) and the evidence of associations between chemical exposures and thyroid disruption 
from human epidemiological studies (section 6.1). 
8.3 Workshop report : Deliberations of the discussion groups 
Workshop participants were split into six groups, to discuss three topics: 
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 Assays and endpoints for thyroid disruption - status quo and perspectives for 
enhancements 
 The human relevance of models of thyroid disruption pathways, and 
 Thyroid systems across taxa: the relevance of mammalian data in environmental 
assessments and of non-mammalian data in human health assessments.  
There were two discussion groups for each of the topics. A consolidated summary of the 
deliberations of each of these 3 pairs is presented below, without always differentiating 
between the parallel-running pairs of discussion groups. 
8.3.1 Discussion groups 1 a b : Assays and endpoints for thyroid 
disruption – status quo and perspective for enhancements 
The deliberations of groups 1a and 1b were based on the presentations at the workshop, 
the workshop materials and especially the document ‘Background and topic outline for 
Discussion Groups 1 a, b’ (given in section 7.1). The suggested discussion topics and 
questions in this document were: 
1. Can a combination of in vitro assays support judgements of adversity with 
relevance to the human, and can this replace studies in whole animals? 
2. Which non-guideline assays or studies and new endpoints, and which 
enhancements to current internationally accepted guideline assays/studies could 
be used to address most adequately thyroid disrupting modes of action and/or 
adverse outcomes? 
3. How could these new endpoints or assays be included in new test strategy 
developments? 
4. In the context of identification of thyroid disrupting substances, should the 
adverse effects of thyroid hormone under- or over-activity on the cardiovascular 
system and on lipid metabolism documented in the human be considered? If so, 
how? 
5. Which in vitro and in vivo endpoints can be regarded as indicating a thyroid mode 
of action? 
Decreases in serum thyroid hormones – an adverse effect? 
Both groups discussed whether decreases in thyroid hormones (mainly T4) seen as a 
result of chemical exposures in animal studies should in themselves be presumed as 
adverse. These discussions were motivated by the recognised relationships between low 
T4 and effects on the developing brain in humans. 
While the question was not answered conclusively, there was agreement that reductions 
in T4 levels should act as a trigger for further studies of F1 generations, for example as 
part of TG 421/422, 426, 443, depending on the other information requirements. 
To some participants it was clear that regulatory decisions based on findings of 
diminished serum T4 would protect against downstream effects (e.g. developmental 
neurotoxicity) in humans. These participants agreed that changes in T4 in animal studies 
are predictive of adverse consequences on the developing human brain and should 
therefore be regarded as sufficient for making regulatory decisions. 
Some participants expressed the view that decreased serum T4 occurring via hepatic 
enzyme induction in rodent studies should be considered relevant in the context of 
regulatory decisions unless, on the basis of further compound specific information, it 
would be possible to exclude the relevance of such effects. In the context of human risk 
assessments, this could for instance be tested in vitro using primary human hepatocytes. 
Discussion group 1b only briefly discussed this and no clear conclusion was formulated. 
However, several experts in the group expressed the view that effects on T4 are signs of 
endocrine effects, irrespective of whether these result from increased breakdown and 
excretion (due to hepatic enzyme induction) or decreased synthesis. 
  
 
There was concern that current guideline studies are insufficiently sensitive for the 
reliable detection of developmental neurotoxicity, even when T4 levels are decreased. 
This lack of suitable and sensitive endpoints makes it problematic to establish potential 
developmental neurotoxicity and to negate possible concerns that arise from T4 effects 
even when developmental neurotoxicity is not observed. 
The relevance of in vitro assays in making judgements about adverse thyroid 
disrupting effects 
Discussion group 1b specifically addressed this question (question 1 in the background 
and topic paper). Participants concluded that observations of effects in a number of in 
vitro assays can provide important Mode of Action (MOA) information which can support 
interpretations of the relevance of adverse effects observed in a model animal species to 
humans. As such, the outcome of in vitro tests is useful for setting priorities for 
subjecting substances to further testing. However, negative in vitro results were 
considered not to be conclusive due to the many MOAs that may lead to thyroid 
disruption and the limited metabolising capacities of in vitro tests. It was concluded that 
combinations of in vitro assays can presently not replace studies in whole animals. 
Participants developed different proposals as described below for the better use of 
endpoints in existing guidelines and saw the need for further guidance in the 
interpretation of thyroid relevant endpoints in existing guidelines in the context of 
AOPs/MOA frameworks. 
Perspectives for improvements of current guideline studies to incorporate 
thyroid disrupting effects 
Both discussions groups made several recommendations on how to improve the existing 
testing for thyroid disruption. The suggestions were sub-divided as follows:-  
 addition of “standard endpoints”, i.e. endpoints that are already routinely 
measured in other TGs, 
 addition of “new endpoints” to existing test guidelines, i.e. endpoints that are 
presently not included in any guidelines and 
 identification of new areas of research, or new assay development that need to be 
performed in order to improve investigation of thyroid disruption in the longer 
term. 
The following sections discuss each of these suggestions in turn. 
Addition of standard endpoints to existing guideline studies 
In discussing the addition of “standard endpoints”, discussion group 1a considered, 
without reaching a consensus, making the developmental neurotoxicity cohort of TG 443 
mandatory. Group 1b also dealt with this issue and recommended that the DNT cohort of 
TG 443 should be mandatory if there is a thyroid concern. This group also recommended 
that TG 443 (but not TG 416) should be mandatory for all substances.  
All participants recommended to make measurements of T4 and TSH mandatory in TG 
407 and 408. TH and TSH measurements need to be performed with methods validated 
for the species used to test for thyroid axis interference. An enhancement of TG 407 (28 
days study) in particular was seen as both relevant and feasible within a short period of 
time by changing the status of thyroid hormone measurements from optional to 
mandatory, as was done in the recently updated TG 422 (combined 28 day and 
reproductive toxicity screen). Significant T4 reductions should trigger further testing in 
the F1 generation. 
Group 1a recommended that T4 changes should also be measured in TG 241 (LAGDA). 
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If exposure to a test chemical is primarily via the dermal or inhalative route, or if no 
mammalian data are available, T4 decreases observed in TG 241 (amphibian) were also 
seen as a trigger for mammalian studies with inclusion of an F1 generation. This 
recommendation was motivated by the conservation of the thyroid system between taxa, 
as succinctly stated in a recent publication: “frogs are little humans that hop” (Sachs and 
Buchholz 2016). Exceptions to this would be in cases where frog metabolism of toxicants 
following exposure via the dermal route is known to be different from mammals.  
Inclusion of new endpoints into existing test guidelines 
Specific investigations of brain morphology in developmentally exposed animals were 
seen by all participants as a very relevant addition to existing test guidelines. In the F1 
generation of TG 421/422, 426 and 443, both discussion groups found it important to 
include sensitive and specific markers of thyroid hormone action in the brain. This could 
probably be obtained by evaluation of heterotopias and oligodendrocyte differentiation in 
brain tissue from perinatally exposed offspring. Cortical heterotopias are indicative of 
gestational T4 deficits in rodent pups, whereas changes in oligodendrocyte differentiation 
are indicative of early postnatal T4 deficits. Both endpoints can be measured in PND 13 
and 22 pups. 
With a view to incorporating thyroid-related effects that go beyond developmental 
neurotoxicity and to include possible effects on the cardiovascular system and on lipid 
metabolism, participants suggested the addition of the following new endpoints to 
existing test guidelines: 
 Comprehensive lipid profiles (cholesterol, TAG, HDL/LDL) 
 Heart histology and heart weight, body temperature, body weight (increase, 
decrease) should be considered 
 Potentially: heart rate and blood pressure, atherosclerosis (in chronic studies), 
although the difficulties of measuring these, and the relative resistance of rats to 
artheriosclerosis, were acknowledged 
 Improvements in assessing thyroid histology by adopting guidance from the 
American Medical Association (Bianco et al. 2014), and GD 82 for AMA 
histopathology 
 Thyroid histology guidance amenable to automation (Hooth and Wolf 1998 Tox 
Path) 
The following changes to study design and study methods could also be implemented:  
 Methods alternative to enzyme immunoassays should be considered for measuring 
thyroid hormones (and their metabolites)  
 Regardless of method, it should be required that laboratories demonstrate 
proficiency in measuring thyroid hormones reliably 
 Samples for hormone analysis should be collected during 9-11 am to reduce 
diurnal variation 
 Guidance from German physicians for hormone measurements should be 
considered (Richtlinien der Bundesaerztekammer) 
 TSH antibodies may be unreliable for measuring TSH changes in rodents, as an 
alternative, TSHβ transcripts could be measured in the pituitaries of rodents, 
amphibians, fish, which would also increase the comparability among taxa  
 Serum volumes may be limiting if using commercially available kits, other 
methods may require smaller volumes  
 
New areas of assay development and research 
Discussion group 1b proposed the development of a new assay, an in vivo thyroid screen. 
This proposal was motivated by the fact that many substances had been studied by using 
  
 
older versions of test guidelines, e.g. TG 407, where no endpoints for effects on thyroid 
hormones were included. Since it seemed disproportionate to fill this data gap by re-
testing with an updated and improved version of e.g. TG 407, testing with an abbreviated 
in vivo thyroid screen with shorter exposure periods could accomplish filling this data gap 
quickly and effectively. The proposal is based on the observation that changes in thyroid 
hormones in adult experimental animals can often be seen already after a relatively short 
exposure period (4-5 days). The proposed screen could be developed based on TG 407 
and/or TG 422, with a correspondingly shorter exposure period. However, thyroid effects 
mediated via hepatic enzyme induction may require a somewhat longer exposure period 
of e.g. 14 days. In the plenary session, a streamlined Intact Adult Male Endocrine 
Screening Assay listed in the OECD Conceptual Framework was recommended for that 
purpose.   
Both groups recommended further development of in vitro tests addressing thyroid MOA, 
for example assays investigating the TPO, TTR, TBG, TRH, TSH, NIS, Mct8, TR-dependent 
transcription, and deiodinases (type 1, 2 and 3). It was recommended to carefully 
consider the selection of reference chemicals (for individual/all in vitro assays) and to 
begin with the OECD thyroid scoping document 207. 
Both groups also discussed several new endpoints that may in the future (short or long 
term) provide relevant evidence for thyroid disrupting MOA and downstream effects and 
potentially for enhancements of existing guidelines or new guidelines. A list of these 
endpoints is given below: 
 In vivo studies: measurements of TPO/NIS transcript in thyroid and TTR/TBG 
transcripts in liver 
 In vitro oligodendrocyte differentiation/development (longer term) 
o Uniquely and specifically thyroid-dependent 
o Can be interpreted with recommended CNS histopathology 
 In vivo brain heterotopia association with decreased maternal T4 needs additional 
investigation 
 New behavioural test(s) for assessment of thyroid-related DNT (research) 
 Distribution of white vs. black matter in brains as marker for thyroid-related effect 
on the developing brain (ongoing, research) 
 In vivo retinal development/electroretinalgrams (after prolonged exposure and/or 
extended observation times) 
 In vivo tissue-specific thyroid effects (e.g. DI activity and transcript, after 
prolonged exposure and/or extended observation times) 
 Indications of altered thyroid hormone signalling in bone 
 Gene markers/expression profiles (short term; literature search) 
o Kits already exist (qPCR in HT format) 
o Validation/literature search needed to confirm response to thyroid active 
compounds 
o Marker genes for brain development detailed in scientific publications 
o Marker genes for thyroid cancer 
o Marker genes for cardiovascular disease 
o Marker genes for lipid metabolism detailed in scientific publications 
 Fish testing – in research phase (variable stages of development?) 
o Zebrafish embryos T3/T4 measurable from embryo day 0 (Chang et al. 
2012) 
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o ZF brain development  
o T4/TSH fish, thyroid histology in in vivo studies, eye development, swim 
bladder inflation 
8.3.2 Discussion groups 2 a b : The human relevance of models of 
thyroid disruption pathways 
The discussions in groups 2a and 2b were based on the presentations at the workshop 
and on the workshop materials, specifically the document ‘Background and topic outline 
for Discussion Groups 2 a, b’ (see section 7.2) distributed before the workshop. The 
suggested discussion topics and questions in this document were: 
1. In the context of thyroid disruption and the identification of thyroid disrupting 
substances: Which in vivo endpoints in experimental studies should be regarded 
as adverse? 
2. Should the induction of thyroid hormone insufficiency through increased hepatic 
conjugation reactions be judged as thyroid disruption? 
3. What is the human relevance of different mechanisms for thyroid disrupting 
effects? 
4. Should the induction of thyroid tumours in rodents be taken to designate a 
substance as a presumed human carcinogen? Are USEPA and IARC guidelines 
which presume that rodent thyroid carcinogens may pose a cancer hazard to 
humans still valid? In the absence of chemical-specific data, should humans and 
rats be assumed to be equally sensitive? 
5. Should the induction of thyroid tumours in rodents be taken to identify a 
substance as a thyroid disruptor and/or a carcinogen? 
6. Should the human relevance of thyroid disrupting effects in animals be judged 
in terms of species (e.g. “the rat is not relevant”) or should these judgements be 
made in relation to specific pathways and mechanisms of thyroid disruption? 
 
Adversity of thyroid-related endpoints 
Dealing with question 1 above, Group 2a began by discussing thyroid histopathological 
changes and quickly arrived at the conclusion that changes in mammalian thyroid 
histopathology should be regarded as indicative of an adverse effect. However, the value 
of histopathological observations on their own (as required in various OECD test 
guidelines) can sometimes be relatively limiting, particularly as the thyroid is not the only 
target organ for thyroid hormone insufficiency (during development this is the brain). 
The interpretation of histopathological findings can be increased by accompanying 
measurements of thyroid hormones. 
The discussion then turned to the relevance of decreases in T4. Group 2a agreed that 
such decreases, when observed in a reliable study, are of concern. If no further 
information is available, and if further data dispelling concerns are unlikely to be 
forthcoming, decreases in T4 should be treated on the basis of the presumption that 
adverse effects might materialize. The same presumption should be made in the case of 
increases in T4. 
Group 2b approached the question of adversity of thyroid-related endpoints from a 
slightly different angle, by considering the WHO/IPCS definition of adversity: 
“A change in the morphology, physiology, growth, development, reproduction or lifespan 
of an organism, system or (sub)population that results in an impairment of functional 
capacity, an impairment of the capacity to compensate for additional stress or an 
increase in susceptibility to other influences.” 
After some debate, group 2b agreed that a lowering of serum T4 alone would not be 
sufficient to demonstrate adversity according to this definition. Some participants had 
argued that the definition, as formulated, implied a requirement for evidence of a 
downstream effect. Others made the point that in the clinical setting a change in serum 
  
 
thyroid hormones can be sufficient to reach a diagnosis. However, whether the patient 
requires treatment typically depends on the presence of other symptoms such as fatigue 
or fluid retention. 
Discussions turned to whether other measures of serum thyroid hormones could help 
interpretation, such as T3 or the free hormones fT3 and fT4, as well as the practical and 
technical difficulties encountered to reliably measure these in experimental animals. Both 
groups agreed that measuring free thyroid hormones appears attractive from a purely 
scientific perspective but pointed to several factors that make such measurements 
challenging or even impossible in practice. Such factors are the high cost of assay kits, 
their reliability, and the amount of serum available from animal studies which often is the 
limiting factor for reliable determinations of free T4. The most informative endpoint was 
suggested to be the ratio T4/T3 and this would be achievable in practice.  
Group 2b agreed that in some cases, the magnitude of the change in T4 (or T4/T3, or 
TSH) may be sufficient to conclude that a substance has an adverse effect. However, 
further research was deemed necessary in order to specify and validate the range beyond 
which a change in thyroid hormones alone is sufficient to conclude on the adversity of the 
effect.  
Participants of both groups agreed that, in all cases, a decrease in T4 should at the very 
least trigger further investigations, although it was currently not clear what those 
investigations should be. In making a decision on whether a decrease in T4 was a 
treatment-related effect, the importance of reliable data was frequently emphasised; i.e. 
sufficient numbers of animals, and the synchronisation of sample collection. Addition of a 
molecular read-out may be sufficient to conclude that an effect is adverse (e.g. existing 
AOP, clinical and epidemiological evidence that support strengthen the plausible link). 
Additional endpoints 
Group 2a discussed current test guidelines of developmental neurotoxicity in relation to 
thyroid disruption. It was agreed that there are issues with the sensitivity of 
developmental neurotoxicity endpoints. Concerns about the high likelihood of false 
negatives were expressed. The group recognized that these tests are insufficiently 
sensitive to detect the magnitude of change in T4 typically seen with environmental 
chemicals. Similar discussions took place in group 2b, with an orientation towards the 
relevance of the rat model for neurodevelopmental effects. Developmental neurotoxicity 
is currently considered the gold standard but it is not necessarily a sensitive enough 
model. Group 2b discussed several suggestions to improve this protocol. As brain 
development occurs also postnatally in the rat, it was proposed that the pups may be 
dosed directly if the substance is thought not to be transferred through lactation. Other 
suggestions included adding the measurement of T4 in the pups or including downstream 
molecular markers of TH action. 
Participants of group 2b also turned their attention to tissue-specific effects. Peripheral 
hormone levels in blood will not predict tissue-specific effects, nor is it possible to 
extrapolate between organs. Tissue-specific readouts are therefore necessary.  
Several additional endpoints that would be informative in this respect were suggested. 
T4/T3 can be measured specifically in the liver, heart, brain, bone and adipose tissue.  
Hepatic deiodinase 1 (D1) was considered an important liver marker of TH status 
For effects on the heart, change in the heart weight is a sensitive if non-specific endpoint 
for hyperthyroidism and is already included in TG 407 (28 days). However it is not 
currently interpreted as a thyroid sensitive endpoint. 
In the pituitary, TSH mRNA levels can be indicative of hypothyroidism. Useful endpoints 
in the brain include the RC3/Neurogranin gene. 
 156 
 
The functional significance of specific thyroid hormone transporting proteins was also 
discussed. It was noted that the human relevance of rodent models is often challenged 
with reference to differences in TBG levels relative to humans (rats have lower TBG). 
However, it was pointed out that the TTR-bound fraction is the most relevant one in 
terms of determining tissue availability of thyroid hormones, and that the TBG-bound 
fraction is less relevant in this respect. Therefore, the relevance of the rat model should 
not be dismissed on the grounds of low TBG levels in adult rats. 
Cholesterol biosynthesis, testis weight or the ovarian cycle can all be affected by 
disruption of thyroid hormone homeostasis. A general comment is that the endpoints 
above are typically sensitive but not specific to thyroid hormone disruption. They will 
therefore need to be considered in context with other endpoints. Of those that are 
already included in validated tests, they tend not to be interpreted in the light of thyroid 
disruption. 
Thyroid hormone insufficiency through induction of hepatic conjugation 
reactions 
Group 2a dealt with thyroid hormone insufficiencies that occur by induction of hepatic 
conjugation reactions in the wider context of other modes of action that also bring about 
thyroid hormone reductions, e.g. via inhibition of NIS or TPO. There was a consensus 
that the latter two modalities, if observed in the rat, should be deemed relevant to all 
species including humans. 
However, among some participants there was a reluctance to extend this stance to 
thyroid insufficiencies induced by the hepatic route. In response, some participants 
pointed to logical inconsistencies if the hepatic mode of action is not deemed relevant 
when NIS or TPO inhibition are. First, if quantitative differences between the rat and 
human thyroid systems are the reason for dismissing liver-mediated T4 reductions in the 
rat as irrelevant, this should equally apply to NIS and TPO inhibition. Second, differences 
in the PXR/CAR systems between rats and humans cannot be the reason for dismissing 
observations in the rat, as the human receptors are similar to the rat. There are also no 
substantial differences between rat and human UDPGT enzymes responsible for 
conjugation of thyroid hormones. 
Concerns were expressed that the existing guidance on interpreting liver-mediated 
thyroid insufficiency for regulatory decision making is biased in favour of protecting 
against false positives, when from a public health point of view, protection against false 
negatives should be imperative. These points could not be resolved, but it was agreed 
that the technical guidance on interpreting increased T4 clearance via hepatic enzyme 
induction in rodents should be revisited in the context of this discussion. The group 
agreed that increased T4 clearance in rodents as a result of hepatic Phase II enzyme 
induction cannot be regarded as irrelevant for humans. It should be presumed to be 
relevant until additional data with other species indicate the opposite. 
Group 2b dealt with the same topic by distinguishing between effects on thyroid and 
other hormones (e.g. estrogens or androgens) resulting from the induction of hepatic 
enzymes and those resulting from frank liver toxicity. Group 2b agreed that the 
WHO/IPCS definition of adversity given above does not distinguish between primary and 
secondary toxicity. Direct effects on the liver will ultimately affect the thyroid system as 
well as other endocrine axes. A distinction was therefore made between a substance that 
induces direct liver toxicity and effects on hormone levels secondary to that toxicity and 
effects on hepatic enzymes. The former would be considered a liver toxicant whereas the 
latter should be considered an endocrine disruption mechanism. The logic for this view 
was that the degradation pathways of hormones, and therefore increased hepatic 
conjugation reactions, are considered key events in maintaining homeostasis, as 
important as hormone synthesis. The same applies to extra-hepatic thyroid hormone 
inactivation which can occur e.g. in gastrointestinal stromal tumours or as consumptive 
hypothyroidism through enhanced thyroid hormone degradation via type 3 deiodinase.  
  
 
Consequently, pathways leading to hormone insufficiency have to be deemed both an 
endocrine-relevant mechanism and relevant to humans, unless information to suggest 
otherwise is available. It was also noted that this interpretation is relevant to other 
hormones such as sex hormones and there is no rational basis for a different 
interpretation pertaining solely to thyroid hormones. During the plenary discussion it was 
noted that the WHO/IPCS definition of an endocrine disruptor and the draft EU criteria 
include the necessity for the demonstration of an adverse effect (for example, 
carcinogenicity, reproductive toxicity). 
Thyroid cancer 
Group 2a considered trends in thyroid cancer and the role of TSH in these trends. The 
associations reported in cross-sectional studies were recognised, but it was pointed out 
that prospective epidemiological studies are needed to further elucidate the role of TSH 
as a potential causal factor. 
The group then discussed the existing USEPA/IARC guidelines which presume that rodent 
thyroid carcinogens may pose a hazard to humans. The group concluded that, in the 
absence of data to the contrary, rats should be assumed to be equally sensitive as 
humans, in line with USEPA/IARC guidance. 
Groups 2a and 2b discussed temporal trends in thyroid cancer diagnoses. Thyroid 
tumours are the most frequent tumour in an endocrine tissue and they are known to be 
sensitive to both environmental factors and nutritional factors such as iodine or selenium 
intake. Further, the thyroid is a vulnerable, slowly proliferating tissue. The increase in 
thyroid papillary tumours was recognised by IARC where a thyroid cancer working group 
has been set up to investigate the factors underlying the dramatic increase in thyroid 
carcinomas. It was highlighted that there is a significant contribution of increased 
awareness and screening to increased trends in diagnosis, as reported in a 2016 IARC 
publication that was mentioned in group 2a. However, it was noted that there is a lack of 
clarity in the scientific literature as to whether screening alone can explain the increase in 
thyroid papillary tumours. 
There was general agreement that there is a need to revisit the evidence base on the 
relevance of the rat model for thyroid cancer (IARC 1998 report), particularly the 
potential role of the strain of rat used in experiments as large differences can be 
observed with different strains of mice. The group also noted that it is difficult to 
distinguish between follicular and papillary tumours in rodents. 
Following the Chernobyl incident, an increase in thyroid cancers was observed in children 
that had been exposed to radiation in utero and the prenatal phase is a known sensitive 
window for thyroid cancer. Group 2b noted however that there is currently no validated 
carcinogenesis test to detect thyroid cancer in offspring exposed prenatally.  
Some discussions took place within the group related to various definitions of 
carcinogens and whether this would include both tumour initiators and substances that 
promote proliferation. Group 2b also noted that not all thyroid tumours arise from an ED 
mechanism. 
Group 2b concluded that at present too little is understood of the etiology of thyroid 
tumours to conclude on the relevance of the rat model for humans. As a result, the rat 
should be assumed relevant to humans by default – a stance similar to that of group 2a.  
Relevance of rat models for human hazard and risk assessment 
Further discussions about the human relevance of the rat model to humans took place 
within group 2b. It was quickly agreed that the rat is more sensitive than the healthy 
adult human, but not uniquely sensitive. The difference between rat and human is 
quantitative not qualitative. Similar conclusions were drawn in Group 2a.  
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Quantitative differences between the rat and the human in terms of thyroid hormone 
storage were discussed further. The ‘buffer’ argument was found not to be applicable to 
sensitive subgroups such as the unborn child, as fetuses do not yet have thyroid 
hormone storage capacity, or iodine-deficient adults, as their TSH is already elevated. 
Further, the group noted that in the case of chronic exposure, this buffer may result in 
increased latency rather than differences in sensitivity. In neonates, the relevant storage 
pool of thyroid hormones is the thyroid itself rather than peripheral storage in the blood. 
8.3.3 Discussion groups 3 a b : Thyroid systems across taxa: the 
relevance of mammalian data in environmental assessments 
and of non-mammalian data in human health risk assessment 
The suggested discussion topics for groups 3a and 3b were: 
1. In which respect can data from rodent studies be used to inform about effects on 
rodents/mammals in the environment? 
2. In which respect can data from amphibian or fish studies be used to inform about 
possible effects in rodents/mammals? 
3. When and how during testing should we take into consideration that the thyroid 
hormone system is highly conserved between taxa? 
4. Should current testing guidelines be enhanced by adding additional endpoints and 
assays? 
Use of laboratory rodent data for purposes of ecotoxicological risk assessment 
in mammalian species 
Participants considered that observations of thyroid disruption in rodent laboratory 
studies are useful for the identification of thyroid disrupting properties in other wildlife 
mammalian species. Such findings would raise concerns, especially when considering the 
well-known similarities in modes of action between taxa. The extrapolation of laboratory 
findings in rodent to the wildlife population may be more difficult since it requires further 
consideration on the relevance of such findings at the population level. 
Group 3b also considered whether data from rodent studies could be used to inform 
about possible effects in other taxa, e.g. fish or amphibians. Participants agreed that 
such data would raise concerns for other taxa, and that mode of action data from 
mammalian laboratory species might trigger additional testing in other taxa, e.g. birds, 
fish or amphibians. 
However, participants cautioned that differences in exposure routes (e.g. dermal in 
amphibians versus oral in rodents) and biological differences (presence of the placenta in 
mammals) might complicate simple species-species extrapolations. There are also 
significant differences in absorption, distribution, metabolism and excretion. 
Use of non-mammalian data for purposes of human hazard and risk 
assessments 
In view of the conservation of the basic features of the thyroid system across taxa, both 
groups concluded that data from non-mammalian tests can be used to inform on the 
mode of action of putative thyroid disrupting chemicals. This is strongly supported by the 
observation that most amphibian thyroid disruptors have elicited positive responses also 
in rodent tests.  
However, both groups considered the issue to be more complicated when it comes to 
assessing adversity, mainly because of the great care with which species-species 
extrapolations have to be conducted. Other complicating factors are differences in the 
exposure routes between e.g. amphibians (dermal more relevant) and mammalian 
species.   
Improvements of existing test guidelines from the ecotoxicology perspective 
  
 
There were extensive discussions of the merits or otherwise of including measurements 
of thyroid hormone levels in non-mammalian tests. The relevance of such measurements 
depends on the life stage considered. For example, there will be a high variability during 
amphibian metamorphosis, with correspondingly low sensitivity. Another question 
concerns the ways in which such test results should be interpreted. Participants felt that 
the measurement of thyroid hormone levels is of considerable value in terms of 
assessments of modes of action, but would not provide additional information in terms of 
adversity at population level. 
Participants of group 3b made detailed recommendations on the inclusion of thyroid 
hormone measurements in relation to specific assays and tests. 
For the AMA, the feasibility was judged as low, and most participants did not rate 
inclusion as of sufficiently high priority. 
For the LAGDA, thyroid hormone measurements were judged to be feasible in plasma, 
together with determinations of vitellogenin levels, but the majority of participants did 
not rate the priority as high. 
In tests on fish, determinations of thyroid hormones were deemed practical, both in 
plasma and in fish homogenates. Most of the group maintained that if other thyroid 
endpoints are included (e.g. eye development, swimbladder function, lateral line) it could 
support the interpretation of data (provide MoA information). One member doubted the 
current need because of difficulties in interpretation of results (lack of understanding of 
importance of crosstalk between different hormonal axes for suggested endpoints in 
fish). 
Participants recommended the development of behavioural tests, as changes in 
behaviour may be downstream effects of thyroid disruption. This was regarded as an 
important endpoint for adversity of effects which can help to fill the gap between modes 
of action and adverse effects in terms of population dynamics. However, more research is 
required before implementation is possible, e.g. to identify behavioural effects directly 
linked to thyroid disruption. Relevant behavioural endpoints to consider include startle 
response, nesting, feeding behavior and 'swim-up', indicative of swim bladder inflation in 
fish. 
The evaluation of specific thyroid-dependent physiological processes in wildlife species 
(e.g. seasonality, smolting, hibernation) was also seen as desirable, as was the 
incorporation of swim bladder inflation and eye development as an endpoint in fish early 
life and generational tests. 
Participants pointed out the importance of controlling iodine and selenium supply during 
testing. 
It was also recommended to add thyroid-relevant endpoints to tests on fish since these 
tests cover a wide range of life stages, with easy wins, especially with the medaka. 
The possibility of determining gene expression levels of direct targets of thyroid hormone 
action, such as Klf9/Bteb, or other thyroid responsive genes regulated by negative 
feedback, e.g. TPO, NIS was also discussed. 
Participants discussed the desirability of integrating multiple endpoints for thyroid 
disruption in non-mammalian tests. 
This was approached from several angles, firstly, in terms of multiple endpoints 
representative of the HPT axis in a single test system. To a degree, this is already 
realised with the LAGDA. Some participants found it helpful to include liver endpoints in 
the AMA. 
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Secondly, the topic was discussed in the sense of the same endpoint in multiple species. 
The group saw the introduction of thyroid endpoints in fish tests as relevant and worthy 
of prioritisation. For well established fish test species such as the fathead minnow, 
thyroid histology could be a valuable endpoint. 
Thirdly, participants considered the possibility of investigating multiple endocrine systems 
in the same species, going beyond the thyroid system. This was seen as a fascinating 
perspective, but one that requires considerable research and development efforts. 
Finally, the topic of maternal transfer of thyroid hormones and of contaminants in non-
mammalian test species was discussed. There was a degree of uncertainty as to the 
importance of maternal transfer in such systems, but a consensus emerged that more 
research is needed to address this issue. 
8.4 Contours of agreements across discussion groups in plenary 
debates 
In plenary sessions, all discussion groups presented summaries of their deliberations for 
debate and criticism. 
Following considerable discussion, all groups came to a consensus regarding the 
interpretation of changes in serum T4 levels. If such changes occur, for any reason, 
including altered hepatic clearance, they should be considered a thyroid effect, unless the 
mechanism of altered clearance (i.e. the specific enzymes or pathways impacted) can be 
determined not to be relevant to humans or wildlife of concern. 
All groups also came to the view that the current OECD testing guidelines are 
insufficiently equipped for capturing all recognised thyroid disrupting effects, and should 
be updated accordingly. This applies to both, tests intended for human-relevant 
assessments, and systems for ecotoxicological evaluations. Several discussion groups 
made specific suggestions for such updates (see above). 
  
  
 
9. CONCLUSIONS 
 
This workshop dealt with issues that surround the interpretation of findings from studies 
relevant to the identification of thyroid disrupting substances. It also identified gaps in 
the test methods that currently exist for the identification of thyroid disrupting 
substances. 
In the course of the workshop it became clear that the interpretation of test results with 
thyroid disrupting agents is most often based on an “idealised view” of the thyroid 
system which is not always in line with experimental observations. In this idealised view, 
decreases in circulating TH should give rise to increases in TSH which in turn stimulate 
the thyroid to synthesise TH, thereby restoring the original hormone serum 
concentrations. 
Accordingly, suppressions of TH serum concentrations seen in the wake of exposure to 
certain substances are expected to also lead to elevated TSH concentrations. When this 
expectation is not met, the relevance of decreased TH is often called into question, with 
follow-on debates about the adversity of TH suppressions and the implications for 
identifying a substance as thyroid disruptor.  
However, there are examples in which TH decreases following chemical exposures are 
not accompanied by correspondingly rising TSH serum concentrations. Sometimes, 
reduced TH concentrations leave TSH entirely unchanged, in other cases, sustained 
supression of TH can even lead to decreases of serum TSH. 
Furthermore, research in the field of thyroid disruption during the last decade has shown 
that autonomous regulation of thyroid hormone action at the tissue level, without 
involvement of the HPT axis, can play an important role, and can affect the organism 
without the corresponding changes in serum thyroid hormones. 
In conclusion, altered TH and TSH levels cannot be seen as the only definitive marker of 
thyroid hormone action, or of thyroid disruption. 
These insights should have significant consequences for the interpretation of data in the 
context of identifying a substance as thyroid disruptor (and by extension, as an 
endocrine disruptor). In order to properly identify all thyroid disrupting chemicals, 
information in chemical dossiers should be supplemented by data on down-stream effects 
of an adverse nature, such as effects on the developing brain, or on other TH target 
organs. 
However, the current test guidelines in the OECD Conceptual Framework for endocrine 
disruptors (e.g. TG 421/422, 426, 443) lack such parameters indicative of down-stream 
adverse effects diagnostic of thyroid disruption. This hampers the reliable identification of 
substances as thyroid disruptors. 
Important perspectives for improving test guidelines are the inclusion of endpoints for 
the identification of adverse effects on brain function and brain morphology in TG 
421/422, 426 and 443, since traditionally used behavioural assays may not be sensitive 
enough to identify all thyroid disrupting chemicals. Also necessary is the inclusion of 
endpoints representative of TH action at the cellular level, e.g. nerve cell migration and 
differentiation, or altered expression of TH-dependent genes. Some of these gaps can be 
filled by including standard endpoints in existing test guidelines (e.g. by making 
determinations of T4 levels mandatory in TG 407, 408), others require the 
implementation of new endpoints as well as research and development efforts. 
Also notable is a lack of internationally validated in vitro assays in the OECD Conceptual 
Framework. Such data can shed light on important mechanistic aspects of thyroid 
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disruption (i.e. whether a substance is capable of inhibiting NIS, TPO or of displacing TH 
from serum transporter proteins, etc.). 
A strategy for developing improved or novel endpoints important for detecting thyroid 
disruptors could unfold at the following levels: 
 Thyroid histology improvements could be made according to guidelines of the 
American Medical Association developed for human clinical studies, taking account 
of improvements in automisation. 
 The timing of exposure should be extended, emphasising developmentally 
exposed animals and including endpoints such as cortical heterotopias and 
oligodendrocyte differentiation. 
 The set of down-stream effects should include brain morphology, especially the 
developing brain (see above), gene markers of brain development, and TH effects 
on lipid metabolism and the cardiovascular system. 
Until these gaps are filled, it is necessary to evaluate substances on the basis of 
incomplete data regarding thyroid disruption. In this context, findings of diminished 
serum TH concentrations in animal studies should be taken as predictive of adverse 
effects in humans. Such observations should act as a trigger for further testing. However, 
if further testing cannot be conducted, and more conclusive data are not forthcoming, 
findings of diminished serum TH levels could form the basis of regulatory decision 
making, as this is likely to protect against adverse downstream effects (e.g. 
developmental neurotoxicity) in humans. 
More specifically, this stance should be extended to substances that provoke 
suppressions of serum TH concentrations by inducing hepatic enzymes involved in the 
clearance of TH in rodents. Such findings should be regarded as relevant for regulatory 
decisions unless, on the basis of further compound specific information, it is possible to 
exclude the human relevance of such effects. Existing guidance on dealing with such 
hepatic effects should be reconsidered and updated. 
Observations of thyroid disruption in rodent laboratory studies can be useful for the 
identification of thyroid disrupting properties in other wildlife mammalian species. 
Considering the preservation of the thyroid system across taxa, such data would also 
raise concerns for e.g. birds, fish or amphibians, although species-species extrapolations 
will not be straight-forward due to differences in exposure routes (e.g. dermal in 
amphibians versus oral in rodents) and other factors (e.g. the presence of the placenta in 
mammals). 
Conversely, data from non-mammalian test species can be used to inform on the mode 
of action of putative thyroid disrupting chemicals in mammals. This is strongly supported 
by the observation that most amphibian thyroid disruptors have elicited positive 
responses also in rodent tests. 
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Workshop on Thyroid Disruption
29
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st
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Country name institution email address
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Denmark Marta Axelstad DTU maap@food.dtu.dk
EU Stefanie Barmaz EFSA Stefania.BARMAZ@efsa.europa.eu
Interest group Remi Bars European Centre for Ecotoxicology and Toxicology of Chemicalsremi.bars@bayer.com
UK Alice Baynes Brunel University London alice.baynes@brunel.ac.uk
Steering group Claire Beausoleil ANSES Claire.BEAUSOLEIL@anses.fr
Norway Christine Bjorge Norwegian Environment Agency christine.bjorge@miljodir.no
Belgium Marie-Noelle Blaude WIV ISP marie-noelle.blaude@wiv-isp.be
Slovak Republik Karol Blesak Ministry of the Economy Karol.Blesak@mhsr.sk
Netherlands Toine FH Bovee RIKILT (Institute of food safety) toine.bovee@wur.nl
Ireland Alan Breen Department of Agriculture, Food and the Marine alan.breen@agriculture.gov.ie
OECD Patience Browne OECD Patience.BROWNE@oecd.org
France Nicolas Chevalier Centre Hospitalier Universitaire de Nice, Nice chevalier.n@chu-nice.fr
Italy Annamaria Colacci Arpae Emilia-Romagna acolacci@arpa.emr.it
USA Kevin Crofton U.S. Environmental Protection Agency Crofton.Kevin@epa.gov
Netherlands ZhiChao Dang RIVM zhichao.dang@rivm.nl
France Barbara Demeneix National Museum of Natural History demeneix@mnhn.fr
Switzerland Anne-Laure Demierre Bundesamt für Gesundheit BAG anne-laure.demierre@bag.admin.ch
Denmark Marianna Dybdahl DTU mdyb@food.dtu.dk
Germany Éva Fetter UBA Eva.Fetter@uba.de
Austria Alexandra Fischer Austrian Agency for Health and Food Safety alexandra.fischer@ages.at
France Frederic Flamant ENSL (Lyon) frederic.flamant@ens-lyon.fr
Industry Alexius Freyberger Bayer Pharma AG alexius.freyberger@bayer.com
USA Mary Gilbert US Environmental Protection Agency gilbert.mary@epa.gov
Steering group Elise Grignard EC DG JRC Elise.GRIGNARD@ec.europa.eu
Netherlands Betty Hakkert RIVM Betty.hakkert@rivm.nl
Netherlands Timo Hamers VU University of Amsterdam timo.hamers@vu.nl
Denmark Ulla Hass DTU ulha@food.dtu.dk
Denmark Henrik Holbech University of South Denmark hol@biology.sdu.dk
Denmark Marie-Louise Holmer Danish Ministry for the Environment mlh@mst.dk 
Austria Bettina Hrdina-Zödl Austrian Agency for Health and Food Safety bettina.hrdina-zoedl@ages.at 
Japan Taisen Iguchi Ozaki National Research Institutes, Yokohama City Universitytaiseni@hotmail.co.jp
Lithuania Agnė Janonytė Environmental Protection Agency a.janonyte@aaa.am.lt
EU Aude Kienzler DG JRC Aude.KIENZLER@ec.europa.eu
Germany Josef Kohrle Charité Universitatsmedizin Berlin Josef.Koehrle@charite.de
UK Andreas Kortenkamp Brunel University London andreas.kortenkamp@brunel.ac.uk
Steering group Peter Korytar EC DG ENV peter.korytar@ec.europa.eu
UK Elizabeth  Lawton Brunel University London
France Joelle Le Moal Santé Publique France j.lemoal@invs.sante.fr
Sweden Margaret Lejonklou KEMI Margareta.HalinLejonklou@kemi.se
Norway Birgitte Lindeman birgitte.lindeman@fhi.no
Austria Anne-Marie Losert Environment Agency Austria Annemarie.Losert@umweltbundesamt.at
Interest group Gwynne Lyons ChemTrust gwynne.lyons@chemtrust.org.uk
Italy Alberto Mantovani Instituto Superiore di Sanita alberto.mantovani@iss.it
Hungary Zoltan Marcsek National Institute of Chemical Safety (OKBI) marcsek.zoltan@okbi.antsz.hu
UK Olwenn Martin Brunel University London olwenn.martin@brunel.ac.uk
OECD 150 Ecotox Peter Matthiessen peter@matthiessen.freeserve.co.uk
United Kingdom Helen McGarry Health and Safety Executive Helen.McGarry@hse.gov.uk
Steering group Cécile Michel ANSES Cecile.MICHEL@anses.fr
Austria Marc Müller Austrian Agency for Health and Food Safety marc.mueller@ages.at
Steering group Sharon Munn EC DG JRC sharon.munn@ec.europa.eu
Sweden Leif Norrgren Swedish University of Agricultural Science (SLU) leif.norrgren@slu.se
OECD 150 HH Jenny Odum jenny.odum@regulatoryscience.com
Slovak Republik Roman Olha roman.olha@mhsr.sk
France Jean-Nicolas Ormsby Anses jean-nicolas.ormsby@anses.fr
Finland Hinni Papponen Hinni.Papponen@tukes.fi
Industry Dan Pickford Syngenta dan.pickford@syngenta.com
EU Francesca Pistollato DG JRC Francesca.PISTOLLATO@ec.europa.eu
Finland Maarit Priha Maarit.Priha@tukes.fi
Steering group Maiken Rasmussen EC DG ENV maiken.rasmussen@ec.europa.eu
Germany Vera RITZ BfR Vera.Ritz@bfr.bund.de
Belgium Martine Rohl FPS Public Health martine.rohl@environnement.belgique.be
France Christophe Rousselle ANSES Christophe.ROUSSELLE@anses.fr
Italy Maristealla Rubbiani maristella.rubbiani@iss.it
France Laurent Sachs CNRS, National Museum of Natural History, Paris laurent.sachs@mnhn.fr
EU Gabriele  Schöning ECHA gabriele.schoening@echa.europa.eu
Germany Agnes Schulte BfR agnes.schulte@bfr.bund.de
EU Andrea TERRON EFSA Andrea.TERRON@efsa.europa.eu
Poland Lidia Tokarz lidia.tokarz@ios.edu.pl
EU Sander van der Linden DG JRC sander.van-der-linden@ec.europa.eu
Interest group Majorie van Duursen Health and Environment Alliance m.vanduursen@uu.nl
France Catherine Viguie INRA catherine.viguie@inra.fr
Norway Gro Dehli Villanger Gro.Dehli.Villanger@fhi.no
Netherlands Theo J Visser Erasmus University Medical Center t.j.visser@erasmusmc.nl
Canada Mike Wade Environmental & Radiation Health Science Directorate, Health CanadaMike.Wade@hc-sc.gc.ca 
France Jean-Louis Wemeau PUPH d'Endocrinologie de Lille, retraite jl-wemeau@hotmail.fr
WCA Consulting Louise Youngs WCA Consulting louise.youngs@wca-consulting.com
USA Tom R Zoeller University of Massachusetts tzoeller@bio.umass.edu
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